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Abstract	The	 neuronal	 ceroid	 lipofuscinoses	 (NCLs/Batten	 disease)	 are	 a	 group	 of	 fatal	autosomal	 recessive	 lysosomal	 storage	 disorders	 (LSDs).	 There	 are	 no	 effective	treatments	 available	 for	 any	 form	 of	 NCL.	 This	 thesis	 focuses	 on	 modelling	 late	infantile	 CLN2	 disease	 (LINCL),	 which	 is	 caused	 by	 mutations	 in	 the	 CLN2	 gene,	resulting	 in	 deficiency	 of	 the	 lysosomal	 enzyme	 tripeptidyl	 peptidase	 I	 (TPP1).	Potential	treatments	of	this	disorder	are	based	upon	delivering	this	missing	enzyme	to	the	 brain	 but	 in	 order	 to	 judge	 the	 efficacy	 of	 future	 therapies,	 pre-clinical	 studies	must	be	carried	out	in	disease	models.	A	mouse	model	of	CLN2	disease	exists,	which	is	deficient	 in	 TPP1	 and	 in	 this	 thesis	 I	 characterised	 the	 disease	 progression	 of	 this	
Tpp1-/-	mouse.	This	analysis	revealed	a	pattern	of	disease	progression	that	is	unique	in	the	NCLs	to	these	Tpp1-/-	mice,	where	neuronal	cell	loss	was	initiated	in	the	thalamus	and	 preceded	 microglial	 and	 astrocytic	 activation.	 Subsequently,	 neuronal	 cell	 loss	spread	 to	 the	 cortical	 target	 regions	 and	 was	 accompanied	 by	 glial	 activation.	 In	addition,	the	effects	of	the	adaptive	immune	system	on	CLN2	disease	progression	were	explored	 by	 examining	 the	 same	 Tpp1-/-	mice	 on	 an	 immunodeficient	 background.	These	immunocompromised	mice	had	a	more	pronounced	disease	phenotype	in	terms	of	 atrophy	 of	 regional	 brain	 structures	 and	 neuronal	 cell	 loss	 in	 the	 somatosensory	cortex	 and	 specific	 thalamic	 nuclei	 than	 the	 equivalent	 TPP1-deficient	mice	with	 an	intact	 immune	 system.	 The	 TPP1-deficient	mice	which	 lacked	 the	 adaptive	 immune	responses	 lived	 longer,	 however	 this	 extended	 lifespan	 allowed	 a	 more	 severe	neurodegerative	phenotype	to	develop.			This	 thesis	 also	 presents	 the	 process	 of	 developing	 a	 human	 neural	 progenitor	 cell	(hNPC)	model	 of	 late	 infantile	 CLN2	 disease	 by	 introducing	 a	 CLN2	 disease-causing	mutation	into	a	hNPC	line	using	genome	editing.	Transcription	activator-like	effector	nucleases	 (TALENs)	 are	 genome-editing	 tools	 that	 fuse	 naturally	 occurring	 DNA-binding	 proteins	 that	 can	 be	 designed	 and	 arranged	 according	 to	 a	 simple	 code	 to	target	a	specific	DNA	sequence,	to	a	DNA	cleavage	domain.	These	TALENs	can	be	used	to	edit	genomes	by	inducing	double	strand	breaks.	In	this	thesis	I	present	my	attempts	to	produce	TALENs	to	target	the	CLN2	gene	and	to	produce	a	clonal	hNPC	cell	line	that	harbours	a	CLN2	disease	mutation.	 I	 show	 that	a	 culture	of	hNPCs	was	 isolated	 that	contained	 largely	wild-type	hNPCs	and	a	smaller	population	of	hNPCs	containing	the	desired	 CLN2	 disease-causing	 mutation.	 I	 also	 describe	 an	 optimised	 method	 for	transfection	of	hNPCs	that	is	now	being	used	by	other	researchers	wishing	to	carry	out	genome	editing	in	this	hNPC	line.	
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Abbreviations	3Rs	 Replacement,	reduction	and	refinement	ABC	 avidin-biotin	solution	AC	 Cerebellar	astrocytes	AD	 Alzheimer’s	disease	AF	 Autofluorescence	APP	 Amyloid-β	precursor	protein	Au1	 Primary	auditory	cortex	BBB	 Blood-brain	barrier	BDNF	 Brain	Derived	Neurotrophic	Factor	BGC	 Bergmann	Glial	Cells	BMT	 Bone	marrow	transplant	Cbln1	 Cerebellin	1	CE	 Coefficient	of	Error	ChAT	 Choline	acetyltransferase	CNS	 Central	Nervous	System	CRISPRs	 Clustered	regulatory	interspaced	short	palindromic	repeats	CSP	 Cysteine	string	protein	CTNS	 Cystinosin	DAB	 3,3’-diaminobenzidine	DAMPs	 damage-associated	molecular	pattern	molecules	DCN	 Deep	cerebellar	nuclei	DCX	 Doublecortin	DdNTP	 Dideoxynucleotide	DG		 Dentate	gyrus	DMSO	 Dimethyl	sulfoxide	
DNAJC5		 DNAJ	homolog	subfamily	C	member	5	dNTP	 Deoxynucleotide	DO	 Diversity	Outbred	DPP1	 Dipeptidyl	peptidase	1	DPX	 p-xylene-bis(pyridinium	bromine	Ds	 Double-stranded	DSB	 Double	stranded	break	DsRNAs	 Double-stranded	RNAs	ER	 Endoplasmic	reticulum	ERT	 Enzyme	Replacement	Therapy	ExoI	 Exonuclease	I	FACS	 Fluorescent	activated	cell	sorting	FLASH	 Fast	ligation-based	automatable	solid-phase	high-throughput	GABA	 Gamma-aminobutyric	acid	GABA	 Gamma	aminobutyric	acid	GAD65	 glutamic	acid	decarboxylase	GALC	 Galactocerebrosidase	GCL		 Granular	cell	layer	GDNF	 Glial	cell-line	derived	neurotrophic	factor	GFAP	 Glial	fibrillary	associated	protein	GLA	 Galactosidase	GnRH	 Gonadotrophin-releasing	hormone	gRNA	 Guide	RNA	GSL	 Glycosphingolipid	HCS	 High	content	screening	HDR	 Homology	directed	repair	HEXA	 β-hexosaminidase-A	HEXB	 β-hexosaminidase-B	HPCs	 Haematopoietic	progenitor/stem	cells	
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The	 neuronal	 ceroid	 lipofuscinoses	 (NCLs)	 are	 a	 group	 of	 inherited	neurodegenerative	diseases	that	mainly	affect	children	(Haltia	and	Goebel,	2013).	They	 are	 classified	 as	 lysosomal	 storage	 disorders	 (LSDs),	 which	 are	 caused	 by	mutations	 in	 genes	 in	 the	 lysosomal/endosomal	 pathway	 (Boustany,	 2013).	 The	NCLs	have	varying	ages	of	onset,	by	which	they	were	originally	classified,	and	the	disease	progression	and	underlying	disease	mechanism	is	different	in	each	of	the	NCLs	as	well	(Cooper,	2010).	Despite	this	variation,	the	NCLs	are	grouped	together	due	 to	 their	 similar	 clinical	 manifestations	 and	 characteristic	 autofluorescent	storage	material	that	accumulates	in	the	cells	of	affected	individuals.		Many	 different	 strategies	 have	 been	 attempted	 to	 attenuate	 the	 disease	progression	of	the	NCLs	and	although	some	do	lead	to	minor	improvements,	none	have	led	to	appreciable	increases	in	survival	rates	in	patients	(Wong	et	al.,	2010).	As	 such,	 an	 improved	 understanding	 of	 the	 underlying	 disease	mechanisms	 and	pathology	 of	 the	 NCLs	 via	 extensive	 preclinical	 studies	 in	 animal	models	 and	 in	
vitro	systems	is	required.	The	neuropathological	features	of	NCL	disease	have	been	described	in	a	number	of	mouse	models	of	NCL	and	similar	landmarks	of	disease	progression,	 such	 as	 neurodegeneration	 and	 neuroinflammation	 have	 been	observed	(Chang	et	al.,	2008,	Pontikis	et	al.,	2004,	Kuhl	et	al.,	2013,	Kuronen	et	al.,	2012,	 Kielar	 et	 al.,	 2007).	 This	 thesis	 describes	 the	 detailed	 characterisation	 of	disease	progression	in	a	mouse	model	of	late	infantile	CLN2	disease	(late	infantile	NCL)	for	the	first	time	and	describes	progress	towards	making	a	human	stem	cell	model	 of	 late	 infantile	 CLN2	 disease,	 which	 will	 be	 used	 to	 complement	 data	obtained	from	the	mouse	model.			
1.1 Lysosomal	Storage	Disorders	




Figure	 1	 Lysosome	 structure.	Lysosomes	contain	acid	hydrolases,	enzymes	that	are	active	in	the	acidic	pH	of	the	lysosome	but	not	the	neutral	pH	of	the	cytosol.	The	acidic	pH	of	the	lysosome	is	created	and	maintained	by	proton	pumps	in	the	membrane	wall	of	the	lysosome,	which	actively	transport	protons	into	the	organelle.	Image	is	based	on	an	image	from	(Cooper,	2000).			Lysosomes	 are	 formed	 by	 the	 fusion	 of	 transport	 vesicles	 that	 bud	 from	the	trans	Golgi	 with	 endosomes	 (Settembre	 et	 al.,	 2013,	 Appelqvist	 et	 al.,	 2013),	which	 contain	molecules	 taken	 up	 by	 endocytosis	 at	 the	cell	 plasma	membrane.	Material	from	outside	the	cell	is	internalized	in	clathrin-coated	endocytic	vesicles,	which	 bud	 from	 the	plasma	 membrane	 and	 fuse	 with	 early	 endosomes,	 which	gradually	 mature	 into	 late	 endosomes	 (Luzio	 et	 al.,	 2000,	 Luzio	 et	 al.,	 2007).	Different	models	are	proposed	as	to	how	material	is	passed	from	late	endosomes	to	lysosomes	(described	in	Figure	2).		
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Figure	 2	Different	models	 of	 delivery	 to	 the	 lysosome.	 (A)	 In	 the	maturation	model,	endosomes	mature	 into	 lysosomes	via	 the	gradual	addition	of	 lysosomal	 features.	 (B)	 In	the	 vesicular	model,	 vesicles	bud	 from	 the	 late	 endosome	and	deliver	 their	 cargo	 to	 the	lysosome.	(C)	 In	the	kiss	and	run	model,	 late	endosomes	and	 lysosomes	transiently	 fuse,	allowing	the	exchange	of	material,	then	separate.	(D)	In	the	hybrid	model,	endosomes	and	lysosomes	permanently	fuse	to	form	a	hybrid	organelle,	and	then	lysosomes	are	re-formed	by	retrieval	of	endosomal	components.	Adapted	from	(Luzio	et	al.,	2007).			The	 majority	 of	 acid	 hydrolases	 are	 targeted	 to	 lysosomes	 by	 mannose-6-phosphate	 (M6P)	 residues,	 which	 are	 recognized	 by	 M6P	 receptors	 in	the	trans	Golgi	network	(TGN),	and	delivered	into	endosomes	(Ghosh	et	al.,	2003,	Luzio	et	al.,	2000,	Luzio	et	al.,	2007).	The	acidic	internal	pH	of	the	late	endosomes	causes	 the	hydrolases	 to	dissociate	 from	the	M6P	receptors	and	be	released	 into	the	lumen	of	the	endosome,	while	the	receptors	are	recycled	to	the	TGN	(Seaman,	2004).	 The	 hydrolases	 subsequently	 continue	 onto	 the	 lysosome	 as	 described	 in	
Figure	2.			The	lysosome	is	not	only	responsible	for	degradation	of	metabolites,	but	also	has	a	role	 in	 phagocytosis	 and	 antigen	 presentation,	 processes	 that	 are	 required	 for	regulating	 inflammation	 and	 autoimmunity	 (Boustany,	 2013).	 Together	 with	endosomes,	 lysosomes	 are	 involved	 in	 regulating	 autophagy,	 apoptosis	 and	 cell	death	 (Muller	 et	 al.,	 2012),	 through	 their	 roles	 in	 signal	 transduction	 and	exocytosis,	 all	 of	 which	 are	 involved	 in	 inflammation	 and	 neurodegenerative	diseases	(Platt	et	al.,	2012).	
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Lysosomal	storage	disorders	(LSDs)	are	caused	by	mutations	in	genes	that	encode	lysosomal	enzymes	such	as	the	hydrolases,	transporters	and	hydrolase	activators	in	 the	 endosome-lysosome	 pathway	 but	 also	 certain	membrane	 proteins	 in	 this	system	 as	 well,	 resulting	 in	 an	 accumulation	 of	 undegraded	material	 within	 the	lysosomes	of	affected	individuals	(Hers,	1965).		The	LSDs	are	hereditary	diseases,	usually	 inherited	 in	 an	 autosomal	 recessive	manner	 although	 some	 are	 X-linked	(Boustany,	2013).			









involved?	Lysosomal	 enzyme	deficiencies	 Fabry	 -galactosidase	(GLA)	 (Lyso)Globotriaosylceramide	 Kidney,	heart	 No	Gaucher	types	1,	2	and	3	 -Glucocerebrosidase	 Glucosylceramide,		glucosylsphingosine	 Spleen,	 liver,	 bone	marrow	 Yes	in	2	and	3	Krabbe	 Galactocerebrosidase	(GALC)	 Galactosylceramide	 Heart	 Yes	Mucopolysaccharides	 Enzymes	involve	in		mucopolysaccharide		catabolism	 Mucopolysaccharides	 Cartilage,	bone,		heart,	lungs	 Yes,	in	most	Pompe	 α-Glucosidase	(GLA)	 Glycogen	 Skeletal	muscle	 No	Sandhoff	 β-hexosaminidase	A		and	B	(HEXB)	 GM2-ganglioside	 	 Yes	Trafficking	 defect	 of	lysosomal	enzymes	 Mucolipidosis	type	II	and	IIIa	 N-acetyl	 glucosamine	phospheryl	transferase	 Carbohydrates,	lipids,	proteins	 Skeleton,	heart		 Yes,	mostly	Defects	 in	 soluble	 non	enzymatic	proteins	 Niemann-Pick	disease	(C2)	 NPC2	 (soluble	 cholesterol	binding	protein)	 Cholesterol,	sphingolipids	 Liver	 Yes	Defects	 in	 lysosomal	membrane	proteins	 Cystinosis	 Cystinosin	 (a	 cysteine	transporter,	CTNS)	 Cystine	 Kidney,	eye	 No	Mucolipidosis	IV	 Mucolipin-I	(MCOLN1)	 Mucopolysaccharides,	lipids	 Cardiac	 and	skeletal	muscle	 Yes	Niemann-Pick	disease	(C1)	 NPC1	 (membrane	 protein	involved	 in	 lipid	transport)	 Cholesterol,	sphingolipids	 Liver	 Yes	Idiopathic	 lysosomal	disorders	 Neuronal	 ceroid	 liposcinoses	(NCLs/Batten	disease)	 Heterogenous	 group	 of	diseases	 with	 genetic	defects	 in	 apparently	unconnected	 genes,	 most	but	 not	 all	 in	 the	lysosomal	system.	





1.2.1 Principle	of	cross	correction	As	described	above,	the	majority	of	lysosomal	hydrolases	are	targeted	to	lysosomes	via	M6P	 receptors	but	 a	proportion	of	 enzymes	are	 instead	 secreted	 from	 the	 cell	(Hasilik	 and	 Lemanskey,	 2004).	 This	 secreted	 enzyme	 will	 be	 re-captured	 by	 the	same	cell	or	nearby	cells	via	cell	surface	M6P	receptors	that	internalise	the	enzyme	and	 direct	 it	 back	 into	 the	 endocytic	 pathway	 and	 eventually	 to	 the	 lysosome	(Neufeld,	2004).	This	aspect	of	lysosomal	enzyme	cell	biology	has	profound	therapeutic	implications	as	 diseased	 cells	 can	 take	 up	 exogenous	 enzyme,	 which	 will	 be	 delivered	 to	 the	lysosome	to	degrade	storage	material	in	a	process	referred	to	cross-correction	(Platt	and	Lachmann,	2009).	Exogenously	supplied	enzyme	can	be	manufactured	outside	the	 body	 and	 transfused	 directly	 into	 the	 blood,	 or	 via	 gene	 therapy	 or	 stem	 cell	transplantation	 to	 supply	 the	 missing	 enzyme.	 With	 gene	 therapy	 and	 stem	 cell	transplantation,	 a	 small	 proportion	 of	 enzyme-producing	 cells	 can	 supply	 the	surrounding	cells	with	 the	missing	enzyme	via	 the	secretion-recapture	mechanism	(Figure	3)(Neufeld,	2004).			
	
Figure	 3	 Principle	 of	 cross	 correction.	 Only	 a	 small	 proportion	 of	 enzyme-producing	 cells	 are	 required	 to	 provide	 therapeutic	 benefit	 as	 enzyme	 will	 be	secreted	 by	 cells	 and	 recaptured	 by	 neighbouring	 cells	 via	 mannose-6-phosphate	receptors	that	target	it	to	the	lysosome.	Adapted	from	(Sands	and	Davidson,	2006).		
1.2.2 Stem	Cell	Therapy	The	ability	to	achieve	cross-correction	via	secretion-reuptake	of	lysosomal	enzymes	mean	 the	 LSDs	 are	 good	 candidates	 for	 stem	 cell	 therapy	 (Hoogerbrugge	 et	 al.,	1995).	 Haematopoietic	 progenitor/stem	 cells	 (HPCs)	 transplants	 have	 been	
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attempted	 in	 a	 number	 of	 LSDs	 (Boelens,	 2006).	 Although	 most	 LSDs	 do	 not	specifically	result	in	haematopoietic	defects,	HPC-mediated	gene	therapy	provides	a	source	 of	 enzyme	 directly	 into	 the	 circulation	 and	 the	HPCs	 can	 infiltrate	 various	tissues	 and	 repopulate	 the	 fixed	 tissue	macrophage	 system	 (Sands	 and	 Davidson,	2006,	van	Gelder	et	al.,	2012).	Allogeneic	 bone	marrow	 transplantation	 (BMT)	was	 the	 first	 attempt	 to	 use	 stem	cell	 therapy	to	treat	the	LSDs	and	it	provides	varying	degrees	of	CNS	and	systemic	improvement	 in	 children	 with	 different	 LSDs	 (Krivit	 et	 al.,	 1999,	 Walkley	 et	 al.,	1994).	One	might	not	expect	to	see	improvement	in	CNS	symptoms	as	the	secreted	enzyme	 would	 not	 cross	 the	 blood-brain	 barrier	 (BBB),	 however,	 these	improvements	may	be	due	to	the	fact	that	microglia	in	the	brain	(see	section	1.6.3)	are	 derived	 from	 the	 bone	 marrow.	 Following	 BMT	 the	 brain	 is	 gradually	repopulated	with	microglia	of	donor	origin,	which	secrete	functional	enzyme.	If	BMT	is	 performed	 early	 enough	 in	 children	 with	 MPS	 I,	 neurodegeneration	 can	 be	reduced	(Lucke	et	al.,	2007).		Despite	 modest	 improvements	 in	 neurological	 symptoms	 with	 BMT,	 a	 major	limitation	is	that	only	a	small	proportion	of	cells	of	bone	marrow	origin	will	migrate	and	differentiate	 into	microglia	(Platt	and	Lachmann,	2009),	 thus	the	CNS	remains	largely	untreated	 following	BMT.	However,	 transplanting	wild	 type	neuronal	 stem	cells	 (NSCs)	 directly	 in	 the	 CNS	 could	 be	 a	 potential	 solution	 to	 this	 problem,	providing	 that	 the	NSCs	 survive,	migrate	 and	 secrete	 the	missing	 enzyme.	 Several	mouse	 models	 of	 LSDs,	 including	 the	 MPS	 VII	 mouse	 (Snyder	 et	 al.,	 1996)	 and	Neimann	 Pick	 C	 (NPC)	mouse	 (Sidman	 et	 al.,	 2007),	 have	 been	 effectively	 treated	and	this	approach	has	now	been	extended	to	one	of	the	NCLs	(Tamaki	et	al.,	2009),	as	is	discussed	in	detail	in	Chapter	5	section	1.1.	In	order	to	maximise	the	probability	that	sufficient	enzyme	will	reach	the	CNS,	it	is	possible	 to	 genetically	modify	 the	NSCs	 to	 overexpress	 the	missing	 enzyme	 (Platt	and	 Lachmann,	 2009),	 therefore	 combining	 stem	 cell	 therapy	 with	 gene	 therapy	(discussed	next).		
1.2.3 Gene	therapy	Gene	therapy	is	based	on	the	concept	of	transferring	DNA	that	encodes	the	missing	functional	 enzyme	 to	 the	 patient’s	 cells	 in	 order	 to	 provide	 the	 missing	 enzyme	(Sands	and	Davidson,	2006).	It	is	an	attractive	means	to	deliver	a	deficient	lysosomal	enzyme	because	unlike	ERT,	 long-term	production	of	 the	protein	by	 the	host	 cells	
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may	 be	 possible	 to	 achieve:	 reducing	 the	 need	 for	multiple	 treatments	 (Platt	 and	Lachmann,	2009).	Because	the	LSDs	are	monogenetic	disorders	and	only	low	levels	of	enzyme	activity	are	required	to	provide	therapeutic	benefit,	LSDs	are	considered	very	 good	 candidates	 for	 gene	 therapy	 (van	 Gelder	 et	 al.,	 2012,	 Seregin	 and	Amalfitano,	2011).	Gene	 therapy	 treatments	can	be	applied	either	ex	vivo	or	 in	vivo	 (van	Gelder	et	al.,	2012).	Ex	vivo	gene	therapy	generally	implies	genetically	modifying	cells	in	vitro	and	then	transplanting	them	into	the	patient.	In	vivo	gene	therapy	refers	to	the	injection	of	 a	 gene	 transfer	 vector,	 encoding	 a	 non-mutated	 copy	 of	 the	 defective	 gene,	directly	 into	a	tissue	(intraparenchymal	 injection),	 into	the	CNS	ventricular	system	(intracerebral	injection)	or	into	the	blood	stream	(systemic	or	intravenous	injection)	(Gritti,	 2011).	 Not	 every	 cell	 would	 need	 to	 be	 successfully	 transfected	 because	cross-correction	 should	 allow	 transport	 of	 the	 enzyme	 throughout	 a	 tissue	 (Sands	and	Davidson,	2006,	Neufeld,	2004).	Despite	 encouraging	 results	 from	 using	 gene	 therapy	 to	 treat	 animal	 models	 in	several	LSDs,	where	widespread	gene	expression	and	effective	cross-correction	was	seen,	 viral	 mediated	 gene	 therapies	 have	 had	 limited	 success	 in	 patients	 so	 far	(Sands	and	Davidson,	2006,	Cardone,	2007,	Gritti,	 2011).	Around	20	gene	 therapy	clinical	 trials	 have	 been	 performed	 in	 patients	 with	 LSDs,	 but	 as	 yet	 none	 have	reached	 Phase	 III	 (Tomanin	 et	 al.,	 2012).	 The	 reasons	 behind	 this	 failure	 are	generally	attributed	to	the	much	larger	volume	of	the	human	brain	compared	to	the	mouse	 brain	 (Platt	 and	 Lachmann,	 2009).	 Larger	 animal	 models	 of	 LSDs	 are	necessary	 to	 provide	 a	 testing	 ground	 for	 strategies	 to	 deal	 with	 the	 problem	 of	scaling	up	the	delivery	of	gene	therapy.	In	addition,	there	are	certain	safety	concerns	with	 the	 use	 of	 viral-mediated	 gene	 therapy	 for	 patients	 such	 as	 the	 method	 of	delivery	 (intracranial	 injections)	 (Crystal,	 2004),	 the	 biosafety	 of	 the	 viral	 vectors	and	 the	 need	 for	 immunosuppression	 in	 already	 vulnerable	 children,	 in	 order	 to	avoid	immunological	rejection	of	the	correct	enzyme	that	they	do	not	possess	(Platt	and	Lachmann,	2009,	Schultz	et	al.,	2011,	Sands	and	Davidson,	2006).			In	order	 to	circumvent	 the	biosafety	 issues	associated	with	viral	vectors,	non-viral	vectors	are	also	being	developed	as	alternative	methods	of	gene	delivery,	including	the	encapsulation	of	DNA	in	polymers,	 liposomes	or	nanoparticles	(Tomanin	et	al.,	2012),	which	may	have	the	added	benefit	of	being	able	to	cross	the	BBB	(Zhang	et	al.,	2008).			
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1.2.4 Enzyme	replacement	Enzyme	Replacement	 Therapy	 (ERT)	 is	 the	most	 common	 treatment	 for	 the	 LSDs	and	 works	 by	 the	 principle	 of	 delivering	 recombinant	 enzyme	 generally	 by	intravenous	infusion	to	treat	the	somatic	manifestations	of	disease	(Neufeld,	2004).	To	 achieve	 this	 goal	 an	 in	 vitro	 system	 for	 making	 recombinant	 enzyme	must	 be	established,	and	this	protein	must	not	only	 fold	properly,	but	undergo	appropriate	post-translational	modifications	 to	be	 sure	 that	 it	 is	biologically	 active	 and	will	 be	trafficked	 appropriately	 around	 the	 cell	 (Pierret	 et	 al.,	 2008).	 Enzyme	 delivered	intravenously	would	not	be	able	to	cross	the	blood	brain	barrier	(BBB)	and	access	the	CNS	to	treat	neurological	symptoms,	but	non-neural	tissues	could	be	treated	in	this	way.	Furthermore,	enzyme	uptake	in	specific	organs	may	be	improved	by	direct	injection	 of	 the	 enzyme	 (van	 Gelder	 et	 al.,	 2012).	 For	 example,	 injection	 into	 the	cerebrospinal	fluid	(CSF)	should	improve	delivery	of	enzyme	to	the	brain	for	those	LSDs	with	CNS	pathology	(Hemsley	and	Hopwood,	2009).	ERT	is	currently	in	clinical	use	for	non-neuropathic	type	I	Gaucher	disease,	Fabry	disease,	MPS	I	and	II,	Pompe	disease	 and	 many	 others	 (reviewed	 in	 (Desnick	 and	 Schuchman,	 2012,	 Platt	 and	Lachmann,	2009,	Neufeld,	2004).		
1.2.5 Other	therapies	for	LSDs	Substrate	 reduction	 therapy	 (SRT)	 is	 a	 small	molecule	 therapy	 (Platt	 and	Butters,	2004),	in	which	the	goal	is	to	decrease	glycosphingolipid	(GSL)	synthesis	to	a	point	that	is	manageable	despite	the	impaired	degradative	capacity	of	the	cell	(Boustany,	2013,	Banecka-Majkutewicz	et	al.,	2012).	In	this	strategy,	a	drug	is	used	to	partially	inhibit	 the	 enzyme	 responsible	 for	 GSL	 synthesis	 and	 as	 a	 result	 fewer	 GSL	molecules	are	synthesized	and	will	enter	the	lysosome	for	degradation	(Urbanelli	et	al.,	2013,	Platt	and	Butters,	2004,	Platt	and	Jeyakumar,	2008,	Maegawa	et	al.,	2009).	This	 treatment	 is	 suitable	 for	 LSDs	 caused	 by	 glucosylceramide	 storage	 such	 as	Gaucher	type	I	and	II	diseases	and	NPC	(Cox	et	al.,	2003).	One	advantage	of	SRT	and	also	pharmocological	chaperones	(discussed	next)	is	that	they	cross	the	BBB	and	can	therefore	treat	neurological	symptoms	(Jeyakumar	et	al.,	2005).		Pharmalogical	 chaperones	 (PCs)	 are	 enzyme	 inhibitors	 that	 are	 provided	 at	suboptimal	 concentrations	 to	 stabilize	 the	 conformation	 of	 mutant	 proteins.	 PCs	bind	 mutant	 proteins	 in	 the	 endoplasmic	 reticulum	 (ER),	 promote	 their	 correct	folding	 and	 trafficking	 to	 the	 lysosome	 and	 hence	 raise	 residual	 enzyme	 activity	(Young-Gqamana	 et	 al.,	 2013,	 van	 Gelder	 et	 al.,	 2012).	 However	 PC-treatment	 is	
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currently	 limited	 to	 a	 small	 subset	 of	 LSD-causing	 mutations	 because	 a	 protein	needs	 to	be	produced	 in	order	 for	 it	 to	be	bound	and	stabilised	by	 the	PC	and	 the	vast	 majority	 of	 LSD-causing	 mutations	 result	 in	 no	 protein	 at	 all.	 In	 suitable	candidates	 dosing	 is	 critical	 to	 ensure	 catalytic	 function	 is	 promoted	 as	 much	 as	possible	(Khanna	et	al.,	2010).		Lastly,	 stop	 codon	 read-through	 therapy	 is	 an	 emerging	 field	 of	 technology	 that	could	potentially	be	used	to	treat	genetic	diseases	that	are	caused	by	mutations	that	result	in	premature	stop	codons,	and	consequently	produce	truncated	proteins	with	poor	or	no	function	(Mayer	et	al.,	2013).	Stop	codon	read-through	technology	uses	small	molecules,	capable	of	crossing	the	BBB,	which	instruct	the	cell	to	disregard	the	premature	stop	codon	and	to	generate	the	full-length,	functional	protein	(Brooks	et	al.,	2006,	Boustany,	2013).		In	 this	 section,	 I	 have	 introduced	 the	 lysosome	 and	 the	 LSDs,	 diseases	 that	 result	from	lysosomal	enzyme	and	other	endosomal/lysosomal	protein	mutations.	Table	2	summarises	the	currently	approved	therapies	and	those	that	are	in	clinical	trials	for	the	LSDs.		
Therapy	 Disease	 Status	 Product/ClinicalTrials.gov	
identifier	Enzyme	replacement	therapy	 Gaucher	disease*	 Approved	 Cerezyme	VPRIV	Eleyso		 Fabry*	 Approved	 Fabrazyme	Replagal		 MPS	I	 Approved	 Aldurazyme		 MPS	II	 Approved	 Elaprase		 MPS	VI	 Approved	 Naglazyme		 Pompe	 Approved	 Myozyme		 NPB	 Clinical	trials	 NCT02004704	 (acid	sphingomyelinase)	Substrate	reduction	therapy	 Type	 1	 Gaucher	disease*	 Approved		Ongoing	 clinical	trials	
Miglustat		NCT00358150	(eliglustat)		 NPC*	 Approved	 (not	 by	FDA)	 Miglustat	Chaperone	therapy	 Fabry*	 Ongoing	 clinical	trials	 NCT01458119	(migalastat)		 Pompe	 Ongoing	 clinical	trials		 NCT01380743	(duvoglustat)	Gene	therapy	 Tay-Sachs*	 Trials	 pending	and	recruiting	 NCT01869270	Bone	 marrow	transplantation	 Multiple	 In	clinical	practice	 N/A	Table	 2	 Approved	 therapies	 for	 lysosomal	 storage	 disorders	 and	 those	 that	 are	 in	 clinical	trials.	*indicates	sphingolipid	disorders.	NPC,	Niemann-Pick	Type	C;	NPB,	Niemann-Pick	Type	B;	MPS,	Mucopolysaccharides.	Modified	from	Platt	(2014).	
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	The	 different	 therapeutic	 options	 available	 for	 the	 LSDs	 depend	 very	 much	 on	whether	they	have	CNS	involvement,	as	many	therapies	cannot	cross	the	BBB.	The	Neuronal	 Ceroid	 Lipofuscinoses	 (NCLs)	 are	 a	 group	 of	 diseases	 within	 the	 LSD	family	with	profound	neuropathology	and	will	be	discussed	next.			
1.3 The	Neuronal	Ceroid	Lipofuscinoses	(NCLs)	
1.3.1 Clinical	presentation	and	classification	of	the	NCLs	The	 Neuronal	 Ceroid	 Lipofuscinoses	 are	 a	 group	 of	 severe	 autosomal	 recessive	inherited	neurodegenerative	disorders	(Schulz	et	al.,	2013,	Alroy	et	al.,	2011).	Each	of	 the	NCLs	 is	 rare	 individually,	 but	 together	 they	 are	 the	most	 common	 cause	 of	childhood	 dementia	 in	 the	 UK	 (Schulz	 et	 al.,	 2013,	 Verity	 et	 al.,	 2010).	 These	disorders	 are	 characterised	 by	 a	 progressive	 decline	 in	 motor	 skills	 and	 mental	capacity,	visual	loss	due	to	retinal	degeneration,	seizures	and	ultimately	premature	death,	 and	 are	 accompanied	 by	 accumulation	 of	 autofluorescent	 storage	 material	that	is	evident	in	post-mortem	samples	(Schulz	et	al.,	2013,	Alroy	et	al.,	2011)	The	NCLs	were	originally	categorized	by	the	onset	of	clinical	symptoms	into	infantile	(CLN1),	 late	 infantile	 (CLN2),	 juvenile	 (CLN3),	 adult	 (CLN4/Kufs	 disease)	 forms,	with	an	 increasing	number	of	variant	 late	 infantile	 (CLN5,	CLN6,	CLN7	and	CLN8),	and	 a	 congenital	 (CLN10)	 form	 subsequently	 identified	 (Haltia	 and	Goebel,	 2013).	More	 recently,	 a	 number	of	 additional	 forms	 (CLN11-CLN14)	have	been	 identified	(Smith	et	al.,	2012,	Bras	et	al.,	2012,	Smith	et	al.,	2013,	Staropoli	et	al.,	2012),	but	it	remains	 unclear	 whether	 these	 truly	 represent	 an	 NCL.	 These	 disorders	 present	very	 heterogeneously:	 there	 is	 often	 wide	 variation	 in	 the	 age	 of	 onset	 and	 the	symptoms	 and	 disease	 progression	 of	 individuals	 bearing	 a	mutation	 in	 a	 specific	gene	(Kousi	et	al.,	2011).	As	such,	a	new	nomenclature	has	been	proposed	in	which	both	 the	mutated	 gene	 and	 the	 age	of	 onset	 are	 taken	 into	 account	 (Williams	 and	Mole,	2012).	For	example	what	would	have	originally	been	referred	to	as	a	late	onset	case	of	infantile	NCL,	would	now	be	referred	to	as	CLN1	disease,	juvenile	(Williams	and	Mole,	 2012)(Kousi	 et	 al.,	 2011).	 To	 reflect	 the	 updated	 nomenclature,	 in	 this	thesis	I	shall	refer	to	classic	late	infantile	NCL	as	late	infantile	CLN2	disease.		To	 date,	 over	 360	mutations	 that	 cause	 NCL	 have	 been	 identified	 in	 14	 different	genes	(see	Table	2	and	www.ucl.ac.uk/ncl/mutation).	The	proteins	that	result	from	these	genes	may	be	soluble	(CLN1,	CLN2,	CLN10	and	CLN13)	or	transmembrane	in	nature	 (CLN3,	 CLN6,	 CLN7	 and	 CLN8)	 (Jalanko	 and	 Braulke,	 2009,	Warrier	 et	 al.,	
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2013,	Kmoch	et	al.,	2013).	Most	of	these	proteins	are	expressed	within	the	lysosome	or	elsewhere	within	the	endosomal-lysosmal	system	such	as	the	ER	(Siintola	et	al.,	2006a).	It	 is	perhaps	surprising	that	deficiencies	in	these	proteins,	which	are	quite	different	in	their	structure	and	often	their	location	in	the	cell,	results	in	neurological	diseases	that	have	similar	characteristics	(Warrier	et	al.,	2013).		In	almost	all	forms	of	NCL	children	are	initially	healthy	and	develop	normally	(Alroy	et	al.,	2011).	As	outlined	above,	the	age	at	which	onset	occurs	and	the	order	in	which	symptoms	 become	 apparent	 vary	 depending	 on	 the	 gene	 that	 is	mutated	 and	 the	specific	mutation	in	that	gene	(Schulz	et	al.,	2013).	I	will	now	describe	the	different	disease	courses	of	the	main	NCL	subtypes	and	then	describe	CLN2	disease	in	more	detail,	as	it	is	the	focus	of	this	thesis.			
Congenital	CLN10	disease	Congenital	 CLN10	 disease	 is	 associated	 with	 deficiency	 of	 the	 lysosomal	 enzyme	cathepsin	D	(Siintola	et	al.,	2006b).	It	is	the	only	form	of	NCL	in	which	the	patients	are	 severely	 affected	 from	birth	 (Schulz	 et	 al.,	 2013).	 Epileptic	 seizures	 can	 occur	while	the	child	in	still	intrauterine	or	soon	after	birth	(Siintola	et	al.,	2006b).	Due	to	the	quick	disease	progression,	death	occurs	in	early	infancy.		
	
CLN1	disease	CLN1	 disease	 is	 associated	 with	 deficiency	 of	 the	 lysosomal	 enzyme	 palmitoyl	protein	 thioesterase	 1	 (PPT1),	 which	 is	 encoded	 by	 the	 CLN1	 gene	 (Vesa	 et	 al.,	1995).	 Patients	 with	 mutations	 in	 the	 CLN1	 gene	 with	 infantile	 onset,	 develop	normally	until	around	6-18	months	of	age	(Autti	et	al.,	2011).	The	 initial	symptom	tends	 to	 be	 a	 withdrawal	 from	 social	 interaction,	 which	 is	 followed	 by	 a	 rapid	decline	 in	 psychomotor	 function	 accompanied	 by	 myoclonus,	 seizures	 and	 visual	failure,	and	ultimately,	patients	develop	spasticity	and	become	vegetative	(Schulz	et	al.,	2013,	Santavouri	et	al.,	1993).		Mutations	in	the	CLN1	gene	can	also	result	in	CLN1	disease	with	a	late	infantile	onset	that	 is	 characterised	 by	 visual	 and	 cognitive	 decline	 and	 subsequent	 ataxia	 and	myoclonus	(Bonsignore	et	al.,	2006).	In	juvenile	CLN1	disease,	symptoms	begin	at	5-10	 years	 (Kalvianen	 et	 al.,	 2007);	 again	 with	 cognitive	 decline	 as	 the	 earliest	recognisable	 symptom	 followed	by	motor	 decline,	 however	 there	 is	 an	 absence	 of	myoclonus	in	juvenile	CLN1	disease	and	visual	loss	occurs	late	in	this	version	of	the	disease	(Autti	et	al.,	2011,	Schulz	et	al.,	2013).	Mutations	in	CLN1	can	also	result	in	
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an	 adult	 form	 of	 NCL,	 with	 onset	 of	 symptoms	 occurring	 after	 18	 years	 of	 age	(Ramadan	et	al.,	2007).			




CLN5	disease	Mutations	in	the	CLN5	gene	typically	result	in	a	late	infantile	onset	and	cases	were	previously	referred	to	as	“Finnish	variant”	late	infantile	NCL	(Savukoski	et	al.,	1998,	Aberg	 et	 al.,	 2011b),	 despite	 the	 mutations	 occurring	 worldwide	 (Lebrun	 et	 al.,	2009).	The	age	at	which	symptoms	first	appear	is	more	variable	than	late	 infantile	CLN2	 disease	with	 cases	 reported	with	 the	 age	 of	 onset	 being	 between	 4	 and	 17	years	 of	 age,	 although	 the	 mean	 age	 of	 onset	 is	 5.6	 years	 (Schulz	 et	 al.,	 2013).	
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Clinically,	 patients	 experience	 psychomotor	 regression,	 ataxia,	 myoclonic	 epilepsy	and	visual	failure	(Alroy	et	al.,	2011).			
CLN6	disease	Mutations	 in	 the	CLN6	gene	result	 in	a	wide	variety	of	age	of	onset	and	symptoms	(Wheeler	 et	 al.,	 2002).	 Late	 infantile	 CLN6	 disease	 symptoms	 may	 first	 arise	between	18	months	and	8	years	(Alroy	et	al.,	2011).		An	early	feature	of	the	disease	is	 seizures	and	vision	 loss	occurs	 in	around	half	of	patients.	 	Death	usually	occurs	between	 5	 and	 12	 years	 of	 age	 (Schulz	 et	 al.,	 2013).	 Mutations	 in	 CLN6	 are	 also	associated	with	 the	Kufs	 type	A	variant	of	 adult	onset	NCL	 (Arsov	et	 al.,	 2011),	 in	which	symptoms	such	as	myoclonic	epilepsy,	dementia,	ataxia	and	dysarthria	arise	when	 patients	 are	 around	 30	 years	 old.	 Death	 usually	 occurs	 within	 10	 years	 of	diagnosis	(Schulz	et	al.,	2013,	Arsov	et	al.,	2011).			
CLN7	disease	Mutations	in	the	CLN7	gene	result	in	a	late	infantile	onset	(Siintola	et	al.,	2007)	and	similarly	 to	 CLN5	 disease	 cases	 were	 thought	 to	 regional,	 and	 were	 previously	referred	to	as	“Turkish	variant”	late	infantile	NCL	(Elleder	et	al.,	2011),	despite	the	mutations	 occurring	worldwide	 (Schulz	 et	 al.,	 2013).	 The	 age	 at	which	 symptoms	first	appear	is	variable	but	usually	within	2	and	7	years	of	age.	The	disease	typically	begins	with	the	development	of	seizures,	followed	by	motor	decline,	myoclonus	and	loss	of	vision	(Elleder	et	al.,	2011,	Schulz	et	al.,	2013).	
	













CLN1/PPT1	 (Vesa	et	al.,	1995)	 64	 p.Arg122Trp	p.Arg151X	 Infantile	Late	Infantile	Juvenile	Adult	
CLN2/TPP1	 (Sleat	et	al.,	1997)	 105	 C509-1G>C	pArg.208X	 Late	Infantile	Juvenile	Protracted	
	CLN3	 (Consortium,	1995)	 57	 1	kb	intragenic	deletion	in	Caucasian	populations	
Juvenile	Protracted	
CLN4/DNAJC5	 (Noskova	et	al.,	2011)	 2	 p.Leu116del	p.Leu115Arg	 Adult	autosomal	dominant	
CLN5	 (Savukoski	et	al.,	1998)	 36	 None	 Late	Infantile	Juvenile	Protracted	Adult	
CLN6	 (Wheeler	et	al.,	2002)	 68	 None	 Late	Infantile	Protracted		Adult	Kufs	Type	A	
CLN7/MSFD8	 (Siintola	et	al.,	2007)	 31	 None	 Late	Infantile	Juvenile	protracted	




CLN10/CTSD	 (Siintola	et	al.,	2006b)	 7	 Not	known	 Congenital	Late	Infantile	Juvenile	Adult	
CLN11/GRN	 (Smith	et	al.,	2012)	 1a	 N/A	 Adult	
Frontotemporal	lobar	
dementia	
CLN12/ATP13A2	 (Bras	et	al.,	2012)	 1b	 N/A	 Juvenile	
Kufor-Rakeb	
syndrome	
CLN13/CTSF	 (Smith	et	al.,	2013)	 5	 N/A	 Adult	Kufs	type	B	
CLN14/KCTD7	 (Staropoli	et	al.,	2012)	 1c	 N/A	 Infantile		Progressive	myoclonic	
epilepsy-3	
SSGH	 (Sleat	et	al.,	2009)	 2d	 N/A	 Adult	
Late	Infantile	MPSIII	
CLCN6	 (Poet	et	al.,	2006)	 2	 N/A	 Adult	(only	found	as	heterozygous	so	far)	
	 	
Table	 3	 Summary	 of	 the	 genes	 that	 cause	 NCL	 and	 the	 correlation	 between	 genotype	 and	
phenotype.	Bold	=	phenotype	 caused	by	 complete	 loss	of	 gene	 function.	 Italics	=	non-NCL	disease	phenotype	associated	with	this	gene.	Adapted	from	(Warrier	et	al.,	2013).	a	Only	causes	NCL	in	homozygous	mutations,	other	mutations	in	heterozygous	form	cause	Frontotemporal	lobar	dementia.	b	One	NCL-causing	mutation	in	this	gene	has	been	identified,	other	mutations	in	this	gene	cause	Kufor-Rakeb	syndrome.	c	One	NCL-causing	mutation	in	this	gene	has	been	identified,	other	mutations	in	this	gene	cause	Progressive	 myoclonic	 epilepsy-3.	 d	 Two	 NCL-causing	 mutations	 in	 this	 gene	 have	 been	 identified,	 other	mutations	in	this	gene	cause	Late	Infantile	MPSIII.			
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1.4 Late	Infantile	CLN2	disease	(Late	infantile	NCL)	As	 well	 as	 being	 clinically	 variable,	 the	 NCLs	 also	 show	 a	 great	 deal	 of	 genetic	heterogeneity	and	different	mutations	within	the	same	gene	cause	variable	disease	severity	and	onset	(Kousi	et	al.,	2011).	This	is	seen	in	the	CLN2	gene,	on	which	this	thesis	focuses.	Mutations	in	the	CLN2	gene	can	result	in	three	different	disease	phenotypes.	Classic	late	infantile	CLN2	disease	usually	presents	around	2-4	years	of	age,	when	the	child	starts	 to	 have	 seizures	 and	mental	 development	 slows	 down	 (Kohlschutter	 et	 al.,	1993,	 Palmer	 et	 al.,	 1992,	 Santavuori,	 1988).	 Unlike	 other	 NCLs	 in	 which	 visual	dysfunction	is	a	pronounced	early	symptom,	retinopathy	may	not	be	apparent	until	towards	 the	 end	 of	 life	 (Kohlschütter	 and	 Schulz,	 2009).	 Later	 in	 the	 disease	progression,	 epilepsy,	myoclonic	 jerks	and	 limb	spasticity	become	pronounced.	By	the	age	of	5	years,	children	are	usually	completely	dependent	and	affected	children	usually	have	truncal	hypotonia	and	will	have	lost	control	of	the	head	and	the	ability	to	 swallow	 (Steinfeld	 et	 al.,	 2002).	 	Mutations	 in	 CLN2	 can	 also	 result	 in	 juvenile	CLN2	disease,	which	has	an	onset	between	6-10	years	and	has	so	far	been	identified	in	8	 children	 (Sklower-Brooks;	 et	 al.,	 1999,	Bessa	 et	 al.,	 2008,	Elleder	 et	 al.,	 2008,	Kohan	et	al.,	2009).	The	third	main	reported	phenotype	in	the	literature	is	Infantile	CLN2	disease,	where	3	cases	have	been	seen	with	onset	below	1	year	(Simonati	et	al.,	2000,	Ju	et	al.,	2002).		Mutations	in	CLN5	(Peltonen	et	al.,	1998),	CLN6	(Cannelli	et	al.,	2009,	Wheeler	et	al.,	2002,	MacDonald	et	al.,	2002,	Lehesjoki	et	al.,	2007)	and	CLN7	 (Kousi	et	al.,	2009,	Lehesjoki	et	al.,	2007)	all	underlie	 the	previously	named	variant	 late	 infantile	NCL	disease.	Due	to	clinical	similarities	in	the	resultant	age	of	onset,	mutations	in	these	genes	 have	 previously	 been	 described	 as	 causing	 the	 same	 ‘variant	 late	 infantile’	disease	(Kousi	et	al.,	2011).	This	is	confusing	and	masks	the	heterogeneity	seen	from	the	 various	 mutations	 that	 occur	 in	 very	 different	 proteins.	 As	 such,	 the	 new	nomenclature	 is	very	welcome	 in	 setting	mutations	 in	 these	genes	apart	 from	 late	infantile	CLN2	disease	and	distinguishing	between	the	different	variant	forms	more	clearly.	Mutations	 in	CLN2	 all	 result	 in	 loss	 or	 reduced	 activity	 of	 tripeptidyl	 peptidase	 1	(TPP1)	 (Wisniewski	et	al.,	2001),	which	has	devastating	effects	upon	 the	CNS.	The	brain	of	these	patients	is	severely	atrophic	and	typically	has	a	weight	of	500-700g,	
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compared	to	the	expected	weight	of	at	least	1350g;	thinning	of	the	cortical	mantle,	the	corpus	callosum	and	enlargement	of	the	ventricles	is	also	seen	(Anderson	et	al.,	2013,	 Haltia	 and	 Goebel,	 2013),	 Elleder	 and	 Tyynela,	 1998).	 Structural	 damage	 is	very	obvious	in	the	cerebellum:	very	few	granule	cells	and	only	a	few	Purkinje	cells	survive	(Chang	et	al.,	2008).	All	the	other	brain	areas	suffer	extensive	neuronal	cell	loss	with	profound	astrocytosis	and	brain	macrophages	present	at	disease	end	stage	(Davidson	et	al.,	2007).	The	severe	neuronal	loss	seen	in	the	cortex	makes	it	appear	spongy	 (Anderson	 et	 al.,	 2013),	 Elleder	 and	 Tyynela,	 1998).	 However,	 the	mechanisms	 that	 lead	 to	 these	 profoundly	 neurodegenerative	 events	 remain	unclear.	
1.4.1 Tripeptidyl	Peptidase	1	(TPP1)	The	 CLN2	 gene	 encodes	 the	 protein	 Tripeptidyl	 Peptidase	 1	 (TPP1)	 (Sleat	 et	 al.,	1997).	 TPP1	 is	 mapped	 to	 chromosome	 11p15	 and	 has	 13	 exons	 and	 12	 introns	(Sharp	et	al.,	1997).	TPP1	produces	a	563-amino	acid	preproenzyme,	of	molecular	weight	66	kDa	with	a	19-amino	acid	signal	peptide	and	a	176-amino	acid	prodomain	and	autoprocesses	to	yield	a	368-amino	acid	mature	enzyme,	of	molecular	weight	46	kDa	(Golabek	et	al.,	2003,	Golabek	et	al.,	2005).	It	has	been	shown	that	TPP1	belongs	to	the	serine	carboxyl	peptidase	family	of	proteins	(Wlodawer	et	al.,	2003)	and	that	it	removes	tripeptides	from	the	unblocked	N-	terminus	of	small	polypeptides	with	a	molecular	weight	of	 less	than	5	kDa,	but	 its	wider	role	 is	unknown	(Golabek	et	al.,	2003),	 Guhaniyogi	 et	 al.,	 2008,	Warburton	 and	 Bernardini,	 2001).	 	TPP1	 is	 found	exclusively	 in	 the	 lysosome	 and	 thus	 has	 maximum	 activity	 levels	 at	 acidic	 pH	(Wlodawer	et	al.,	2003).	Many	 substrates	 for	 TPP1	 have	 been	 described	 in	vitro,	 including	 cholecystokinin,	neuromedin	 B,	 neuropeptide	 Y,	 angiotensins	 II	 and	 III,	 substance	 P	 and	 the	individual	 chains	 of	 insulin-A	 and	 –B	 (Vines	 and	 Warburton,	 1997,	 Junaid	 and	Pullarkat,	2000,	Bernardini	and	Warburton,	2001,	Warburton	and	Bernardini,	2001,	Kopan	 et	 al.,	 2004,	 Oyama,	 2005).	 TPP1	also	 initiates	 degradation	 of	 subunit	 c	 of	mitochondrial	 ATPase	 (SCMAS),	 which	 is	 a	 major	 component	 of	 the	 lysosomal	storage	material	 (Ezaki	 et	 al.,	 2000)	 that	 builds	 up	 in	 CLN2	disease	 patient’s	 cells	(storage	material	will	 be	 discussed	 in	 section	 1.6.1	 of	 this	 Chapter).	However,	 the	normal	 in	 vivo	 substrates	 of	 TPP1	 remain	 more	 obscure.	 TPP1	 is	 apparently	required	 for	 the	 partial	 or	 complete	 digestion	 of	 certain	 neuropeptides	 such	 as	neuromedin	B	(Kopan	et	al.,	2004	)	by	brain	lysosomes,	but	it	is	possible	that	TPP1’s	
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substrates	 are	 much	 more	 extensive.	 It	 remains	 unclear	 which	 specific	protein/proteins	 that	when	unmodified	by	TPP1	cause	such	profound	problems	 in	CLN2	disease,	and	this	is	an	important	area	of	research	that	will	need	to	be	resolved.	The	CLN2	gene	is	expressed	ubiquitously	throughout	the	body	and	northern	blotting	shows	the	highest	levels	are	seen	in	the	heart	and	placenta	(Sleat	et	al.,	1997).	In	a	more	extensive	study,	expression	profiling	showed	the	spleen	and	thymus	have	the	highest	 levels	 of	 the	 TPP1	mRNA	 transcript	 (Liu	 et	 al.,	 1998).	 Despite	 high	 TPP1	expression	 levels	 throughout	 the	body,	 the	 visceral	 organs	 appear	 to	 be	 relatively	unaffected	 in	 CLN2	 disease	 (Elleder	 and	 Tyynela,	 1998).	 It	 is	 surprising	 therefore	that	most	 of	 the	 problems	 seen	 from	 TPP1	deficiency	manifest	 themselves	 in	 the	CNS.	However,	 the	peripheral	 tissues	may	be	spared	because	they	express	another	peptidase,	di-peptidyl	peptidase	1,	(DPP1),	which	has	extensive	activity	on	peptides	and	 can	 compensate	 for	 the	 loss	 of	 TPP1	 (Bernadini	 and	 Warburton,	 2002	 ,	Warburton	and	Bernadini,	2002).		
1.5 Animal	models	of	the	NCLs	Despite	knowing	the	genetic	basis	for	the	NCLs,	we	do	not	know	how	mutations	in	proteins	with	seemingly	disparate	functions	cause	such	devastating	effects.	As	such	a	 series	 of	 animal	models	 have	 been	 developed	 to	 explore	 the	 underlying	 disease	mechanisms	 and	 to	 begin	 developing	 therapeutic	 strategies	 (Bond	 et	 al.,	 2013,	Cooper,	2010,	Shacka,	2012).			
1.5.1 Small	non-vertebrate	animal	models	
Yeast		Yeast	models	are	highly	amenable	to	genetic	manipulation	and	analysis,	have	short	generation	times	and	provide	a	valuable	model	for	the	basic	cell	biology	of	the	NCLs	(Bond	et	al.,	2013,	Khurana	and	Lindquist,	2010).	The	budding	yeast	Saccharomyces	
cerevisae	 (S.	 cervisae)	 has	 orthologues	 of	 CLN3	 and	 CLN10	 (Chattopadhyay	 et	 al.,	2000,	Marques	et	al.,	2006),	whilst	the	fission	yeast	Schizosaccharomyces	pombe	(Sz.	
Pombe)	has	orthologues	of	CLN1,	CLN3	and	CLN10	(Cho	and	Hofmann,	2004,	Codlin	et	 al.,	 2008a,	 Hughes	 et	 al.,	 1996).	 Yeast	 models	 are	 particularly	 well	 suited	 to	analysis	 of	 global	 changes	 in	 gene	 expression,	 and	 the	 Sz.	Pombe	model	 for	 CLN3	disease	has	been	used	extensively	in	this	way	to	investigate	the	metabolome	of	cells	deficient	 in	 btn1	 (the	 yeast	 orthologue	 of	 CLN3)	 (Haines	 et	 al.,	 2009).	 Sz.	 Pombe	
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deficient	 in	 btn1	 show	 alterations	 in	 vacuolar	 pH,	 morphology	 and	 cell	 polarity	(Codlin	 et	 al.,	 2008b,	 Gachet	 et	 al.,	 2005,	 Codlin	 et	 al.,	 2008a),	 among	many	 other	dysfunctional	 phenotypes.	 Similarly,	 S.	 cervisae	 yeast	 deficient	 in	 btn1	 also	 show	alterations	 in	 vacuolar	 and	 cellular	 pH	 and	 additionally	 reduced	 nitric	 oxide	production	and	amino	acid	trafficking	(Chattopadhyay	et	al.,	2000,	Wolfe	et	al.,	2011,	Pearce	 et	 al.,	 1999,	Kim	et	 al.,	 2003,	Osorio	 et	 al.,	 2007).	The	 conservation	of	NCL	genes	from	yeast	to	humans	proposes	a	fundamental	role	for	their	encoded	proteins	in	 eukaryotic	 cell	 biology	 and	 the	 use	 of	 unicellular	 organisms	 such	 as	 yeast	represents	 a	 powerful	 tool	 for	 investigating	 cellular	 consequences	 of	 loss	 of	 gene	function	in	the	NCLs	(Bond	et	al.,	2013).			
Fly	Similarly	to	yeast,	the	fruitfly	Drosophila	melanogaster	is	well	suited	to	investigating	the	 functional	 pathways	 that	 the	 NCL	 genes	 operate	 in,	 as	 they	 are	 genetically	amenable	and	have	a	short	generation	time	(Lu,	2009).	Drosophila	have	homologues	of	 the	 NCL	 genes	CLN10	 (cathepsin	D;	 cathD),	 CLN1	 (Ppt1),	 CLN3	 (Cln3)	and	CLN7	
(Cln7)	 (Bond	 et	 al.,	 2013).	 It	 is	 predicted	 that	 Drosophila	 proteins	 have	 similar	functions	to	that	of	their	human	counterparts	because	the	Drosophila	proteins	have	high	amino	acid	similarity;	and	the	fly	forms	are	found	in	the	same	cellular	locations	and	 display	 similar	 expression	 patterns	 as	 the	 human	 proteins	 (Tuxworth	 et	 al.,	2009,	 Bannan	 et	 al.,	 2008),	 although	 not	 all	 the	 human	 NCL	 genes	 have	 fly	homologues	(Bond	et	al.,	2013).	




Zebrafish	The	 zebrafish	 (Danio	 rerio)	 is	 a	 small	 freshwater	 tropical	 fish	 that	 has	 many	advantages	 for	 use	 as	 an	 experimental	 animal	model	 (Santoriello	 and	 Zon,	 2012).	Firstly	zebrafish	are	vertebrates	and	thus	much	closer	to	humans	than	invertebrate	models.	Secondly,	they	produce	large	numbers	of	offspring	(a	few	hundred	eggs	per	spawning)	 that	 are	 externally	 fertilised	meaning	 that	 they	 can	 be	manipulated	 as	whole	animals	 from	fertilisation	onwards	(Xi	et	al.,	2011,	Bond	et	al.,	2013).	These	offspring	 are	 also	 transparent	 during	 their	 development,	 allowing	 researchers	 to	view	the	internal	organs	and	specific	genetic	markers	to	be	visualized	in	live	animals	(Xi	et	al.,	2011).		Zebrafish	 genes	 can	 be	 silenced	 using	 approaches	 based	 on	 microinjection	 of	antisense	 morpholino	 oligonucleotides	 (MOs)	 into	 one-cell	 stage	 embryos	 (Eisen	and	 Smith,	 2008).	 Zebrafish	 are	 also	 amenable	 to	 many	 of	 the	 genomic	 editing	techniques	described	in	Chapter	6	section	2,	such	as	RNA	interference	(RNAi)	(Dong	et	 al.,	 2013	 ),	 zinc-finger	 nucleases	 (ZFNs)	 (Doyon	 et	 al.,	 2008),	 Tal-effector	nucleases	(TALENs)	(Schmid	and	Haass,	2013)	or	 	clustered,	regularly	 interspaced,	short	palindromic	repeats	(CRISPR)	(Hwang	et	al.,	2013)	systems	to	alter	or	ablate	gene	function.	Zebrafish	 share	 high	 genetic	 similarity	 to	 humans	 and	 it	 has	 been	 reported	 that	approximately	 70%	 of	 human	 genes	 have	 homologues	 in	 zebrafish	 (Langheinrich,	2003).	Unfortunately,	the	characteristics	of	disease	caused	by	orthologous	genes	are	sometimes	very	different	 in	 zebrafish	and	humans,	 and	 the	 zebrafish	genome	also	contains	duplications	of	some	genes,	which	complicates	the	 interpretation	of	some	findings	 (Postlethwait	 et	 al.,	 2004).	 This	 is	 seen	 in	 some	 of	 the	CLN	 genes	where	there	 are	 more	 than	 one	 potential	 orthologue,	 however	 there	 are	 single	 gene	orthologues	 for	CLN1,	CLN2,	CLN3,	CLN5,	CLN8,	CLN10,	CLN12,	CLN13,	CLCN6	 and	
SGSH	(Bond	et	al.,	2013).	The	consequences	of	knockdown	of	cln	genes	in	zebrafish	has	 so	 far	 had	 relatively	 limited	 exploration	 with	 the	 notable	 exception	 of	 cln2	(tpp1).	Zebrafish	homozygous	for	a	tpp1sa0011	mutation	have	a	reduced	lifespan	and	display	a	severe,	early	onset	neurodegenerative	phenotype,	with	small	retina	and	a	small	head	and	curved	body	(Mahmood	et	al.,	2013).		A	detailed	analysis	of	neuron	survival	and	glial	activation	is	yet	to	be	undertaken	in	these	mutant	fish,	but	will	be	valuable	 for	 comparison	 to	 data	 from	 dog	 and	 mouse	 models	 of	 CLN2	 disease.	
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Nevertheless,	 it	 is	clear	that	the	neurodegeneration	in	these	fish	results	 in	a	motor	impairment,	 which	 is	 preceded	 by	 hyperactivity	 consistent	 with	 seizures:	 two	phenotypes	 that	 could	 be	 used	 in	 high	 throughput	 studies	 to	 assay	 therapeutic	outcomes	(Mahmood	et	al.,	2013).	Modelling	the	NCLs	in	the	zebrafish	has	great	potential	for	mechanistic	studies,	and	for	testing	experimental	therapies.	However,	how	useful	each	NCL	zebrafish	model	will	 prove	 is	 dependent	 on	how	 closely	 each	one	 resembles	 the	human	disease	 in	terms	of	recapitulating	pathology.		
Mouse		Mouse	models	are	well	suited	for	exploring	the	pathogenesis	of	neurodegenerative	diseases.	The	use	of	NCL	mouse	models	has	significantly	advanced	our	knowledge	of	the	 molecular	 mechanisms	 underlying	 NCL,	 and	 is	 essential	 for	 evaluating	 the	feasibility	 and	 efficacy	 of	 therapeutic	 interventions	 (Shacka,	 2012,	 Cooper,	 2010,	Palmer	et	al.,	2013).			The	existing	NCL	mouse	models	result	either	from	naturally	occurring	spontaneous	mutants,	or	more	commonly	through	targeting	a	specific	gene	or	gene	locus	to	mimic	human	NCL-causing	mutations	(Bond	et	al.,	2013).	As	a	result,	several	mouse	models	are	available	 to	model	 the	major	NCLs	of	childhood	(Table	 3).	Mouse	models	also	exist	that	have	NCL-like	phenotypes	but	lack	human	correlates	(Shacka,	2012).	For	instance,	targeted	deletion	of	palmitoyl	protein	thioesterase	2	(Ppt2)	in	mice,	induces	accumulation	 of	 autofluorescent	 storage	 material	 accompanied	 by	 a	neurodegenerative	phenotype	(Gupta	et	al.,	2003).	Most	of	 the	NCL	mouse	models	are	 not	 genetically	 accurate,	 and	 are	 not	 direct	 copies	 of	 human	 NCL-causing	mutations,	 with	 some	 notable	 exceptions	 (marked	 with	 *	 in	Table	 3).	 The	 CLN2	disease	 mouse	 that	 is	 the	 focus	 of	 this	 thesis	 is	 described	 in	 detail	 in	 Chapter	 3	section	1.2.	 Collectively	 the	NCL	mouse	models	 reflect	 human	NCL	disease	 in	 that	they	 display	 behavioural	 and	motor	 deficits,	 brain	 atrophy	 presumably	 caused	 by	the	 extensive	 neuronal	 cell	 death	 seen	 in	 most	 NCL	 mouse	 models	 and	autofluorescent	storage	accumulation,	which	varies	according	to	the	disease-causing	mutation	 in	 the	 mouse	 (Bond	 et	 al.,	 2013).	 More	 will	 be	 discussed	 in	 terms	 of	pathological	 landmarks	of	 disease	 in	 this	Chapter	 in	 section	1.6.	However,	murine	models	do	not	 completely	 recapitulate	human	pathology	because	mice	have	a	 less	complex	 neuroanatomical	 organisation	 and	 a	 lissencephalic	 brain	 (Weber	 and	
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CLN10	disease	 *Ctsd-/-knockout	 Exon	4	neo	cassette	insertion	 No	enzyme	activity	 3	weeks	 (Saftig	et	al.,	1995)	CLN1	disease,	infantile	 Ppt1-/-	 Exon	9	neo	cassette	insertion	 No	enzyme	activity	 <	2	months	 (Gupta	et	al.,	2001)	




Cln5-/-	knockout	 Exon	3	neo	cassette	insertion	 Deleted	mRNA	 13	weeks	 (Kopra	et	al.,	2004)	CLN6	disease,	variant	late	infantile	
*Cln6nclf	spontaneous	 Single	base	pair	insertion	 Frameshift	after	Pro102	 <	8	months	 (Bronson	et	al.,	1998)	CLN8	disease,	variant	late	infantile	











1.5.3 Large	animal	models	There	 are	 a	 number	 of	 naturally	 occurring	 large	 animals	 that	 display	 NCL-like	pathology	 such	as	dogs,	 sheep	and	cattle	 (Palmer	et	al.,	 2011).	These	 large	animal	models	display	similar	phenotypes	to	their	human	NCL	counterparts	and	the	longer	lifespan	 of	 these	 large	 animal	 models	 allows	 long-term	 evaluation	 of	 disease	pathology	and	therapeutic	interventions	(Weber	and	Pearce,	2013).		
	
Canine	As	they	are	identified,	dogs	deficient	in	different	CLN	proteins	are	proving	valuable,	both	 as	 disease	 models	 and	 for	 testing	 therapeutic	 strategies	 in	 a	 larger	 brain	(compared	to	mice),	that	should	more	closely	recapitulate	human	disease	(Bond	et	al.,	 2013).	Although	many	canine	models	of	NCL	have	been	 idetified,	 experimental	colonies	 have	 so	 far	 only	 been	 established	 in	 Longhaired	 Dachshunds	 for	 CLN2	disease	(Katz	et	al.,	2008,	Awano	et	al.,	2006)	and	in	English	Setters	for	CLN8	disease	(Katz	 et	 al.,	 2005).	 The	 Longhaired	 Dachshund	 model	 of	 CLN2	 disease	 has	 been	particularly	 useful	 in	 evaluating	 different	 experimental	 therapeutic	 approaches,	such	as	intrathecal	and	intracerebral	delivery	of	TPP1	enzyme	to	the	brain	(Whiting	et	al.,	2014,	Vuillemenot	et	al.,	2011,	Vuillemenot	et	al.,	2014a).	To	date	the	extent	of	neuropathology	in	this	model	is	 limited	to	judging	the	efficacy	of	these	therapeutic	approaches	 and	 no	 systematic	 survey	 of	 its	 onset	 and	 progression	 has	 been	undertaken.	Nevertheless	the	great	value	of	such	canine	models	is	readily	apparent	and	 the	 creation	 of	 further	 colonies	with	mutations	 in	 different	NCL	 genes	would	provide	 an	 invaluable	 resource	 for	 the	 evaluation	 of	 experimental	 therapies	 for	additional	NCLs	(Bond	et	al.,	2013).		
Ovine	There	are	four	well	characterised	ovine	models	of	NCL,	the	most	influential	of	which	is	the	South	Hampshire	CLN6	model	(Jolly	et	al.,	1980),	but	there	is	also	a	genetically	distinct	Merino	CLN6	model	(Cook	et	al.,	2002),	a	Borderdale	CLN5	model	(Frugier	et	al.,	2008)	and	a	congenital	CLN10	Swedish	Landrace	model	(Tyynela	et	al.,	2000),	which	 is	 no	 longer	 available	 as	 a	 research	 colony.	 The	 ovine	models	 of	 NCL	 have	been	most	insightful	in	terms	of	elucidating	the	disease	mechanisms	of	the	NCLs	in	the	context	of	a	more	complex	brain	 (Bond	et	al.,	2013).	The	ovine	models	of	NCL	highlight	that	a	 larger	more	complex	brain	is	affected	more	severely	pathologically	than	 the	 corresponding	 mouse	 model	 (Oswald	 et	 al.,	 2005,	 Oswald	 et	 al.,	 2008,	
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Thelen	et	al.,	2012).	They	have	also	highlighted	that	SCMAS	is	the	major	component	of	storage	material,	and	neuroinflammation	was	found	to	play	an	important	role	in	NCL	pathogenesis,	opening	up	new	therapeutic	 targets	 for	 the	NCLs	(Palmer	et	al.,	2011,	Oswald	et	al.,	2005,	Oswald	et	al.,	2008,	Kay	et	al.,	2006).		I	 will	 now	 discuss	 progress	 made	 using	 the	 animal	 models	 outlined	 above,	 in	understanding	the	disease	mechanisms	that	contribute	to	NCL	pathogenesis.			
1.6 NCL	pathogenesis	Through	 the	 study	 of	 animal	models	 a	 number	 of	 common	phenotypes	 have	been	identified	 as	 typifying	 NCL	 pathogenesis.	 In	 this	 section	 I	 will	 explore	 several	 of	these	 features	 of	 NCL	 pathology	 including	 storage	 material	 accumulation,	neurodegeneration,	glial	activation	and	the	adaptive	immune	system	and	how	they	contribute	to	the	process	of	neuroinflammation.			
1.6.1 Storage	Material	A	 key-defining	 feature	 of	 all	 the	 NCLs	 is	 the	 intralysosomal	 accumulation	 of	autofluorescent	 storage	material,	 which	 was	 initially	 described	 as	 resembling	 the	lipopigments	 ceroid	 and	 lipofuscin,	 hence	 the	 name	 of	 this	 group	 of	 disorders	(Palmer	et	al.,	2013,	Jalanko	and	Braulke,	2009).	Ceroid	and	lipofuscin	are	insoluble	polymers	 that	 result	 from	 lipid	 peroxidation,	 which	 appear	 as	 yellow-brown	pigments	in	the	lysosomes	of	post-mitotic	cells	over	time	and	cannot	be	degraded	by	lysosomal	hydrolases	(Terman	and	Brunk,	2004).	 In	other	LSDs	the	analysis	of	the	stored	material	has	been	informative	in	identifying	the	enzyme	defect.	However,	in	the	 NCLs,	 the	 nature	 of	 the	 undegraded	 material	 does	 not	 appear	 to	 be	 directly	related	 to	 the	 defective	 protein,	 even	 in	 those	 NCLs	 caused	 by	 defects	 in	 soluble	enzymes	such	as	TPP1	and	PPT1	 (Xu	et	al.,	 2010,	Tyynela	et	 al.,	 1993,	 Junji	Ezaki,	2000).	This	suggests	that	although	storage	material	 in	classic	LSDs	appears	to	be	a	simple	cause	and	effect	phenomenon	(Boustany,	2013),	in	the	NCLs	the	nature	of	the	storage	 material	 may	 be	 a	 secondary	 response	 from	 processes	 such	 as	 altered	endosome/lysosome	trafficking	and	a	generalised	failure	in	the	lysosome’s	ability	to	degrade	 this	 material.	 	 Analysis	 of	 the	 storage	 bodies	 in	 the	 CLN6	 ovine	 model	revealed	 that	 the	 major	 component	 of	 the	 storage	 material	 was	 subunit	 C	 of	mitochondrial	ATP	synthase	(SCMAS),	and	the	rest	was	mainly	lipids	(Palmer	et	al.,	1986b,	Palmer	et	al.,	1986a,	Palmer	et	al.,	1989,	Palmer	et	al.,	1988).	SCMAS	has	also	been	confirmed	to	be	the	major	component	of	storage	material	in	CLN2,	CLN3,	CLN5,	
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CLN7	and	CLN8	diseases	(Palmer	et	al.,	1997,	Palmer	et	al.,	1992).	It	has	been	shown	that	the	structure	of	the	stored	SCMAS	is	identical	to	the	mature	functional	protein,	including	post-translational	modifications	such	as	trimethylation	of	lysine	43	(Chen	et	 al.,	 2004),	 so	 it	 does	 not	 appear	 to	 be	 a	 partial	 degradation	 product	 of	 a	proteolytic	 pathway.	 Interestingly,	 none	 of	 the	 other	 ATP	 synthase	 subunits	 are	stored	 in	 any	 form	 of	 NCL	 (Fearnley	 et	 al.,	 1990),	 indicating	 that	 the	 turnover	pathway	for	SCMAS	is	specifically	disrupted	in	the	NCL	diseases	where	it	is	stored.	In	CLN1,	 CLN4	 and	 CLN10	 diseases,	 additional	 proteins	 are	 also	 stored	 such	 as	sphingolipid	activator	proteins	 (SAPs)	A	and	D	(Nijssen	et	al.,	2003,	Tyynela	et	al.,	2004,	 Tyynela	 et	 al.,	 1993).	 Despite	 this	 variable	 biochemical	 composition	 of	 the	stored	material	between	forms	of	NCL,	 it	 is	nevertheless	apparent	that	 its	physical	properties	are	consistent	enough	to	typically	result	in	autofluorescence	that	can	be	triggered	 at	multiple	wavelengths.	 Indeed,	 so	 consistent	 is	 this	 feature	 that	 it	 has	long	been	considered	the	key	pathological	hallmark	of	these	disorders.	Until	recently,	it	was	considered	that	the	accumulated	storage	material	contributed	centrally	to	pathogenesis	and	is	in	some	way	related	to	the	loss	neurons	in	the	NCLs	(Palmer	 et	 al.,	 2013).	 Such	 ideas	 that	 stored	 material	 may	 be	 toxic	 in	 some	 way	persist	 from	other	LSDs,	but	current	opinion	 is	 that	 there	 is	no	direct	 relationship	between	 the	build	up	of	 storage	material	 and	neuron	 loss	 in	 the	NCLs.	 If	 the	 time	course	and	distribution	of	storage	accumulation	are	plotted,	they	do	not	correspond	with	 where	 and	 when	 neurons	 die	 (Oswald	 et	 al.,	 2005,	 Palmer	 et	 al.,	 2002).	Moreover,	clearing	large	amounts	of	storage	material	does	not	necessarily	improve	disease	outcome	(Griffey	et	al.,	2006),	and	the	pharmacological	induction	of	storage	material	 does	 not	 appear	 to	 directly	 kill	 neurons	 (Ivy,	 1992,	 Ivy	 et	 al.,	 1984).	However,	 as	 different	 cells	 in	 the	 body	 appear	 to	 be	 differentially	 sensitive	 to	mutations	in	CLN	genes,	as	is	seen	in	the	selective	loss	of	neuronal	populations	and	the	general	sparing	of	the	visceral	tissues,	 it	stands	to	reason	that	different	cells	in	the	body	could	also	be	differentially	sensitive	to	storage	material	accumulation.		
1.6.2 Neurodegeneration	Neurodegeneration	 is	 widespread	 at	 the	 end	 of	 disease	 progression,	 however	certain	 populations	 have	 proven	 to	 be	 more	 vulnerable	 in	 the	 earlier	 stages	 of	disease	 (Cooper	 et	 al.,	 2006,	 Cooper,	 2010,	 Palmer	 et	 al.,	 2013)	 and	 the	 extent	 of	neurodegeneration	appears	to	vary	between	animal	models	of	different	species.	For	example,	the	pronounced	atrophy	that	seen	in	ovine	NCL	disease	models	is	similar	to	
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that	seen	in	human	patients	(Oswald	et	al.,	2001,	Oswald	et	al.,	2005),	compared	to	more	 modest	 reductions	 in	 brain	 volume	 in	 mouse	 models	 (Chang	 et	 al.,	 2008,	Pontikis	et	al.,	2004,	Kuhl	et	al.,	2013,	Kuronen	et	al.,	2012,	Kielar	et	al.,	2007),	more	accurately	reflecting	the	more	severe	disease	phenotype	seen	in	a	larger	brain.	As	discussed	above,	it	appears	that	storage	material	accumulation	does	not	directly	relate	 to	 neuron	 loss.	 The	 majority	 of	 visceral	 and	 CNS	 cells	 in	 affected	 animal	models	accumulate	 storage	bodies,	but	 it	 appears	 that	only	 specific	populations	of	neurons	are	 lost.	 Indeed,	 even	within	 the	neuronal	 subsets	 that	 are	most	 affected,	there	 is	 no	 obvious	 correlation	 between	 neurodegeneration	 and	 storage	 body	accumulation,	 as	 seen	 in	 ovine	 CLN6	 models	 and	 mouse	 models	 (Cooper,	 2010,	Cooper	et	al.,	2006b).		Human	 and	 ovine	 NCLs	 show	 pronounced	 interneuron	 loss	 in	 the	 cortex	 and	hippocampus	 (Oswald	 et	 al.,	 2008,	 Tyynela	 et	 al.,	 2004),	 and	 these	 regional	interneuron	 populations	 are	 also	 selectively	 vulnerable	 in	 NCL	 mouse	 models,	though	perhaps	to	a	lesser	extent	(Bible	et	al.,	2004,	Cooper	et	al.,	1999,	Mitchison	et	al.,	1999,	Kielar	et	al.,	2007,	Lonka	et	al.,	2004,	Pontikis	et	al.,	2005,	Morgan	et	al.,	2013).	 Interneuron	 populations	 in	murine	NCL	models	 appear	 to	 be	 differentially	vulnerable,	 depending	 on	 their	 location	 and	 which	 calcium	 binding	 protein	 or	neuropeptide	 is	 expressed	 by	 each	 neuronal	 subset.	 Interneurons	 that	 express	calretinin	 are	 consistently	 more	 resistant	 to	 NCL	 disease	 pathology	 in	 mice	compared	 to	 their	 somatostatin	 and	 parvalbumin-expressing	 counterparts,	 a	phenotype	that	is	also	seen	in	sheep	(Bible	et	al.,	2004,	Cooper	et	al.,	1999,	Oswald	et	al.,	2001).	Cooper	 et	 al.,	 (2010)	 suggest	 that	 cellular	 location	 and	 connectivity	 may	 also	 be	important	 determinants	 of	 neuronal	 survival	 rather	 than	 just	 phenotypic	 identity.		Indeed,	 cortical	 neurodegeneration	 is	 the	 predominant	 feature	 in	 large	 animal	models	 of	 NCL	 and	 in	 human	 patients,	 in	 particular	 the	 superficial	 layers	 of	 the	occipital	and	somatosensory	cortices	(Palmer	et	al.,	2011,	Jolly	et	al.,	1989,	Mayhew	et	al.,	1985,	Oswald	et	al.,	2005,	Oswald	et	al.,	2008).	In	most	murine	models	cortical	regions	 are	 less	 affected	 and	 although	 the	 sensory	 thalamocortical	 pathways	 are	consistently	vulnerable	early	in	disease	progression	(Cooper,	2010),	the	thalamus	is	usually	affected	first	and	neuron	loss	is	only	subsequently	seen	in	the	corresponding	cortical	 region	 (Kielar	 et	 al.,	 2007,	 Kuronen	 et	 al.,	 2012,	 Partanen	 et	 al.,	 2008,	Weimer	 et	 al.,	 2006).	 The	 only	 current	 exception	 to	 this	 pattern	 of	 neuron	 loss	 is	seen	 in	Cln5	mutant	mice,	 in	which	 cortical	neuron	 loss	precedes	 thalamic	neuron	
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loss	 (von	 Schantz	 et	 al.,	 2009).	 Regardless	 of	 where	 neuron	 loss	 starts,	 it	 is	invariably	preceded	by	localised	glial	activation,	which	will	be	explored	next.	
1.6.3 Neuroinflammation	Neuroinflammation	is	indicated	in	a	number	of	lysosomal	storage	diseases	with	CNS	involvement	(Castaneda	et	al.,	2008),	and	this	certainly	extends	to	the	NCLs	(Archer	et	al.,	2014,	Palmer	et	al.,	2013).	Neuroinflammation	is	a	complex	process	where	the	innate	 immune	 response	 cells	 of	 the	 brain,	 the	 astrocytes	 and	 microglia,	 become	activated	 and	 recruit	 other	 (including	 adaptive)	 immune	 cells	 (Galea	 and	 Perry,	2007,	Skaper	et	al.,	2014).	The	 innate	 immune	system	in	the	brain	 is	comprised	of	dendritic	 cells,	 infiltrated	 macrophages,	 astrocytes	 and	 microglia	 (Delves	 et	 al.,	2011).	 In	 glial	 activation,	 astrocytes	 and	 microglia	 change	 their	 morphology	 and	behaviour	in	response	to	neuronal	damage	or	injury	(Czirr	and	Wyss-Coray,	2012).	Each	of	these	will	now	be	considered	in	relation	to	the	NCLs.		
Astrocytes	and	their	activation	Astrocytes	 can	 be	 divided	 into	 two	 main	 subtypes:	 protoplasmic	 or	 fibrous	(Sofroniew	 and	 Vinters,	 2010).	 Protoplasmic	 astrocytes	 are	 found	 throughout	 the	grey	 matter	 and	 their	 morphology	 is	 described	 as	 globoid,	 with	 several	 stem	branches	giving	 rise	 to	many	 finely	branching	processes	 (Ramon	and	Cajal,	1909).	Fibrous	 astrocytes	 meanwhile,	 are	 found	 throughout	 the	 white	 matter	 and	 they	possess	many	 long	 fibre-like	processes	 (Ramon	and	Cajal,	1909).	The	processes	of	protoplasmic	astrocytes	envelop	 synapses,	 and	 the	processes	of	 fibrous	astrocytes	contact	 nodes	 of	 Ranvier	 and	 both	 subtypes	 make	 extensive	 contacts	 with	 blood	vessels	and	form	gap	junctions	between	distal	processes	of	neighbouring	astrocytes	(Peters	 et	 al.,	 1991).	Astrocytes	 are	 responsible	 for	 an	 extensive	 array	of	 complex	and	essential	 function	 in	 the	healthy	CNS,	 such	as	 regulating	 local	CNS	blood	 flow	(Gordon	 et	 al.,	 2007),	 clearing	 glutamate,	 gamma-aminobutyric	 acid	 (GABA)	 and	glycine	 from	 the	 synaptic	 cleft	 and	 preventing	 their	 detrimental	 accumulation	(Sattler	and	Rothstein,	2006,	Seifert	et	al.,	2006),	 in	addition	to	regulating	synaptic	transmission	 (Perea	 et	 al.,	 2009)(for	 review	 of	 astrocytes	 in	 healthy	 and	 diseased	CNS	see	(Sofroniew	and	Vinters,	2010)).	Immunohistochemistry	 can	 be	 used	 to	 detect	 specific	 molecular	 markers,	 and	identify	 and	 characterise	 cells	 in	 healthy	 and	 diseased	 tissue.	 Glial	 fibrillary	 acid	protein	 expression	 (GFAP)	 is	 typically	 used	 to	 identify	 reactive	 astrocytes,	 and	 is	considered	 a	 sensitive	 and	 reliable	 marker	 that	 labels	 the	 majority	 of	 reactive	
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Microglia	and	their	activation	Resident	macrophages	are	found	in	all	tissues	of	the	body,	and	in	the	CNS,	microglia	are	 the	 most	 abundant	 resident	 macrophage	 population	 (Stoll	 and	 Jander,	 1999,	Perry	 and	Teeling,	 2013).	 CNS	microglia	 are	derived	 from	myeloid	precursor	 cells	and	enter	the	CNS	during	embryogenesis	(Gordon	and	Taylor,	2005,	Ransohoff	and	Perry,	2009).	Resting	microglia	possess	long	ramified	processes,	which	are	thought	to	support	their	immune	surveillance	functions	(Davalos	et	al.,	2005,	Nimmerjahn	et	al.,	 2005).	 Any	 insult	 to	 the	 brain	 such	 as	 injury	 or	 infection	 leads	 to	 microglial	activation,	which	results	in	a	change	of	its	morphology	and	the	upregulation	of	cell	surface	receptors	(Kreutzberg,	1996).		Microglial	 activation	 is	 characterised	 by	 two	 major	 alterations.	 Firstly	 the	 cell	morphology	 changes	 from	 being	 small	 highly	 branched	 and	 ramified	 cells	 to	 an	ameboid	 form	 (Perry	 and	 Teeling,	 2013).	 Secondly	 in	 the	 presence	 of	 neuronal	death,	 these	 ameboid	 cells	 transform	 into	phagocytic	 cells	 in	 order	 to	 remove	 cell	debris	 (Raivich	et	 al.,	 1999,	Kettenmann	et	 al.,	 2013).	During	activation,	many	 cell	surface	receptors	are	upregulated	by	microglia,	including	CD68,	which	is	a	member	of	the	lysosomal/endosomal-associated	membrane	glycoprotein	(LAMP)	family	and	a	scavenger	receptor	family	member	(Perego	et	al.,	2011).	CD68	recognizes	a	wide	range	 of	 molecules	 including	 apoptotic	 cells	 and	 cell	 surface	 antigens	 of	microorganisms,	 and	 has	 been	 implicated	 in	 phagocytosis	 (de	 Beer	 et	 al.,	 2003,	Ramprasad	et	al.,	1996).	Indeed,	CD68	is	the	marker	I	used	in	this	thesis	to	identify	activated	microglia.	Activated	microglia	recruit	macrophages	from	the	peripheral	tissues,	which	migrate	into	 the	brain	parenchyma	 (Perego	et	 al.,	 2011).	Together	 activated	microglia	 and	recruited	macrophages	can	promote	neurogenesis	and	 lesion	repair	(Capone	et	al.,	2007,	Lalancette-Hebert	et	al.,	2007,	Neumann	et	al.,	2006),	via	their	positive	actions	including	 glutamate	 uptake	 (Nakajima	 et	 al.,	 2008),	 cell	 debris	 removal	 (Stoll	 and	Jander,	1999)	and	release	of	neurotrophic	factors,	such	as	insulin-like	growth	factor-1	 (IGF-1),	 glial	 cell-line	 derived	 neurotrophic	 factor	 (GDNF)	 and	 brain-derived	neurotrophic	 factor	 (BDNF)	 (Thored	 et	 al.,	 2009,	 Lu	 et	 al.,	 2005,	 Bachelor	 et	 al.,	1999).	 In	 addition,	 following	 neuronal	 cell	 damage,	 stimulated	 microglia	 can	physically	 remove	 synapses,	 a	 process	 called	 synaptic	 stripping	 (Perry	 and	O'Connor,	 2010).	 Without	 additional	 damage	 to	 neurons,	 microglia	 decrease	 in	number	and	lose	their	activation	markers	(Kreutzfeld,	1996).		
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However,	 it	 has	 also	 been	 posited	 that	 activated	 microglia	 and	 recruited	macrophages	 can,	 in	 some	 situations,	 adversely	 affect	 neuronal	 function	 and	promote	 neurotoxicity	 as	 a	 positive	 feedback	 loop	 exists,	 in	 which	 microglia	activated	 by	 neurodegeneration	 secrete	 neurotoxic	 molecules,	 which	 promote	further	 neurodegeneration,	 thereby	 creating	 a	 self-perpetuating	 situation	(Friedlander,	2003).	Indeed,	microglia	possess	a	diverse	array	of	receptors	on	their	surfaces	that	can	respond	to	the	presence	of	so-called	damage-associated	molecular	pattern	molecules	 (DAMPs),	which	are	released	 from	 injured	or	degenerating	cells	(Bianchi,	 2007,	 Kono	 and	 Rock,	 2008).	 The	 receptors	 that	 detect	 DAMPs	 include	Toll-like	receptors,	scavenger	receptors	and	the	receptor	for	advanced	glycation	end	products	 (RAGE)	 (Haynes	 et	 al.,	 2006).	 Microglia	 respond	 to	 DAMPs	 by	 releasing	pro-inflammatory	 cytokines,	 such	 as	 interleukin-1β	 (IL-1β)	 and	 tumor	 necrosis	factor	 (TNF),	 which	 further	 promote	 neuronal	 degeneration	 (Allan	 and	 Rothwell,	2003,	Wang	et	al.,	2007).		
1.6.4 Glial	activation	in	the	NCLs	In	 all	NCL	models,	 localised	 glial	 activation	 is	 seen	 in	 the	 same	brain	 regions	 that	subsequently	 experience	 the	 most	 pronounced	 neuron	 loss	 (Cooper	 et	 al.,	 2006,	Oswald	et	al.,	2005,	Kay	et	al.,	2006).	It	is	not	yet	clear	whether	this	glial	activation	represents	a	neuroprotective	response,	or	whether	it	actually	contributes	to	neuron	loss	by	some	of	the	possible	mechanisms	outlined	above.	One	of	the	most	striking	examples	of	glial	activation	in	an	animal	model	of	NCL	is	the	CLN6	 ovine	 models,	 where	 immunohistochemical	 analysis	 revealed	 that	 glial	activation	 is	 apparent	 before	 storage	 material	 accumulation	 or	 neuron	 loss	 has	begun	 (Palmer	 et	 al.,	 2011,	 Oswald	 et	 al.,	 2005,	 Kay	 et	 al.,	 2006,	 Tammen	 et	 al.,	2006).	In	fact,	 in	the	CLN6	South	Hampshire	sheep	model,	astrocyte	activation	was	apparent	 in	 the	 grey	matter	 of	 these	 CLN6	 sheep	 20	 days	 before	 birth	 and	 in	 the	white	 matter	 20-40	 days	 before	 birth	 (Kay	 et	 al.,	 2006),	 with	 hypertrophy	 and	proliferation	of	perivascular	cells	evident	20	days	before	birth	in	the	white	matter,	and	activated	microglia	detected	 in	the	upper	cortical	grey	matter	at	12	days	after	birth	(Kay	et	al.,	2006).	These	data	suggest	that	glial	activation	occurs	much	earlier	in	pathogenesis	than	had	previously	been	suspected,	and	highlight	the	importance	of	determining	 whether	 this	 activation	 contributes	 positively	 or	 negative	 to	 disease	progression.	
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Glial	 activation	 is	 certainly	 seen	 in	 all	 mouse	 models	 of	 NCL	 that	 have	 been	characterised	 so	 far	 (Kielar	 et	 al.,	 2007,	 Pontikis	 et	 al.,	 2004,	 Pontikis	 et	 al.,	 2005,	Weimer	et	al.,	2009,	Kuronen	et	al.,	2012,	Macauley	et	al.,	2011,	von	Schantz	et	al.,	2009),	although	 the	nature	and	extent	of	 this	glial	activation	varies	between	 these	different	models.	PPT1-deficient	mice	exhibit	 localised	glial	activation	in	regions	in	which	neuron	loss	is	later	seen	that	becomes	more	widespread	throughout	the	brain	with	age	(Bible	et	al.,	2004,	Kielar	et	al.,	2007,	Zhang	et	al.,	2007).	PPT1-deficiency	in	these	mice	also	results	in	increased	S100β	and	RAGE	expression	(Saha	et	al.,	2008).	RAGE	 signalling	 leads	 to	 release	of	 pro-inflammatory	 cytokines	 such	 as	 Il-1	β,	 Il-6	and	TNF	by	glia	(Saha	et	al.,	2008,	Allan	and	Rothwell,	2003,	Wang	et	al.,	2007),	as	outlined	above.	Taken	together,	these	findings	suggest	that	glial	activation	could	be	exhibiting	 pro-inflammatory	 effects	 in	 brain	 regions	 where	 neurodegeneration	occurs	in	PPT1-deficient	mice.	
Cln3∆ex7/8	mice	also	exhibit	an	early,	but	in	this	case	more	modest	level	of	astrocyte	and	microglia	activation,	 although	 this	 response	appears	 to	be	attenuated	because	the	glia	do	not	appear	to	fully	change	their	morphology	upon	activation	(Pontikis	et	al.,	2004,	Pontikis	et	al.,	2005).	These	findings	raise	the	question	of	whether	the	glia	are	 dysfunctional	 in	 Cln3∆ex7/8	 mice	 or	 in	 other	 NCL	 animal	 models	 and	 indeed	humans,	and	whether	this	exacerbates	neurodegeneration	(Palmer	et	al.,	2013).	This	is	an	 idea	that	 is	explored	 in	more	detail	 later	 in	the	general	discussion	Chapter	8,	along	with	assessing	methods	to	reduce	neuroinflammation	in	animal	NCL	models.	Despite	the	weight	of	evidence	in	favour	of	this	sequence	of	events,	 it	appears	that	the	temporal	relationship	of	neuron	loss	being	preceded	by	glial	activation	does	not	hold	 true	 for	 all	 neuronal	 subpopulations.	 One	 example	 comes	 from	 South	Hampshire	 CLN6	 sheep	 in	 which	 over	 80%	 of	 gonadotrophin-releasing	 hormone	(GnRH)	positive	neurons	 in	 the	hypothalamus	are	 lost	despite	an	absence	of	overt	glial	activation	in	this	brain	region	(Kay	et	al.,	2011).			In	the	light	of	these	findings	it	is	now	not	entirely	clear	whether	glial	activation	can	always	be	considered	an	accurate	predictor	of	neuron	loss	in	all	forms	of	NCL,	or	for	all	 neuron	populations.	However	 there	 is	 strong	 evidence	 that	neuroinflammatory	processes	 have	 the	 potential	 to	 influence	 neurodegeneration,	 and	 that	 there	 are	mechanisms	by	which	glia	could	cause	damage	in	the	NCL	brain.			
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1.6.5 The	Adaptive	Immune	Response	in	the	NCLs	As	well	as	the	innate	immune	system	being	activated	in	the	CNS	of	NCL	models,	one	should	consider	that	other	components	of	the	immune	system,	such	as	the	adaptive	immune,	may	 also	 contribute	 to	neuroinflammation	 and	pathogenesis	 in	 the	NCLs	(Palmer	et	al.,	2013).	Lymphocytes	are	specialised	cells	from	the	peripheral	immune	system	 that	 can	 broadly	 be	 characterised	 into	 natural	 killer	 (NK)	 cells,	 which	function	 in	 cytotoxic	 innate	 immunity,	 and	 the	 T-	 and	 B-lymphocytes,	 which	 are	members	of	the	adaptive	immune	system	(Kersey	and	Gajl-Peczalska,	1975,	LeBien	and	Tedder,	2008).	T-lymphocytes	are	involved	in	cell-mediated	adaptive	immunity,	whilst	B-lymphocytes	are	responsible	 for	 the	production	of	antibodies	 (Abbus	and	Lichtman,	2011,	Delves	et	al.,	2011).		It	was	previously	 accepted	 that	 in	 the	healthy	CNS,	 the	BBB	prevents	 the	 entry	of	plasma	 components,	 including	 lymphocytes,	 into	 the	 brain	 (Goverman,	 2009).	However,	 it	 is	now	widely	accepted	 that	T-lymphocytes	are	present	 in	 the	healthy	CNS	(Kivisakk	et	al.,	2009).	Blood-borne	immune	cells,	including	dendritic	cells	and	T-lymphocytes,	 continuously	 monitor	 the	 CNS	 (reviewed	 in	 Ousmann	 and	 Kubes,	2012).	 During	 neuroinflammation	 and	 neurodegeneration,	 the	 BBB	 can	 become	compromised,	resulting	in	additional	lymphocytes	infiltrating	and	migrating	into	the	brain	 (Banks,	 2014).	 In	 the	 diseased	 brain,	 these	 immune	 cells	 are	 activated,	releasing	 pro-inflammatory	 mediators	 and	 creating	 a	 positive	 feedback	 loop,	 as	described	for	microglia,	in	which	additional	neuronal	damage	occurs	(Das	and	Basu,	2008).		Juvenile	 CLN3	 disease	 patients	 raise	 autoantibodies	 against	 glutamic	 acid	decarboxylase	(GAD65),	and	display	elevated	levels	of	brain-bound	immunoglobulin	G	(IgG),	a	phenotype	that	is	replicated	in	Cln3∆ex1-6	mice	(Chattopadhyay	et	al.,	2002a,	Chattopadhyay	 et	 al.,	 2002b).	 Size-selective	 breaches	 in	 the	BBB	 of	Cln3∆ex1-6	mice	have	been	observed,	allowing	the	passage	of	IgG	and	other	pro-inflammatory	serum	proteins	into	the	brain,	and	lymphocyte	infiltration	becomes	apparent	at	the	end	of	disease	progression	in	Cln3∆ex1-6	mice	and	CLN3	disease	patients	(Lim	et	al.,	2007).	The	 BBB	 is	 also	 disrupted	 in	 Ppt1-/-	 mice,	 mediated	 by	 CD4-positive	 T-helper	 17	(TH17)	lymphocytes,	which	stimulate	the	production	of	metalloproteinases	(MMPs)	to	disrupt	 the	 tight	 junctions	necessary	 for	maintaining	BBB	 integrity	 (Saha	 et	 al.,	2012).	 The	 disrupted	 BBB	may	 be	what	 allows	 the	 infiltration	 of	 CD8-positive	 T-lymphocytes	that	has	also	been	observed	in	Ppt1-/-	mice	(Groh	et	al.,	2013).	
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Because	the	BBB	appears	to	be	disrupted	in	at	least	two	models	of	NCL	(Saha	et	al.,	2012,	 Groh	 et	 al.,	 2013),	 and	 the	 adaptive	 immune	 system	has	 been	 implicated	 in	NCL	 disease	 progression,	 several	 research	 groups	 have	 investigated	 the	 effects	 of	genetic	 ablation	 of	 the	 adaptive	 immune	 response	 in	 NCL	 mouse	 models.	 The	neuropathology	of	Tpp1neoinsArg446His	mice	in	the	absence	of	the	adaptive	immune	response	are	documented	 in	Chapter	4	of	 this	 thesis	 and	 the	effects	on	other	NCL	models	are	explored	in	the	discussion	in	Chapter	4.		The	NCLs	broadly	share	common	themes	of	pathogenesis	 including	glial	activation	and	the	infiltration	of	adaptive	immune	cells	leading	to	neuroinflammation,	which	in	itself	has	been	shown	to	be	neurotoxic	(Viviani	et	al.,	2014).	Different	populations	of	neurons	 are	 varyingly	 affected	 by	 NCL	 disease,	 perhaps	 due	 to	 their	 intrinsic	vulnerability	to	the	lack	of	a	particular	CLN	protein,	or	they	are	more	susceptible	to	the	 damage	 caused	 by	 neuroinflammation,	 or	 possibly	 even	 the	 storage	 material	itself.	 Therapeutic	 strategies	 for	 the	 NCLs	 concentrate	 on	 delivering	 the	 missing	protein,	particularly	in	the	case	of	the	soluble	enzyme	forms.	However	based	on	the	pathological	mechanisms	just	described,	such	therapies	should	also	begin	to	target	dysfunctional	 glia,	 neuroinflammation,	 the	 adaptive	 immune	 system	 via	 immune	suppression,	and	be	targeted	to	the	specific	populations	of	neurons	affected	by	the	disease.			
1.7 Therapeutic	strategies	for	the	NCLs	Currently,	there	is	no	cure	or	successful	treatment	for	any	form	of	NCL	(Wong	et	al.,	2010).	Palliative	care	to	improve	the	quality	of	life	of	patients	is	very	important	and	this	 can	 be	 tailored	 to	 the	 symptoms	 of	 the	 form	of	NCL	 that	 has	 been	 diagnosed	(Kohlschütter	and	Schulz,	2009).	A	number	of	therapeutic	approaches	that	are	used	to	treat	LSDs	are	also	suitable	to	treat	the	soluble	enzyme	forms	of	the	NCLs	as	the	principle	of	 cross-correction	outlined	 in	 this	Chapter	 in	 section	1.2.1,	 is	 applicable	for	 these	diseases	 too	(Wong	et	al.,	2010,	Kohan	et	al.,	2011).	However,	one	of	 the	greatest	 challenges	 for	 the	NCLs	 remains	 to	design	 treatments	 that	 are	 capable	 of	crossing	the	BBB,	or	alternatively	their	delivery	directly	into	the	CNS.	Treatment	of	the	 soluble	 enzyme	 forms	 of	 NCL	 therefore	 concentrate	 on	 delivering	 therapeutic	levels	 of	 the	missing	 enzyme	 via	 ERT,	 gene	 therapy	 or	 stem	 cell	 therapy,	 into	 the	brain	 to	 restore	 CNS	 functionality	 (Wong	 et	 al.,	 2010).	 Treatments	 for	 the	 NCLs	caused	by	mutations	in	transmembrane	proteins	are	much	more	challenging	as	the	
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defect	needs	 to	be	addressed	 in	many	more	cells,	but	 several	novel	 therapies	may	have	some	promise	for	these	diseases	too.				
1.7.1 Enzyme	Replacement	Therapy	As	 in	 other	 LSDs	 (section	 1.2.4),	 via	 the	 principle	 of	 cross-correction	 (Sands	 and	Davidson,	2006),	exogenous	administration	of	enzyme	to	the	soluble	enzyme	forms	of	NCL	should	have	a	therapeutic	effect	(Wong	et	al.,	2010,	Hawkins-Salsbury	et	al.,	2013).	 Delivery	 of	 exogenous	 enzyme	 to	 the	 brain	 remains	 a	 problem,	 with	intravenously	 (IV)	 injected	 enzymes	 unable	 to	 cross	 the	 BBB	 and	 intracranial	injections	 being	 invasive,	 and	 the	 possibility	 of	 the	 body	 raising	 antibodies	 to	 the	foreign	enzyme	to	be	considered	(Harmatz	et	al.,	2004,	Linthorst	et	al.,	2004).	Nevertheless,	 intravenous	 delivery	 of	 PPT1	 into	 Ppt1-/-	 mice	 does	 result	 in	 a	significant	 reduction	 in	 visceral	 storage,	 but	 this	 systemically	delivered	PPT1	only	reached	the	CNS	if	it	was	delivered	neonatally	before	the	BBB	is	fully	formed.	Such	treatments	 provided	 positive	 effects	 on	 lifespan	 and	motor	 performance,	whereas	treatment	 delayed	 until	 8	 weeks	 of	 age	 when	 the	 BBB	 had	 fully	 formed,	 did	 not	produce	such	improvements	(Hu	et	al.,	2012).	Several	 routes	have	been	employed	 to	administer	ERT	 in	 the	mouse	model	of	 late	infantile	 CLN2	 disease.	 In	 2008,	 Chang	 et	 al.	 delivered	 recombinant	 human	 TPP1	(rhTPP1)	 into	 the	 lateral	 ventricle	 and	 through	 the	 cerebrospinal	 fluid	 (CSF)	 to	
Tpp1-/-	mice,	 leading	 to	 the	distribution	and	activity	of	 rhTPP1	 throughout	 several	regions	of	the	brain	of	treated	mice.	Significantly,	ERT-treated	mice	showed	reduced	neuropathology	and	decreased	tremor	compared	to	vehicle-treated	mice	(Chang	et	al.,	2008).		This	method	of	ERT	via	the	CSF	has	been	scaled	up	and	used	to	treat	large	animal	 models	 of	 CLN2	 disease.	 The	 TPP1-/-	 Dachshund	 model	 was	 treated	 via	infusion	into	the	CSF	every	other	week,	and	the	efficacy	of	this	treatment	assessed	upon	 both	 neuropathological	 and	 neurological	 function,	 in	 addition	 to	 tests	 of	cognitive	 performance	 (Katz	 et	 al.,	 2014,	 Vuillemenot	 et	 al.,	 2014a).	 The	 only	neuropathological	 information	 available	 from	 this	 dog	model	 is	 limited	 to	 disease	end	stage,	but	TPP1	administration	resulted	in	reduced	levels	of	storage	burden	and	the	 associated	 neuronal	 hypertrophy,	 less	 astrocytosis,	 although	 no	 impact	 upon	microglial	activation	and	neuron	survival	were	apparent	(Vuillemenot	et	al.,	2014a).		Perhaps	 more	 importantly,	 enzyme	 replacement	 produced	 long	 lasting	improvements	 in	 tests	 of	 neurological	 function	 and	 cognitive	 performance	 and	 a	prolonged	lifespan	(Katz	et	al.,	2014).	
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	Together	with	the	finding	that	direct	infusion	of	rhTPP1	into	the	CNS	of	cynomolgus	monkeys	 is	well	 tolerated	with	no	drug	 related	 safety	 findings	 (Vuillemenot	 et	 al.,	2014b),	these	pre-clinical	studies	in	CLN2	disease	dogs	prompted	a	Phase	I	clinical	trial	evaluating	the	safety	of	administering	rhTPP1	into	the	CNS	of	children	with	late	infantile	 CLN2	 that	 has	 recently	 been	 initiated	(http://www.clinicaltrials.gov/ct2/show/NCT01907087).		In	order	 to	 enhance	delivery	of	TPP1	 to	 the	brain	during	 IV	 injection,	 rhTPP1	has	been	 co-administered	with	 a	 36-residue	 peptide	 that	 consists	 of	 polylysine	 and	 a	low-density	 lipoprotein	 receptor	 binding	 sequence	 from	 apolipoprotein	 E,	 called	K16ApoE,	 which	 mediates	 rhTPP1	 delivery	 to	 the	 brain	 (Meng	 et	 al.,	 2014).	Compared	to	systemically	delivered	rhTPP1,	this	method	enhanced	enzyme	delivery	to	the	brains	of	Tpp1-deficient	mice	and	resulted	in	more	pronounced	reductions	in	storage	material,	 increased	 lifespan	and	 improved	neurological	 functions	 (Meng	et	al.,	 2014).	 Future	 ERT	 trials	 may	 include	 K16ApoE	 to	 enhance	 enzyme	 delivery,	nevertheless,	an	issue	that	remains	to	be	solved	for	ERT	is	that	lysosomal	enzymes	like	 TPP1	 have	 a	 relatively	 short	 half-life	 and	 will	 need	 to	 be	 administered	frequently,	which	may	make	them	prohibitively	expensive.		
 
1.7.2 Gene	Therapy	Initial	 gene	 therapy	 experiments	 for	 the	 NCLs	 were	 carried	 out	 in	 Ppt1-/-	mice	(Griffey	et	al.,	2004).	AAV2	(adeno-associated	virus	serotype	2)	expressing	rhPPT1	were	 intercranially	 injected	 into	 PPT1-deficient	 mice,	 resulting	 in	 reduced	autofluorescent	 storage	 material	 and	 brain	 pathology,	 however	 no	 significant	improvements	 in	 lifespan	were	seen	(Griffey	et	al.,	2006).	 Improvements	 in	vector	design	led	to	more	efficient	delivery	of	rhPPT1	via	the	AAV2/5	vector	into	the	brains	of	 Ppt1-/-	mice	 and	 significantly	 reduced	 neuroinflammation	 and	 neuropathology	(Macauley	 et	 al.,	 2012,	 Roberts	 et	 al.,	 2012).	 Additionally,	 Macauley	 et	 al.,	 (2012)	found	a	synergistic	effect	of	CNS-directed	gene	therapy	and	BMT,	where	the	addition	of	BMT	further	increased	the	lifespan	of	the	AAV2/5-rhPPT1	treated	mice,	although	this	is	yet	to	be	replicated.	On	 the	 basis	 of	 promising	 safety	 data	 obtained	 from	 healthy	 rats	 and	 non-human	primates	 injected	 with	 AAV2	 vectors	 expressing	 CLN2	 showing	 that	 TPP1	 was	produced	 and	 not	 adversely	 received	 (Sondhi	 et	 al.,	 2005,	 Hackett	 et	 al.,	 2005),	 a	
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Phase	 I	 clinical	 trial	of	AAV2CUhCLN2	was	approved.	This	produced	a	variable	and	only	very	modest	attenuation	of	disease	 in	children	with	CLN2	disease	(Worgall	et	al.,	 2008)(http://www.clinicaltrials.gov/ct/show/NCT00151216).	 This	 may	 be	explained	 by	 data	 from	 TPP1-deficient	mice	 intercranially	 injected	with	 the	 same	AAV2CUhCLN2	vector	that	showed	that	the	vector	did	not	spread	well	throughout	the	brains	of	diseased	mice	(Passini	et	al.,	2006).	Vectors	with	higher	 transduction	 efficiencies	 such	 as	AAVrh.10	have	 subsequently	been	used	to	more	effectively	treat	TPP1-deficient	mice	(Sondhi	et	al.,	2007).	These	AAVrh.10CUhCLN2-treated	 Tpp1-/-	 mice	 showed	 behavioural	 improvements	including	improved	gait	and	nest-making	abilities,	increased	balance	beam	abilities	and	grip	strength,	as	well	as	increased	lifespan	(Sondhi	et	al.,	2007).	On	the	basis	of	this	 data	 and	 the	 earlier	 clinical	 trial,	 an	 additional	 trial	 was	 approved	 treating	children	 with	 CLN2	 disease	 using	 the	 AAV10	 CUhCLN2	 vector	http://www.clinicaltrials.gov/ct2/show/NCT01161576.	Initial	 results	 from	CLN2	Dachshunds	 treated	with	 intraventricular	 administration	of	 AAV4CUhCLN2	 suggest	 that	 ependymal	 transduction	 with	 this	 vector	 results	 in	secretion	of	the	enzyme	into	the	lateral	ventricle	and	it’s	subsequent	spread	in	the	CLN2	dog	brain	to	reduce	neurological	signs	of	disease,	and	an	apparent	reduction	in	glial	activation	(Tecedor	et	al.,	2014	NCL	Conference).	As	yet	 these	promising	data	are	preliminary,	and	it	will	be	important	to	undertake	a	more	detailed	quantitative	analysis	of	the	impact	upon	neuropathology.	However,	it	appears	that	transduction	of	 the	eppendyma	offers	an	alternative	 to	 trying	 to	 target	widespread	areas	of	 the	brain	 parenchyma,	 instead	 relying	 on	 the	 distribution	 of	 secreted	 enzyme	 via	 the	CSF.	 It	 will	 be	 interesting	 to	 see	 the	 results	 of	 further	 pre-clinical	 tests	 of	 gene	therapy	in	CLN2	dogs,	perhaps	using	the	more	efficient	AAVrh.10CUhCLN2	vector.		Gene	therapy	for	the	non	soluble	enzyme	forms	of	NCL	would	require	a	much	higher	level	of	transduction	efficiency	in	order	to	treat	and	genetically	correct	as	many	cells	as	possible.	At	the	same	time,	over-expression	of	the	transmembrane	protein	CLN3	has	 been	 shown	 to	 result	 in	 pronounced	 toxicity	 (Tuxworth	 et	 al.,	 2009).	Nevertheless	this	gene	therapy	strategy	has	been	attempted,	and	treating	Cln3∆ex7/8	mice	 with	 AAVrh.10	 expressing	 human	 CLN3	 resulted	 in	 reduced	 autofluorescent	storage	material	and	modest	reductions	 in	neuroinflammation,	with	 little	evidence	for	neurotoxic	and	 inflammatory	responses	associated	with	 the	procedure	(Sondhi	et	al.,	2014),	but	no	significant	neuroprotective	effects.	Despite	the	promising	results	seen	 from	pre-clinical	 gene	 therapy	 experiments	 in	 the	NCLs	 (Sondhi	 et	 al.,	 2005,	
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Sondhi	et	al.,	2007,	Passini	et	al.,	2006,	Sondhi	et	al.,	2014),	the	potential	side	effects	of	 over	 expressing	 missing	 enzymes	 or	 transmembrane	 proteins	 must	 not	 be	excluded	and	should	be	further	investigated	(Sands	and	Davidson,	2006).	
	
1.7.3 Other	therapies	
Stem	Cell	therapy	As	 outlined	 in	 section	 1.2.2	 of	 this	 Chapter,	 stem	 cell	 therapy	 is	 designed	 to	 be	 a	long-lived	source	of	 the	missing	enzyme.	As	a	main	component	of	 this	 thesis,	stem	cell	therapy	for	the	NCLs	is	described	in	detail	in	Chapter	5	section	1.1	and	the	fate	and	migration	of	transplanted	human	neural	stem	cells	in	Tpp1neoinsArg446His	mice	is	evaluated.	
	
Immune	suppression	The	 involvement	 of	 the	 innate	 and	 adaptive	 immune	 systems	 in	 the	 NCLs	 is	increasingly	becoming	more	apparent	(Chattopadhyay	et	al.,	2002a,	Lim	et	al.,	2007,	Seehafer	 et	 al.,	 2011,	 Groh	 et	 al.,	 2013)	 and	 immunomodulatory	 therapies	 for	 the	NCLs	are	discussed	in	Chapter	4	and	in	the	main	discussion	in	Chapter	8.		
Chaperones	and	Stop	Codon	read	through	Competitive	inhibitors	of	lysosomal	hydrolases	have	been	used	successfully	in	some	cases	 to	 treat	 LSDs	 that	 result	 from	 mis-folded	 proteins	 or	 mis-sense	 mutations.	(Young-Gqamana	 et	 al.,	 2013,	 van	 Gelder	 et	 al.,	 2012,	 Khanna	 et	 al.,	 2010).	 This	approach	has	now	been	 trialled	 for	 infantile	CLN1	disease	 (Dawson	et	 al.,	 2010a).	Competitive	 inhibitors	 of	 PPT1	were	 synthesized,	 two	 of	which	were	 taken	 up	 by	lymphoblasts	 from	 CLN1	 disease	 patients,	 each	 inhibitor	 was	 specific	 to	 a	 single	disease-causing	 mutation,	 and	 increased	 PPT1	 activity	 (Dawson	 et	 al.,	 2010a).	However	 it	 remains	 to	 be	 seen	whether	 this	 approach	would	work	 in	vivo	and	 as	outlined	 in	 section	 1.2.5,	 very	 few	 mutations	 are	 suitable	 candidates	 for	 this	approach.		Stop	codon	read-through	therapy	for	infantile	CLN1	disease	has	also	been	proposed	(Sarkar	et	al.,	2011).	Nonsense	mutations	in	CLN1	account	for	31%	of	CLN1	disease	patients	 in	 the	 U.S.A	 (Das	 et	 al.,	 1998).	 PTC124	 is	 a	 compound	 that	 facilitates	ribosomal	 read-through	 of	 premature	 termination	 codons,	 allowing	 a	 full-length	protein	 to	 be	 produced	 (Welch	 et	 al.,	 2007).	 PCT124-treatment	 of	 fibroblasts	 and	lymphoblasts	 cultured	 from	 CLN1	 disease	 patients	 showed	 modest	 increases	 in	PPT1	activity	in	a	dose-dependent	manner	(Sarkar	et	al.,	2011).	The	mdx	mouse,	is	
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an	animal	model	for	Duchenne	muscular	dystrophy,	and	harbours	a	premature	stop	codon	 in	 the	dystrophin	protein	(Sicinski	et	al.,	1989).	PCT124	has	been	shown	to	induce	the	full-length	functional	dystrophin	in	the	mdx	mouse	(Finkel,	2010),	and	is	currently	 in	 phase	 III	 clinical	 trials	 in	 Duchenne	 muscular	 dystrophy	 patients	(clinicaltrials.gov	 identifierNCT00803205).	 These	 findings	 show	 the	 potential	 for	this	 stop	 codon	 read-through	 small	molecule	 in	 the	 treatment	 of	 human	 patients,	although	this	will	take	much	longer	to	realise	in	the	NCLs	due	to	the	heterogeneity	of	disease-causing	mutations.	Additional	therapies	exist	for	the	NCLs	such	as	targeting	dysfunctional	 glia,	 which	 shall	 be	 discussed	 in	 the	 main	 discussion	 in	 Chapter	 8	section	5.	Taken	together,	these	examples	highlight	the	progress	and	difficulties	in	treating	the	NCLs	 and	 further	 pre-clinical	 work	 is	 required	 to	 clearly	 define	 the	 pathological	landmarks	 in	 certain	 NCL	 mouse	 models,	 such	 as	 the	 Tpp1neoinsArg446His	mice	described	 in	 this	 thesis,	 in	 order	 to	 judge	 if	 therapeutic	 interventions	 ameliorate	disease	progression.	I	shall	now	outline	the	aims	of	this	thesis.		
1.8 Aims	of	this	Thesis	The	 initial	 aim	 of	 this	 thesis	 was	 to	 characterise	 the	 disease	 progression	 of	
Tpp1neoinsArg446His	 (Tpp1-/-)	mice.	 In	 particular,	 the	 aim	 was	 to	 determine	 the	relative	 timing	 of	 events	 such	 as	 glial	 activation,	 neurodegeneration	 and	 storage	material	accumulation.	The	hypothesis	is	that	histological	analysis	of	these	mice	will	reveal	pronounced	neurodegeneration,	which	is	preceded	by	glial	activation	in	those	areas	 most	 affected	 as	 is	 seen	 in	 other	 NCL	 animal	 models,	 and	 that	 the	 disease	phenotype	 will	 reflect	 the	 severely	 shortened	 lifespan	 compared	 with	 other	 NCL	mouse	models.		In	 addition,	 I	wanted	 to	 determine	 the	 effects	 of	 the	 adaptive	 immune	 system	on	CLN2	disease	progression	by	analyzing	the	same	disease	landmarks	in	these	TPP1-deficient	mice	 backcrossed	 onto	NODSCID	mice	 that	 lack	 adaptive	 immunity.	 This	analysis	 was	 performed	 in	 order	 to	 characterise	 TPP1-deficient	mice	 without	 the	adaptive	immune	system,	which	could	later	be	used	for	determining	the	therapeutic	outcome	 of	 neural	 stem	 cell	 therapy	 in	 these	mice.	 In	 addition,	 the	 phenotype	 of	these	mice	was	compared	to	those	with	an	intact	immune	system	and	the	hypothesis	here	was	that	removing	the	adaptive	 immune	system	would	result	 in	a	 less	severe	disease	phenotype,	as	is	seen	in	other	NCL	mouse	models.	Furthermore,	I	sought	to	
60	








2.1 Mice	All	 animal	 procedures	 were	 carried	 out	 in	 accordance	 with	 the	 respective	 local	university	committee	on	animal	use	in	the	USA.		
2.1.1 	Tpp1+/+	and	Tpp1-/-	mice:	Fixed	 CNS	 tissue	 from	 wild	 type	 control	 (+/+)	 and	 TPP1-deficient	(Tpp1neoinsArg446His)	mice	 brains,	 originally	 generated	 as	 described	 in	 Chapter	 3	section	1.2	(Sleat	et	al.,	2004),	were	kindly	provided	by	Dr	Matthew	Miscenyi	at	the	Albert	 Einstein	 College	 of	Medicine,	NY,	 USA.	 These	mice	were	 backcrossed	 for	 at	least	 ten	 generations	 onto	 the	 C57BL/6J	 strain	 background.	 Further	 information	about	 the	 breeding	 program	 was	 not	 provided	 on	 request;	 the	 implications	 of	different	breeding	programs	are	outlined	further	in	the	discussion	in	Chapter	3.	The	mice	 were	 culled	 at	 varying	 ages	 in	 order	 to	 study	 disease	 progression	 of	 TPP1-deficient	 mice.	 The	 brains	 provided	 from	 the	 Albert	 Einstein	 College	 of	 Medicine	included:	a)	Tpp1+/+	mice	at	3,	6,	9	and	13	weeks	n	=	5	for	each	group;	b)	Tpp1-/-	mice	at	3,	6,	9	and	13	weeks	n	=	5	for	each	group	(Chapter	3).		
2.1.2 Tpp1+/-/NODSCID	and	Tpp1-/-/NODSCID	mice		TPP1-deficient	mice	on	a	NODSCID	background	were	kindly	provided	by	StemCells	Inc,	 CA,	 USA.	 	Tpp1neoinsArg446His	 (Tpp1-/-)	mice	were	 generated	 as	 described	 in	Chapter	3	section	1.2	(Sleat	et	al.,	2004)	and	backcrossed	for	at	least	ten	generations	onto	 the	C57BL/6J	 strain	background.	The	Tpp1-/-/NODSCID	 strain	was	generated	by	 backcrossing	 into	 NOD	 Scid	 and	 screening	 for	 Neo	 gene	 by	 PCR,	 followed	 by	Blood	testing	for	the	absence	of	TPP1	enzyme	activity	as	well	as	the	absence	of	T	and	B	 cells.	 	Following	 extensive	 backcross	 for	 at	 least	 10	 generations,	 the	mice	were	immunodeficient;	hence	the	C57BL/6J	background	was	replaced	by	the	SCID	(Pkdc	scid)	and	NOD	background.	Breeding	was	conducted	either	with	Tpp1+/-/NODSCID	female	 x	 Tpp1-/-/NODSCID	 male	 or	 Tpp1+/-/NODSCID	 female	 x	 Tpp1+/-/NODSCID	male.	 The	 implications	 of	 this	 breeding	 strategy	 are	 outlined	 in	 the	 discussion	 in	Chapter	4.	NODSCID	mice	lack	T	and	B-cell	mediated	immunity	(Ito	et	al.,	2002);	this	is	 necessary	 so	 that	 any	 transplanted	human	 cells	 are	not	 rejected	 (see	Chapter	4	section	1).	The	brains	provided	from	StemCells	Inc.	included:		a)	 non-grafted	 Tpp1+/-/NODSCID	 and	 Tpp1-/-/NODSCID	 mice	 for	 establishing	pathological	landmarks	(Chapter	4),	n	=	5	for	each	group;	
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b)	Tpp1+/-/NODSCID	and	Tpp1-/-/NODSCID	mice	grafted	with	huCNS-SCs	(Uchida	et	al.,	2000)	as	neonates	(p0),	as	early	post-natal	mice	(p21)	or	at	both	ages	(p0	and	p21),	(Chapter	5),	n	=	5	for	each	group.	Neonatal	 mice	 received	 transplants	 bilaterally	 into	 the	 lateral	 ventricle,	 anterior	cortex	with	hCNS-SCns	(4	sites)	with	3	x	105	or	6	x	105	cells	per	site.	Post-natal	mice	received	 transplants	 bilaterally	 into	 8	 sites	 within	 the	 brain	 parenchyma	 and	cerebellum	with	8	x	105	cells	per	site.	These	mice	were	then	maintained	until	between	4-6	months	(an	age	at	which	Tpp1-/-	mice	would	be	considered	severely	affected),	and	then	transcardially	perfused	and	this	fixed	CNS	tissue	was	shipped	blind	to	genotype	and	treatment	to	the	Pediatric	Storage	Disorders	Laboratory	(King’s	College	London,	UK)	for	histological	analysis.			
2.2 Histological	Processing	The	 brains	 were	 cut	 along	 the	 midline	 and	 the	 cerebellum	 was	 removed.	 The	forebrains	were	then	cut	coronally	(or	sagittally	for	one	brain	per	treatment	group	for	Tpp1+/-/NODSCID	and	Tpp1-/-/NODSCID	mice	transplanted	with	huCNS-SCs)	and	the	 cerebellae	 of	 Tpp1+/-/NODSCID	 mice	 and	 Tpp1-/-/NODSCID	 mice	 were	 cut	sagittally,	 into	 40	 µm	 sections	 on	 a	 Microm	 freezing	 microtome	 (Carl	 Zeiss	Microsystems,	Welwyn	Garden	City)	(Bible	et	al.,	2004,	Griffey	et	al.,	2004,	Griffey	et	al.,	 2006).	 The	 sections	 were	 collected	 one	 section	 per	 well	 in	 96	 well-	 plates,	containing	cryoprotectant	solution	(TBS/30%	ethylene	glycol/15%	sucrose/0.05%	sodium	azide)	and	stored	at	4°C.		
2.3 Nissl	Staining	To	visualise	neuronal	cytoarchitecture	a	1	in	6	series	of	sections	was	mounted	onto	gelatin-chrome	alum	coated	Superfrost	microscope	slides	(VWR,	Dorset,	UK),	dried	overnight	and	Nissl	stained	with	cresyl	fast	violet	according	to	a	standard	protocol	(Bible	et	al.,	2004).	The	slides	were	incubated	for	45	min	at	65°C	in	a	0.05%	cresyl	fast	 violet	 and	0.05%	acetic	 acid	 (VWR)	 solution	and	were	 then	 rinsed	 in	distilled	water.	 Finally,	 the	 slides	 were	 differentiated	 through	 a	 graded	 series	 of	 alcohols,	cleared	in	50:50	xylene:	I.M.S,	then	cleared	in	100%	xylene	(VWR)	and	coverslipped	with	DPX	(VWR).			
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2.4 Measuring	Cortical	Thickness	Cortical	 thickness	 was	 assessed	 in	 four	 regions	 that	 have	 been	 shown	 to	 exhibit	pathology	 in	mouse	models	 of	 NCL	 (Kielar	 et	 al.,	 2007):	 the	 primary	motor	 (M1),	somatosensory	barrelfield	 (S1BF),	 visual	 (V1)	and	 lateral	 entorhinal	 (Lent)	 cortex,	as	 representative	 cortical	 regions	 that	 serve	 a	 variety	 of	 functions,	 as	 described	previously	(Bible,	2004).	In	each	area,	ten	perpendicular	lines	were	drawn	from	the	pial	surface	to	the	dorsal	boundary	of	the	corpus	callosum,	and	the	mean	length	of	these	lines	was	used	to	calculate	cortical	thickness	for	each	region.	This	analysis	was	performed	 on	 three	 consecutive	 sections	 from	 one	 in	 six	 mounted	 Nissl	 stained	sections	 (Cooper	 et	 al.,	 2007,	 Pontikis	 et	 al.,	 2004,	 Pontikis	 et	 al.,	 2005).	 Cortical	thickness	expressed	in	μm	for	each	animal	was	collected	and	the	mean	thickness	for	each	region	was	obtained	for	control	and	Tpp1-/-/NODSCID	mice.		
2.5 Stereological	Analysis	In	 this	 thesis	 design-based	 stereology	 was	 used	 to	 quantify	 differences	 between	pathological	 phenotypes	 in	 the	brains	of	TPP1-deficient	mice	 compared	 to	 control	mice,	 enabling	 estimates	 of	 regional	 volumes,	 and	 neuron	 numbers	 to	 be	 made	(Schmitz	 and	Hof,	 2005).	These	methods	are	described	as	 ‘design-based’	 since	 the	probes	and	sampling	methods	are	designed	a	priori,	and	are	therefore	independent	of	 the	 size,	 shape	 and	 spatial	 orientation	 and	 distribution	 of	 the	 features	 being	investigated	 (West	 and	 Sutula,	 2002).	 The	 design-based	 stereology	 method	 helps	eliminate	user	bias	of	prior	assumptions	about	shape	and	size	of	brain	structures	as	a	result	of	disease	(West,	1993).			The	 accuracy	 of	 design-based	 stereological	 methods	 is	 dependent	 on	 the	 reliable	identification	 of	 brain	 regions.	 To	 this	 end,	 the	 cytoarchitecture	 of	 sections	 was	visualised	 using	 Nissl	 staining,	 enabling	 identification	 of	 discrete	 boundaries	between	white	and	grey	matter.	To	assign	the	boundaries	of	each	region	of	interest	(ROI),	 ‘The	 mouse	 brain	 in	 stereotactic	 coordinates’	 was	 used	 as	 reference	 of	 the	relevant	neurological	landmarks	(Paxinos	and	Franklin,	2001).					The	 stereological	 analysis	 was	 carried	 out	 using	 Stereoinvestigator	 software	(Microbrightfield	 Inc.,	Williston,	 VT),	which	 allows	 data	 to	 be	 collected	 in	 a	 semi-automated	manner.	All	measurements	were	performed	on	a	Zeiss	Axioskop	2	MOT	
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(Zeiss,	Germany)	linked	to	a	DAGE-MTI	CCD	-100	camera	(Dage-MTI,	Michigan	City,	IA)	and	were	conducted	blind	to	genotype.		
2.5.1 Measuring	Volume	using	the	Cavalieri	Probe	Cavalieri	 recognised	 that	 a	 series	 of	 sections	 through	 an	 object	 can	 be	 used	 to	estimate	 its	 total	volume	(Gunderson	et	al.,	1999).	The	sections	must	be	separated	by	a	regular	interval	of	a	known	distance	and	the	first	section	must	be	at	a	random	location	 within	 the	 section	 interval.	 In	 this	 thesis,	 all	 brains	 were	 cut	 to	 give	 a	section	 thickness	 of	 40µm	 and	 either	 a	 1	 in	 6,	 or	 1	 in	 12	 series	 of	 sections	(depending	 on	 the	 area	 of	 interest)	was	 analysed.	 The	 volume	 of	 the	 object	 to	 be	measured	 is	 estimated	 by	 multiplying	 the	 total	 area	 of	 the	 region	 of	 interest	(ROI)(the	 sum	of	 all	 highlighted	 areas	 on	 each	 section)	with	 the	 distance/interval	between	each	section	(Lucocq,	2007).	A	grid	is	placed	with	suitable	point	probes	on	top	of	 each	 section	 and	 all	 points	 falling	within	 the	 region	of	 interest	 are	 counted	(Figure	 4).	 Volume	 estimations	 collected	 in	 this	 way	 are	 vulnerable	 to	 over-projection	(overestimation	of	volume),	but	this	can	be	minimised	by	performing	the	analyses	 with	 a	 systematic-random	 series	 of	 sections	 (as	 described	 above)	 in	addition	 to	 correcting	 for	 over-projection	 by	 not	 including	 the	 section	 with	 the	largest	 projection	 area	 (Schmitz	 and	 Hof,	 2005,	 Gunderson	 and	 Jenson,	 1985).	Finally	the	accuracy	of	the	volume	estimation	was	assessed	by	co-efficient	of	error	and	 variance	 estimate	 calculations.	 With	 sufficient	 point	 density,	 the	 Cavilieri	method	 can	 be	 successfully	 employed	 to	 estimate	 the	 area	 of	 many	 biological	entities	 and	has	been	 regularly	used	 in	 this	 field	 in	 the	past	 (Pontikis	 et	 al.,	 2004,	Kielar	et	al.,	2007,	Pontikis	et	al.,	2005,	Bible	et	al.,	2004).		The	Cavalieri	method	was	used	to	produce	unbiased	estimates	of	the	volume	of	the	cortex,	 thalamus,	 striatum	and	hippocampus,	using	Nissl	 stained	sections	 (Bible	et	al.,	 2004,	 Cooper	 et	 al.,	 2007,	 Pontikis	 et	 al.,	 2004,	 Pontikis	 et	 al.,	 2005,	 Cavalieri,	1665).	 The	 boundaries	 of	 each	 region	 were	 defined	 using	 neuroanatomical	landmarks	described	by	Paxinos	and	Franklin	(2001).	A	sampling	grid	that	varied	in	size	depending	on	the	ROI,	was	superimposed	over	the	sections	and	the	number	of	points	covering	 the	appropriate	regions	was	counted	using	an	X	2.5	objective.	The	size	of	 the	sampling	grid	 for	each	region	was	determined	so	 that	 the	coefficient	of	error	 (CE)	 was	 always	 less	 than	 0.1	 and	 the	 results	 are	 expressed	 as	 the	 mean	volume	 in	 μm3	for	 each	 region	 for	 each	 age	 and	 genotype	 of	mice.	 The	 grid	 sizes	
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were	 kept	 constant	 for	 each	 ROI	 for	 all	 the	 mouse	 genotypes	 and	 ages,	 to	 allow	unbiased	comparisons	between	the	groups.				
	
Figure	4	Representation	of	volume	estimation	using	the	Cavalieri	Method.	A)	the	Cavalieri	method	is	applied	to	any	section	object	such	as	a	mouse	brain.	Sections	of	the	 mouse	 brain	 that	 are	 spaced	 at	 consistent	 intervals	 (k)	 are	 randomly	 selected.	 The	investigator	draws	around	the	region	of	interest	(ROI)	in	every	section	it	appears.	(B)	A	grid	is	superimposed	over	each	section	of	known	dimensions	(d1	by	d2)	 (C)	Every	cross/	point	that	 falls	 within	 the	 selected	 area	 is	 counted	 (P).	 (D)	 Points	 are	 only	 counted	 if	 the	intersection	of	 the	cross	 is	within	 the	ROI	(arrow).	The	total	area	of	 the	ROI	 is	 the	sum	of	each	section	A	=	Σ	P	x	d1	X	d2.	The	overall	volume	is	the	total	cross-sectional	area	multiplied	by	the	distance	between	each	section,	V	=	A	x	k.	Adapted	from	(Lucocq,	2007)		
2.5.2 Assessing	Neuronal	Cell	Loss	using	the	Optical	Fractionator	Probe	In	most	experimental	contexts,	it	is	not	feasible	to	count	all	the	neurons	within	the	ROI.	 The	 optical	 fractionator	 method	 allows	 researchers	 to	 count	 only	 a	 known	subset	of	neurons/cells	and	subsequently	estimate	the	total	number	that	would	be	present	 in	 the	 entire	 ROI,	 and	 it	 combines	 the	 optical	 dissector	 method	 with	 the	
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fractionator	sampling	method	(West	et	al.,	1991).	The	optical	dissector	incorporates	optical	 planes	 by	moving	 the	 focal	 plane	 up	 and	 down	 and	 allows	 estimations	 of	neuron	 numbers	 without	 assumptions	 about	 their	 size	 and	 shape,	 whilst	 the	fractionator	 is	 a	 systematic	 random	 sampling	 method	 within	 a	 defined	 ROI	(Gunderson	and	Jenson,	1985,	West	et	al.,	1991,	Schmitz	and	Hof,	2005).	To	conduct	unbiased	design-based	cell	counts,	 the	 investigator	 initially	defines	 the	boundaries	of	the	brain	ROI,	by	tracing	around	the	ROI	as	defined	by	the	‘The	mouse	
brain	 in	 stereotactic	 co-ordinates’	 (Paxinos	 and	 Franklin.,	 2001)	 at	 low	 power	magnification	 (X2.5).	 Next,	 a	 grid	 of	 known	 dimensions	 is	 superimposed	 onto	 the	ROI	and	random	dissector	“counting	frames”	are	applied	onto	the	section	according	to	this	sampling	grid	size.	The	counting	frames	and	grid	sizes	were	kept	constant	for	each	 ROI	 for	 all	 the	 mouse	 genotypes	 and	 ages,	 to	 allow	 unbiased	 comparisons	between	the	groups.	The	researcher	switches	to	high	power	magnification	in	order	to	visualise	the	neurons.	Only	cells	within	the	frame	are	counted.	In	order	to	avoid	over-sampling,	only	cells	within	or	touching	the	green	acceptance	line	are	counted,	while	cells	touching	the	red	exclusion	line	are	not	included	(Figure	5).			
	
Figure	5	Criteria	for	counting	neurons	with	optical	fractionator	probe.	Schematic	 diagram	 of	 Nissl	 stained	 cells	 with	 superimposed	 counting	 frame.	 Only	 cells	within	 the	counting	 frame	are	counted.	Cells	within	or	 touching	 the	green	acceptance	 line	are	counted	(marked	with	yellow	stars),	while	cells	touching	the	red	exclusion	line	are	not	included.		Because	Nissl	stains	nucleic	acid	in	both	neurons	and	glia,	this	method	relies	on	the	skill	of	 the	researcher	 to	correctly	 identify	which	cells	are	neurons	on	 the	basis	of	
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their	morphology.	To	minimise	the	incorrect	identification	of	cells	as	neurons,	strict	morphological	 criteria	 were	 used	 and	 only	 cells	 displaying	 these	 characteristics	were	counted	as	neurons.	 In	 spite	of	 this	 limitation,	Nissl	 staining	 is	often	used	 in	preference	to	immunohistochemical	staining	(Baiguera	et	al.,	2012,	Padurariu	et	al.,	2012,	 Rubinow	 et	 al.,	 2014).	 This	 is	 because	 immunostaining	methods	 depend	 on	visualising	proteins	that	can	be	downregulated	below	detection	thresholds,	and	cells	that	are	still	present	in	the	section	are	therefore	not	counted.	This	is	a	possibility	in	all	pathological	studies	as	dying	cells	change	their	expression	profiles	of	many	genes,	before	 they	die	 (Kielar	et	al.,	2009,	Andersson	et	al.,	2009).	As	a	 result,	 all	neuron	counts	in	this	thesis	have	been	performed	with	Nissl	stained	sections.	The	 optical	 fractionator	 probe	 was	 used	 to	 estimate	 the	 number	 of	 neurons	 in	laminae	IV,	V	and	VI	of	 the	somatosensory	cortex	(S1BF)	or	visual	cortex	(V1),	 the	somatosensory	 thalamic	 relay	 nucleus,	 the	 ventral	 posteromedial	 nucleus	(VPM/VPL)	 and	 the	 visual	 thalamic	 relay	 nucleus,	 the	 lateral	 geniculate	 nucleus,	(LGNd)	from	every	sixth	Nissl	stained	section.	Cells	were	counted	using	a	x100	oil-objective	with	a	high	numerical	aperture	(1.4)	and	only	 if	 they	displayed	neuronal	morphology	 with	 a	 large	 cell	 body,	 light	 coloured	 nissl	 stained	 cytoplasm	 and	 a	defined	nucleus.	Glia,	which	are	distinguishable	by	 their	smaller	somas	and	darkly	stained	granular	cytoplasm,	were	not	counted.	The	mean	coefficient	of	error	(CE)	for	all	 optical	 fractionator	was	 calculated	 according	 to	 the	method	 of	 Gundersen	 and	Jensen	(1987)	and	was	less	than	0.1	in	all	samples	to	ensure	sufficient	sampling.		
2.6 Immunohistochemical	Staining	
2.6.1 Immunohistochemical	Procedure	To	 determine	 the	 degree	 of	 microglial	 activation,	 astrocytosis	 and	 lysosomal	activation,	 a	 1	 in	 6	 series	 of	 40	 μm	 coronal	 sections	 were	 stained	 for	 either	 the	microglial	 marker	 CD68,	 glial	 fibrillary	 associated	 protein,	 GFAP,	 or	 lysosomal	associated	 membrane	 protein	 1,	 LAMP-1,	 calbindin,	 SC121	 or	 Fox3	 (Table	 4	 for	concentrations).	Sections	were	incubated	in	1%	H2O2	in	TBS	for	30	minutes	to	block	endogenous	 peroxide	 activity,	 rinsed	 in	 TBS	 and	 then	 incubated	 in	 15%	 normal	serum	 (Vector	 laboratories,	 Peterborough,	 UK)	 in	 TBS-T	 for	 30	 minutes	 to	 block	non-specific	 protein	 binding.	 The	 sections	 were	 then	 incubated	 overnight	 at	 4	 °C	with	constant	gentle	agitation,	with	 the	primary	antiserum	(Table	 4)	diluted	with	10%	normal	serum	in	TBS-T.	The	sections	were	rinsed	in	TBS	and	then	incubated	in	
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Company	 	[2°	Ab]	Microglia	 Rat	 α	CD68	 Serotec,	Oxford,	UK	 1:2000	 Goat	α	rat	 Dako,	Ely,	UK	 1:1000	Activated	astrocytes	 Rabbit	 α	GFAP	 Serotec	 1:4000	 Swine	 α	rabbit	 Dako	 1:1000	huCNS-SCs	 Mouse	 α	SC121	 StemCells	Inc,	 CA,	USA	 1:1000	 Rat	 α	mouse	 Dako	 1:1000	Lysosomal	activity	 Rabbit		 α	LAMP1	 Serotec	 1:2000	 Swine	 α	rabbit	 Dako	 1:1000	Purkinje	cells	 Rabbit	 α	Calbindin	 AbCam,	Cambridge	 1:8000	 Swine	 α	rabbit	 Dako	 1:1000	Neurons	 Rabbit	 α	Fox3	 AbCam,	Cambridge	 1:4000	 Swine	 α	rabbit	 Dako	 1:1000	
Table	5	Primary	antiserum	information	used	for	immunohistochemical	staining.		
2.6.2 Quantitative	Analysis	of	Immunohistochemical	Staining	To	quantify	and	allow	comparison	of	the	relative	 levels	of	GFAP,	CD68	and	LAMP1	immunoreactivity	 between	 genotypes	 and	 age	 groups,	 the	 optical	 density	 of	immunoreactivity	 (visualised	 by	 DAB)	 was	 determined	 using	 thresholding	 image	analysis,	as	previously	described	(Pontikis	et	al.,	2004,	Kielar	et	al.,	2007,	Pontikis	et	al.,	2005,	Bible	et	al.,	2004).	Blinded	for	genotype,	age	and	where	relevant	treatment,	using	 the	 sections	 stained	 for	 CD68,	 GFAP	 and	 LAMP1	 markers,	 thirty	 non-overlapping	images	representing	the	region	of	interest	(thalamic	VPM/VPL	nucleus,	cortical	S1BF	region	or	 striatum)	and	were	 taken	 from	three	consecutive	sections,	
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using	a	live	video	camera	(JVC,	3CCD,	KY-F55B,	London,	UK),	mounted	onto	a	Zeiss	Axioplan	 microscope	 with	 a	 x40	 objective	 (Zeiss,	 Lambda	 Photometrics	 Ltd.,	Harpenden,	 UK).	 Lamp	 intensity,	 video	 camera	 setup	 and	 microscope	 calibration	were	 kept	 constant	 during	 the	 analysis	 to	 minimize	 variability	 in	 the	 images.	Following	 image	capture,	Image	Pro	Plus	software	(Media	Cybernetics,	Chicago,	 IL)	was	 used	 to	 quantify	 the	 intensity	 of	 staining	 for	 each	 antigen.	 A	 threshold	 was	chosen	to	distinguish	between	specific	immunoreactivity	for	each	antigen	and	non-specific	 background	 and	 kept	 constant	 for	 all	 images	 analyzed.	 Macros	 were	designed	 to	 open	 the	 image	 files	 for	 analysis	 and	 transfer	 the	 pixel	 data	 to	 a	Microsoft	 Excel	 spread	 sheet	 for	 further	 statistical	 analysis.	 The	 results	 of	 each	region	 and	 antigen	were	 presented	 as	mean	 percentage	 area	 of	 immunoreactivity	per	measured	field	(±	SEM).	In	 order	 to	 compare	 immunostaining	 results	 from	 samples	 processed	 across	different	time	periods,	the	thresholds	were	set	in	order	that	the	same	proportion	of	positively	 immunostained	cells	was	detected	across	 the	 samples.	The	 thresholding	analysis	 was	 then	 performed	 using	 a	macro	 that	 incorporated	 all	 the	 animals	 for	each	 antigen,	 blind	 to	 the	 genotype	 of	 the	 mouse	 (Tpp1-/-/NODSCID,	 Tpp1+/-
/NODSCID,	Tpp1-/-	or	Tpp1+/+)	and	the	age	of	the	mouse.			
2.7 Representative	Images	To	record	the	resulting	immunohistochemical	staining,	representative	images	of	cell	morphology	and	distribution	of	immunoreactivity	throughout	the	tissue	were	taken	with	 a	 x5,	 x10,	 x20,	 x40	 or	 x63	 objective	 on	 a	 Leica	 DMRB	 microscope	 (Leica	Mikroskopie	 &	 Systeme	 GmbH,	Wetzlar)	 with	 a	 Zeiss	 AxioCam	 HRc	 Rev	 2	 digital	camera	and	processed	using	the	software	AxioVision	(version	4.7.2).		
2.8 Mapping	of	human	Neural	Stem	Cells	Using	sagittal	sections	stained	for	SC121	(see	section	2.6),	I	plotted	the	distribution	of	SC121	positive	cells	and	their	relative	density	within	different	brain	regions.	This	was	 achieved	 by	 observing	 sections	 at	 lower	 power	 to	 assess	 which	 regions	contained	 these	 cells,	 and	at	higher	magnification	 to	assess	 their	morphology,	 and	hence	 their	 post-transplantation	 fate.	 To	 do	 this,	 mouse	 brain	 atlas	 maps	 from	Paxinos	and	Watson.,	(2001)	were	coloured	according	to	the	relative	cell	density	in	each	 brain	 region.	 Red	 indicates	 densely	 packed	 cell	 clusters;	 orange	 indicates	
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regions	of	densely	packed	cells	where	individual	cells	could	be	distinguished;	yellow	less	 densely	 packed	 regions	 in	 which	 cells	 did	 not	 touch	 one	 another;	 and	 pale	yellow	to	denote	regions	where	only	sparse	SC121	positive	cells	were	present.		
2.9 Statistical	Analysis	To	 detect	 statistically	 significant	 differences	 in	 quantitative	 data	 between	 Tpp1-/-	and	Tpp1+/+	mice	of	ages	3-13	weeks	two-way	ANOVA’s	(with	age	and	genotype	as	independent	variables	were	conducted	with	Bonferroni	post	hoc	tests	performed.	To	test	 for	 potentially	 significant	 differences	 between	 Tpp1+/-/NODSCID	 and	 Tpp1-/-
/NODSCID	 mice	 student’s	 T-tests	 were	 performed	 (only	 one	 age	 group	 was	analysed).	 Statistical	 analysis	 was	 performed	 using	 Graph	 Pad	 Prism	 6	 software	(Graph	 Pad	 software,	 Inc.	 CA,	 USA)	 and	 statistical	 significance	 was	 considered	 at	p≤0.05.			 	
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Chapter	3 	




3.1.1 Why	study	mouse	models?	In	order	to	investigate	the	underlying	neurobiology	of	the	NCLs	and	move	towards	targeted	therapies,	it	is	necessary	to	model	the	diseases	in	non-human	systems.	The	use	of	animal	models	has	 improved	our	understanding	of	disease	mechanisms	and	 helped	 us	 to	 discover	 not	 only	 landmarks	 of	 disease	 progression,	 but	 also	 to	identify	therapeutic	targets.	Human	post-mortem	tissue	is	useful	for	defining	exactly	what	 pathology	 looks	 like	 at	 end-stage	 in	 human	 patients	 (McGonigle,	 2014).	However,	this	material	can	only	gives	us	a	snapshot	of	the	extreme	pathology	seen	at	the	 end	 of	 the	 disease,	 whereas	 animal	 models	 can	 be	 examined	 from	 early	neurodevelopment	to	death	(Hartung,	2008).	This	can	be	used	to	build	up	a	picture	of	 the	 successive	 disease	 progression	 and	 inform	 where	 therapies	 should	 be	targeted	 to	 first.	 Such	 detailed	 data	 about	 the	 onset	 and	progression	 of	 pathology	also	provide	invaluable	data	for	judging	the	efficacy	of	such	experimental	therapies	(Cooper	et	al.,	2006b).	As	described	in	Chapter	1	section	5,	gene	conservation	between	species	has	allowed	us	 to	 use	 many	 different	 species	 including	 yeast,	 flies,	 fish	 and	 mice	 as	 disease	models	in	order	to	study	the	effects	of	mutations	in	human	genes	and	the	resulting	diseases	(Palmer	et	al.,	2013,	Shacka,	2012).	Larger	animal	models	(such	as	sheep	or	dogs)	 more	 closely	 recapitulate	 human	 disease	 however,	 they	 are	 much	 more	expensive	 to	work	with	 and	more	 ethically	 restricted	 (Palmer	 et	 al.,	 2011,	Weber	and	Pearce,	2013).		Mice	 are	 generally	 the	most	widely	used	model	 animals	 as	 they	are	 easy	 to	breed	and	 robust	 methods	 exist	 for	 genetic	 manipulations,	 and	 for	 characterising	 the	resulting	phenotypes	(Perrin,	2014).	Mouse	models	for	neurological	disorders	exist	from	a	variety	of	sources	 including	as	a	result	of	naturally	occurring	mutations,	as	well	 as	 arising	 from	 large-scale	mutation	 screens,	 or	more	 commonly	via	 targeted	genetic	 modification	 techniques,	 such	 as	 homologous	 recombination	 (McGonigle,	2014).	So-called	‘knockout	mice’	carry	a	gene	that	has	been	inactivated,	resulting	in	disrupted	gene	expression	and	loss	of	function	(Hall	et	al.,	2009).	In	contrast,	‘knock-in’	mice	are	produced	by	 inserting	a	modified	 form	of	a	gene	 into	a	 specific	 locus,	and	so	can	recreate	the	exact	mutation	present	in	the	human	disease	(Brakebusch,	2010).	 Such	 knock-in	 mice	 are	 usually	 considered	 preferable	 when	 they	 are	available,	as	they	should	in	theory	more	accurately	recapitulate	the	human	disease	(Brakebusch,	2010).		
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Gene-specific	mouse	models	are	available	 for	each	of	 the	genetically	 characterised	human	NCL	subtypes	(Shacka,	2012,	Bond	et	al.,	2013).	The	characterisation	of	these	models	 has	 provided	 a	 wealth	 of	 new	 data	 about	 the	 staging	 of	 pathogenesis,	behavioural	 and	 neuropathological	 landmarks	 of	 disease	 progression,	 and	 has	provided	an	invaluable	testing	ground	for	the	evaluation	of	a	variety	of	pre-clinical	therapeutic	approaches	(Cooper	et	al.,	2006b).		
3.1.2 A	mouse	model	of	CLN2	disease	Murine	Cln2	was	 targeted	 to	generate	a	mutant	mouse	with	undetectable	 levels	of	tripeptidyl	peptidase	1	(TPP1).	The	Cln2/Tpp1	gene	was	disrupted	by	the	insertion	of	 a	 neomycin	 (neo)	 selection	 cassette	 into	 exon	 11	 of	 this	 gene,	 and	 by	incorporating	 an	 Arg446His	missense	mutation	 immediately	 upstream	 of	 the	 neo	insertion	(Sleat	et	al.,	2004).	The	mouse	was	designed	ultimately	to	be	a	hypomorph	following	 cre	 (cAMP	 response	 element)–mediated	 excision	 of	 the	 neomycin.	However,	 the	 mutant	 mouse	 retains	 the	 intronic	 neo	 insertion	 as	 well	 as	 the	Arg446His	mutation	and	is	therefore	properly	designated	Tpp1neoinsArg446His.		When	 the	 targeting	 construct	 was	 designed,	 it	 was	 found	 that	 the	 chromosomal	region	 proximal	 to	 the	murine	 Cln2	 gene	 is	 very	 gene-rich	 (Liu	 et	 al.,	 1998).	 The	targeting	approach	for	Cln2	therefore	had	to	be	sensitive	to	the	potential	positional	effects	on	neighbouring	genes,	in	particular	transcription	factor	TAF10B	(Sleat	et	al.,	2004).	As	such,	the	Cln2	gene	was	to	be	disrupted	with	a	point	mutation	as	opposed	to	a	major	deletion	and,	 in	addition,	neo	was	 inserted	 into	an	 intronic	region	with	low	 homology	 between	 human	 and	 mouse,	 with	 LoxP	 sites	 so	 that	 it	 could	 be	removed	later	(Sleat	et	al.,	2004).	The	reason	for	taking	this	approach	was	because	of	 the	 suspected	presence	of	 a	 transcript	of	unknown	 function	 that	overlaps	CLN2	and	 is	 transcribed	 in	 the	opposite	direction.	The	choice	of	an	 intronic	 sequence	of	low	conservation	for	inserting	the	neo	cassette	was	made	because	such	sites	are	less	likely	to	overlap	exonic	sequences	of	such	transcripts	than	those	regions	with	higher	homology.	Three	 targeting	 constructs	 were	 produced:	 a	 null,	 a	 hypomorph	 and	 a	 control	(Arg446X,	 Arg446His	 and	 Arg446Arg446,	 respectively);	 however,	 of	 these	constructs	only	Arg446His	successfully	produced	a	positive	clone	(Sleat	et	al.,	2004).	From	 this	 clone,	 the	 Cln2-targeted	 mouse	 used	 in	 this	 thesis	 was	 subsequently	produced.	 Still,	 the	 mutant	 mouse	 retains	 the	 intronic	 neo	 insertion,	 as	 well	 the	Arg446His	mutation	and	is	therefore	properly	designated	Tpp1neoinsArg446His.	
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Sleat	 et	 al.,	 (2004)	 note	 that	 there	 is	 a	 very	 low	 frequency	 for	 homologous	recombination	 at	 the	 CLN2	 gene,	 which	 will	 become	 relevant	 for	 the	 cellular	modelling	 studies	 described	 in	 Chapters	 6	 and	 7.	 In	 combination	with	 the	 severe	splicing	 defect	 caused	 by	 neo	 insertion,	 the	 Arg446His	 mutation	 caused	 a	 null	phenotype.	 The	 neo	 insertion	 disrupts	 the	CLN2	 gene	 transcription	 in	 such	 a	way	that	 only	 4%	 CLN2	 mRNA	 is	 normally	 spliced	 and	 it	 contains	 the	 deleterious	mutation	 (Sleat	 et	 al.,	 2004).	 This	 results	 in	 no	 detectable	 TPP1	 and	 despite	 their	complex	means	of	construction	these	mice	are	therefore	routinely	called	Tpp1	null-mutants	(Tpp1-/-)	(Sleat	et	al.,	2004),	as	is	done	in	this	thesis.			
3.1.3 Phenotypic	observations	of	Tpp1-/-	Mice	The	growth	and	development	of	Tpp1-/-	mice	 is	apparently	normal	and	both	males	and	 females	 are	 fertile	 (Sleat	 et	 al.,	 2004).	 There	 are	 no	 discernable	 differences	between	Tpp1-/-	mice	and	wild	 types	until	 7	weeks,	when	a	 slight	 constant	 tremor	becomes	noticeable.	The	mice	continue	to	grow	as	normal,	but	the	tremor	becomes	progressively	more	 severe	with	 age,	 and	 has	 been	 used	 as	 a	 disease	 landmark	 in	therapeutic	studies	(Chang	et	al.,	2008).	At	end-stage	in	addition	to	the	tremor,	the	mice	have	locomotor	difficulties	including	an	abnormal	gait	and	splayed	hind	limbs	in	a	tail	suspension	test,	as	well	as	ataxia	(Sleat	et	al.,	2004).	The	original	colonies	of	TPP1-deficient	mice	were	on	a	mixed	C57BL/6J:129SV	genetic	background	(Sleat	et	al.,	2004).	The	Tpp1-/-	mice	analysed	here	are	on	a	C57BL/6J	background.	To	 provide	 behavioural	 landmarks	 for	 assessing	 therapeutic	 efficacy,	 a	 series	 of	general	behavioural	studies	have	been	conducted	on	these	Tpp1-/-	mice	between	the	ages	of	9	and	18	weeks	(Sondhi	et	al.,	2007).	TPP1-deficient	mice	show	altered	nest	making	behavior	with	a	reduced	ability	to	create	and	upkeep	nests,	as	well	as	having	a	disordered	gait	and	dragging	of	 the	 limbs	(Sondhi	et	al.,	2007).	The	rotarod	test,	which	 measures	 a	 combination	 of	 motor	 coordination,	 physical	 strength	 and	cognition,	found	no	differences	in	the	performance	of	Tpp1-/-	mice	compared	to	age-matched	control	until	14	weeks,	when	performance	dropped	very	steeply	(Sondhi	et	al.,	 2005).	 On	 the	 rocking	 rotarod,	 the	 performance	 of	 the	 Tpp1-/-	 mice	 was	decreased	from	10	weeks	of	age	(Sleat	et	al.,	2004).	Epileptic	seizures	are	a	hallmark	of	 classic	 late	 infantile	 CLN2	 disease	 pathology	 in	 human	 patients	 and	 a	 minor	percentage	 of	 TPP1-deficient	 mice	 do	 exhibit	 myoclonic	 jerks	 and	 sudden	 brief	seizures,	 but	 this	 does	 not	 appear	 to	 be	 universally	 recapitulated	 in	 Tpp1-/-	mice	(Sleat	et	al.,	2004).	
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In	 contrast	 to	 these	 behavioural	 studies,	 relatively	 little	 is	 known	 about	 the	 onset	and	 progression	 of	 neuropathological	 changes	 in	Tpp1-/-	mice.	 Reports	 are	 largely	confined	to	documenting	the	presence	of	storage	material,	overall	brain	atrophy	and	glial	activation	(Sleat	et	al.,	2004).	The	most	detailed	analysis	has	been	performed	in	the	 cerebellum	 of	 these	mice,	mostly	 in	 terms	 of	 assessing	 the	 impact	 of	 enzyme	replacement	 (Chang	et	 al.,	 2008).	Therefore	 in	 this	 study	we	undertook	a	detailed	quantitative	survey	of	the	onset	and	progression	of	neuropathological	changes	in	the	forebrain	of	Tpp1-/-	mice	at	different	stages	of	disease	progression.		
3.2 Results	
3.2.1 Cortical	thickness	is	not	reduced	in	Tpp1-/-	mice	It	 has	 previously	 been	 shown	 in	 the	 infantile	 CLN1	disease	mouse	model	 (Ppt1-/-)	that	 cortical	 atrophy	 occurs	 to	 varying	 degrees	 in	 the	 sensory	 and	motor	 regions	(Bible	et	al.,	2004).	This	thinning	of	the	cortex	occurs	relatively	late	in	this	model	of	infantile	 CLN1	 disease,	 occurring	 first	 in	 the	 visual	 cortex	 (V1)	 followed	 by	 the	primary	auditory	cortex	(Au1)	and	the	motor	cortex	(M1).	Cortical	thinning	does	not	reach	significance	even	at	7	months	in	the	somatosensory	barrel	field	cortex		(S1BF)	nor	in	the	lateral	entorhinal	cortex	(LEnt),	which	is	considered	to	be	end-stage	in	the	disease	 (Kielar	et	 al.,	 2007).	Although	Sleat	et	 al.,	 (2004)	noted	 that	 sections	were	noticeably	thinner	in	their	CLN2-targeted	mice	at	disease	end	stage,	this	difference	was	not	quantified.		To	 determine	 the	 extent	 of	 cortical	 atrophy	 in	 this	 mouse	model	 of	 late	 infantile	CLN2	 disease,	 a	 similar	 approach	 was	 taken.	 Thickness	 measurements	 were	performed	 on	 regularly	 spaced	 Nissl	 stained	 sections	 from	 Tpp1-/-	 mice	 and	 age-matched	 controls	 between	 3	 and	 13	 weeks	 old	 in	 the	M1,	 S1BF,	 V1	 and	 Lent,	 as	representative	 cortical	 regions	 that	 serve	 different	 functional	 roles.	 Surprisingly,	there	were	no	overt	effects	upon	cortical	thickness	in	Tpp1-/-	mice	versus	wild-type	control	mice	(Figure	6)	in	any	of	the	cortical	subfields	examined	at	any	age.	These	unexpected	data	point	to	a	relatively	mild	disease	phenotype	in	this	cohort	of	Tpp1-/-	mice.						
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Figure 6	 Lack	 of	 cortical	 atrophy	 in	Tpp1-/-	mice	 versus	Tpp1+/+	controls.	There	 is	no	detectable	 thinning	 of	 the	 cortical	 mantle	 in	 (A)	 the	 primary	motor	 cortex	 (M1),	 (B)	 the	somatosensory	 barrel	 field	 (S1BF),	 (C)	 the	 primary	 visual	 cortex	 (V1)	 or	 (D)	 the	 lateral	entorhinal	 cortex	 (LEnt)	 between	 3	 and	 13	 weeks,	 for	 Tpp1-/-	 mice	 compared	 to	 age-matched	Tpp1+/+	controls.	n=5	(*=	p<0.05,	**=	p<0.01,	***=	p<0.001,	2-way	ANOVA	with	post	hoc	Bonferroni	analysis).			
3.2.2 Atrophy	of	the	striatum	becomes	apparent	late	in	disease	progression	Regional	atrophy	of	the	brain	has	been	documented	in	multiple	NCL	mouse	models	(Bible	et	al.,	2004,	Pontikis	et	al.,	2004,	Kuhl	et	al.,	2013,	Kuronen	et	al.,	2012).	Since	such	 volume	 measurements	 are	 more	 likely	 to	 detect	 macroscopic	 effects,	 we	decided	to	look	at	the	whole	volume	of	the	cortex	in	order	to	detect	any	more	subtle	atrophy,	 and	 also	 to	 survey	whether	 any	 other	 regions	might	 be	 affected.	 In	 their	initial	studies	of	Tpp1-/-	mice,	Sleat	et	al.,	(2004)	noted	that	brains	from	Tpp1-/-	mice	displayed	mild	to	moderate	atrophy	in	the	forebrain,	which	is	suggestive	of	neuronal	loss,	 but	 this	 atrophy	 was	 not	 quantified	 in	 terms	 of	 regional	 volume.	 To	 obtain	these	data,	unbiased	Cavalieri	estimates	of	regional	volume	in	Nissl	stained	sections	were	carried	out	in	the	cortex,	striatum,	thalamus	and	hippocampus	of	both	Tpp1+/+	and	Tpp1-/-	mice	at	different	stages	of	disease	progression.		These	regional	volume	estimates	confirmed	a	lack	of	cortical	atrophy	in	Tpp1-/-	mice	versus	 controls,	with	no	 significant	 changes	 in	 cortical	 volume	at	 any	 age,	 even	at	disease	end	stage	of	13	weeks	(Figure	7A).	However	there	was	a	consistent	 trend	
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towards	 a	 progressively	 reduced	 volume	 of	 the	 other	 brain	 regions	 examined,	although	its	extent	differed	between	these	regions.	There	was	a	significant	reduction	in	 the	 volume	 of	 the	 striatum	 of	 Tpp1-/-	 mice	 at	 13	 weeks	 (10%,	 p<0.05),	 which	appears	to	start	at	9	weeks	(Figure	7B).	There	was	also	a	trend	towards	atrophy	of	the	 thalamus	 of	 Tpp1-/-	 mice	 from	 9	 weeks	 onwards	 (Figure	 7C),	 which	 was	maintained	to	13	weeks	however	this	did	not	reach	statistical	significance.	A	similar,	but	less	pronounced	phenotype	was	also	evident	in	the	hippocampus	of	Tpp1-/-	mice	(Figure	 7D).	 Taken	 together,	 these	 data	 suggest	 that	 there	 is	 not	 a	 pronounced	reduction	in	regional	brain	volume	in	this	cohort	of	Tpp1-/-	mice,	even	at	disease	end	stage	 at	 13	 weeks	 of	 age,	 and	 only	 modest	 overall	 atrophy	 in	 the	 thalamus	 and	striatum	of	these	mice.				 													
Figure	 7	 Moderate	 atrophy	 in	 Tpp1-/-	 mice	 versus	 Tpp1+/+	 age-matched	 controls.	Histograms	 of	 unbiased	 Cavalieri	 estimates	 of	 regional	 volume	 suggest	 there	 is	 no	detectable	 atrophy	 of	 the	 cortex	 (A).	 Significant	 atrophy	 of	 the	 striatum	 (B)	 is	 apparent,	which	starts	from	9	weeks	and	is	significantly	reduced	at	13	weeks.		There	is	some	evidence	of	a	 trend	of	decreasing	volume	 in	 the	 thalamus	 (C)	 from	9	weeks,	however	 this	does	not	reach	significance.	Hippocampal	volume	is	not	reduced	in	Tpp1-/-	mice	(D).	n=5	(*=p<0.05,	**=	p<0.01,	***=	p<0.001,	2-way	ANOVA	with	post	hoc	Bonferroni	analysis).					
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3.2.3 Microglial	activation	 in	Tpp1-/-	mice	occurs	 towards	 the	end	of	disease	





in	 Tpp1-/-	 mice.	 (A)	 Immunohistochemical	 staining	 for	 the	 microglial	 activation	 marker	CD68	reveals	 its	upregulation	with	 increased	age	 in	 the	somatosensory	barrel	 field	cortex	(S1BF)	 in	 Tpp1-/-	 mice	 compared	 to	 age-matched	 controls.	 (B)	 Representative	 image	 of	optimization	 for	 the	 detection	 of	 CD68-positive	 cells,	 highlighted	 in	 blue.	 (C)	Quantitative	thresholding	 analysis	 confirms	 progressive	 microglial	 activation	 in	 Tpp1-/-	mice,	 which	 is	significant	from	9	weeks	and	further	increases	at	13	weeks.	(D)	Representative	pictures	of	microglial	morphology	with	 increasing	age	 in	Tpp1-/-	mice	 in	 the	S1BF.	n=5	(*=p<0.05,	**=	
p<0.01,	***=	p<0.001,	2	way	ANOVA	with	post	hoc	Bonferroni	analysis).	Scale	bars	=	1000	μm.			Similar	to	in	the	cortical	mantle,	CD68	stained	microglia	in	the	thalamus	of	wild	type	mice	also	showed	a	quiescent	morphology	at	all	ages.	Microglia	in	the	Tpp1-/-	mice	at	3	and	6	weeks	displayed	a	similar	morphology	to	that	seen	in	wild-type	mice.	At	9	weeks	 of	 age,	 there	 were	 more	 darkly	 stained	 microglia	 present	 in	 the	 ventral	posterior	 thalamic	 nucleus	 (VPM/VPL)	 of	 Tpp1-/-	mice,	 compared	 to	 surrounding	nuclei	 (Figure	 9a).	 At	 13	 weeks,	 the	 VPM/VPL	 of	 these	 mutant	 mice	 was	 highly	populated	 with	 intensely	 stained	 CD68-positive	 microglia	 with	 an	 enlarged	 and	swollen	cell	body	with	a	brain	macrophage-like	morphology	(Figure	9a	and	9b).				
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Figure 9 Progressive	activation	of	microglia	in	the	ventral	posterior	thalamic	nucleus.	(A)	 Immunohistochemical	 staining	 for	 the	 microglial	 marker	 CD68	 reveals	 localised	microglial	activation	within	the	ventral	posterior	nucleus	(VPM/VPL)	appearing	at	9	weeks	and	 increases	 at	 13	 weeks	 in	 Tpp1-/-	 mice.	 20X	 magnification	 reveals	 CD68-positive	microglia	 with	 brain	macrophage-like	morphology	 in	 Tpp1-/-	 mice	 but	 are	 not	 present	 in	age-matched	controls.	(B)	Representative	pictures	of	microglial	morphology	with	increasing	age	 in	 Tpp1-/-	 mice	 in	 the	 VPM/VPL.	 (C)	 Quantitative	 thresholding	 analysis	 of	 CD68	demonstrates	the	progressive	elevation	of	CD68	in	Tpp1-/-	mice.	CD68	immunoreactivity	 is	first	increased	in	Tpp1-/-	mice	at	9	weeks	and	becomes	significantly	higher	than	Tpp1+/+	mice	at	 13	 weeks.	 n=5	 (*=p<0.05,	 **=	 p<0.01,	 ***=	 p<0.001,	 2	 way	 ANOVA	 with	 post	 hoc	Bonferroni	analysis).	Scale	bar	=	1000	μm. 	Quantitative	thresholding	image	analysis	confirmed	that	a	similar	progressive	trend	of	 increased	microglial	activation	to	that	seen	in	the	cortex	was	also	evident	in	the	thalamus,	with	 elevated	 CD68	 immunoreactivity	 apparent	 from	9	weeks,	 reaching	significantly	higher	levels	than	control	animals	at	13	weeks.	The	relative	increase	in	CD68	 immunoreactivity	 was	 markedly	 higher	 in	 the	 thalamus	 compared	 to	 the	cortex	 (7%	 and	 2%	 increases,	 respectively),	 despite	 the	 earlier	 detection	 of	microglial	activity	in	the	cortex	(Figure	9c).	These	 data	 revealed	 the	 presence	 of	 activated	 macrophage-like	 cells	 within	 the	thalamocortical	system	of	Tpp1-/-	mice	from	9	weeks	of	age	onwards.	However,	it	is	not	yet	clear	whether	these	CD68-positive	cells	are	resident	microglia	or	recruited	
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monocytes	 from	 the	peripheral	 system.	 Further	 studies	 are	 required	 to	 assess	 the	origin	of	these	cells.	
3.2.4 Astrocytosis	occurs	at	the	end	of	disease	progression	Astrocytosis	 classically	 accompanies	 neuronal	 loss,	 however	 it	 may	 also	 indicate	neuronal	 damage	 or	 dysfunction	 (Sofroniew	 and	 Vinters,	 2010,	 Sofroniew,	 2009).	Such	astrocyte	activation	is	seen	early	in	the	disease	progression	in	many	models	of	NCL,	 and	 is	 especially	pronounced	 in	 thalamic	 sensory	 relay	nuclei	 that	project	 to	the	cortical	mantle	(Bible	et	al.,	2004,	Kay	et	al.,	2006,	Kielar	et	al.,	2007,	Macauley	et	al.,	2011,	Pontikis	et	al.,	2004).	Previous	descriptions	of	astrocytosis	in	Tpp1-/-	mice	have	 reported	a	progressive	astrocytosis,	but	did	not	 consider	 the	 thalamocortical	system	in	any	detail	(Chang	et	al.,	2008).		To	obtain	data	about	the	extent	of	thalamic	astrocytosis	in	this	Tpp1-/-	mouse	model,	sections	 from	control	 and	mutant	mice	between	 the	ages	of	3	and	13	weeks	were	stained	 for	 the	 astrocyte	 marker	 glial	 fibrillary	 associated	 protein	 (GFAP),	 and	subsequently	processed	using	thresholding	 image	analysis	 to	quantify	the	 levels	of	immunoreactivity	within	the	cortex	and	thalamus.	Intense	GFAP	immunoreactivity	was	apparent	in	the	cortex	and	thalamus	of	Tpp1-/-	mice	 compared	 to	 controls,	 but	 this	 was	 really	 only	 evident	 in	 the	most	 severely	affected	mice	rather	than	the	early	onset	of	astrocytosis	seen	in	other	models	(Kielar	et	 al.,	 2007).	 Indeed,	 the	 relative	 staining	 intensity	 of	 GFAP	 immunoreactivity	appeared	similar	in	the	cortex	of	Tpp1-/-	mice	and	controls	at	3,	6	and	9	weeks	of	age,	with	astrocytes	changing	 little	 in	 their	distribution	and	staining	 intensity.	At	 these	ages,	GFAP	immunoreactive	astrocytes	were	predominantly	present	 in	 the	deepest	and	 most	 superficial	 cortical	 laminae,	 with	 the	 occasional	 positively	 stained	astrocytes	scattered	 in	between	(Figure	 10a).	At	13	weeks	of	age,	however,	 there	was	a	sudden	and	marked	difference	in	immunoreactivity	between	genotypes,	with	all	laminae	now	containing	intensely	GFAP	positive	astrocytes,	which	contrasted	to	the	 pattern	 of	microglial	 activation	where	 lamina	V	was	 relatively	 spared	 (Figure	
10a	 and	 d).	 Quantitative	 thresholding	 analysis	 confirmed	 that	 level	 of	 GFAP	immunoreactivity	 in	 the	 S1BF	 is	 indistinguishable	 from	 control	 mice	 from	 3-9	weeks,	but	was	significantly	increased	in	Tpp1-/-	mice	at	13	weeks	of	age	(p=<0.001)	(Figure	10c).			
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Figure	 10.	 Late	 onset	 of	 astrocytosis	 in	 the	 somatosensory	 region	 of	 the	 cortex	 in	
Tpp1-/-	 mice.	 (A)	 Immunohistochemical	 staining	 for	 glial	 fibrillary	 associated	 protein	(GFAP)	reveals	its	sudden	upregulation	at	13	weeks	in	the	somatosensory	barrel	field	cortex	(S1BF)	 in	 Tpp1-/-	 mice	 compared	 to	 age-matched	 controls.	 (B)	 Representative	 image	 of	optimisation	 for	 the	 detection	 of	 GFAP-positive	 cells,	 highlighted	 in	 blue.	 (C)	Quantitative	thresholding	analysis	confirms	acute	astrocytic	activation	in	Tpp1-/-	mice,	with	no	significant	difference	 in	 GFAP	 intensity	 between	 3	 and	 9	 weeks	 and	 a	 sharp	 rise	 in	 GFAP	immunoreactivity	at	13	weeks.	 (D)	Representative	pictures	of	astrocytic	morphology	with	increasing	age	in	Tpp1-/-	mice.	n=5	(*=p<0.05,	**=	p<0.01,	***=	p<0.001,	2	way	ANOVA	with	post	hoc	Bonferroni	analysis).	Scale	bars	=	1000	μm.		Similar	 to	 the	 cortex,	 it	 appears	 that	 there	was	 also	 a	 late	 onset	 and	 pronounced	activation	 of	 astrocytes	 in	 the	 thalamus	 of	 13	 week	 old	 Tpp1-/-	 mice.	Characteristically,	 this	 astrocytosis	 within	 the	 thalamus	 was	 very	 localized	 to	 the	VPM/VPL	and	was	virtually	absent	from	adjacent	nuclei.	There	was	some	evidence	of	increased	astrocytosis	in	the	LGNd	region	of	the	thalamus,	which	contained	many	darkly	stained	hypertrophied	astrocytes	that	was	only	present	in	Tpp1-/-	mice	at	13	weeks	 of	 age	 (Figure	 11a	 and	 b).	 Quantitative	 analysis	 confirmed	 that	 the	 GFAP	immunoreactivity	significantly	increased	from	near	zero	levels	at	9	weeks	to	become	dramatically	higher	than	levels	in	control	mice	(p=<0.001)	(Figure	11c).	Prior	to	13	weeks	 of	 age,	 there	 is	 no	 significant	 increase	 in	GFAP	 immunoreactivity	 in	Tpp1-/-	mice	versus	age-matched	controls.		
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Figure	 11	 Acute	 astrocytosis	 in	 the	 ventral	 posterior	 thalamic	 nucleus.	 (A)	Immunohistochemical	staining	 for	 the	astrocytic	marker,	glial	 fibrillary	associated	protein,	(GFAP)	 reveals	 localised	 astrocytic	 activation	 within	 the	 ventral	 posterior	 nucleus	(VPM/VPL)	 appearing	 suddenly	 at	 13	 weeks	 in	 Tpp1-/-	mice.	 20X	 magnification	 reveals	GFAP-positive	astrocytes	 in	Tpp1-/-	mice	 that	are	not	present	 in	age-matched	controls.	 (B)	Quantitative	 thresholding	 analysis	 of	 GFAP	 confirms	 there	 is	 no	 difference	 in	 GFAP	immunoreactivity	between	Tpp1-/-	mice	and	Tpp1+/+	controls.	GFAP	immunoreactivity	is	first	significantly	elevated	at	13	weeks	in	Tpp1-/-	mice.	n=5	(*=p<0.05,	**=	p<0.01,	***=	p<0.001,	2	way	ANOVA	with	post	hoc	Bonferroni	analysis).	Scale	bar	=	1000	μm.			This	study	showed	astrocytes	are	activated	in	the	thalamus	and	cortex	relatively	late	in	 disease	 progression.	 As	 microglial	 activation	 and	 astrocytosis	 have	 previously	been	shown	to	precede	neuronal	loss,	we	wanted	to	assess	if	this	late	glial	activation	phenotype	is	accompanied	by	delayed	neuronal	cell	loss.		
3.2.5 Progressive	loss	of	thalamocortical	neurons	in	Tpp1-/-	mice	In	 all	 forms	 of	 NCL	 neuron	 loss	 is	widespread,	 but	 analysis	 of	mouse	models	 has	revealed	that	certain	neuron	populations	are	lost	first	(Bible	et	al.,	2004,	Hachiya	et	al.,	2006,	Kielar	et	al.,	2007,	Oswald	et	al.,	2001,	Oswald	et	al.,	2008,	Pontikis	et	al.,	2004,	 Pontikis	 et	 al.,	 2005).	 In	 addition	 to	 Purkinje	 neurons	 and	 deep	 cerebellar	nuclei,	 the	 thalamocortical	 system	 is	 a	 particular	 pathological	 target	 in	 these	
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disorders	in	the	vast	majority	of	mouse	models,	 including	and	preceded	the	loss	of	cortical	 excitatory	 or	 interneuron	 populations	 (Kielar	 et	 al.,	 2007,	 Pontikis	 et	 al.,	2004)	In	 order	 to	 quantify	 the	 nature	 and	 extent	 of	 neuronal	 loss	 in	 this	Tpp1-/-	 mouse	model,	 unbiased	 optical	 fractionator	 estimates	 of	 Nissl	 stained	 neuronal	 number	were	obtained	for	the	two	thalamic	sensory	relay	nuclei	that	have	previously	been	shown	 in	 other	NCLs	 to	 be	 particularly	 vulnerable	 (the	 ventral	 posterior	 thalamic	nucleus,	 VPM/VPL,	 that	 relays	 somatosensory	 information,	 and	 the	 dorsal	 lateral	geniculate	nucleus,	LGNd,	that	relays	visual	information).	This	analysis	revealed	that	both	 the	 VPM/VPL	 and	 the	 LGNd	 showed	 a	 significant	 and	 progressive	 loss	 of	neurons	from	a	relatively	early	age.	
Figure	12	Progressive	loss	of	neurons	in	the	somatosensory	thalamocortical	system	of	
Tpp1-/-	mice.	Histograms	of	unbiased	optical	fractionator	estimates	of	the	number	of	Nissl	stained	 thalamic	 relay	 neurons	 in	 the	 ventral	 posterior	 nucleus	 (VPM/VPL)	 reveal	 the	number	 of	 neurons	 declines	 in	 Tpp1-/-	mice	 from	 6	 weeks	 (A).	 	 Neuronal	 cell	 loss	 is	 not	significant	in	lamina	IV	within	the	somatosensory	barrel	field	region	of	the	cortex	(S1BF,	B)	but	is	seen	in	lamina	V	(C)	and	VI	(D),	becoming	more	severe	with	age.	n=5	(*=p<0.05,	**=	
p<0.01,	***=	p<0.001,	2-way	ANOVA	with	post	hoc	Bonferroni	analysis).		There	was	a	significant	loss	of	Nissl	stained	neurons	within	VPM/VPL	of	Tpp1-/-	mice	by	6	weeks	of	age,	and	this	became	more	severe	with	time,	increasing	to	an	overall	30%	decrease	 in	the	number	of	neurons	 in	this	nucleus	 in	these	mutant	mice	by	9	weeks	 of	 age	 (Figure	 12a).	 This	 reduction	 in	 neuronal	 number	 in	 TPP1-deficient	mice	was	maintained	 in	13-week-old	mice	but	was	not	any	more	pronounced.	The	
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VPM/VPL	relays	sensory	information	to	the	S1BF	region	of	the	cortex	(von	Schantz	et	 al.,	 2009),	 and	 to	determine	 the	 relative	 timing	 in	 this	 cortical	 target	 region	we	also	obtained	optical	fractionator	estimates	of	the	number	of	Nissl	stained	neurons	in	 laminae	 IV	 to	 VI	 of	 S1BF.	 There	were	 different	 degrees	 of	 neuron	 loss	 in	 these	laminae,	 that	 started	 at	 different	 ages	 and	 reached	 different	 extents,	 with	 no	significant	change	in	the	number	of	lamina	IV	neurons	of	the	S1BF	even	in	severely	affected	 13-week-old	Tpp1-/-	mice	 (Figure	 12b).	 In	 contrast,	 neuronal	 cell	 loss	 in	lamina	 V	 of	 SIBF	 first	 became	 apparent	 in	 Tpp1-/-	 mice	 from	 9	 weeks	 of	 age,	 an	average	of	9%	of	neuronal	cells	were	lost.	As	seen	in	the	VPM/VPL	thalamic	nuclei,	neuronal	cell	loss	was	maintained	in	lamina	V	at	13	weeks	of	age	in	Tpp1-/-	mice	but	did	 not	 become	 any	 more	 severe	 compared	 to	 age-matched	 wild	 type	 controls	(Figure	12c).	Neuron	loss	was	also	evident	in	lamina	VI	of	the	S1BF	of	Tpp1-/-	mice,	but	did	not	become	significant	until	13	weeks	of	age,	when	there	was	a	much	larger	decrease	in	cell	number,	compared	to	the	other	laminae,	of	18%	(Figure	12d).		As	 seen	 in	 the	 VPM/VPL	 region,	 there	 was	 also	 a	 profound	 effect	 on	 thalamic	neuronal	cell	number	in	the	LGNd	of	Tpp1-/-	mice	(Figure	13a).	By	6	weeks	of	age,	the	number	of	Nissl	stained	LGNd	neuron	number	in	these	mutant	mice	had	already	decreased	significantly	by	22%,	and	continued	to	decrease	with	disease	progression	until	at	13	weeks	of	age	there	was	on	average	52%	less	neurons	in	the	LGNd	of	Tpp1-




mice.		Histograms	of	unbiased	optical	fractionator	estimates	of	the	number	of	Nissl	stained	thalamic	relay	neurons	in	the	dorsal	lateral	geniculate	nucleus	(LGnD)	reveal	the	number	of	neurons	declines	dramatically	 in	Tpp1-/-	 from	6	weeks	(A).	Neuronal	cell	 loss	 is	evident	 in	lamina	IV	within	the	primary	visual	region	of	the	cortex	(V1,	B)	from	6	weeks	but	does	not	reach	 significance	 in	 lamina	 V	 (C)	 despite	 the	 same	 trend	 and	 a	 reduction	 in	 neuronal	number	is	also	seen	from	6	weeks	in	lamina	VI	(D)	n=5(*=p<0.05,	**=	p<0.01,	***=	p<0.001,	2-way	ANOVA	with	post	hoc	Bonferroni	analysis).		Taken	 together	 these	 data	 suggest	 that	 the	 thalamocortical	 pathways	 are	 also	affected	 in	 TPP1-deficient	mice,	 with	 the	 thalamic	 relay	 neurons	 consistently	 lost	before	 their	 cortical	 counterparts	 and	 to	 a	 greater	 extent.	 These	 degenerative	changes	appear	to	be	more	pronounced	within	visual	pathways	at	a	thalamic	level,	but	less	prominently	within	the	visual	than	the	somatosensory	cortex.	
3.2.6 Assessing	the	level	of	storage	material	accumulation	in	Tpp1-/-	mice	The	classic	pathological	hallmark	of	the	NCLs	is	the	intralysosomal	accumulation	of	autofluorescent	storage	material	(Cooper,	2003),	and	the	initial	characterisation	the	




Figure	14	Autofluorescent	storage	material	 in	Tpp1-/-	 versus	Tpp1+/+	mice.	Unstained	sections	 from	 Tpp1-/-,	 Tpp1+/+	 and	 Cln3-/-	 mice	 were	 mounted	 on	 slides	 and	 the	autofluorescent	 storage	material	was	 visualized	 using	 a	 confocal	microscope	 and	 the	 488	laser.	 The	 phenotypes	 shown	 here	 were	 seen	 throughout	 the	 brains	 of	 these	 mice	 but	representative	pictures	were	taken	from	the	thalamus.	(A)	Sections	from	Tpp1+/+	mice	at	13	weeks	of	age	show	no	autofluorescence.	(B)	Sections	from	Tpp1-/-	mice	at	13	weeks	of	age	show	no	autofluorescence.	(C)	As	a	comparison,	sections	from	Cln3-/-	mice	at	13	months	of	age	(end-stage)-show	autofluorescent	storage	material	granules	in	the	cytoplasm	of	cells.			Given	these	negative	data,	I	decided	to	find	another	surrogate	marker	to	address	the	level	of	storage	burden	in	our	Tpp1-/-	mouse	tissue.		
3.2.7 LAMP1	expression	is	progressively	increased	in	Tpp1-/-	mice	The	 initial	 characterisation	 of	Tpp1-/-	 mice	 not	 only	 reported	 the	 accumulation	 of	autofluorescent	material,	but	also	qualitatively	described	variably	increased	staining	for	 the	 lysosomal	 associated	 membrane	 protein	 1	 (LAMP1),	 but	 did	 not	 quantify	these	 changes	 (Sleat	 et	 al.,	 2004).	 LAMP1	 is	 involved	 in	 maintaining	 lysosomal	membrane	 integrity	 and	 has	 previously	 been	 demonstrated	 amongst	 lysosomal	membrane	 proteins	 to	 exhibit	 the	 greatest	 increase	 in	 expression	 in	 a	 variety	 of	LSDs	(Meikle	et	al.,	1997a).	As	such,	it	may	be	considered	a	useful	surrogate	marker	for	storage	material	accumulation. To	reveal	 changes	 in	LAMP1	expression	during	disease	progression,	 sections	 from	
Tpp1-/-	 and	 control	 wildtype	 mice	 were	 immunostained	 for	 this	 marker.	 This	analysis	revealed	a	progressive	increase	in	LAMP1	immunoreactivity	in	the	brains	of	
Tpp1-/-	 mice,	 but	 this	 appeared	 to	 differ	 in	 extent	 between	 brain	 regions.	Concentrating	 upon	VPM/VPL	 of	 the	 thalamus,	 there	was	 an	 obvious	 and	marked	increase	in	the	intensity	of	LAMP1	staining	in	this	region	of	Tpp1-/-	mice	versus	the	control	animals	from	6	weeks	of	age	onwards	(Figure	15a).	At	higher	magnification,	these	cells	appeared	to	have	a	neuronal	morphology	and	displayed	intense	punctate	LAMP1	staining	in	their	cytoplasm,	whereas	in	wild	type	mice	LAMP1	staining	was	much	more	 pale	 and	 did	 not	 correlate	 with	 cells	 of	 a	 neuronal	 morphology.	 This	
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staining	became	more	intense	and	appeared	to	spread	and	fill	the	cytoplasm	of	these	cells	 in	 mutant	 mice	 at	 13	 weeks	 (Figure	 15b)	 and	 there	 was	 some	 evidence	 of	LAMP1	staining	extending	along	the	processes	of	the	cell.		
	
Figure 15 Increased	LAMP1	expression	 in	 the	 ventral	 posterior	 thalamic	nucleus	 in	
Tpp1-/-	 mice.	 (A)	 Immunohistochemical	 staining	 for	 the	 lysosomal	 activity	 marker,	lysosome	 associated	membrane	 protein	 1,	 (LAMP1)	 shows	 there	 is	 a	 notable	 increase	 in	LAMP1	 in	 the	 ventral	 posterior	 thalamic	 nucleus	 (VPM/VPL)	 in	Tpp1-/-	mice	 compared	 to	age-matched	 controls.	 (B)	 Representative	 pictures	 of	 LAMP1	 immunostaining	 with	increasing	 age	 in	 Tpp1-/-	mice	 in	 the	 VPM/VPL.	 (C)	 Quantitative	 thresholding	 analysis	 of	LAMP1	 demonstrates	 the	 progressive	 elevation	 of	 LAMP1	 in	 Tpp1-/-	 mice.	 LAMP1	immunoreactivity	 is	 first	 increased	 in	 Tpp1-/-	 mice	 at	 6	 weeks	 and	 becomes	 significantly	higher	 than	 Tpp1+/+	mice	 at	 9	 weeks.	 n=5	 (*=p<0.05,	 **=	 p<0.01,	 ***=	 p<0.001,	 2	 way	ANOVA	with	post	hoc	Bonferroni	analysis).	Scale	bar	=	1000	μm. 			A	similar,	but	less	pronounced	increase	in	the	intensity	of	LAMP1	immunoreactivity	was	 also	 evident	 in	 the	 S1BF	 of	 Tpp1-/-	 mice	 (Figure	 16	 a	 and	 d).	 Quantitative	thresholding	image	analysis	was	used	to	quantify	the	progressive	increase	in	LAMP1	immunoreactivity	 and	 confirmed	 that	 there	 was	 a	 significant	 increase	 in	 LAMP1	staining	in	the	VPM/VPL	of	Tpp1-/-	mice	at	9	weeks	of	age	and	this	increases	further	at	 13	 weeks	 (Figure	 15c).	 In	 contrast,	 while	 LAMP1	 immunoreactivity	 also	increased	progressively	in	the	S1BF	of	these	mutant	mice,	it	only	became	significant	
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at	 13	 weeks	 in	 this	 cortical	 region	 (Figure	 16c).	 LAMP1	 immunoreactivity	 was	higher	in	VPM/VPL	compared	to	that	seen	in	S1BF	at	13	weeks	of	age	in	Tpp1-/-	mice	(4%	 versus	 2.5%,	 respectively).	 This	 reflects	 the	 more	 severe	 disease	 phenotype	seen	in	the	thalamus	compared	to	the	cortex	in	Tpp1-/-	mice.		
	
Figure	16	Increased	LAMP1	expression	in	the	somatosensory	region	of	the	cortex	in	
Tpp1-/-	 mice.	 (A)	 Immunohistochemical	 staining	 for	 the	 lysosomal	 activity	 marker,	lysosome	 associated	membrane	 protein	 1,	 (LAMP1)	 shows	 there	 is	 a	 notable	 increase	 in	LAMP1	 in	 the	 somatosensory	 barrel	 field	 cortex	 (S1BF)	 in	Tpp1-/-	mice	 compared	 to	 age-matched	 controls.	 (B)	 Representative	 image	 of	 optimisation	 for	 the	 detection	 of	 LAMP1-positive	 cells,	 highlighted	 in	 blue.	 (C)	Quantitative	 thresholding	 analysis	 confirms	 there	 is	higher	LAMP1	intensity	in	the	S1BF	from	9	weeks	activation	in	Tpp1-/-	mice,	which	increases	significantly	at	13	weeks.	n=5	(*=p<0.05,	**=	p<0.01,	***=	p<0.001,	2	way	ANOVA	with	post	hoc	Bonferroni	analysis).	Scale	bars	=	1000	μm.			
3.3 Summary	and	Discussion	This	 study	 provides	 the	 first	 detailed	 description	 of	 the	 onset	 and	 progression	 of	neuropathological	 changes	 in	 Tpp1-/-	 mice.	 This	 data	 reveals	 a	 pattern	 of	 disease	progression	that	is	unique	within	the	currently	characterized	NCL	mouse	models	to	these	Tpp1-/-	mice,	where	neuronal	cell	loss	is	initiated	in	the	thalamus	and	precedes	microglial	and	astrocytic	activation.	Subsequently,	neuronal	cell	loss	spreads	to	the	
91	
cortical	target	regions	and	is	accompanied	by	glial	activation.	In	addition,	lysosomal	storage	 material	 accumulation	 followed	 a	 similar	 pattern	 to	 glial	 activation,	following	 neuronal	 loss	 in	 the	 thalamus	 and	 coinciding	 with	 neuronal	 loss	 in	 the	cortex	(Table	5).		This	 cohort	 and	 the	 Tpp1-/-	 mice	 used	 by	 our	 collaborators	 on	 the	 C57BL/6J	background,	 has	 a	 significantly	 shorter	 lifespan	 than	 the	 TPP1-deficient	 mice	initially	characterised	by	Sleat	et	al.,	(2004)	which	were	on	a	mixed	C57BL/6J:129SV	genetic	background.	This	suggests	that	there	may	be	strain	specific	modifiers,	which	affect	the	disease	course	in	TPP1-deficient	mice.		
3.3.1 Breeding	program	to	create	Tpp1-/-	mice	The	mice	used	in	this	chapter	were	TPP1-deficient	(Tpp1neoinsArg446His)	mice	and	were	originally	generated	as	described	in	Chapter	3	section	1.2	(Sleat	et	al.,	2004).	They	were	kindly	provided	by	Dr	Matthew	Miscenyi	at	the	Albert	Einstein	College	of	Medicine,	NY,	USA.	These	mice	were	backcrossed	 for	at	 least	 ten	generations	onto	the	C57BL/6J	strain	background.	However,	 further	 information	about	the	breeding	program	 was	 not	 provided	 on	 request.	 Depending	 on	 how	 the	 breeding	 was	conducted	this	may	have	different	implications.	Breeding	may	have	been	conducted	either	with	 Tpp1+/-/NODSCID	 female	 x	 Tpp1-/-/NODSCID	 or	 Tpp+/-/NODSCID	male,	
Tpp1-/-/NODSCID	 female	 x	 Tpp1-/-/NODSCID	 or	 Tpp+/-/NODSCID	 male.	 In	 the	potential	 breeding	 programs	 in	 which	 the	 female	 was	 heterozygous	 for	 the	 Tpp1	gene,	 it	 is	 possible	 that	 TPP1	 enzyme	 produced	 in	 the	 mother	 could	 cross	 the	placenta	 via	 the	 bloodstream	and	 enter	 the	Tpp1-/-	 offspring.	 It	 is	most	 likely	 that	
Tpp1+/-	 females	were	used	 for	mating	because	they	are	healthy	enough	to	produce	offspring;	mating	with	Tpp1-/-	female	mice	is	not	feasible	as	the	mice	are	too	sick	to	finish	 gestation.	 As	 such,	 although	 there	 is	 a	 possibility	 a	 small	 amount	 of	 TPP1	enzyme	may	have	crossed	the	placenta	and	affected	the	developing	embryo,	there	is	no	viable	way	to	control	for	this.	Indeed,	as	all	human	cases	of	CLN2	disease	are	the	product	of	heterozygous	parents,	the	mouse	model	reflects	this.		
3.3.2 The	thalamocortical	system	is	affected	in	Tpp1-/-	mice	For	 reasons	 that	 remain	 unclear,	 the	 thalamocortical	 system	 appears	 to	 be	 a	particular	target	in	the	NCLs.	In	nearly	all	NCL	models,	except	Cln5-/-	mice	where	the	complete	opposite	order	 is	observed	 (von	Schantz	et	 al.,	 2009),	 the	 thalamic	 relay	neurons	are	lost	early	followed	by	neurodegeneration	in	the	corresponding	cortical	
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region.	This	pattern	is	seen	in	several	models	of	 juvenile	CLN3	disease	(Weimer	et	al.,	 2009,	 Pontikis	 et	 al.,	 2005),	 infantile	 CLN1	 (Kielar	 et	 al.,	 2007)	 and	 congenital	CLN10	disease	(Partanen	et	al.,	2008).	Consistent	with	these	observations,	this	study	reveals	that	thalamic	neurons	relaying	different	sensory	information	are	lost	earliest	in	the	disease	progression	in	Tpp1-/-	mice	as	well.			Contrary	to	the	preliminary	studies	carried	out	on	Tpp1-/-	mice	by	Sleat	et	al.,	(2004)	on	a	mixed	C57BL/6J:129SV	genetic	background,	which	 found	 that	 there	was	very	little	 neurodegeneration	 in	 the	 afferent	 visual	 projections,	 in	 this	 cohort	 of	 TPP1-deficient	mice,	the	most	pronounced	effects	on	neuronal	cell	loss	were	in	the	visual	system;	just	as	in	CLN3-	(Pontikis	et	al.,	2004),	Ppt1-	(Kielar	et	al.,	2007)	and	CLN5-	(von	Schantz	et	al.,	2009)	deficient	mice	where	visual	relay	neurons	are	lost	earliest	in	disease	progression.	Neuronal	cell	 loss	 is	significant	at	6	weeks	and	over	half	of	the	neurons	 in	 the	LGNd	are	 lost	 at	13	weeks.	Neuronal	 cell	 loss	was	also	 seen	 in	specific	laminae	(IV	and	VI)	of	the	visual	cortex,	which	the	LGNd	projects	to.	Retinal	degeneration	 and	 vision	 loss	 is	 a	 prominent	 feature	 in	 late	 infantile	 CLN2	disease	patients	(Schulz	et	al.,	2013,	Jalanko	and	Braulke,	2009).	However,	such	early	loss	of	neurons	in	the	visual	relay	system	suggests	that	visual	failure	in	TPP1-deficient	mice	would	 be	 due	 to	 pathology	 in	 the	 central	 visual	 pathways	 rather	 than	 retinal	degeneration	 alone.	 Indeed,	 photoreceptors	 and	 other	 cell	 layers	 in	 Tpp1-/-	C57BL/6J:129SV	mutant	retina	are	primarily	intact	(Sleat	et	al.,	2004),	although	this	should	also	be	investigated	on	the	C57BL/6J	background	alone.	Early	loss	of	neurons	in	the	LGNd	is	also	seen	in	CLN3-deficient	mice	and	may	be	the	cause	of	the	visual	defects	seen	in	juvenile	CLN3	disease	(Weimer	et	al.,	2007).	Such	data	suggests	that	in	these	mouse	models	of	NCL,	visual	problems	are	not	necessarily	caused	by	defects	within	 the	 retina	 itself,	 but	 pathology	 within	 the	 other	 components	 of	 the	 visual	thalamocortical	 system	 (Weimer	 et	 al.,	 2006),	 and	 the	 initial	 report	 of	 these	mice	suggested	 relatively	 little	 degeneration	 in	 the	 visual	 pathways	 (Sleat	 et	 al.,	 2007).	However,	our	data	clearly	reveal	a	loss	of	neurons	in	both	the	thalamic	visual	relay	nucleus	(LGNd)	and	in	the	primary	visual	cortex.	Surprisingly,	 the	extent	of	retinal	pathology	and	visual	function	are	yet	to	be	assessed	in	TPP1	deficient	mice,	and	we	did	 not	 receive	 their	 eyes	 for	 analysis.	 However,	 retinal	 pathology	 is	 certainly	present	 in	 TPP1-deficient	 dogs	 and	 zebrafish	 (Katz	 et	 al.,	 2008,	 Mahmood	 et	 al.,	2013),	and	it	will	be	important	to	relate	the	timing	of	degeneration	in	the	retina	of	
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TPP1-deficient	mice	with	the	data	we	have	collected	from	the	more	central	parts	of	the	visual	pathway.	 	The	somatosensory	thalamocortical	pathway	is	similarly	affected	in	Tpp1-/-	mice	and	indeed	in	all	other	mouse	models	of	NCL	(Shacka,	2012,	Cooper	et	al.,	2006b,	Kielar	et	 al.,	 2007,	 Kuronen	 et	 al.,	 2012,	 Partanen	 et	 al.,	 2008,	 Pontikis	 et	 al.,	 2005,	 von	Schantz	 et	 al.,	 2009).	 Neurons	 in	 the	 VPM/VPL	 are	 significantly	 reduced	 from	 6	weeks	of	age	and	neurons	in	the	deeper	laminae	of	the	S1BF	are	lost	from	9	weeks	of	age.	 These	 cell	 populations	 are	 also	 affected	 in	 Ppt1-/-	mice	 (Kielar	 et	 al.,	 2007).	These	 results	are	 interesting	as	 there	 is	not	an	overt	 somatosensory	phenotype	 in	human	 late	 infantile	CLN2	disease	patients	recorded	 in	 the	 literature.	This	may	be	due	 to	 the	 fact	 that	 humans	 and	 mice	 are	 differentially	 dependent	 on	 sensory	modalities.	Mice	are	much	more	reliant	on	their	somatosensory	system	as	they	use	their	 whiskers	 to	 sense	 changes	 in	 their	 environment;	 whereas	 humans	 use	 the	visual	system	to	a	greater	extent.			That	said,	in	late	infantile	CLN5	disease	patients	(Finnish	variant	LINCL),	who	have	a	similar	 clinical	 phenotype	 to	 classic	 late	 infantile	 CLN2	disease	patients,	 there	 are	believed	to	be	significant	somatosensory	abnormalities.	Myoclonic	epilepsy	 is	seen	in	 infantile	 CLN1,	 late	 infantile	 CLN2	 and	 variant	 late	 infantile	 CLN5	 and	 CLN6	diseases	 (Berkovic	 et	 al.,	 1993)	 and	 is	 often	 associated	with	 giant	 somatosensory	evoked	potentials	(SEPs).	A	study	evaluating	SEPs	in	CLN5	deficient	patients	showed	there	is	increased	somatosensory	cortical	excitability	in	the	primary	and	secondary	somatosensory	areas	(Lauronen	et	al.,	2002).	This	phenotype	is	yet	to	be	explored	in	late	 infantile	 CLN2	 disease	 patients	 but	 it	 is	 conceivable	 that	 a	 somatosensory	phenotype	is	also	present.				 	
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Table	 6	 Comparison	 table	 summarizing	 the	 differences	 in	 neuropathological	
landmarks	 between	Tpp1-/-	 and	Tpp1+/+	 mice.	 The	 table	 summarises	 the	 results	 of	 the	experiments	 described	 in	 more	 detail	 in	 this	 Chapter.	 In	 the	 first	 column:	 the	 type	 of	analysis;	in	the	second	column:	the	region	of	interest;	in	the	third	column:	the	difference	in	
Tpp1-/-	mice	in	relation	to	Tpp1+/+	mice.	Symbols:	=	no	difference,	é	significant	increase,	(é)	increasing	trend,	without	significance,	ê	significant	decrease,	(ê)	decreasing	trend	without	significance.		
	 	 3	 6	 9	 13	
Cortical	
thickness	
M1	 =	 =	 =	 =		 S1BF		 =	 =	 =	 =		 V1		 =	 =	 =	 =		 Lent		 =	 =	 =	 =	
Regional	
volume	 Cortex	 =	 =	 =	 =	
	 Striatum	 =	 =	 	(ê)	  ê		 Thalamus		 =	 =	 				(ê)	 (ê)		 Hippocampus		 =	 =	 =	 =	
Microglial	
activation	 S1BF	 =	 =	 ééé	 ééé		 VPM/VPL		 =	 =	 (é)	 ééé	
Astrocytosis	 S1BF		 =	 (é)	 =	 ééé		 VPM/VPL		 =	 =	 =	 ééé	
Lysosomal	
storage	
S1BF	 =	 =	 =	 ééé		 VPM/VPL		 =	 =	 =	 ééé	
Neuronal	Cell	
Counts	 VPM/VPL	 =	 êê	 êêê	 êêê		 S1BF	lamina	IV		 =	 (ê)	 (ê)	 (ê)	
	 S1BF	lamina	V		 =	 (ê)	 ê	 ê		 S1BF	lamina	VI		 =	 =	 (ê)	 ê		 LGNd		 =	 ê	 êêê	 êêê	
	 V1	lamina	IV		 =	 ê	 (ê)	 (ê)		 V1	lamina	V		 =	 (ê)	 (ê)	 (ê)		 V1	lamina	VI		 =	 ê	 (ê)	 (ê)	
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	We	know	that	in	human	late	infantile	CLN2	disease	patients,	there	is	extensive	and	severe	loss	of	neurons	in	the	cerebral	cortex,	causing	severe	cortical	atrophy	(Sleat	et	al.,	2004,	Schulz	et	al.,	2013,	Alroy	et	al.,	2011).	This	is	not	seen	to	the	same	extent	in	 this	 cohort	 of	 Tpp1-/-	 mice	 that	 we	 have	 studied	 in	 this	 thesis.	 In	 contrast	 to	previous	qualitative	observations	(Sleat	et	al.,	2004),	I	found	no	apparent	effects	on	thickness	of	the	cortical	mantle	or	it’s	volume	of	the	cortex	in	this	study.	These	data	highlight	that	the	extent	of	neuron	loss	we	documented	in	this	tissue	was	clearly	not	extensive	enough	to	cause	cortical	atrophy.	While	the	data	presented	in	this	Chapter	does	 reveal	 that	 neuronal	 degeneration	 has	 begun	 in	 the	 neocortex	 of	 our	Tpp1-/-	mice	at	13	weeks	of	age,	 it	 is	 to	a	much	lower	extent	than	that	seen	in	human	late	infantile	CLN2	disease	 (Schulz	et	 al.,	 2013,	Alroy	et	 al.,	 2011,	 Jalanko	and	Braulke,	2009).	Although	it	is	tempting	to	explain	this	very	simply	as	due	to	the	much	shorter	lifespan	of	mice	compared	 to	humans,	 it	 is	also	part	of	a	consistent	 trend	 that	our	data	 reveal	 a	 milder	 neuropathological	 phenotype	 than	 seen	 in	 previous	 reports	from	these	Tpp1-/-	mice	(Sleat	et	al.,	2004).	This	is	a	topic	that	is	discussed	in	more	detail	below.	
3.3.3 Glial	Activation	has	a	late	onset	in	Tpp1-/-	mice	Early	and	localized	glial	activation	has	been	seen	in	most	NCL	animal	models:	Ppt1-/-	mice	 (Kielar	 et	 al.,	 2007),	Cln3	 knock-out	 and	 knock-in	mice	 (Cotman	 et	 al.,	 2002,	Pontikis	 et	 al.,	 2004,	 Pontikis	 et	 al.,	 2005),	Cln5-/-	mice	 (von	 Schantz	 et	 al.,	 2009),	
Cln6-/-/nclf	mice	(Bronson	et	al.,	1998),	CLN6-deficient	sheep	(Oswald	et	al.,	2005),	
Cln8-/-/mnd	mice	(Cooper	et	al.,	1999)	and	in	familial	Cln10-/-	mice	(Partanen	et	al.,	2008).	The	same	phenotype	has	also	been	documented	in	human	NCL	tissue	(Tyynela	et	al.,	2004).	 Tissue	 specimens	 from	 late	 infantile	 CLN2	 disease	 patients	 show	 similar	pathological	hallmarks:	increased	astrocytosis	is	seen	in	sections	taken	through	the	motor	 cortex	 and	 hypertrophied	 astrocytes	 surround	 a	 portion	 of	 the	 remaining	cortical	neurons	and	there	is	evidence	of	clusters	of	microglia	being	present	(Chang	et	 al.,	 2008).	 These	 observations	 have	 led	 to	 the	 growing	 realisation	 that	neuroinflammation	must	play	a	central	role	in	the	pathogenesis	of	the	NCLs.		Consistent	 with	 other	 NCL	 mouse	 models,	 in	 Tpp1-/-	mice	 astrocytosis	 was	 also	confined	 to	 specific	 regions	 within	 individual	 thalamic	 nuclei,	 most	 notably	 the	VPM/VPL	and	this	coincides	with	where	microglial	activation	was	also	seen.	Indeed,	in	the	cortex,	very	high	levels	of	CD68	and	GFAP	immunoreactivity	are	seen	in	both	
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laminae	IV	and	VI	of	S1BF,	with	slightly	lower	levels	seen	in	lamina	V	of	Tpp1-/-	mice.	Spatially,	neuronal	 cell	 loss	overlaps	with	microglial	 and	astrocytic	 activation.	The	degree	 of	microglial	 activation	was	 not	 directly	 proportional	 to	 neuronal	 cell	 loss	because	 lamina	 IV	 subjectively	 contained	 the	 most	 activated	 microglia,	 however	neuronal	 cell	 loss	 was	 least	 significant	 here.	 Astrocytosis	 was	 present	 relatively	homogenously	 throughout	 S1BF	 of	 TPP1-deficient	mice	 and	 perhaps	 represents	 a	better	 correlation	 with	 the	 neuronal	 cell	 loss	 patterns	 seen	 in	 these	 mice.	 In	 the	thalamus,	 CD68	 immunostained	 microglia	 and	 GFAP	 immunostained	 astrocytes	clearly	 define	 the	 border	 of	 VPM/VPL	 in	 Tpp1-/-	 mice	 and	 both	 markers	 of	 glial	actiavtion	 correlate	 with	 neuronal	 cell	 loss	 in	 this	 area.	 This	 illustrates	 that	neuroinflammation	 is	 occurring	 in	 precisely	 the	 same	 areas	 that	 we	 observe	neuronal	cell	loss	in	TPP1-deficient	mice.	Whereas	glial	activation	generally	precedes	neuronal	loss	in	NCL	animal	models,	the	data	 from	 this	 cohort	 of	 Tpp1-/-	mice	 shows	 that	 both	 astrocytosis	 and	microglial	activation	were	not	present	until	the	end	of	disease	progression,	after	I	had	already	documented	the	onset	of	neuron	loss	which	was	already	significant	in	the	VPM/VPL	region	at	6	weeks	of	age,	whereas	GFAP	immunoreactivity	does	not	reach	significant	levels	 until	 13	 weeks	 and	 before	 this	 age	 very	 little	 astrocytosis	 was	 evident.	Although	 different	 relative	 timings	 of	 astrocytosis	 and	 microglial	 activation	 have	been	 seen	 in	 other	NCL	mice	 (Kielar	 et	 al.,	 2007)	 the	 temporal	 progression	of	 the	microglial	marker	CD68	was	similar	to	that	seen	of	the	astrocytosis	marker	GFAP,	in	this	TPP1-deficient	tissue.	CD68	was	not	significantly	upregulated	until	13	weeks	of	age	in	mutant	mice;	meanwhile	40%	of	VPM/VPL	neurons	had	already	been	lost	at	9	weeks.	 These	 data	 suggest	 a	 distinctive	 temporal	 pattern	 of	 neuronal	 cell	 loss	preceding	glial	activation	in	the	thalamus	in	TPP1-deficient	mice.			The	data	from	this	cohort	of	TPP-1-deficient	mice	emphasises	that	this	relatively	late	onset	of	glial	activation	relative	to	neuron	loss	was	not	confined	to	the	thalamus,	but	was	also	evident	 in	 the	cortex.	Highly	activated	microglia,	with	brain	macrophage-like	morphology	were	evident	 in	 the	somatosensory	cortex	of	TPP1-deficient	mice	from	9	weeks	of	age,	 coinciding	with	 the	 timing	of	 significant	neuronal	cell	 loss	 in	lamina	V.	 Interestingly,	a	recent	study	 in	Ppt1-/-	mice	 found	that	neuronal	 loss	and	glial	 activation	 did	 not	 precede	 neuronal	 loss	 as	 is	 seen	 in	most	 NCL	models	 but	actually	occurred	at	the	same	time	in	VPM/VPL	(Kuhl,	2013).	This	suggests	there	is	also	no	prior	activation	of	the	innate	immune	response	before	neuronal	loss	in	some	
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cohorts	of	PPT1-deficient	mice	 in	 some	regions	as	well	 as	 in	 this	 cohort	of	Tpp1-/-	mice.	It	 is	 not	 clear	 whether	 the	 presence	 of	 microglia	 in	 the	 TPP1-deficient	 forebrain	represents	 an	 attempted	 regenerative	 response,	 but	 activated	microglia	 can	 cause	additional	neuronal	damage	through	the	expression	of	inflammatory	mediators,	and	induce	neuronal	apoptosis	 (Allan	and	Rothwell,	2003,	Perego	et	al.,	2011,	Wang	et	al.,	 2007).	 Likewise,	 astrocytosis	 regulates	 CNS	 inflammation	 by	 releasing	 either	pro-	or	anti-inflammatory	molecules	(Eddleston	and	Mucke,	1993,	John	et	al.,	2003)	and	 exerting	 pro-	 and	 anti-inflammatory	 effects	 on	 microglia	 (Min	 et	 al.,	 2006).	These	 pro	 and	 anti-inflammatory	 responses	 may	 be	 exerted	 at	 different	 times	following	insults	or	depending	what	the	insult	was.		The	contribution	of	glial	activation	to	neurodegenerative	disease	is	explained	in	this	Chapter	 in	 sections	 1.6.3	 and	 1.6.4.	 However,	 co-culture	 of	 mutant	 Cln3-/-	 glia	separately	with	Cln3-/-	and	wild-type	neurons	has	been	shown	to	negatively	 impact	the	health	of	both.	The	mutant	neurons	were	most	affected	by	co-culture	with	Cln3-/-	glia,	undoubtedly	because	of	their	own	compromised	biology	(Parvainen,	2013).	It	 will	 be	 important	 to	 investigate	 this	 relationship	 between	 microglial	 and	astrocytic	activation	and	neuronal	cell	loss.	One	possible	explanation	for	the	delayed	astrocytosis	 phenotype	 seen	 in	 the	 TPP1-deficient	 mice	 in	 this	 thesis	 is	 that	 the	biology	of	 the	astrocytes	 is	 impaired,	as	 is	 seen	 in	both	Ppt1-/-	and	Cln3-/-	astrocyte	cultures.	Cln3-/-	astrocytes	have	a	disrupted	actin	cytoskeleton	and	perhaps	because	of	 that	 they	have	an	attenuated	response	to	stimulation	in	vitro	(Parvainen,	2013).	Equally,	 Ppt1-/-	 astrocytes	 morphologically	 appear	 already	 stimulated	 prior	 to	stimulation	and	respond	incompletely	to	further	stimulation	in	culture	(Marta	Mila,	MSc	 Student,	 personal	 communication).	 We	 have	 already	 started	 to	 investigate	whether	the	same	phenotypes	are	seen	in	astrocytes	from	TPP1-deficient	mice	with	the	 same	 C57BL/6J	 background	 used	 in	 this	 thesis.	 Despite	 astrocytes	 being	biologically	 impaired	 in	 Ppt1-/-	 mice,	 preventing	 the	 morphological	 change	 in	astrocytes	that	are	classically	associated	with	glial	activation	in	PPT1-deficient	mice	results	in	accelerated	disease	progression	(Macauley	et	al.,	2011).	This	was	achieved	by	preventing	GFAP	upregulation	in	reactive	astrocytes	by	generating	mice	with	null	mutations	 for	 GFAP,	 Vimentin	 and	 PPT1.	 GFAP-/-Vim-/-Ppt1-/-	 mice	 had	 shorter	lifespans	 and	 increased	 neurodegeneration,	 immune	 cell	 infiltration	 and	autofluorescent	 storage	 material	 compared	 to	 Ppt1-/-	mice,	 suggesting	 that	 GFAP	upregulation	 is	 neuroprotective	 in	 PPT1-deficient	 mice	 (Macauley	 et	 al.,	 2011).	
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However,	given	that	GFAP	is	also	present	in	neural	progenitors	effects	on	these	cells	cannot	be	ruled	out.	The	possible	contribution	of	glial	activation	and	neuroinflammation	to	late	infantile	CLN2	 disease	 is	 further	 explored	 in	 Chapter	 8	 sections	 3	 and	 5.	 	 However,	 these	observations	raise	questions	as	to	whether	the	accelerated	disease	progression	that	occurs	 in	 the	 TPP1-deficient	 mice	 in	 this	 thesis,	 could	 in	 part	 be	 due	 to	 the	astrocytes.	 One	 hypothesis	 is	 that	 astrocytes	 in	 Tpp1-/-	 mice	 also	 have	 currently	unknown	 impaired	 biology	 so	 that	 they	 have	 a	 delayed	 reaction	 to	 stimuli.	 As	 a	result,	the	neuroprotective	role	of	GFAP	upregulation	during	astrocyte	activation	in	late	 infantile	 CLN2	 disease	 occurs	 too	 late,	 causing	 the	 disease	 to	 progress	 more	rapidly.	So,	targeting	microglia	and	astrocytes	may	be	a	future	avenue	to	explore	in	improving	disease	outcomes	 for	 late	 infantile	CLN2	disease	patients.	 Indeed,	 bone	marrow	transplant	(BMT)	improved	survival	and	efficacy	of	gene	therapy	in	Ppt1-/-	mice	 (Macauley	 et	 al.,	 2012)	 and	 one	possible	 explanation	 is	 that	BMT	 introduces	normal	microglia	 into	 the	CNS,	suppressing	the	activated	microglia	and	decreasing	neuronal	apoptosis	(Wada	et	al.,	2000).		
3.3.4 Lysosomal	storage	does	not	necessarily	predict	neuronal	loss	Accumulation	of	autofluorescent	storage	material	in	the	lysosome	is	characteristic	of	the	NCLs	(Cooper,	2003,	Anderson	et	al.,	2013),	however	there	is	currently	no	direct	evidence	 that	 this	 is	 linked	 to	 neuronal	 cell	 death.	 Most	 cells	 in	 the	 CNS	 and	peripheral	 tissues	 in	 NCL	models	 contain	 storage	material	 but	 specific	 subsets	 of	neuronal	cells	are	lost.	Within	the	affected	subsets	of	neuronal	populations	there	has	been	no	definitive	evidence	linking	neurodegeneration	and	neuroinflammation	with	increased	 storage	material	 accumulation	 in	 various	NCL	models	 (Kay	 et	 al.,	 2006,	Cooper	et	al.,	2006,	Oswald	et	al.,	2005,	Oswald	et	al.,	2008).		Our	 data	 revealed	 that	 increased	 LAMP1	 expression,	 which	 is	 associated	 with	increased	 lysosomal	 storage	 (Meikle	 et	 al.,	 1997b),	 is	 elevated	 progressively	throughout	the	brains	of	Tpp1-/-	mice.	However,	this	occurred	to	different	extents	in	different	 brain	 regions.	 Intriguingly	 LAMP1	 expression	 was	 highest	 in	 the	 areas	where	 neuronal	 cell	 loss	 was	 most	 evident	 (Figure	 16).	 This	 increase	 in	 LAMP1	immunoreactivity	may	be	caused	by	the	infiltration	of	microglia,	which	exhibit	high	expression	 levels	 of	 LAMP1	 (Sleat	 et	 al.,	 2004)	 and	 further	 immunohistochemical	stainings	could	be	conducted	to	investigate	CD68	and	LAMP1	coexpression.	Indeed,	CD68	and	LAMP1	show	similar	temporal	and	spatial	expression	patterns	in	the	S1BF	
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and	 the	VPM/VPL.	And/or	 the	 increase	 in	LAMP1	 intensity	 is	 caused	by	 increased	neuronal	LAMP1	levels	as	a	result	of	a	secondary	response	to	the	storage	material	in	the	cells.		Although	we	will	need	to	do	colocalisation	studies	to	be	sure	this	increased	storage	isn’t	simply	present	in	microglia	it	appears	that	in	this	form	of	NCL	(or	at	least	in	this	cohort	 of	 TPP1-deficient	mice	 on	 a	 C57BL/6J	 genetic	 background)	 that	 there	 is	 a	closer	 relationship	 between	 where	 storage	 occurs,	 how	 much	 it	 occurs	 and	 the	extent	of	neuron	loss.	It	will	be	important	to	stain	for	the	storage	material	itself	and	Subunit	c	of	mitochondrial	ATP	synthase	(SCMAS)	as	the	major	protein	component	of	 storage	material	 in	 the	human	disease	 (Anderson	et	 al.,	 2013,	Hall	 et	 al.,	 1991)	should	also	be	examined	in	this	mouse	model	(despite,	unfortunately,	the	antibodies	being	 rather	 poor)	 to	 determine	 if	 there	 is	 any	 relationship	 between	 its	accumulation	and	the	neuron	loss	that		have	been	documented	in	this	thesis.		
3.3.5 What	is	killing	these	Tpp1-/-	mice?	Taken	together	our	data	show	modest	neuronal	degeneration	in	the	thalamocortical	pathways	followed	by	a	pronounced	but	late	onset	glial	activation	with	the	absence	of	fluorescent	autofluorescent	storage	material	but	increased	lysosomal	number	and	size.	They	are	perhaps	not	what	one	might	expect	to	see	at	disease	end	stage	for	a	mouse	 model,	 which	 causes	 an	 aggressive	 late	 infantile	 CLN2	 disease	 phenotype.	Certainly	 these	 phenotypes	 are	 milder	 than	 those	 reported	 in	 the	 initial	characterisation	 of	Tpp1-/-	mice	 on	 a	mixed	C57BL/6J:129SV	background	 (Sleat	 et	al.,	2004).	The	TPP1-deficient	mice	on	a	congenic	C57BL/6J	background	used	in	this	study	die	predictably	at	14	weeks	of	age	are	usually	culled	at	around	13	weeks	of	age	for	humane	reasons.	These	are	not	isolated	observations,	but	are	consistent	for	our	mice	house	here	at	KCL,	and	our	collaborators	at	AECOM	who	supplied	the	fixed	tissue	 for	 this	 histological	 analysis.	 This	 premature	 death	 is	 surprisingly	 much	earlier	 than	 the	 death	 of	 PPT1-deficient	 mouse	 model	 of	 infantile	 CLN1	 disease,	which	dies	at	approximately	8	months	of	age.	This	highlights	a	disconnect	between	the	mouse	 and	 human	 condition,	 because	 the	 survival	 rate	 of	 late	 infantile	 CLN2	disease	patients	is	generally	longer	than	infantile	CLN1	disease	patients.		Importantly	our	current	colonies	of	C57BL/6J	congenic	Tpp1-/-	mice	predictably	die	at	 around	 90	 days,	which	 is	 also	 considerably	 earlier	 than	 the	median	 survival	 of	
Tpp1-/-	mice	 on	 a	 mixed	 strain	 background,	 C57BL/6J:129SV,	 which	 was	 initially	reported	to	be	138	days	(nearly	20	weeks	of	age),	with	90%	of	animals	found	dead	
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between	108	and	169	days	(Sleat	et	al.,	2004).	The	reason	for	the	reduced	mortality	in	 current	 strains	 is	 not	 clear,	 but	may	 reflect	 the	 inbred	nature	of	 the	C57	 strain	background	or	a	strain	specific	modifier	of	the	CLN2	phenotype	as	indicated	by	the	longer	 survival	 rates	 seen	 on	 an	 isogenic	 129SV	 background	 (median	 164	 days)	(Sleat	et	al.,	2004).	Alternatively,	it’s	possible	that	genetic	drift	may	have	occurred	in	the	 prolonged	 maintenance	 of	 these	 mice,	 but	 since	 we	 (and	 our	 collaborators)	periodically	backcross	our	mutants	with	control	mice	to	prevent	this	happening	this	seems	unlikely.		It	 may	 well	 be	 that	 the	 relatively	 mild	 neuropathological	 phenotypes	 we	 have	documented,	of	delayed	glial	activation,	absence	of	autofluorescent	storage	material,	very	modest	regional	atrophy	of	the	brain	but	moderate	neurodegeneration	within	specific	thalamic	nuclei,	would	become	more	severe	if	the	mice	were	to	live	longer.	In	 this	 respect	 it	 will	 be	 important	 to	 identify	 why	 do	 these	 C57	 congenic	 TPP1-deficient	mice	die	earlier	now,	and	so	suddenly?	One	possibility	is	the	TAF10B	gene,	which	sits	proximal	to	CLN2	(Sleat	et	al.,	2004).	When	designing	their	CLN2	targeting	strategy,	 Sleat	 et	 al.,	 (2004)	 realised	 the	possibility	 that	because	 the	CLN2	 locus	 is	very	gene-rich,	 it	was	possible	that	other	genes	could	be	inadvertently	targeted.	 In	the	original	Tpp1-/-	mice	population,	 real-time	PCR	 showed	 there	were	85%	±10%	TBP-associated	 factor	 10b	 (TAF10B)mRNA	 levels	 compared	 to	 control	 wild	 type	brains.	TAF10B	is	a	transcription	factor	needed	to	control	the	cell	cycle	(Martinez	et	al.,	 1998).	 These	 authors	 concluded	 that	 the	 positional	 effects	 on	 TAF10B	 do	 not	contribute	 to	 the	 observed	 phenotype	 of	 their	 TPP1-deficient	 mice,	 however	 our	data	suggest	that	maybe	there	are	such	effects	that	have	only	now	become	apparent		In	 addition,	 it	 is	 important	 to	 remember	 that	 the	Tpp1neoinsArg446His	mutation	 is	not	 an	 exact	 copy	 of	 a	 human	 mutation	 (Sleat	 et	 al.,	 2004).	 Compound	heterozygosity	for	a	null	allele	combined	with	an	Arg447His	missense	mutation	(the	equivalent	mutation	 in	humans),	 causes	CLN2	disease	with	a	 relatively	 later	onset	(Sleat	 et	 al.,	 1997).	 Patients	with	 this	 rare	 combination	develop	 symptoms	 from	8	years	old	and	disease	progression	is	relatively	slow.	Indeed,	some	patients	with	the	mutation	have	survived	into	their	fourth	decade	of	life	(Sleat	et	al.,	1997).	Such	data	further	highlight	 the	differences	 in	human	versus	mouse	NCL	disease	phenotypes.	Sleat	et	al.,	(2004)	concluded	that	the	relative	difference	in	longevity	between	mice	and	 humans	 with	 the	 equivalent	 mutation	 can	 be	 attributed	 to	 species-specific	metabolic	differences,	but	it	would	be	important	to	define	the	precise	nature	of	such	
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effects.	As	discussed	in	the	introduction,	large	animal	models	of	late	infantile	CLN2	disease,	 such	 as	 the	 exisiting	 dog	model,	 would	 have	 the	 advantage	 of	 larger	 and	more	complex	gyrencephalic	brains	that	more	closely	resemble	the	human	brain.	In	this	 respect,	 large	 animal	 models	 have	 certain	 advantages	 for	 modelling	 CNS	diseases,	 and	 for	 addressing	 practical	 issues	 like	 the	 biodistribution	 of	 proteins	delivered	to	the	brain.	However,	at	present	there	has	been	no	systematic	analysis	of	the	onset	and	progression	of	neuropathology	in	TPP1	deficient	Dachshunds,	and	the	only	 data	 available	 are	 from	 the	 end	 stage	 of	 disease	 (Vuillemenot	 et	 al.,	 2011,	Vuillemenot	 et	 al.,	 2014a).	 As	 such,	 there	 is	 no	 information	 available	 about	 how	storage	material	accumulation,	neuron	loss	and	glial	activation	relate	to	one	another.	What	 is	 apparent	 though,	 from	 both	 published	 and	 unpublished	 data	 is	 that	 at	disease	end	stage	the	TPP1	deficient	Dachshund	brain	is	very	severely	affected	with	pronounced	 cortical	 thinning,	 very	 pronounced	 astrocytosis	 and	 microglial	activation	 and	 massive	 amounts	 of	 storage	 material	 present	 (Vuillemenot	 et	 al.,	2014a;	 Cooper,	 personal	 communication).	 It	 will	 be	 important	 to	 determine	 the	relative	 staging	of	 these	 events	 so	 that	 comparisons	 can	be	made	with	our	mouse	data.		Nevertheless,	 it	 is	apparent	that	the	extent	of	neuropathology	is	qualitatively	more	pronounced	in	the	TPP1-deficient	Dachshunds	than	in	the	corresponding	mice,	with	the	cortical	mantle	much	more	affected	in	dogs	than	mice	(Vuillemenot	et	al.,	2014a,	Sleat	et	al.,	2007,	data	in	this	thesis).	This	is	consistent	with	observations	comparing	Cln6nclf	 mice	 and	 CLN6	 deficient	 sheep	 (Oswald	 et	 al.,	 2005,	 2008;	 Morgan	 et	 al.,	2013),	 with	 the	 suggestion	 being	 that	 more	 complex	 brains	 are	 more	 severely	affected.	 It	 is	 important	 to	 recognise	 that	 TPP1	 deficient	 zebrafish,	 despite	 a	relatively	 simple	 CNS	 do	 show	 pronounced	 retinal	 and	 brain	 degeneration	(Mahmood	 et	 al.,	 2013).	 In	 this	 sense,	 it	 may	 be	 that	 there	 are	 species-specific	consequences	of	CLN2/TPP1	deficiency,	 and	data	 from	different	models	 should	be	interpreted	with	caution.		With	animal	models	of	TPP1	deficiency	now	existing	from	several	different	species,	it	 is	 likely	 that	 they	 will	 have	 their	 own	 advantages	 and	 limitations	 for	 different	experimental	 purposes.	Nevertheless,	 TPP1	deficient	 zebrafish	 are	perhaps	 ideally	suited	 for	 drug	 screening	 approaches	 (Mahmood	 et	 al.,	 2013).	 Moreover,	 TPP1-deficient	 mice	 have	 proven	 crucial	 for	 the	 testing	 of	 both	 gene	 therapy	 and	 ERT	approaches	(Whiting	et	al.,	2014,	Vuillemenot	et	al.,	2011,	Vuillemenot	et	al.,	2014a),	
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which	 were	 subsequently	 tested	 in	 TPP1-deficient	 dogs	 leading	 to	 the	 successful	initiation	of	an	ERT	trial	in	CLN2	disease	patients.		
3.3.6 Comparison	of	Tpp1-/-	mouse	pathology	with	other	CLN2	disease	models	Several	 animal	models	 of	 TPP1	deficiency	now	exist,	 and	 according	 to	 the	 species	they	 are	 in	 will	 have	 their	 own	 advantages	 and	 limitations	 according	 to	 the	complexity	of	 the	brain.	 It	 is	 also	 apparent	 that	not	 all	 of	 these	models	have	been	characterised	 to	 the	 same	 extent,	 and	 certain	 pieces	 of	 data,	 like	 for	 example	 the	extent	of	retinal	pathology	in	mice,	are	still	missing.	TPP1	deficient	zebrafish	show	pronounced	retinal	and	brain	degeneration,	and	a	range	of	behavioural	defects	that	lend	themselves	to	dug	screening	approaches	(Mahmood	et	al.,	2013).	The	extent	of	cortical	pathology	of	TPP1	deficient	mice	is	generally	less	pronounced	that	that	seen	in	TPP1	deficient	dogs	 (Katz	et	 al.,	 2008,	Vuillemenot	et	 al.,	 2014)	but	 reflects	 the	relative	 simplicity	 of	 the	 mouse	 brain.	 Nevertheless,	 both	 of	 these	 species	 have	demonstrated	 their	 usefulness.	 TPP1-deficient	 mice	 have	 proven	 crucial	 for	 the	testing	of	both	gene	therapy	and	ERT	approaches	(Whiting	et	al.,	2014,	Vuillemenot	et	 al.,	 2011,	 Vuillemenot	 et	 al.,	 2014a),	 which	were	 subsequently	 tested	 in	 TPP1-deficient	dogs	leading	to	the	successful	initiation	of	a	trial	in	CLN2	disease	patients.		This	 study	 reveals	 how	 important	 it	 is	 that	 this	Tpp1-/-	mouse	model	 is	 studied	 in	more	 depth.	 Therapeutic	 efforts	 have	 so	 far	 concentrated	 on	 this	 model	 without	properly	 defining	 that	 the	 disease	 progresses	 very	 suddenly,	 and	 becomes	 severe	just	 before	 the	 mice	 die.	 It	 has	 not	 been	 possible	 to	 look	 at	 more	 neuronal	populations	 in	 this	 study,	 however	 due	 to	 the	 atrophy	 seen	 in	 the	 striatum,	 this	warrants	further	investigation.	In	addition,	the	cerebella	of	Tpp1-/-	mice	may	give	us	more	 insight	 into	 the	 short	 lifespan	 of	 these	 mice.	 In	 the	 next	 section,	 the	 same	neuropathological	 landmarks	 will	 be	 investigated	 in	 Tpp1-/-	 mice	 on	 an	immunodeficient	 genetic	 background.	 This	 will	 reveal	 the	 involvement	 of	 the	immune	system	in	the	disease	outcome.				 	
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Chapter	4 	
Neuropathology	 of	 TPP1-deficient	 mice	 on	 an	
Immunodeficient	background		 	
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4.1 Introduction	In	 this	 chapter,	 I	 sought	 to	 characterise	 TPP1-deficient	mice	without	 the	 adaptive	immune	system,	which	could	later	be	used	for	determining	the	therapeutic	outcome	of	neural	stem	cell	therapy	in	these	mice	(as	discussed	in	Chapter	5).	It	is	important	to	characterise	these	mice	in	order	to	evaluate	the	therapeutic	benefit	of	neural	stem	cell	 transplantion	 on	 CLN2	 disease	 progression.	 The	 same	 neuropathological	phenotypes	 that	were	 investigated	 in	 Chapter	 4	 in	Tpp1-/-	mice	were	 examined	 in	TPP1-deficient	on	an	immunodeficient	background.		In	 addition,	 the	 phenotype	 of	 these	 TPP1-deficient	 mice	 on	 an	 immunodeficient	background	 was	 compared	 to	 those	 with	 an	 intact	 immune	 system.	 An	immunodeficient	 mouse	 model	 of	 juvenile	 CLN3	 disease	 (Seehafer	 et	 al.,	 2011)	demonstrates	 reduced	 neuroinflammation	 and	 vulnerable	 neuronal	 populations	were	protected,	compared	to	Cln3-/-	mice	with	an	intact	immune	system	(Seehafer	et	al.,	 2011).	 In	 addition,	 PPT1-deficient	mice	 that	 lack	 the	 adaptive	 immune	 system	(Groh	 et	 al.,	 2013)	 have	 an	 attenuated	 disease	 onset,	 with	 a	 delayed	 astrocyte	response	and	relatively	lower	levels	of	microglial	activation	in	the	early	stages	of	the	disease	 (Groh	 et	 al.,	 2013,	Kuhl,	 PhD	 thesis,	 2013)	 and	 these	mice	 have	 increased	lifespan	compared	to	PPT1-deficient	mice	with	an	intact	immune	system	(Groh	et	al.,	2013).		As	such,	the	hypothesis	here	was	that	removing	the	adaptive	immune	system	in	TPP1-deficient	mice	would	result	in	a	less	severe	disease	phenotype,	as	is	seen	in	these	two	other	NCL	mouse	models.		
4.2 Why	NODSCID	mice	and	what	are	they?	Treatment	of	the	soluble	enzyme	forms	of	NCL	is	based	upon	delivering	the	missing	enzyme	to	the	brain	(Kohan	et	al.,	2011).	One	method	to	achieve	this	goal	could	be	to	use	human	central	nervous	system	stem	cells	(huCNS-SCs)	as	a	cell-based	delivery	system	to	deliver	this	enzyme,	which	can	be	taken	up	by	cells	 in	the	brain	to	cross	correct	 the	disease	 (see	Chapter	1	 section	2.1)	 (Tamaki	 et	 al.,	 2002,	Tamaki	 et	 al.,	2009,	 Uchida	 et	 al.,	 2000).	 It	 has	 previously	 been	 shown	 that	 huCNS-SCs	transplanted	into	a	mouse	model	of	infantile	CLN1	disease	survive	grafting,	secrete	the	 missing	 enzyme	 and	 may	 provide	 therapeutic	 benefits	 (Tamaki	 et	 al.,	 2009).	Early	 transplantation	 resulted	 in	 improved	 motor	 function	 and	 a	 reduction	 in	autofluorescent	 lipofuscin.	 It	 is	hypothesized	that	 late	 infantile	CLN2	disease	could	
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be	 treated	 in	 a	 similar	way.	 In	 Chapter	 5,	 the	 fate	 of	 huCNS-SCs	 transplanted	 into	TPP1-deficient	mice	will	be	determined.			The	TPP1-deficient	mice	used	in	this	study	were	backcrossed	with	immunodeficient	NODSCID	mice,	which	 lack	T	and	B-lymphocyte	mediated	 immunity	 (Schultz	et	al.,	1995),	 in	order	 that	 transplanted	huCNS-SCs	are	not	 rejected	 (Ito	et	al.,	2002,	van	der	 Loo	 et	 al.,	 1998).	 An	 alternative	 strategy	 to	 avoid	 immune	 rejection	 of	 the	transplanted	 huCNS-SCs	 is	 to	 use	 chemical	 immune	 suppression,	 such	 as	
Mycophenolate	motefil,	 as	might	be	used	 in	 clinical	 trials	 in	CLN2	disease	patients.	However,	 our	 collaborators	 chose	 to	 develop	 Tpp1-/-/NODSCID	 mice	 in	 order	 to	avoid	 complicated	 daily	 dosing	 strategies	 that	 still	 may	 not	 accurately	 reflect	 the	patient’s	 dose	 or	 completely	 remove	 T-cell	 function	 (Nubuko,	 Stem	 Cells	 Inc.,	personal	 communication).	 NODSCID	 mice	 are	 generated	 by	 back	 crossing	 severe	combined	 immunodeficiency	 (scid)	 mice	 with	 nonobese	 diabetic	 (NOD)	 mice	 to	produce	 a	 population	 of	mice	with	multiple	 defects	 in	 adaptive	 and	 non-adaptive	immune	function,	which	are	also	diabetes	and	insulitis-free	throughout	life	(Schultz	et	 al.,	 1995).	 Before	 the	 efficacy	 of	 huCNS-SCs	 treatment	 can	 be	 successfully	evaluated,	 the	 neuropathology	 of	 this	 mouse	 model	 needs	 to	 be	 established.	 In	addition,	given	the	influence	of	the	immune	system	in	other	forms	of	NCL	(Seehafer	et	 al.,	 2011,	 Blom	 et	 al.,	 2013,	 Groh	 et	 al.,	 2013,	 Lim	 et	 al.,	 2006),	 I	 decided	 to	compare	 the	 phenotype	 of	 these	 immune-deficient	 NODSCID	Tpp1-/-	 mice,	 to	 that	seen	in	TPP1-deficient	mice	with	an	intact	immune	system. 
	
4.3 RESULTS	
4.3.1 	Regional	Atrophy	and	cortical	thinning	in	Tpp1-/-/NODSCID	mice	As	 previously	 described,	 all	 mouse	 models	 of	 NCL	 display	 regional	 atrophy	 of	different	 brain	 regions	 that	 occurs	 to	 different	 extents	 according	 to	 the	 disease	model	 (Bible	 et	 al.,	 2004,	 Pontikis	 et	 al.,	 2004,	 Pontikis	 et	 al.,	 2005,	 Pearce	 et	 al.,	2006,	 Cooper	 et	 al.,	 2007,	 Kuhl	 et	 al.,	 2013,	 Kielar	 et	 al.,	 2007,	 von	 Schantz	 et	 al.,	2009).	However,	in	the	Tpp1-/-	mice	on	a	C57BL/6J	background,	assessed	in	Chapter	3,	significant	atrophy	was	only	evident	in	the	striatum	at	13	weeks.	To	determine	the	extent	of	regional	atrophy	in	Tpp1-/-/NODSCID	mice,	the	Cavalieri	method	was	used	to	measure	 the	volume	of	4	areas	of	 the	brain	(cortex,	hippocampus,	 striatum	and	thalamus).	This	analysis	revealed	there	was	a	significant	decrease	in	the	volumes	of	
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the	 cortex,	 thalamus	 and	 striatum,	 but	 not	 the	 hippocampus,	 of	 Tpp1-/-/NODSCID	mice	at	16	weeks	of	age,	compared	to	control	mice.		In	 16-week	 old	 Tpp1-/-/NODSCID	 mice	 there	 was	 significant	 cortical	 atrophy	compared	 to	 control	 animals	 (p=0.017,	Figure	 17a).	 In	 the	 striatum,	 there	was	 a	significant	 (p=0.027,	 Figure	 17a)	 reduction	 in	 volume	 in	 Tpp1-/-/NODSCID	 mice	compared	 to	 Tpp1+/-/NODSCID	mice.	 The	 largest	 change	 in	 regional	 volume	 in	 in	




Figure	 17	 Regional	 atrophy	 and	 cortical	 thinning	 in	 Tpp1-/-/NODSCID	 mice	 versus	
Tpp1+/-/NODSCID	 controls.	 (A)	 Histograms	 of	 unbiased	 Cavalieri	 estimates	 of	 regional	volume	demonstrate	 significant	 atrophy	 in	 the	 cortex,	 striatum	and	 thalamus,	 but	 not	 the	hippocampus	 in	16	week-old	Tpp1-/-/NODSCID	mice	compared	 to	controls.	 (B)	Histograms	of	 cortical	 thickness	 measurements	 reveal	 significant	 thinning	 of	 the	 cortical	 mantle	 to	different	extents	in	the	primary	motor	cortex	(M1),	the	somatosensory	barrel	field	(S1BF),	the	primary	visual	cortex	(V1)	and	the	Lateral	entorhinal	cortex	(LEnt)	in	Tpp1-/-/NODSCID	mice	 compared	 to	 Tpp1+/-/NODSCID	 controls.	 (C)	 Representative	 pictures	 of	 cortical	thickness	(*=p<0.05,	**=	p<0.01,	***=	p<0.001,	Unpaired	Student’s	T-test).	Scale	bar=	1000	μm.		To	 determine	 whether	 the	 cortical	 atrophy	 seen	 was	 regionally	 specific,	measurements	 of	 cortical	 thickness	 in	 four	 brain	 regions,	 including	 the	 primary	motor	(M1),	somatosensory	(S1BF),	visual	 (V1)	and	 lateral	entorhinal	 (LEnt)	were	taken	 from	 Nissl	 stained	 coronal	 sections.	 This	 analysis	 revealed	 there	 to	 be	 a	statistically	 significant	 decrease	 in	 the	 thicknesses	 of	 all	 these	 areas	 in	 TPP1-deficient	mice	(Figure	17b).		In	 the	 M1,	 the	 cortical	 thickness	 was	 significantly	 (p=0.016)	 reduced	 by	 13%	 in	
Tpp1-/-/NODSCID	mice	end	stage	mice	(Figure	17b)	versus	Tpp1+/-/NODSCID	mice.	The	somatosensory	barrel	 field	cortex	(S1BF)	was	significantly	(p=0.0016)	thinner	by	 12%	 in	 16-week-old	Tpp1-/-/NODSCID	mice	 compared	 to	 control	mice	 (Figure	
17b).		In	addition,	the	primary	visual	cortex	(V1)	showed	a	significant	(p=0.016)	reduction	in	 thickness	 of	 13%	 in	 Tpp1-/-/NODSCID	 mice	 (Figure	 17b).	 Lastly	 the	 lateral	entorhinal	cortex	(LEnt)	also	showed	a	significant	(p=0.014)	reduction	in	thickness,	
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with	a	14%	reduction	 in	 the	 thickness	of	 the	 cortical	mantle	 this	 region	of	Tpp1-/-
/NODSCID	mice	versus	Tpp1+/-/NODSCID	mice	(Figure	17b).		The	 widespread	 and	 severe	 thinning	 of	 the	 cortical	 mantle	 could	 be	 an	 effect	 on	shortening	or	 loss	of	dendritic	arbours	on	cells	or	 indeed	 loss	of	glial	populations,	which	 contribute	 to	 the	 thickness	 of	 the	 cortical	 mantle.	 Alternatively,	 or	concurrently	it	could	be	as	a	result	of	extensive	neuronal	loss	in	these	regions.			
4.3.2 Thalamocortical	neuron	loss	in	Tpp1-/-/NODSCID	mice	It	has	previously	been	shown	neuron	loss	is	seen	throughout	the	brain	of	many	NCL	models	 (Kuhl	 et	 al.,	 2013,	Kielar	 et	 al.,	 2007,	 von	 Schantz	 et	 al.,	 2009,	Bible	 et	 al.,	2004).	However	it	has	become	apparent	that	certain	neuronal	populations	are	more	vulnerable	 and	 affected	 earlier	 in	 the	 disease:	 the	 GABAergic	 interneurons,	thalamocortical	projection	neurons	and	the	cerebellar	Purkinje	neurons	(Cooper	et	al.,	2006a,	Sleat,	2004).	The	thalamocortical	system	is	severely	affected	in	all	mouse	models	 of	NCL.	 Severe	neurodegeneration	 is	 seen	 in	 the	 cortex	 but	 neuron	 loss	 is	first	seen	in	the	thalamus	in	mouse	models	of	juvenile	CLN3	disease	(Pontikis	et	al.,	2005),	infantile	CLN1	disease	(Kielar	et	al.,	2007)	and	CLN8	disease	(Kuronen	et	al.,	2012).	 In	 the	C57BL/6J	congenic	Tpp1-/-	mice	studied	here,	with	an	 intact	 immune	system	 (Chapter	 3),	 neuronal	 cell	 loss	 was	 extensive	 in	 the	 somatosensory	 and	visual	 thalamic	 relay	 nuclei,	 and	 also	 significant	within	 the	 cortical	 target	 regions	that	they	project	to	(Figures	12	and	13).		To	 investigate	whether	a	 similar	phenotype	was	evident	 in	Tpp1	-/-/NODSCID	mice	the	design	based	optical	fractionator	was	again	used	to	obtain	unbiased	estimates	of	the	number	of	Nissl	 stained	neurons	 in	 laminae	 IV,	V	and	VI	of	 the	S1BF,	which	 is	known	to	be	particularly	affected	in	mouse	models	of	other	forms	of	NCL	(Bible	et	al.,	2004,	Pontikis	et	al.,	2005).	The	same	unbiased	stereological	method	was	used	to	measure	 the	 number	 of	 neurons	 in	 the	 ventral	 posterior	 thalamic	 nucleus	(VPM/VPL),	 which	 relays	 somatosensory	 information	 to	 the	 S1BF	 and	 the	 lateral	geniculate	 nucleus	 (LGNd),	 the	 visual	 relay	 nucleus	 that	 relays	 information	 to	primary	visual	cortex	(V1).			Significant	neuron	loss	was	evident	in	the	VPM/VPL	thalamic	nucleus	of	16-week	old	
Tpp1-/-/NODSCID	 mice,	 with	 a	 39%	 percent	 reduction	 in	 neuronal	 number	(p=0.0060)	compared	to	Tpp1+/-/NODSCID	mice	(Figure	18a).	Significant	(p=0.082)	and	pronounced	neuronal	 cell	 loss	was	 also	 seen	 in	 the	LGNd	of	Tpp1-/-/NODSCID	mice,	with	19%	of	neurons	lost	in	this	nucleus	(Figure	18b).		
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Figure	 18	Loss	 of	 sensory	 and	 visual	 thalamocortical	 neurons	 in	 Tpp1-/-/	NODSCID	
mice.	Histograms	of	unbiased	optical	fractionator	estimates	of	the	number	of	Nissl	stained	neurons	 in	 (A)	 the	 ventral	 posterior	 nucleus	 (VPM/VPL),	 (B)	 the	 dorsal	 lateral	 geniculate	nucleus	 (LGNd)	 and	 (C)	 the	 individual	 laminae	 of	 the	 somatosensory	 barrel	 field	 cortex	(S1BF).	Neuronal	loss	was	significant	in	all	of	these	regions	but	was	most	pronounced	in	the	somatosensory	thalamic	relay	nucelus,	 the	VPM/VPL.	(*=p<0.05,	**=	p<0.01,	***=	p<0.001,	Unpaired	Student’s	T-test).		In	the	cortex,	the	individual	laminae	of	the	S1BF	consistently	showed	significant	but	varying	 degrees	 of	 neuron	 loss	 in	 Tpp1-/-/NODSCID	 mice	 compared	 to	 Tpp1+/-
/NODSCID	mice.	In	S1BF	lamina	IV	of	Tpp1-/-/NODSCID	mice	there	was	a	significant	decrease	 (p=0.029)	 in	 the	 number	 of	 Nissl	 stained	 neurons	 at	 16	 weeks	 of	 age	(Figure	 18c).	 Within	 S1BF,	 Tpp1-/-/NODSCID	 mice	 showed	 the	 most	 significant	neuronal	loss	in	lamina	V,	with	a	reduction	of	29%	in	neuronal	number	compared	to	control	mice	(p=0.0031,	Figure	18c).	Significant	neuronal	 loss	was	also	present	 in	lamina	 VI	 of	 S1BF	 in	 16-week-old	 Tpp1-/-/NODSCID	 mice	 compared	 to	 control	
Tpp1+/-/NODSCID	mice	(p=0.012,	Figure	18c).			
4.3.3 Astrocytic	activation	in	the	thalamocortical	system	of	Tpp1	-/-/NODSCID	
mice				An	early	neuroimmune	response	is	seen	in	murine	models	of	infantile	CLN1	(Kielar	et	 al.,	 2007,	 Bible	 et	 al.,	 2004)	 and	 juvenile	 CLN3	 disease	 (Pontikis	 et	 al.,	 2004,	Pontikis	et	al.,	2005)	and	this	glial	activation	not	only	precedes	neuron	loss,	but	also	appears	to	predict	it’s	distribution	(Pontikis	et	al.,	2004,	Pontikis	et	al.,	2005,	Cooper	et	al.,	2007,	Gillingwater	et	al.,	2009).	Previously	astrocytosis	has	been	reported	in	
Tpp1-/-	 mice,	 specifically	 within	 the	 M1,	 hippocampus,	 striatum	 and	 cerebellum	(Chang	et	al.,	2008).	In	the	cohort	of	Tpp1-/-	mice	in	this	study,	I	have	extended	these	observations	to	include	the	somatosensory	thalamocortical	system,	which	displayed	extensive	 astrocytosis	 was	 seen	 at	 the	 latest	 time	 point	 of	 13	 weeks	 (Chapter	 3	section	3.4).		
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However,	 it	 is	 not	 clear	what	 effect	 the	 NODSCID	 background	will	 have	 upon	 the	relative	 level	of	astrocytic	activation	 in	TPP1-deficient	mice.	 In	order	to	determine	the	 extent	 of	 astrocytosis	 in	 Tpp1-/-/NODSCID	 mice,	 free	 floating	 sections	 were	immunostained	for	the	marker	GFAP.		A	 qualitative	 survey	 of	 GFAP	 staining	 in	wild	 type	 and	mutant	mice	 revealed	 that	astrocytosis	 is	 greatly	 increased	 in	 Tpp1-/-/NODSCID	mice	 	 (Figure	 19a	 and	 b),	compared	to	their	wild	type	or	heterozygous	mutant	counterparts.	There	were	many	more	 GFAP	 positive	 astrocytes	 present	 in	 these	 Tpp1-/-/NODSCID	 mice,	 with	individual	cells	 intensely	stained	with	a	hypertrophied	cell	soma	and	thick	twisted	processes.	As	 in	 the	Tpp1	-/-	mice	with	an	 intact	 immune	system	(Chapter	3.4),	 the	astrocytosis	in	the	thalamus	of	Tpp1	-/-/NODSCID	mice	appeared	to	be	largely	limited	to	 the	 VPM/VPL	 (Figure	 19b).	 This	 thalamic	 nucleus	 was	 completely	 full	 of	intensely	 stained	 activated	 astrocytes,	 however	 there	 was	 very	 little	 spread	 of	astrocytosis	 into	 the	 surrounding	 thalamic	 nuclei.	 Semi-automated	 thresholding	analysis	was	used	to	quantify	the	relative	 level	of	astrocytosis	 in	Tpp1	-/-/NODSCID	mice	 versus	 control	 Tpp1+/-/NODSCID	 mice,	 and	 confirmed	 there	 is	 a	 significant	increase	 in	 GFAP	 expression	 in	 the	 VPM/VPL	 of	 these	 mutant	 mice	 (p=0.0003,	
Figure	19c).			Astrocytosis	was	 also	 greatly	 increased	 in	 the	 S1BF	 cortex	of	 16-week	old	Tpp1	-/-
/NODSCID	 mice	 compared	 to	 control	 Tpp1+/-/NODSCID	 mice.	 However,	immunoreactive	GFAP-positive	astrocytes	did	not	present	equally	across	all	laminae	in	the	S1BF;	there	appeared	to	be	less	activated	astrocytes	in	lamina	IV	compared	to	laminae	V	and	VI	of	Tpp1-/-/NODSCID	mice	(Figure	19a).	Quantitative	thresholding	image	analysis	confirmed	there	was	a	significant	increase	in	GFAP	immunoreactivity	in	 the	 somatosensory	 cortex	 in	 Tpp1-/-/NODSCID	 mice	 compared	 to	 controls	(p=0.0164,	Figure	19c).				
111	
	




mice			In	 the	 congenic	 C57BL/6J	 Tpp1-/-	 mice	 described	 in	 Chapter	 3,	 pronounced	microglial	activation	was	first	apparent	in	both	the	VPM/VPL	and	the	S1BF	region	of	the	cortex	from	9	weeks	of	age	and	increased	with	age	(Chapter	3.3).		However,	it	is	not	clear	what	effect	 the	NODSCID	background	will	have	upon	the	relative	 level	of	microglial	 activation	 in	 TPP1-deficient	 mice.	 In	 order	 to	 determine	 the	 extent	 of	microglial	 activation	 in	 16-week-old	 Tpp1-/-/NODSCID	 mice,	 free	 floating	 sections	were	immunostained	for	CD68	(which	marks	microglia).			A	 qualitative	 survey	 of	 CD68	 staining	 revealed	 that	 there	 is	 much	 more	 CD68	immunostaining	 in	 the	 somatosensory	 thalamocortical	 system	of	Tpp1-/-/NODSCID	mice	 at	16	weeks	of	 age	 compared	 to	Tpp1+/-/NODSCID	mice	 (Figure	 20a	 and	 b)	and	it	is	more	intense	in	the	mutants.	In	these	Tpp1-/-/NODSCID	mice	both	S1BF	and	VPM/VPL	were	densely	packed	with	intensely	stained	CD68	positive	microglia	that	displayed	an	enlarged	brain-macrophage-like	morphology,	compared	to	their	palely	stained	appearance	with	a	small	cell	soma	and	thin-branched	processes	in	wild	type	tissue.	The	activated	microglia	in	the	cortex	of	Tpp1-/-/NODSCID	mice	did	not	seem	to	 have	 any	 specificity	 for	 any	 individual	 lamina	 of	 S1BF,	 instead	 CD68-positive	migroglia	were	evenly	present	throughout	the	cortical	mantle	(Figure	20a).			Thresholding	analysis	was	used	to	quantify	the	relative	difference	in	CD68	staining	in	the	S1BF	and	revealed	there	to	be	a	significant	increase	in	CD68	immunoreactivity	in	Tpp1-/-/NODSCID	mice,	compared	to	control	animals	(p=<0.0001,	Figure	20c).		In	 the	 thalamus	 of	 16-week-old	 Tpp1-/-/NODSCID	 mice,	 intensely	 stained	 CD68	positive	microglia	were	generally	confined	to	the	VPM/VPL	thalamic	nuclei	(Figure	




Figure 20 Microglial activation in 16-week-old Tpp1-/-/NODSCID	 mice.	 (A)	Immunohistochemical	 staining	 for	 CD68,	 an	 activated	 microglial	 marker,	 in	 the	somatosensory	 barrel	 field	 cortex	 (S1BF)	 compared	 to	 controls	 (Tpp1+/-/NODSCID).	 CD68	immunoreactive	microglia	 were	 evident	 within	 all	 laminae	 of	 the	 S1BF	 and	 were	 largely	absent	from	controls.	(B)	Tpp1-/-/NODSCID	mice	exhibited	pronounced	microglial	activation,	which	was	 confined	 to	 the	 ventral	 posterior	medial	 (VPM/VPL)	 nucleus	 in	 the	 thalamus.	CD68-positive	microglia	with	brain	macrophage-like	morphology	were	present	 in	Tpp1-/-/	NODSCID	 mice	 and	 were	 absent	 from	 control	 animals	 in	 this	 region.	 (C)	 Histograms	 of	quantitative	 image	 thresholding	 analysis	 confirm	 a	 significant	 increase	 in	 CD68	immunoreactivity	 in	 both	 the	 S1BF	 and	 VPM/VPL	 in	Tpp1-/-/NODSCID	mice	 compared	 to	age-matched	 controls.	 (*=p<0.05,	 **=	 p<0.01,	 ***=	 p<0.001,	 Unpaired	 Student’s	 T-test).	Scale	bar=	1000	μm	in	top	images,	500	μm	in	bottom	images.			
4.3.5 LAMP1	Immunoreactivity	is	increased	in	Tpp1-/-/NODSCID	mice	As	 was	 previously	 documented	 in	 the	 Tpp1-/-	 mice	 described	 in	 Chapter	 3,	autofluorescent	storage	material	was	not	readily	apparent	when	viewing	unstained	sections	 from	 Tpp1-/-/NODSCID	 mice	 by	 either	 confocal	 or	 epifluorescence	microscopy	(Figure	21).	As	such,	the	relative	level	of	LAMP1	immunoreactivity	was	
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also	used	in	tissue	from	Tpp1-/-/NODSCID	mice	as	a	measure	of	the	size	and	number	of	 lysosomes	 present,	 and	 because	 it	 has	 been	 shown	 to	 be	 a	 useful	 surrogate	marker	for	the	amount	of	storage	material	in	the	cells	(Meikle	et	al.,	1997b).		
	
Figure	 21	 Autofluorescent	 storage	 material	 in	 Tpp1+/-/NODSCID	 versus	 Tpp1-/-
/NODSCID	 mice.	 Unstained	 sections	 from	 Tpp1+/-/NODSCID,	 Tpp1-/-/NODSCID	 and	 Cln3-/-	mice	were	mounted	on	slides	and	the	autofluorescent	storage	material	was	visualized	using	a	confocal	microscope	and	the	488	laser.	The	phenotypes	shown	here	were	seen	throughout	the	 brains	 of	 these	 mice	 but	 representative	 pictures	 were	 taken	 from	 the	 thalamus.	 (A)	Sections	from	Tpp1+/-/NODSCID	mice	at	16	weeks	of	age	show	no	autofluorescence	(AF)	in	the	lysosome,	small	amounts	of	AF	may	be	due	to	blood	vessels,	from	incomplete	perfusion.	(B)	 Sections	 from	 Tpp1-/-/NODSCID	 mice	 at	 16	 weeks	 of	 age	 show	 little	 to	 no	 AF	 in	 the	lysosome,	 again	 there	 is	 AF	 that	 is	 characteristic	 of	 AF	 from	 blood.	 (C)	 As	 a	 comparison,	sections	 from	 Cln3-/-	 mice	 at	 13	 months	 of	 age	 show	 characteristic	 punctate	 AF	 storage	material	granules	in	the	cytoplasm	of	cells.		In	 the	 analysis	 of	Tpp1-/-	mice	 in	 Chapter	 3,	 LAMP1	 expression	was	 progressively	and	 significantly	 increased	 in	 the	 somatosensory	 cortex	 and	 VPM/VPL	 of	 these	mutant	mice.	In	order	to	determine	the	effect	of	the	NODSCID	background	on	LAMP1	expression	 in	 TPP1-deficient	 mice,	 free-floating	 sections	 from	 Tpp1-/-/NODSCID	mice	 and	 Tpp1+/-/NODSCID	 control	 mice	 were	 immunostained	 for	 LAMP1	 and	revealed	evidence	 for	widespread	 increased	 lamp1	expression	 in	Tpp1-/-/NODSCID	mice	compared	to	control	animals.	LAMP1	immunoreactivity	was	also	examined	in	the	striatum	due	to	the	pronounced	atrophy	that	was	observed	in	Chapter	3	section	2.2	in	13-week-old	Tpp1-/-	mice.	The	striatum	 of	 Tpp1-/-/NODSCID	mice	 was	 filled	 with	 many	 intensely	 lamp1-positive	cells,	 with	 clusters	 of	 punctate	 staining	 that	 completely	 filled	 their	 cytoplasm	(Figure	22a).	In	contrast,	there	was	less	LAMP1	immunoreactivity	in	the	striatum	of	




Figure	 22	 LAMP1	 immunostaining	 in	 16-week-old	 Tpp1-/-/	 NODSCID	 mice.	 (A)	Immunohistochemical	 staining	 for	 lysosomal	 associated	membrane	 protein	 1,	 (LAMP1)	 a	lysosomal	protein	whose	expression	is	proportional	to	the	number	and	size	of	lysosomes	in	cells,	in	the	striatum	compared	to	age	matched	controls	(Tpp1+/-/NODSCID).	LAMP1	positive	cells	 were	 much	 more	 prominent	 in	 the	 striatum	 of	 Tpp1-/-/	 NODSCID	 mice	 (B)	 Tpp1-/-/NODSCID	mice	exhibited	higher	 levels	of	LAMP1	staining	throughout	the	thalamus	and	in	particular	the	ventral	posterior	medial	(VPM/VPL)	nucleus	in	the	thalamus.	(C)	Histograms	of	 quantitative	 image	 thresholding	 analysis	 confirm	 a	 significant	 increase	 in	 LAMP1	immunoreactivity	in	both	the	striatum	and	VPM/VPL	in	Tpp1-/-/	NODSCID	mice	compared	to	age-matched	controls.	(*=p<0.05,	**=	p<0.01,	***=	p<0.001,	Unpaired	Student’s	T-test).	Scale	bar=	1000	μm	in	top	images,	500	μm	in	bottom	images.		Although	LAMP1	staining	was	widespread	throughout	all	nuclei	 in	the	thalamus	of	
Tpp1-/-/NODSCID	 mice,	 this	 immunoreactivity	 was	 more	 intense	 within	 cells	 of	VPM/VPL	and	LGNd	thalamic	nuclei	 compared	 to	 the	surrounding	 thalamic	nuclei.	Intense	 punctate	 LAMP1	 staining	 completely	 filled	 the	 cytoplasm	 of	 cells	 in	 the	VPM/VPL	 of	 Tpp1-/-/NODSCID	 mice	 (Figure	 22b).	 Semi-automated	 quantitative	
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image	 thresholding	 analysis	 revealed	 LAMP1	 immunoreactivity	 was	 significantly	increased	in	the	VPM/VPL	region	of	the	thalamus	(p	<0.0001,	Figure	22c).		Compared	to	control	Tpp1+/-/NODSCID	mice,	cortical	LAMP1	immunoreactivity	was	markedly	 increased	 in	both	motor	and	somatosensory	regions	 in	Tpp1-/-/NODSCID	mice.	In	these	cortical	regions	LAMP1	positive	cells	were	present	throughout	the	M1	(Figure	 23a)	 and	 S1BF	 (Figure	 23b)	 without	 obvious	 predominance	 in	 any	particular	 lamina.	 Quantitative	 image	 thresholding	 analysis	 confirmed	 LAMP1	immunoreactivity	 was	 significantly	 increased	 in	 the	 M1	 (p<0.0001)	 and	 S1BF	(p=0.002,	Figure	23c).		
	
Figure	23	LAMP1	immunostaining	in	16-week-old	Tpp1-/-/	NODSCID	mice.		(A)	Immunohistochemical	staining	for	lysosomal	associated	membrane	protein	1,	(LAMP1),	in	 the	 primary	motor	 cortex	 (M1)	 compared	 to	 controls	 (Tpp1+/-/NODSCID).	 LAMP1	was	increased	 within	 the	 cytoplasm	 of	 Tpp1-/-/NODSCID	 mice	 in	 the	 M1.	 (B)	 In	 the	somatosensory	 barrel	 field	 cortex	 (S1BF),	 LAMP1	 staining	 was	 also	 increased	 in	 Tpp1-/-
/NODSCID	mice	 compared	 to	 controls	 (Tpp1+/-/NODSCID).	 (C)	 Histograms	 of	 quantitative	image	 thresholding	 analysis	 confirm	 a	 significant	 increase	 in	 LAMP1	 immunoreactivity	 in	both	the	motor	and	somatosensory	regions	of	the	cortex	in	Tpp1-/-/NODSCID	mice	compared	to	controls.	(*=p<0.05,	**=	p<0.01,	***=	p<0.001,	Unpaired	Student’s	T-test).	Scale	bar=	1000	μm	in	top	images,	500	μm	in	bottom	images.		
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4.3.6 How	 does	 the	 NODSCID	 immunodeficient	 background	 affect	 TPP1-
deficient	mice?	A	number	of	steps	were	taken	in	order	to	fairly	compare	TPP1-deficient	mice	on	a	C57BL/6J	 background,	 with	 those	 on	 an	 immunodeficient	 background,	 as	 these	experiments	were	carried	out	at	different	times.	Firstly,	the	accuracy	of	stereological	methods	is	dependent	on	the	reliable	identification	of	brain	regions.	Following	Nissl	staining	using	an	 identical	method	at	each	time	point,	 the	boundaries	between	the	white	 and	 grey	 matter	 could	 easily	 be	 identified.	 ‘The	mouse	 brain	 in	 stereotactic	
coordinates’	was	used	as	a	reference	of	the	relevant	neurological	landmarks	(Paxinos	and	Franklin,	2001).	For	volume	measurements:	the	exact	same	bregma	and	number	of	 sections	were	used;	 grid	 sizes	were	kept	 constant	 for	 each	ROI;	 and	previously	defined	 landmarks	were	used	 to	 identify	 the	ROI,	 for	 all	 genotypes	 and	 ages.	 	 For	neuronal	cell	counts:	the	counting	frames	and	grid	sizes	were	kept	constant	for	each	ROI;	 and	 previously	 defined	 landmarks	 were	 used	 to	 identify	 the	 ROI,	 for	 all	genotypes	and	ages.	In	addition,	to	compare	the	immunostaining	results	as	fairly	as	possible:	 each	antigen	was	developed	 for	 a	pre-determined	amount	of	 time	 for	 all	genotypes	 and	 ages,	 with	 the	 same	 method	 and	 reagents.	 In	 order	 to	 compare	immunostaining	 results	 from	samples	processed	across	different	 time	periods,	 the	thresholds	were	set	on	ImagePro	Plus	software	in	order	that	the	same	proportion	of	positively	 immunostained	cells	was	detected	across	 the	 samples.	The	 thresholding	analysis	 was	 then	 performed	 using	 a	macro	 that	 incorporated	 all	 the	 animals	 for	each	 antigen,	 blind	 to	 the	 genotype	 of	 the	 mouse	 (Tpp1-/-/NODSCID,	 Tpp1+/-
/NODSCID,	Tpp1-/-	or	Tpp1+/+)	and	the	age	of	the	mouse.		In	 this	 study,	 the	 control	 for	 the	 16-week-old	 Tpp1-/-/NODSCID	mice	 were	 16-24	week-old	Tpp1+/-/NODSCID	mice.	In	Chapter	3,	I	compared	13-week-old	Tpp1-/-mice	to	wild-type	age-matched	controls.	In	order	to	compare	the	effects	of	the	NODSCID	background	on	TPP1-deficient	mice,	it	 is	 worth	 considering	 how	 age	 and	 NODSCID	 background	 could	 affect	 disease	landmarks	in	Tpp1+/-/NODSCID	control	mice	compared	to	wild	type	control	mice.	There	 was	 no	 significant	 difference	 in	 the	 volume	 of	 the	 cortex,	 striatum	 or	hippocampus	and	in	the	thickness	of	the	cortical	mantle	in	16-24	week-old	Tpp1+/-
/NODSCID	 mice	 versus	 13-week-old	 wild-type	 mice.	 Similarly	 there	 was	 no	significant	 difference	 in	 neuronal	 cell	 number	 in	 either	 of	 the	 thalamic	 nuclei	evaluated,	 the	 VPM/VPL	 and	 the	 LGNd,	 in	 16-24	week-old	Tpp1+/-/NODSCID	mice	versus	13-week-old	wild-type	mice.	Taken	together	this	suggests	that	there	is	not	a	
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significant	effect	of	age,	the	NODSCID	background	or	the	heterozygosity	for	Tpp1	on	the	volume	of	these	brain	regions	and	neuronal	cell	number	in	these	thalamic	nuclei.	However,	 the	volume	of	 the	 thalamus	 is	 significantly	 smaller	 in	13-week-old	wild-type	mice	 compared	 to	16-24	week-old	Tpp1+/-/NODSCID	mice.	 	 In	 addition,	 in	 all	three	 laminae	 (IV-	 VI)	 of	 the	 S1BF	 examined	 there	were	 significant	 differences	 in	neuronal	number	in	16-24	week-old	Tpp1+/-/NODSCID	mice	compared	to	13-week-old	 wild-type	 mice.	 This	 suggests	 that	 age,	 the	 NODSCID	 background	 or	 the	heterozygosity	 for	 Tpp1	 does	 affect	 the	 size	 of	 the	 thalamus	 and/or	 neuronal	number	 in	 the	 S1BF.	 In	 the	 case	 of	 the	 difference	 in	 neuronal	 cell	 number	 in	 the	S1BF	 16-24	 week-old	 Tpp1+/-/NODSCID	 mice	 versus	 13-week-old	 wild-type	 mice,	this	may	be	attributed	to	there	being	slight	damage	to	the	NODSCID	batch	of	brains	and	hence	the	neuronal	counts	were	taken	in	a	slightly	different	region	of	the	S1BF.		In	 the	 majority	 of	 landmarks,	 13-week-old	 wild-type	 mice	 and	 16-24	 week-old	
Tpp1+/-/NODSCID	mice	do	not	differ	significantly.	 	As	such,	the	effect	of	a	NODSCID	background	on	TPP1-deficient	mice	 can	be	 evaluated	by	 comparing	 the	data	 from	16-week-old	Tpp1-/-/NODSCID	mice	to	that	of	13-week-old	Tpp1-/-mice	whilst	being	aware	of	these	issues.	Whereas	 16-week-old	 Tpp1-/-/NODSCID	 mice	 showed	 significant	 atrophy	 of	 the	cortex,	 thalamus	 and	 striatum	 (Figure	 24B),	 in	 13-week-old	Tpp1-/-	mice	with	 an	intact	immune	system,	the	only	significant	reduction	in	regional	volume	was	seen	in	the	striatum.	Similarly,	no	significant	thinning	of	the	cortical	mantle	was	observed	in	13-week-old	Tpp1-/-	mice	 (Figure	 24A),	whilst	 cortical	 thickness	was	 significantly	reduced	in	all	regions	examined	in	16-week-old	Tpp1-/-/NODSCID	mice.	
	
Figure	 24	 Thickness	 and	 Volume	 measurements	 in	 TPP1-deficient	 mice	 on	 a	
C57/BL6J	or	NODSCID	background		The	significant	neuronal	cell	 loss	seen	 in	the	VPM/VPL	thalamic	nuclei	 in	both	16-week-old	 Tpp1-/-/NODSCID	 mice	 and	 13-week-old	 Tpp1-/-	 mice	 was	 more	pronounced	 in	 TPP1-deficient	 mice	 on	 a	 NODSCID	 background	 (Figure	 25A).	
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However,	the	opposite	was	seen	in	the	LGNd	thalamic	nuclei,	where	the	significant	cell	 loss	 observed	 in	 both	 16-week-old	 Tpp1-/-/NODSCID	 mice	 and	 13-week-old	
Tpp1-/-	mice	 (Figure	 25A)	was	more	 severe	 in	TPP1-deficient	mice	with	 an	 intact	immune	system.	In	 the	 somatosensory	 cortex,	 there	was	variation	 in	 the	number	of	neurons	 in	 the	control	16-24	week-old	Tpp1+/-/NODSCID	mice	versus	13-week-old	wild-type	mice.	Still,	 relative	 to	 their	own	controls,	 neuronal	 cell	 loss	was	 significant	 in	 laminae	V	and	 VI	 only	 in	 13-week-old	 Tpp1-/-	 mice	 compared	 to	 16-24	 week-old	 Tpp1-/-/NODSCID	 mice,	 where	 neuronal	 cell	 loss	 was	 significant	 in	 all	 laminae	 (Figure	
25B).				
	
Figure	 25	Neuronal	 cell	 counts	 in	 thalamic	 nuclei	 and	 the	 somatosensory	 cortex	 in	
TPP1-deficient	mice	on	a	C57/BL6J	or	NODSCID	background.		Significantly	 increased	 GFAP	 immunoreactivity	 was	 evident	 in	 both	 13-week-old	




Figure	26	Glial	activation	 in	 thalamic	nuclei	and	 the	somatosensory	cortex	 in	TPP1-
deficient	mice	on	a	C57/BL6J	or	NODSCID	background.			In	 addition,	 LAMP1	 staining	 showed	 similar	 distribution	 patterns	 for	 16-week-old	




TPP1-deficient	mice	on	a	C57/BL6J	or	NODSCID	background.		Taken	 together,	 these	 data	 suggest	 that	 TPP1-deficient	 mice	 on	 a	 NODSCID	background	at	16	weeks	of	age	generally	have	a	worse	disease	phenotype	in	terms	of	 regional	 brain	 volume	 and	 neuronal	 cell	 loss	 but	 have	 similar	 patterns	 of	 glial	activation	and	lysosome	size	and	number,	compared	to	TPP1-deficient	mice	with	an	intact	immune	system	at	13	weeks	of	age.			
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4.4 Discussion	This	study	reveals	new	information	about	the	nature	and	extent	of	neuropathology	in	TPP1-deficient	mice	on	the	immunodeficient	NODSCID	background,	both	in	terms	of	 glial	 activation	 and	neuronal	 cell	 loss	within	 the	 thalamocortical	 system.	 It	 also	explores	 evidence	 relating	 to	 the	 effect	 of	 the	 adaptive	 immune	 system	 on	 the	pathogenesis	of	late	infantile	CLN2	disease	mice.		This	Chapter	has	presented	data	that	shows	that	TPP1-deficient	mice	on	a	NODSCID	background	 at	 16	 weeks	 of	 age	 generally	 have	 a	 more	 pronounced	 disease	phenotype	in	terms	of	atrophy	of	regional	brain	structures	and	neuronal	cell	loss	in	the	 somatosensory	 cortex	 and	 specific	 thalamic	 nuclei	 than	 TPP1-deficient	 mice	with	 an	 intact	 immune	 system	 at	 13	weeks	 of	 age.	 I	 have	 also	 shown	 that	 TPP1-deficient	 mice	 have	 similar	 patterns	 of	 glial	 activation	 and	 lysosome	 size	 and	number	whether	they	possess	an	intact	immune	system	or	not.			
4.4.1 The	breeding	program	for	Tpp1-/-/NODSCID	mice		The	TPP1-deficient	mice	on	a	NODSCID	background	described	in	this	chapter	were	kindly	provided	by	StemCells	Inc,	CA,	USA	and	generated	as	described	in	Chapter	3	section	 1.2	 (Sleat	 et	 al.,	 2004).	 Breeding	 was	 conducted	 either	with	 Tpp1+/-/NODSCID	 female	 x	 Tpp1-/-/NODSCID	 male	 or	 Tpp1+/-/NODSCID	 female	 x	 Tpp1+/-/NODSCID	 male.	 Because	 the	 female	 in	 both	 of	 these	 breeding	 strategies	 was	heterozygous	 for	 the	Tpp1	 gene,	 it	 is	 possible	 that	 TPP1	 enzyme	 produced	 in	 the	mother	could	cross	the	placenta	via	the	bloodstream	and	enter	the	Tpp1-/-/NODSCID	offspring.	The	reason	for	using	Tpp1+/-/NODSCID	females	for	mating	is	that	they	are	healthy	 enough	 to	 produce	 offspring;	 as	 outlined	 in	 the	 discussion	 in	 Chapter	 3	mating	Tpp1-/-/NODSCID	mice	is	not	feasible	as	the	mice	are	too	sick	by	the	end	of	gestation.	 As	 such,	 although	 there	 is	 a	 possibility	 that	 a	 small	 amount	 of	 TPP1	enzyme	may	have	crossed	the	placenta	and	affected	the	developing	embryo,	there	is	no	viable	way	to	control	for	this.	Indeed,	as	all	human	cases	of	CLN2	disease	are	the	product	of	heterozygous	parents,	the	mouse	model	reflects	this.		As	outlined	above,	in	these	mice	the	C57BL/6J	background	was	replaced	by	the	SCID	(Pkdc	 scid)	 and	NOD	 background,	 it	 is	 therefore	worth	 noting	 that	 any	 change	 in	phenotype	 of	 these	 mice	 could	 also	 be	 due	 to	 loss	 of	 the	 C57BL/6J	 background,	rather	than	gain	of	the	NODSCID.	
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4.4.2 The	 NODSCID	 immunodeficient	 background	 may	 increase	 lifespan	 of	
TPP1	deficient	mice	As	discussed	 in	Chapter	3,	 the	Tpp1-/-	mice	 in	our	animal	 facility	 at	KCL	 live	 fairly	reliably	to	14	weeks	of	age	when	they	suddenly	die,	for	reasons	that	remain	unclear.	A	very	similar	life	expectancy	is	seen	by	our	collaborators	at	Albert	Einstein	College	of	Medicine,	who	provided	 the	 founders	 for	our	 colony.	As	discussed	 in	Chapter	3	section	3.4,	this	is	much	shorter	than	the	original	lifespan	reported	for	these	mice	on	a	 mixed	 strain	 background	 (Sleat,	 2004).	 In	 contrast,	 the	 Tpp1-/-/NODSCID	 mice	characterised	 in	 this	Chapter	have	a	 life	span	of	around	16	weeks	or	 longer	 in	 the	animal	 facility	 of	 Stem	 Cell	 Inc.,	 who	 supplied	 these	 mice	 (Uchida,	 personal	communication).	 A	 variety	 of	 different	 environmental	 influences	 may	 account	 for	the	variation	in	disease	progression	that	is	seen	between	these	different	cohorts	of	mice.	These	mice	were	raised	 in	different	animal	 facilities,	with	different	handlers,	feeding	regimes	and	litter	conditions.	Any	or	all	of	these	variables	could	account	for	some	of	the	differences	in	neuropathological	phenotypes	we	have	documented.	That	being	said	 it	could	also	be	 the	case	 that	 the	 lack	of	adaptive	 immunity	 that	results	from	the	NODSCID	background	may	increase	the	lifespan	of	TPP1-deficient	mice.	For	this	 study,	 Tpp1-/-	 mice	 were	 backcrossed	 onto	 the	 NODSCID	 background	 for	 10	generations	 under	 specific	 pathogen-free	 (SPF)	 conditions.	 As	 such,	 the	 increased	lifespan	 may	 have	 been	 further	 influenced	 by	 the	 maintenance	 of	 these	 Tpp1-/-




Table	 7	 Comparison	 table	 summarizing	 neuropathological	 landmarks	 between	 Tpp1-/-







Cortical	thickness	 M1	 ê		 S1BF		 êê		 V1		 ê		 Lent		 ê	
Regional	volume	 Cortex	 êê	
	 Striatum	 ê		 Thalamus		 êê		 Hippocampus		 =	
Microglial	activation	 S1BF	 ééé		 VPM/VPL		 ééé	
Astrocytosis	 S1BF		 é		 VPM/VPL		 ééé	
Lysosomal	storage	 Striatum	 ééé		 VPM/VPL		 ééé		 M1		 ééé		 S1BF		 ééé	
Neuronal	Cell	Counts	 VPM/VPL	 êê		 S1BF	lamina	IV	 ê	








	 S1BF		 ê		 V1		 ê		 Lent		 ê	
Regional	volume	 Cortex	 ê	
	 Striatum	 ê	
	 Thalamus		 ê		 Hippocampus		 =	
Microglial	activation	 S1BF	 é		 VPM/VPL		 é	
Astrocytosis	 S1BF		 é		 VPM/VPL		 é	
Lysosomal	storage	 S1BF	 ê		 VPM/VPL		 ê	
Neuronal	Cell	Counts	 VPM/VPL	 ê		 S1BF	lamina	IV	 ê	
	 S1BF	lamina	V	 ê		 S1BF	lamina	VI	 ê		 LGNd		 é	
	
Table	8	Comparison	table	summarizing	neuropathological	landmarks	between	Tpp1-/-	
and	Tpp1-/-/NODSCID	mice.	The	table	summarises	the	results	of	the	experiments	described	in	more	detail	 in	Chapter	3	and	this	Chapter,	4.	In	the	first	column:	the	type	of	analysis;	 in	the	 second	 column:	 the	 region	 of	 interest;	 in	 the	 third	 column:	 the	 neuropathological	landmarks	examined	in	Tpp1-/-/C57BL6J	mice	relative	to	Tpp1-/-/	NODSCID	mice.	Symbols:	=	no	 difference	 in	 analysis	 between	 16-week-old	 Tpp1-/-/NODSCID	and	 13-week-old	 Tpp1-/-	mice,	é	 Higher	 value	 for	 thickness,	 volume,	 neuronal	 cell	 number	 or	 immunostaining	 in	
Tpp1-/-/	C57BL/6J	mice	 (relative	 to	Tpp1-/-	 /NODSCID	mice),	ê	Lower	value	 for	 thickness,	volume,	 neuronal	 cell	 number	 or	 immunostaining	 in	 Tpp1-/-/	 C57BL/6J	 mice	 (relative	 to	
Tpp1-/-	/NODSCID	mice).			
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However,	 if	we	assume	that	the	NODSCID	phenotype	contributes	to	the	differences	seen	 in	 TPP1-deficient	mice	 on	 a	 C57BL/6J	 versus	 a	 NODSCID	 background,	 these	results	could	be	could	interpreted	as	the	cells	of	the	adaptive	immune	system	partly	contributing	to	the	pathogenesis	of	late	infantile	CLN2	disease.	As	described	briefly	in	 the	 introduction	 for	 this	 chapter,	 there	 is	 a	 precedent	 for	 this	 type	 of	 data,	 in	observations	that	have	recently	been	made	in	an	immunodeficient	mouse	model	of	juvenile	 CLN3	 disease	 (Seehafer	 et	 al.,	 2011).	 In	 these	 experiments,	 C57BL/6J	congenic	μMT	mice	were	backcrossed	with	129SV	wildtype	or	Cln3-/-	mice	for	10-12	generations.	μMT	mice	lack	all	B	cells,	have	abnormal	lymphoid	tissue	architecture	and	 have	 greatly	 reduced	 T	 cell	 responses	 (Gonnella	 et	 al.,	 2001).	 With	 adaptive	immunity	 disrupted	 as	 described,	 Cln3-/-/μMT	 mice	 showed	 decreased	neuroinflammation	and	vulnerable	neuronal	populations	were	protected,	compared	to	 Cln3-/-	 mice	 with	 an	 intact	 immune	 system	 (Seehafer	 et	 al.,	 2011).	 Most	importantly,	 immune	 suppression	 resulted	 in	 significant	 improvements	 in	 motor	function	 in	 CLN3-deficient	 mice.	 Similar	 results	 were	 achieved	 by	 pharmalogical	suppression	of	the	immune	system	in	Cln3-/-	mice.	As	such,	 immune	suppression	is	one	of	the	first	plausible	therapies	for	juvenile	CLN3	disease	(Seehafer	et	al.,	2011).			This	 phenomenon	 has	 also	 been	 observed	 in	 a	 mouse	 model	 of	 infantile	 CLN1	disease.		PPT1-deficient	mice	have	been	crossed	with	mice	deficient	for	Rag-1	(Groh	et	 al.,	 2013),	 a	 protein	 essential	 for	 the	 maturation	 process	 of	 T	 and	 B	 cells	(Mombaerts	 et	 al.,	 1992).	 The	 resulting	 Ppt1-/-/Rag-1-/-	 mice	 lack	 PPT1	 and	functioning	T-	and	B-lymphocytes.	Compared	to	PPT1-deficient	mice	with	an	intact	immune	 system,	 Ppt1-/-/Rag-1-/-	 mice	 had	 an	 attenuated	 disease	 onset,	 with	 a	delayed	astrocyte	response	and	relatively	lower	levels	of	microglial	activation	in	the	early	stages	of	the	disease.	However,	by	end	stage	there	was	no	significant	difference	in	neuronal	death	and	astrocytosis	between	Ppt1-/-	and	Ppt1-/-/Rag-1-/-	mice	(Groh	et	al.,	2013,	Kuhl,	PhD	thesis,	2013).		The	 same	model	 of	 immunosuppression	 in	 infantile	 CLN1	 disease	 has	 also	 shown	improvements	 in	behavioural	 tests.	Ppt1-/-/Rag-1-/-	mice	show	greater	visual	acuity	and	 decreased	 frequency	 of	 myoclonic	 jerks	 compared	 to	 their	 Ppt1-/-/Rag-1+/+	counterparts	(Groh	et	al.,	2013).	This	is	promising	as	it	suggests	that	the	reduction	in	neuroinflammation	and	increase	in	neuroprotection	that	immune	suppression	has	shown,	has	positive	effects	beyond	improvements	in	neuropathological	landmarks.		Immune	suppression	may	also	have	positive	effects	on	 lifespan.	 It	has	been	shown	that	Ppt1-/-/Rag-1-/-	mice	have	 increased	 lifespan	compared	to	Ppt1-/-/Rag-1+/+	mice	
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(Groh	et	al.,	2013).	A	longer	lifespan	is	an	attractive	benefit	of	 immunosuppressive	therapy,	however	behavioural	tests	in	addition	to	those	described	above	should	be	carried	out	 in	order	to	determine	the	quality	of	 the	additional	days.	 Indeed,	 in	our	
Tpp1-/-/NODSCID	mice,	the	neuropathology	of	these	older	mice	appears	more	severe	than	 end	 stage	 Tpp1-/-	 mice	 with	 an	 intact	 immune	 system.	 As	 such,	 behavioural	tests	should	also	be	carried	out	in	our	Tpp1-/-/NODSCID	and	Tpp1-/-	mice	in	order	to	examine	this	 issue	 in	TPP1-deficient	animals	as	well.	 In	addition,	 it	 is	not	clear	yet	whether	 the	positive	effects	of	 immune	suppression	 in	 infantile	CLN1	and	 juvenile	CLN3	mouse	models,	 would	 confer	 the	 same	 benefits	 in	 the	 clinic.	 Administering	immune	 suppression	 to	patients	would	have	 to	be	 adjusted	 in	order	 to	determine	the	 level	of	 immunosupression	 required	but	also	minimize	harmful	 side	effects,	 in	already	compromised	patients.		Taken	 together,	 these	 observations	 suggest	 that	 immunosuppression	 has	 positive	effects	 on	 lifespan	 on	 the	 NCLs	 but	 varying	 improvements	 are	 seen	 in	neuropathological	landmarks	and	behaviour.			
4.4.3 Neuron	 loss	 is	more	 pronounced	 in	 end-stage	 immunodeficient	 TPP1-
deficient	mice		The	 data	 in	 this	 chapter	 suggests	 that,	 in	 addition	 to	 life	 span,	 moving	 TPP1-deficiency	 onto	 a	NODSCID	background	 has	 further	 consequences	within	 the	 CNS.	Regional	atrophy	is	apparent	in	all	models	of	NCL,	but	different	brain	regions	appear	to	be	affected	to	varying	extents	(Bible	et	al.,	2004,	Pontikis	et	al.,	2004,	Pontikis	et	al.,	2005,	Pearce	et	al.,	2006,	Cooper	et	al.,	2007,	Kielar	et	al.,	2009,	von	Schantz	et	al.,	2009,	Kielar	et	al.,	2007).	Although	brain	atrophy	has	been	mentioned	previously	in	this	 mouse	 model	 (Chang	 et	 al.,	 2008,	 Sleat,	 2004),	 quantitative	 observations	 of	regional	 atrophy	 have	 not	 previously	 been	 recorded	 in	 Tpp1-/-	 mice.	 The	 data	 in	
Chapter	3	revealed	that	regional	atrophy	in	these	mice	was	relatively	modest,	with	the	striatum	being	the	only	region	to	be	significantly	affected	(Figure	7,	Chapter	3,	
section	3.2.2).	In	the	current	Chapter,	regional	atrophy	was	confirmed	in	this	cohort	of	Tpp1-/-/NODSCID	mice	of	age	16	weeks,	but	was	more	widespread	including	the	cortex,	 thalamus	 and	 striatum	 of	 these	 mice	 (Figure	 17b).	 Although	 cortical	thinning	did	not	occur	in	Tpp1-/-	mice	(Figure	6,	Chapter	3,	section	3.2.1),	as	might	be	 expected	 from	 the	 lack	 of	 cortical	 atrophy	 observed,	 the	 cortical	 mantle	 was	profoundly	 atrophied	 in	 Tpp1-/-/NODSCID	 mice,	 with	 significant	 thinning	 of	 all	regions	examined,	a	phenotype	that	is	more	severe	than	that	seen	in	PPT1-deficient	
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mice	 with	 an	 intact	 immune	 system,	 where	 significant	 cortical	 thinning	 was	 not	evident	 in	 the	 somatosensory	 or	 LEnt	 regions	 but	 was	 similarly	 observed	 in	 the	motor	and	visual	cortex	and	additionally	the	auditory	cortex	(Au1-	not	examined	in	this	thesis)	(Kielar	et	al.,	2007).	Such	 differences	 in	 the	 phenotypes	 of	 Tpp1-/-	 and	 Tpp1-/-/NODSCID	mice	 can	 be	interpreted	 in	 several	 ways.	 Firstly,	 it	 may	 be	 that	 the	 3	 weeks	 difference	 in	 age	between	the	Tpp1-/-	and	Tpp1-/-/NODSCID	mice	cohorts	is	sufficient	to	allow	enough	neuronal	 degeneration	 to	 occur	 to	 bring	 about	 these	 changes	 in	 regional	 brain	atrophy.	Alternatively,	the	lack	of	adaptive	T-	and	B-lymphocyte-mediated	immunity	may	 be	 detrimental	 to	 TPP1-deficient	 mice	 and	 accelerates	 disease	 progression,	causing	 the	 more	 aggressive	 phenotypes	 seen	 here.	 These	 two	 theories	 can	 be	integrated	 with	 a	 third	 hypothesis	 that	 without	 the	 responses	 of	 the	 adaptive	immune	response,	TPP1-deficient	mice	will	live	longer,	however	the	continued	lack	of	TPP1	is	still	damaging	enough	to	cause	neuronal	cell	death.		As	discussed	above,	Kuhl	et	al.,	(PhD	thesis,	2013	and	Groh	et	al.,	2013)	observed	in	both	Ppt1-/-	and	Cln3-/-	that	the	adaptive	response	of	the	immune	system	appeared	to	increase	 astrocytosis	 and	 microglial	 activation	 and	 accelerate	 neuronal	 cell	 loss.	Thus,	 immune	 suppression	 reduced	 the	 degree	 of	 innate	 immune	 activation	 and	delayed	neuronal	cell	loss.		As	our	data	reveal,	neuron	loss	 in	the	thalamus	is	already	underway	in	the	ventral	medial	posterior	nucleus	 from	6	weeks	 in	Tpp1-/-	mice	and	 this	 increases	with	age	(Figure	 12,	 Chapter	 3,	 section	 3.2.5).	This	 finding	of	VPM/VPL	neuron	 loss	was	confirmed	 in	Tpp1-/-/NODSCID	mice	 at	 16	weeks,	where	 the	 loss	 of	 these	neurons	was	 even	 further	 pronounced	 (Figure	 18a).	However	 in	 the	 visual	 thalamic	 relay	nucleus	LGNd,	neuron	loss	was	actually	much	worse	in	mice	with	an	intact	immune	system	(Figure	13	versus	Figure	18b).	This	leaves	the	unanswered	question	as	to	whether	the	immune	system	specifically	damages	the	visual	pathway	in	some	way,	or	 is	 this	 just	 an	 unusual	 phenotype	 of	 this	 cohort	 of	Tpp1-/-	mice?	 In	 accordance	with	 the	 idea	 that	 the	visual	 system	 is	particularly	vulnerable	 to	 the	effects	of	 the	adaptive	 immune	system,	Groh	et	al.,	2013,	 looked	specifically	at	 the	effects	of	 the	adaptive	 immune	system	on	the	thalamocortical	visual	pathways	 in	PPT1-deficient	mice.	In	Ppt1-/-	mice,	the	vulnerable	thalamic	LGNd	neurons	and	cortical	V1	neurons	were	relatively	spared	when	T	and	B	lymphocyte-mediated	immunity	was	removed	(Groh	et	al.,	2013).	What	ever	the	underlying	mechanism,	it	is	apparent	the	extent	of	cortical	neuron	loss	was	also	influenced	by	the	presence	or	absence	of	the	adaptive	
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immune	 system,	with	 neurons	 in	 laminae	 IV	 to	VI	 of	 the	 somatosensory	 cortex	 of	
Tpp1-/-	 mice	 being	 lost	 from	 as	 early	 as	 9	 weeks	 of	 age	 (Figure	 12,	 Chapter	 3,	
section	3.2.5),	whilst	the	loss	of	these	cell	populations	was	even	more	extensive	in	
Tpp1-/-/NODSCID	mice	(Figure	18c).	Taken	together	these	data	suggest	that	similar	events	influence	neuron	loss	in	the	thalamus	and	cortex	of	CLN3-,	PPT1-	and	TPP1-deficient	 mice	 and	 that	 the	 adaptive	 immune	 system	 may	 have	 a	 role	 to	 play	 in	accelerating	this	process.	Indeed,	Kuhl	 et	 al.,	 (2012)	 concluded	 that	 the	 lack	of	T-	 and	B-lymphocytes	 in	 the	mouse	 models	 of	 late	 infantile	 CLN1	 disease	 and	 juvenile	 CLN3	 disease	 did	 not	prevent	 neuronal	 cell	 death,	 but	 instead	 slowed	 it	 down	 (Kuhl,	 PhD	 thesis,	 2013).	Other	 neurodegenerative	 diseases,	 including	 Alzheimer’s	 disease	 and	 multiple	sclerosis,	also	display	an	improved	phenotype	without	adaptive	immune	responses	(reviewed	in	(Amor	and	Woodroofe,	2014)).	Neuronal	death	is	clearly	not	prevented	in	Tpp1-/-/NODSCID	mice,	but	it	is	not	possible	to	make	meaningful	statements	about	whether	 the	 rate	 of	 neuron	 loss	 is	 slowed	down	without	 having	data	 from	earlier	time	 points	 in	Tpp1-/-/NODSCID	mice.	 Either	way	 similarly	 to	Tpp1-/-	mice,	Tpp1-/-
/NODSCID	mice	still	have	a	severely	shortened	 lifespan	(Sleat,	2004),	compared	to	what	 might	 be	 expected	 due	 to	 the	 longer	 disease	 course	 in	 humans	 with	 late	infantile	CLN2	disease	relative	what	is	seen	in	human	infantile	CLN1	disease	(Bible	et	 al.,	 2004,	 Jalanko	 and	 Braulke,	 2009)	 and	 the	 precise	 mechanism	 that	 causes	neurodegeneration	to	occur	is	still	yet	to	be	defined.		Because	the	disease	progression	is	relatively	so	rapid	in	our	cohort	of	Tpp1-/-	mice	(Sleat	et	al.,	2004),	 the	precise	 timing	of	neuropathological	events	 is	 impossible	 to	fully	 determine	 without	 additional	 and	 more	 closely	 spaced	 survival	 times.	 This	directly	 affects	 our	 ability	 to	 discriminate	 further	 whether	 the	 adaptive	 immune	system	ameliorates	or	enhances	disease	progression	in	TPP1-deficient	mice.	Ideally	one	 would	 look	 in	 detail	 at	 the	 onset	 and	 progression	 of	 neuropathological	phenotypes	 in	 both	TPP1-deficient	mice	with	 an	 intact	 immune	 system	 and	 those	with	a	NODSCID	background,	using	samples	obtained	at	shorter	intervals	of	time.	In	addition,	 it	 would	 be	 informative	 to	 evaluate	 the	 extent	 of	 adaptive	 immune	 cell	infiltration	 into	 the	CNS	of	TPP1-deficient	mice,	and	whether	 this	differs	 from	that	seen	 in	 PPT1-	 and	 CLN3-	 deficient	 mice	 (Kühl,	 PhD	 thesis,	 2013).	 However,	 this	would	be	very	expensive	in	terms	of	animal	costs	and	the	time	and	resources	taken	to	perform	these	studies,	and	was	not	possible	to	include	in	this	thesis.			
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4.4.4 Glial	activation	in	TPP1	deficient	mice	is	largely	unaffected	at	end	stage	
by	the	NODSCID	background	The	astrocyte	response	in	Tpp1-/-/NODSCID	mice	is	broadly	similar	to	the	response	seen	 in	Tpp1-/-	mice	with	 an	 intact	 immune	 system,	with	massive	 upregulation	 of	GFAP	 immunoreactivity	 in	 the	 somatosensory	 thalamocortical	 pathways	 (Figure	
19).	 It	 is	not	yet	clear	 if	 this	event	 is	associated	with	proliferation	of	astrocytes	 in	TPP1-deficient	 mice,	 or	 simply	 higher	 GFAP	 expression	 in	 the	 same	 number	 of	astrocytes.	 However,	 studies	 in	 CLN3-deficient	 mice	 suggested	 that	 similar	 data	were	due	to	an	increase	in	GFAP	expression	within	astrocytes	rather	than	increased	astrocytic	 proliferation	 (Pontikis	 et	 al.,	 2005).	 Nevertheless,	 our	 data	 suggest	 that	the	astrocytic	response	to	TPP1	deficiency	is	arguably	more	pronounced	in	animals	with	an	intact	immune	system	(Figure	19	versus	Figures	10	and	11,	Chapter	3,	
section	3.2.4),	although	the	pattern	of	astrocytosis	is	very	similar.	The	significance	of	 this	 similar	 astrocytic	 response	 in	 Tpp1-/-	 and	 Tpp1-/-/NODSCID	 mice	 is	 as	 yet	unknown.	The	astrocytes	may	 simply	be	 responding	 to	 the	degenerative	events	 in	the	same	populations	of	neurons,	irrespective	of	their	immune	status.	Alternatively,	the	modest	reduction	in	astrocytosis	seen	in	Tpp1-/-/NODSCID	mice	is	further	proof	that	the	adaptive	immune	system	enhances	neuroinflammation	in	the	NCLs	and	may	be	deleterious	to	neuronal	survival.	The	 data	 in	 Chapter	 3	 showed	 the	 presence	 of	 activated	 macrophage-like	 cells	within	 the	 brain	 of	Tpp1-/-	mice	 from	9	weeks	 of	 age	 onwards.	However,	 it	 is	 not	clear	if	these	cells	are	resident	microglia,	or	perhaps	monocytes	recruited	from	the	peripheral	 immune	 system	 (Perego	 et	 al.,	 2011,	 Stoll	 and	 Jander,	 1999).	However,	although	microglial	cells	can	easily	be	distinguished	from	other	brain	cells	this	is	not	always	 possible	 in	 the	 case	 of	 non-CNS	 monocytes	 (Zhang	 et	 al.,	 2002).	 This	 is	because	 the	 CNS-invading	 cells	 from	 the	 periphery	 share	 the	 same	 lineage	 origin	with	resident	microglia	and	their	expression	profiles	overlap	considerably	(Cosenza-Nashat	 et	 al.,	 2006).	 That	 being	 said,	 the	 relative	 levels	 of	 CD45	 expression	 have	been	exploited	 in	order	 to	distinguish	between	 them.	Resident	microglia	generally	have	 a	 low	CD45	expression	 level,	whereas	 infiltrating	monocytes	 tend	 to	 express	high	levels	of	CD45	(Ford	et	al.,	1995,	Sedgwick	et	al.,	1993).	Further	studies	would	be	 required	 to	 evaluate	 the	 origin	 of	 macrophage-like	 activated	 cells	 in	 TPP1-deficient	mice,	perhaps	comparing	CD45	expression	as	outlined.	Nevertheless,	 it	 is	interesting	to	note	that	the	pattern	of	microglial	activation	seen	in	Tpp1-/-	and	Tpp1-
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/-/NODSCID	 mice	 was	 almost	 exactly	 the	 same,	 suggesting	 that	 the	 microglia	 are	activated	by	molecular	cues,	which	are	independent	of	the	T-	and	B-	lymphocytes.		It	 is	 difficult	 to	make	 unbiased	 quantitative	 comparisons	 between	 the	Tpp1-/-	 and	
Tpp1-/-/NODSCID	 brain	 sections,	 which	 were	 immunostained	 at	 different	 times,	subjectively	however	CD68	immunostaining	was	more	intense	in	13-week-old	Tpp1-
/-	mice	compared	to	16-week-old	Tpp1-/-/NODSCID	mice	(Figure	20	versus	Figures	
8	 and	 9,	 Chapter	 3,	 section	 3.2.2).	 In	 line	with	 our	 findings	 Kuhl	 et	 al.,	 (2013)	found	that	without	 the	adaptive	 immune	response,	 innate	 immune	responses	such	as	 astrocytosis	 and	 microglial	 activation	 were	 relatively	 reduced	 in	 Ppt1-/-	mice	(Kuhl,	PhD	thesis,	2013).	Taken	 together,	 our	 results	 suggest	 that	 removing	 the	 adaptive	 immune	 system	results	 in	modest	 reductions	 in	 neuroinflammation	 in	 TPP1-deficient	mice.	 These	reductions	are	not	 sufficient	 to	confer	any	benefits	 in	 terms	of	neuron	survival,	 as	the	vulnerable	cell	populations	of	the	thalamocortical	system	are	still	lost.			
4.4.5 LAMP1	immunoreactivity	is	similar	in	TPP1	deficient	mice	regardless	of	
immunological	status	The	quantity	of	autofluorescent	storage	material	inside	neurons	is	often	evaluated	in	models	 of	 NCL	 as	 an	 indication	 of	 disease	 progression	 or	 the	 effectiveness	 of	 a	therapy	 (Griffey	 et	 al.,	 2006).	 As	 is	 described	 in	 Chapter	 3	 section	 3.2.6,	autofluorescent	 storage	 material	 was	 not	 sufficiently	 apparent	 in	 TPP1-deficient	mice	 in	 order	 to	 evaluate	 storage	 material	 accumulation	 over	 time.	 As	 a	 result	 I	looked	at	LAMP1	expression,	which	correlates	with	lysosomal	size	and	number	and	has	been	shown	to	relate	to	the	amount	of	storage	material	in	the	lysosome	(Meikle	et	 al.,	 1997b).	 LAMP1	 staining	 demonstrated	 similar	 distribution	 patterns	 for	 16-week-old	Tpp1-/-/NODSCID	mice	(Figure	16,	Chapter	3,	section	3.2.7)	and	13-week-old	Tpp1-/-	mice	(Figures	22	and	23)	throughout	the	striatum,	cortex	and	thalamus.	Both	 showed	 significant	 quantitative	 increases	 of	 LAMP1	 immunoreactivity	 in	 the	S1BF	 and	 VPMVPL.	 LAMP1	 staining	 also	 marks	 activated	 microglia	 that	 have	engulfed	 storage	 material,	 in	 addition	 to	 neurons	 that	 are	 distended	 by	 storage	material.	 However,	 it	 is	 possible	 to	 distinguish	 between	 them	 on	 the	 basis	 of	morphology,	although	double	immunostaining	would	be	needed	to	confirm	this. From	 these	 observations,	 one	 can	 conclude	 that	 the	 increase	 in	 LAMP1	immunoreactivity	 in	 neurons	 of	 TPP1-deficient	 mice	 occurs	 independently	 from	influences	 of	 the	 adaptive	 immune	 system.	 Indeed,	 in	 Ppt1-/-	 mice	 with	 a	 Rag1	
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deficiency	 (which	 removes	 functioning	 T-	 and	 B-lymphocytes)	 autofluorescent	storage	material	in	neurons	also	still	accumulated	(Groh	et	al.,	2013).	Taken	 together,	 these	 data	 suggest	 that	 the	 accumulation	 of	 storage	material	 and	increase	in	LAMP1	expression	observed	in	late	infantile	CLN2	disease	and	infantile	CLN1	disease	 is	 as	 a	 direct	 result	 of	 the	missing	 lysosmal	 enzyme	 and	 not	 due	 to	secondary	 effects	 of	 the	 recruitment	 of	 the	 adaptive	 immune	 system.	 This	 is	important,	 as	 if	 the	 accumulation	 of	 storage	 material	 is	 detrimental	 to	 neuronal	populations	 as	 our	 new	 data	 in	 Chapter	 3	 suggests	 could	 be	 the	 case,	immunosuppressive	therapies	will	not	be	sufficient	in	treating	these	diseases.				
4.4.6 How	 does	 the	 adaptive	 immune	 system	 exert	 its	 effects	 on	 TPP1	
deficient	mice?	The	mechanism	by	which	mutations	in	genes	encoding	lysosomal	enzymes	or	other	members	 of	 the	 lysosomal-endosomal	 pathway,	 result	 in	 recruitment	 of	inflammatory	 cells	 is	 currently	 unclear	 (Groh	 et	 al.,	 2013).	 It	 is	 possible	 that	 the	accumulation	of	storage	material	may	cause	cellular	stress	(Zhang	2006,	Ahtiainen	2007,	Wei	2008),	which	may	 lead	 to	 expression	of	MHC	 class	 I	molecules	 and	 the	release	of	proinflammatory	cytokines	from	target	cells	as	seen	in	vivo	in	Ppt1-/-	mice	(Groh	et	al.,	2013)	and	 in	vitro	 in	astrocyte	cultures	from	Ppt1-/-	(Saha	et	al.,	2008)	and	Cln3-/-	mice	(Parvainen,	PhD	thesis,	2013).		In	conclusion,	TPP1-deficient	mice	on	the	NODSCID	background	have	an	 increased	lifespan	 but	 the	 extent	 of	 neurodegeneration	 and	 neuroinflammation	 that	 results	from	 the	 absence	of	TPP1	 is	 still	 present.	Thus,	 the	 adaptive	 immune	 system	may	potentially	have	a	deleterious	role	to	play	in	the	disease	progression	of	late	infantile	CLN2	disease	mice	but	is	not	the	major	cause	of	the	severe	phenotype	we	see	in	the	




4.5.1 Why	are	we	looking	at	the	cerebellum?		Many	human	late	infantile	CLN2	disease	cases	show	marked	cerebellar	atrophy	that	is	even	more	severe	than	the	pronounced	atrophy	seen	 in	 the	 forebrain	(Verma	et	al.,	 2013).	 Given	 these	 pronounced	 cerebellar	 phenotypes	 in	 late	 infantile	 CLN2	disease	 individuals,	 it	 is	 important	 to	 quantify	 the	 cerebellum	 neuropathology	further	in	mice	with	a	TPP1	deficiency.	The	cerebellum	contains	unique	cells	that	are	vulnerable	in	neurodegenerative	disease,	which	will	be	introduced	here	and	further	discussed	later.			
4.5.2 Cerebellar	architecture	The	 cerebellum	 is	 a	 region	 of	 the	 brain	 that	 is	 essential	 for	 controlling	 motor	coordination,	 balance,	 learning	 and	 proprioception	 (Voogd	 and	 Glickstein,	 1998,	Manto	 et	 al.,	 2012).	Figure	 24a	 shows	 a	 sagittal	 section	 of	 the	 cerebellar	 vermis	showing	 the	 stereotypical	 foliation	 pattern	 of	 the	 ten	 lobules	 and	 how	 they	 are	divided	into	anterior	and	posterior	regions.			
	
Figure	 28	 Cerebellar	 architecture	 in	 mouse	 sagitall	 sections.	 (A)	 Schematic	representation	of	cerebellar	lobes,	anterior	to	posterior.	(Macauley	et	al.,	2009)	(B)	The	cell	bodies	 of	Bergmann	glial	 cells	 (BGC)	 are	 found	 in	 the	Purkinje	 cell	 layer	 (PCl),	where	 the	somata	 of	 Purkinje	 cells	 (PC)	 align.	 In	 the	molecular	 layer	 (ml),	 BGC	 processes	 associate	closely	with	PC	dendrites.	 Cerebellar	 astrocytes	 (AC)	 are	 present	 in	 the	 granule	 cell	 layer	(gcl)	and	white	matter	(wm).	Adapted	from	(Macauley	et	al.,	2009).				
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The	cerebellar	cortex	is	made	up	of	three	layers:	an	outer	synaptic	 layer	called	the	molecular	layer,	an	intermediate	discharge	layer	called	the	Purkinje	cell	layer	and	an	inner	receptive	area,	the	granular	layer	(Sarna	and	Hawkes,	2003).	The	Purkinje	cell	somas	 form	a	monolayer	 in	between	the	granular	 layer,	which	 is	 full	of	very	small	granular	 neurons	 (granular	 cells),	 and	 the	 molecular	 layer,	 which	 contains	 the	dendrites	 of	 the	 Purkinje	 cells	 (Palay	 and	 Chan-Palay,	 1974)	 (Figure	 24b).	 The	Purkinje	 cells	 are	 large	 gamma-aminobutyric	 acid	 (GABA)-ergic	 neurons	 with	 a	single	 long	 axon	 and	 many	 branching	 dendrites	 or	 ‘arbors’	 (Ito,	 1998,	 Palay	 and	Chan-Palay,	 1974).	 Cerebellar	 granule	 cells	 send	 parallel	 fibres	 up	 through	 the	Purkinje	cell	 layer	 into	 the	molecular	 layer	where	 they	branch	outwards	and	 form	thousands	of	Purkinke	and	granule	cell	synapses	(Nieuwenhuys	et	al.,	1998).		During	 development,	 Bergmann	 glia	 act	 as	 a	 radial	 scaffold	 to	 which	 newly	generated	 granule	 cells	 can	 migrate	 from	 the	 external	 to	 internal	 regions	 of	 the	cerebellum	(Buffo	and	Rossi,	2013,	Edwards	and	Yanamoto,	1990).	The	Bergmann	glial	cells	are	unique	in	the	fact	that	they	are	maintained	in	the	mature	brain	and	are	derived	 from	 the	 radial	 glial	 cells	 of	 the	 cerebral	 cortex	 (Das,	 1976).	The	 retained	Bergmann	glia	 form	a	scaffold,	which	provides	structure	and	molecular	support	 to	the	neighbouring	cells	(Rakic,	2003,	Howard	et	al.,	2008).	Their	precise	function	in	the	 mature	 brain	 has	 not	 been	 completely	 defined,	 however	 it	 is	 postulated	 that	Bergmann	glia	interact	with	synapses	of	Purkinje	dendrites	and	serve	a	homeostatic	role	 in	 glutamate	 and	 K+	 clearance	 (Bellamy,	 2006,	 Hertz	 and	 Zielke,	 2004,	Takahashi	et	al.,	1996).		Bergmann	 glia	 are	 activated	 in	 response	 to	 Purkinje	 cell	 degeneration,	 but	 the	functions	 of	 Bergmann	 glia	 are	 likely	 to	 be	 more	 extensive	 (Verschuuren	 et	 al.,	1996).	Experiments	have	shown	that	when	Bergmann	glia’s	functions	are	attenuated	this	 results	 in	 granule	 neuron	 degeneration,	 alterations	 in	 Purkinke	 cell	 dendritic	arbors	and	disruption	of	 junction	between	the	molecular	and	granule	cell	 layers	 is	disrupted	(Cui	et	al.,	2001,	Yue	et	al.,	2005,	Rakic,	2004).	These	data	suggest	that	the	Bergmann	glial	are	essential	as	scaffolds	that,	together	with	the	organising	function	of	 Purkinje	 cells,	 are	 necessary	 to	 achieve	 the	 normal	 pattern	 of	 layering	 in	 the	cerebellar	cortex	(Buffo	and	Rossi,	2013).		
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4.5.3 Cerebellar	deficits	are	seen	in	NCL	patients	and	mouse	models	The	 cerebellum	 is	 affected	 in	 many	 forms	 of	 NCL,	 and	 this	 has	 been	 successfully	modelled	 in	 mice.	 Cerebellar	 atrophy	 in	 juvenile	 CLN3	 disease	 patients	 has	 been	observed	using	magnetic	resonance	imaging	(MRI)	(Autti	et	al.,	1996,	Nardocci	et	al.,	1995).	Additionally,	Bergmann	glial	 activation	 throughout	 the	molecular	 layer	and	corresponding	Purkinje	 cell	 loss	 is	 seen	 in	 juvenile	CLN3	disease	 cerebellar	 tissue	(Weimer	 et	 al.,	 2009).	 In	 CLN3-deficient	 mice,	 extensive	 neuron	 loss	 was	 also	observed	in	the	medial	deep	cerebellar	nuclei.		There	is	also	activation	of	Bergmann	glia,	which	correlates	precisely	with	areas	of	Purkinje	cell	loss,	exactly	as	is	seen	in	human	 juvenile	 CLN3	 disease	 tissue	 samples	 (Weimer	 et	 al.,	 2009).	 These	 data	demonstrate	 the	 broad	 similarity	 in	 disease	 phenotype	 for	 this	 aspect	 of	 CLN3-deficiency	in	both	mice	and	humans.	In	human	infantile	CLN1	disease	patients,	motor	deficits	are	present	and	cerebellar	degeneration	is	present	at	autopsy	(Hawkins-Salsbury	et	al.,	2013,	Vanhanen	et	al.,	2004,	Williams	et	al.,	2006).	This	 is	recapitulated	in	Ppt1-/-	mice,	with	Purkinje	cell	loss	 being	 seen	 in	 PPT1-deficient	 mice	 from	 3	 months	 of	 age	 onwards,	 which	 is	accompanied	 by	 reactive	 gliosis	 (Macauley	 et	 al.,	 2009).	 Granule	 cell	 loss	 is	 also	apparent,	but	only	in	the	later	stages	of	disease,	along	with	microglial	activation	and	demyelination	(Macauley	et	al.,	2009).		In	 human	 late	 infantile	 CLN2	 disease	 cerebellum	 tissue,	 the	 molecular	 layer	 is	atrophic	 and	 there	 is	 pronounced	 granule	 cell	 loss	 and	 a	 complete	 absence	 of	Purkinje	cells,	any	Purkinje	cells	 that	remain	are	swollen	with	cytoplasmic	storage	material	 (Chang	 et	 al.,	 2008).	 The	 TPP1-deficient	mouse	 shows	 similar	 cerebellar	pathology.	Sleat	et	al.,	(2004)	reported	that	as	the	disease	approaches	end	stage	in	





4.6.1 	Loss	of	Purkinje	cells	in	Tpp1-/-/NODSCID	mice		In	order	to	investigate	Purkinje	cell	numbers	in	Tpp1-/-/NODSCID	mice,	a	one	in	six	series	of	free-floating	sagittal	cerebellar	sections	were	immunostained	for	calbindin,	a	 calcium	 binding	 protein,	 which	 can	 be	 used	 to	 specifically	 identify	 Purkinje	neurons	 from	 the	 surrounding	 cerebellar	 cell	 types.	 Calbindin	 staining	 has	 been	shown	 to	 be	more	 accurate	 compared	 to	 nissl	 staining	when	 used	 in	 this	 context	(Whitney	 et	 al.,	 2008),	 and	 I	 also	 found	 this	 to	 be	 the	 case,	with	Nissl	 staining	 of	Purkinje	 neurons	 being	 too	 faint	 to	 reliably	 count	 their	 number.	 To	 examine	Purkinje	 cell	 survival,	 StereoInvestigator	 software	 was	 used	 to	 obtain	 unbiased	optical	fractionator	estimates	of	the	number	of	these	calbindin	positive	cells.	These	counts	were	made	in	the	cerebellar	vermis	where	all	10	lobes	were	visible.	Purkinje	cells	 were	 only	 counted	 if	 they	 had	 a	 well-defined	 cytoplasm	 and	 clear	 nucleus;	those	 cells	 that	 appeared	 to	 be	 undergoing	 degeneration	 with	 a	 shrunken	 or	distorted	 appearance	 were	 not	 counted.	 The	 sizes	 of	 the	 sampling	 grid	 and	 the	dissector	frame	were	determined	in	order	to	count	all	the	Purkinje	cells	in	a	section,	not	to	merely	sample	a	subset	them.		Purkinje	cell	counts	were	recorded	for	the	total	cerebellar	 vermis	 and	 then	 for	 each	 individual	 lobule	 of	 the	 control	 Tpp1+/-
/NODSCID	mice	and	the	diseased	Tpp1-/-/NODSCID	mice.		At	 low	magnification	 in	 control	Tpp1+/-/NODSCID	mice,	 the	Purkinje	 cell	 layer	 is	 a	one	 cell-thick	 continuous	 monolayer	 of	 calbindin-stained	 Purkinje	 cells	 sitting	 in	between	the	molecular	and	granular	cell	layers	(Figure	24).	The	molecular	layer	is	filled	with	darkly	stained	dendritic	branches.	However,	at	 low	magnification	 in	the	mutant	 Tpp1-/-/NODSCID	mice,	 there	 were	 gaps	 in	 the	 calbindin	 staining	 and	 the	contiguous	 layer	 of	 Purkinje	 cells	 seen	 in	 control	 mice	 is	 disrupted.	 At	 higher	magnification	 it	 is	 clear	 that	 Purkinje	 cell	 loss	 in	 Tpp1-/-/NODSCID	 mice	 is	widespread	 and	 their	 axonal	 projections	 through	 the	 granular	 cell	 layer	 are	disorganised	 (Figure	 25c).	 Many	 of	 the	 remaining	 Purkinje	 cells	 also	 looked	unhealthy	in	these	diseased	mice,	with	a	swollen	cytoplasm	and	a	foamy	appearance	that	 is	 indicative	 of	 lysosomal	 enlargement	 (Figure	 25b).	 Fragmented	 dendritic	branches	 were	 evident	 in	 the	 molecular	 layer	 of	 Tpp1-/-/NODSCID	mice,	 which	 is	suggestive	of	dysfunction	and/or	dying	Purkinje	neurons.	 In	order	 to	quantify	 this	
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apparent	 neuron	 loss,	 Purkinje	 cell	 counts	 were	 performed	 throughout	 the	cerebellar	vermis	across	all	ten	lobes	and	individually	for	each	lobe.			At	 end	 stage,	 the	 total	 number	 of	 Purkinje	 cells	 in	 the	 cerebellar	 vermis	 had	significantly	 decreased	 by	 33%	 (p=0.0034)	 (Figure	 25a).	 Regionally,	 lobe	 I/II	showed	a	21%	decrease	in	Purkinje	cell	number	(significant	with	p=0.034)	(Figure	
25d).	 In	 lobe	III	there	was	a	17%	decrease	in	the	number	of	Purkinje	cell	number,	however	 this	 did	 not	 reach	 statistical	 significance	 because	 of	 the	 high	 degree	 of	variation	in	the	extent	of	Purkinje	cell	loss	within	this	lobe	in	Tpp1-/-/NODSCID	mice.	In	lobes	IV/V	there	was	a	significant	decrease	(p=0.0090)	in	the	number	of	Purkinje	cells,	which	 reached	33%	(Figure	 25d).	 	 Lobes	VI/VII	 and	 lobe	VII	 also	 showed	a	dramatic	and	significant	decrease	in	the	number	of	surviving	Purkinje	cells	at	33%	(p=0.0006)	and	25%	(p=0.0030)	less,	respectively	(Figure	25d).	The	greatest	level	of	 Purkinje	 cell	 degeneration	 was	 seen	 in	 lobe	 IX,	 where	 there	 was	 a	 38%	(p<0.0001)	 reduction	 in	 the	 number	 of	 Purkinje	 cells,	 which	 was	 very	 consistent	between	all	the	Tpp1-/-/NODSCID	brains	(Figure	25d).	Lastly	lobe	X	also	had	severe	neuronal	cell	loss,	with	36%	of	the	neurons	lost	(p=0.0003)(Figure	25d).		
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Figure	29	Loss	of	Purkinje	cells	in	Tpp1-/-/	NODSCID	mice	cerebellae.	(A)	Sections	from	16	week	old	Tpp1-/-/	NODSCID	mice	and	controls	were	immunohistochemically	stained	for	calbindin,	a	marker	of	purkinje	cells.	Unbiased	optical	fractionator	estimates	of	the	number	of	purkinje	 cells	were	made	 from	 these	 sections	and	 reveal	 a	pronounced	decrease	 in	 the	total	number	of	purkinje	cells.	(B)	Representative	images	of	calbindin-stained	Purkinje	cells,	showing	 cell	 loss	 in	 Tpp1-/-/NODSCID	 mice.	 (C)	 Representative	 image	 of	 cerebellae	 from	




4.6.2 Absence	of	granule	cell	loss	in	Tpp1-/-/NODSCID	mice	Because	the	greatest	loss	of	Purkinje	cells	was	recorded	in	lobe	IX	of	the	cerebellum,	it	was	 decided	 that	 investigations	 into	 granule	 cell	 survival	 should	 start	 there.	 To	assess	 granule	 cell	 survival	 within	 lobule	 IX	 of	 the	 cerebellum,	 StereoInvestigator	
Software	was	used	to	obtain	unbiased	optical	 fractionator	estimates	of	granule	cell	number	from	a	one	is	six	series	of	sagittal	cerebellar	Nissl	stained	sections.		The	total	number	of	granule	cells	in	control	Tpp1+/-/NODSCID	mice	was	estimated	to	be	 2.14	 x	 105	 cells,	 and	 the	mean	 number	 of	 cells	 in	 the	 granular	 layer	 of	Tpp1-/-
/NODSCID	mice	was	only	slightly	lower	at	2.04	x	105	cells	with	slight	decrease	not	being	 statistically	 significant	 (p=0.66)	 (Figure	 26).	 Therefore,	 granule	 cell	populations	do	not	seem	to	be	affected	in	Tpp1-/-/NODSCID	mice.	
Figure	30	Granule	cell	populations	are	unaffected	in	Tpp1-/-/NODSCID	mice	cerebella.		Histograms	 showing	 optical	 fractionator	 estimates	 of	 granule	 cell	 number	 do	 not	 differ	significantly	between	Tpp1+/-/NODSCID	and	Tpp1-/-/NODSCID	mice.	
	
	
4.6.3 Astrocytosis	 and	 glial	 activation	 in	 the	 cerebellum	 of	 in	 Tpp1-/-
/NODSCID	mice	Astrocytosis	 can	be	visualized	using	glial	 fibrillary	protein	 (GFAP)	upregulation	as	outlined	before	in	Chapter	3,	section	3.2.4.	Chang	et	al	(2008)	found	that	Tpp1-/-	mice	displayed	reactive	astrocytosis	in	the	granule	cell	layer	of	the	cerebellum,	which	was	homogenous	throughout	this	structure.	To	determine	what	the	extent	and	nature	of	astrocytosis	was	in	the	cerebellum	of	Tpp1-/-/NODSCID	mice,	immunohistochemistry	was	 carried	 out	 for	 the	 astrocytic	marker	 GFAP,	 using	 a	 one	 in	 six	 series	 of	 free-floating	sagittal	cerebellar	sections.	Looking	at	both	the	anterior	and	posterior	lobes	of	 the	 cerebellum	 at	 low	 power	 magnification,	 there	 was	 a	 clear	 increase	 in	astrocytosis	and	a	marked	upregulation	of	GFAP	immunoreactivity	in	the	cerebellae	of	 in	 Tpp1-/-/NODSCID	 mice,	 particularly	 within	 the	 molecular	 cell	 layer	 (Figure	
27a).	At	higher-level	magnification,	 there	was	a	distinct	 increase	 in	 the	number	of	
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GFAP-positive	 Bergmann	 glia	 in	 Tpp1-/-/NODSCID	 mice,	 with	 intensely	 GFAP	immunoreactive	cell	bodies	and	processes,	which	extended	radially	in	the	molecular	layer	 to	 the	 cortical	 surface	 of	 the	 cerebellum	 (Figure	 27c).	 	 Quantitative	thresholding	analysis	within	the	molecular	layer	showed	there	was	a	significant	13-fold	increase	in	immunoreactivity	for	GFAP	in	the	anterior	lobes	of	Tpp1-/-/NODSCID	mice	compared	to	control	mice	(p=0.0080,	Figure	27b).	There	was	also	a	similarly	marked	astrocytic	 response	 in	 the	posterior	 lobes	of	 these	Tpp1-/-/NODSCID	mice,	where	 there	 was	 a	 14-fold	 increase	 in	 immunoreactivity	 for	 GFAP	 compared	 to	control	(p=0.0156,	Figure	27b).	
	





4.6.4 Microglial	activation	is	increased	in	the	Tpp1-/-/NODSCID	cerebellum		Macauley	et	al.,	(2009)	described	a	relatively	delayed	microglial	activation	response	in	 the	 cerebellum	 of	 Ppt1-/-	 mice,	 with	 a	 progressive	 increase	 in	 the	 number	 of	microglia	evenly	dispersed	throughout	the	molecular	and	granular	layers.	In	 comparison	microglial	 activation	 has	 not	 been	 fully	 characterised	 in	 cerebellae	from	TPP1-deficient	mice.	Therefore,	 to	determine	whether	a	similar	phenotype	 is	seen	in	Tpp1-/-/NODSCID	cerebellae,	free-floating	sagittal	sections	of	the	cerebellum	from	Tpp1-/-/NODSCID	and	Tpp1+/-/NODSCID	control	mice	were	stained	for	CD68,	a	marker	 of	 microglial	 activation.	 At	 low	 magnification,	 CD68-positive	 cells	 were	apparent	 throughout	 all	 lobes	 of	 the	 cerebellum	 in	 Tpp1-/-/NODSCID	 mice,	particularly	in	the	anterior	lobes	(Figure	28a).	At	higher	power	it	was	clear	that	the	CD68-positive	cells	were	evenly	distributed	throughout	the	molecular,	Purkinje	cell	and	granular	cell	layers	of	Tpp1-/-/NODSCID	mice,	with	no	concentration	within	any	of	these	layers.	The	morphology	of	these	CD68-positive	cells	was	variable	but	most	showed	 enlarged	 cell	 soma	 and	 thickened	 processes,	 and	 there	 were	 some	 with	brain	macrophage-like	morphology	(Figure	28c).			In	contrast,	there	was	generally	a	much	lower	level	of	CD68	staining	in	the	anterior	lobes	 of	 the	 control	Tpp1+/-/NODSCID	mice	 cerebellae,	 although	 this	 was	 variable	with	 some	 control	 cerebellae	 exhibiting	 higher	 levels	 of	 staining.	 As	 such,	quantitative	thresholding	image	analysis	revealed	that	in	the	Tpp1-/-/NODSCID	mice,	that	 although	 there	was	 a	 2-fold	 increase	 in	 CD68	 immunoreactivity,	 this	was	 not	statistically	significant	(p=0.085,	Figure	28b).		In	 the	 posterior	 cerebellar	 lobes,	 CD68	 immunoreactivity	 in	 the	Tpp1+/-/NODSCID	mice	 was	 markedly	 lower	 than	 in	 the	 anterior	 lobes.	 Nevertheless,	 compared	 to	controls,	 there	was	 still	 a	 significant	 3-fold	 increase	 in	 CD68	 immunoreactivity	 in	these	in	the	Tpp1-/-/NODSCID	mice	(p=0.0040,	Figure	28b).		
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Figure	 32	 Increased	 microglial	 activation	 in	 Tpp1-/-/NODSCID	mice	 cerebellae.	 (A)	Sections	 from	 16-week-old	 Tpp1-/-/NODSCID	 mice	 and	 controls	 were	immunohistochemically	 stained	 for	CD68,	 a	marker	of	 activated	microglia.	Representative	images	 of	 CD68-stained	 cerebellae	 reveal	 an	 increase	 in	 microglial	 activation	 in	 Tpp1-/-
/NODSCID	mice,	which	 is	particularly	pronounced	 in	 the	anterior	 lobes.	 (B)	Histograms	of	quantitative	image	thresholding	analysis	reveals	significantly	increased	levels	of	microglial	activation	in	the	posterior	but	not	anterior	lobes	of	the	cerebellum	in	Tpp1-/-/NODSCID	mice.	(C)	 Immunostain	 for	 CD68	 reveals	 CD68	 positive	 microglia,	 with	 large	 cell	 soma	 and	shortened	 thickened	processes	 in	Tpp1-/-/NODSCID	mice	but	not	controls.	 	 (*=	p<0.05,	 **=	
p<0.01,	***=	p<0.001,	Unpaired	Student’s	T-test).	Scale	bar=	1000	μm	in	A,	500	μm	in	C.		
4.7 Discussion	So	 far	 I	 have	 described	 neuropathological	 changes	 in	 the	 forebrain	 of	 Tpp1-/-
/NODSCID	 in	 detail	 (Chapter	 4),	 now	 this	 analysis	 has	 been	 extended	 to	 reveal	similar	phenotypes	in	the	hindbrain	of	these	mice.	Because	reports	of	 late	infantile	CLN2	disease	patients	describe	profound	cerebellar	pathology	(Nardocci	et	al.,	1995,	Topcu	et	al.,	2004),	characterisation	of	cerebellar	pathology	in	TPP1-deficient	mice	is	an	important	goal.	The	data	in	this	Chapter	demonstrates	that	there	is	substantial	pathology	 within	 the	 Tpp1-/-/NODSCID	 cerebellum,	 which	 is	 consistent	 with	 the	human	presentation	of	the	disease.		At	end	stage,	 there	was	profound	 loss	of	Purkinje	cell	neurons	 in	severely	affected	
Tpp1-/-/NODSCID	mice,	at	a	comparable	level	to	that	seen	in	end-stage	7-month-old	
Ppt1-/-	 mice	 (Macauley	 et	 al.,	 2009),	 where	 there	 was	 a	 50%	 reduction	 in	 total	Purkinje	 cell	 number.	 The	 same	 study	 in	 Ppt1-/-	 mice,	 reported	 that	 Purkinje	 cell	death	is	not	random,	but	rather	occurs	as	a	stereotyped	wave	of	cell	death	beginning	
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in	the	anterior	lobes	of	the	cerebellar	vermis	from	3	months	of	age,	correlating	with	changes	in	rotarod	performance	and	affecting	the	posterior	lobes	later;	by	end	stage	however,	 there	 is	 significant	 Purkinje	 cell	 loss	 in	 all	 lobes	 regardless	 of	 location	(Macauley	 et	 al.,	 2009).	 The	 mammalian	 cerebellum	 is	 organised	 into	 several	hundred	individual	topographic	units,	which	are	conserved	between	individuals	and	species,	 therefore	 it	 is	unsurprising	 that	 cell	death	may	be	 regionalized	as	well.	 In	sagittal	sections,	regionalization	manifests	 itself	as	a	dominance	of	aldolase	c	(also	called	 zebrin	 II)-positive	 Purkinje	 cells	 in	 the	 posterior	 lobes	 compared	 to	 more	aldolase	 c-negative	 Purkinje	 cells	 in	 the	 anterior	 lobes	 (reviewed	 in	 (Sarna	 and	Hawkes,	 2003)).	 Alodolase	 c	 is	 an	 isoenzyme	 of	 a	 glycolysis	 enzyme	 and	 those	Purkinje	 cells	 that	 express	 aldolase	 c	 in	 a	mouse	model	 of	 the	 LSD	Niemann-Pick	type	c	disease	(in	the	posterior	lobes)	are	relatively	spared	compared	to	those	that	do	 not	 (the	 anterior	 lobes	 (Sarna	 et	 al.,	 2003)).	 	 Thus	 Purkinje	 cell	 death	 can	 be	associated	with	aldolase	c	expression	or	lack	thereof	(Pakan	et	al.,	2007).	In	the	absence	of	earlier	time	points	 it	 is	not	clear	whether	the	same	phenotype	 is	seen	in	Tpp1-/-/NODSCID	mice.	Although	extensive	cell	loss	was	seen	in	the	anterior	cerebellar	 lobes	 of	 Tpp1-/-/NODSCID	 mice,	 the	 posterior	 lobes	 were	 similarly	affected	in	this	model.	It	 is	possible	that	like	in	other	NCLs	and	LSDs,	the	posterior	lobes	are	initially	more	resistant	to	toxic	insults	but	are	still	affected	later	in	disease	progression	(Sarna	and	Hawkes,	2003,	Macauley	et	al.,	2009).	Or	 it	 is	possible	that	the	 predicted	wave	 of	 Purkinje	 cell	 loss	 from	anterior	 to	 posterior	 lobes	 does	 not	occur	in	Tpp1-/-/NODSCID	mice.	It	has	also	been	proposed	that	the	Purkinje	cells	of	the	 posterior	 lobes	 are	 protected	 via	 increased	 expression	 of	 metabolic	 enzymes	(Slemmer	 et	 al.,	 2007)	 and	 gluatamate	 transporters	 (Welsh	 et	 al.,	 2002),	 but	 the	mechanism	of	variable	Purkinje	cell	vulnerability	is	still	unclear.	Human	 late	 infantile	 CLN2	 disease	 cerebellum	 tissue	 specimens	 show	 prominent	astrocytosis	 in	 the	 granular	 cell	 layer,	 accompanied	 by	 Bergmann	 gliosis	 in	 the	molecular	 layer	(Chang	et	al.,	2008).	 	Astrocyte	activation	in	the	cerebellum	is	also	seen	in	a	number	of	NCL	mouse	models.	In	PPT1-deficient	mice,	GFAP	upregulation	begins	at	3	months	of	age,	where	patchy	Bergmann	gliosis	 is	evident	 throught	 the	anterior-posterior	axis	(Macauley	et	al.,	2009).	At	end	stage	in	the	same	Ppt1-/-	mice,	GFAP	 was	 upregulated	 throughout	 the	 entire	 molecular	 layer	 in	 all	 lobes	 of	 the	cerebellar	vermis	and	at	high	magnification	there	was	an	increase	in	the	number	of	GFAP	immunoreactive	glial	processes	in	the	molecular	layer	(Macauley	et	al.,	2009).	The	degree	of	GFAP	upregulation	was	proportional	 to	 the	disease	progression	and	
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the	 age	 of	 the	 mouse.	 The	 data	 presented	 in	 this	 Chapter	 confirms	 that	 GFAP	upregulation	also	occurs	 in	Tpp1-/-/NODSCID	mice,	as	was	seen	in	 initial	studies	 in	immunocompetent	Tpp1-/-	mice	(Chang	et	al.,	2008)	where	the	cerebellar	molecular	layer	 of	 Tpp1-/-	but	 not	Tpp1+/-	mice,	 displayed	 sporadic	 patches	 of	 gliosis,	 which	corresponded	 to	 reactive	 Bergmann	 glia,	 but	 there	 was	 no	 particular	 pattern	 of	which	 lobules	 were	 most	 susceptible	 (Chang	 et	 al.,	 2008).	 There	 was	 also	 found	evidence	for	activation	of	Bergmann	glia	in	both	anterior	and	posterior	lobes	of	the	
Tpp1-/-/NODSCID	 mice	 cerebellum.	 Similar	 to	 Chang	 et	 al.,	 (2008)	 we	 also	 saw	increased	 GFAP	 immunostaining	 homogenously	 throughout	 the	 granule	 cell	 layer,	whilst	the	molecular	layer	exhibited	sporadic	patches	of	gliosis,	which	correspond	to	reactive	Bergmann	glia.		Previous	 studies	 from	 late	 infantile	 CLN2	 disease	 human	 tissue	 showed	 evidence	that	 microglial	 activation	 also	 occurs	 in	 the	 cerebellum	 (Chang	 et	 al.,	 2008).	Surprisingly,	 microglial	 activation	 has	 not	 previously	 been	 explored	 in	 TPP1-deficient	 cerebellum.	 The	 data	 in	 this	 Chapter	 confirms	 that	 prominent	microglial	activation	 within	 the	 cerebellum	 is	 a	 robust	 phenotype	 in	 end	 stage	 Tpp1-/-




Evaluating	 the	 fate	 of	 transplanted	 human	 Neural	 Stem	
Cells	in	Tpp1-/-/NODSCID	mice		 	
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In	 Chapter	 4,	 the	 neuropathology	 of	 TPP1-deficient	 mice	 on	 an	 immunodeficient	background	was	described.	 In	 this	 Chapter	 I	will	 outline	 the	 fate	of	 human	neural	stem	 cells	 (huCNS-SCs)	 transplanted	 into	 this	mouse	model	 and	 evaluate	 how	 the	location	and	timing	of	grafting	affects	the	migration	and	engraftment	of	these	cells.		
5.1 Introduction		As	 in	 other	 enzyme	 deficient	 forms	 of	 NCL	 (Wong	 et	 al.,	 2010),	 experimental	treatments	 for	 late	 infantile	 CLN2	 disease	 all	 depend	 on	 delivering	 the	 missing	enzyme	 to	 the	 CNS	 (see	 Chapter	 1.2.1).	 All	 such	 approaches	 depend	 upon	 the	principle	of	cross-correction	(Neufeld	and	Fratanto.Jc,	1970),	whereby	exogenously	supplied	enzyme	is	taken	up	by	binding	to	mannose-6-phosphate	receptors	that	are	present	on	the	surface	of	all	cell	types,	even	in	an	enzyme	deficient	brain	(Sands	and	Davidson,	 2006).	 Studies	 of	 cross-correction	 in	 fibroblasts	 derived	 from	 a	 late	infantile	 CLN2	 disease	 patient,	 have	 shown	 that	 diffusible	 TPP1	 enzyme	 can	 be	provided	by	cells	 transduced	with	a	viral	vector	expressing	CLN2,	 and	 the	TPP1	 is	taken	 up	 via	 mannose	 6-phosphate	 receptors	 and	 appropriately	 delivered	 to	 the	lysosomal	system,	restoring	function	in	vitro	(Sondhi	et	al.,	2005).	This	has	also	been	replicated	in	mouse	and	human	fibroblasts	deficient	in	PPT1	(Tamaki	et	al.,	2009).	Delivering	the	missing	or	defective	enzyme	in	LSDs	and	in	the	soluble	enzyme	forms	of	 NCL	 has	 been	 proposed	 through	 enzyme	 replacement	 therapy	 (ERT),	 gene	therapy	and	neural	stem	cell	(NSC)	therapy	(discussed	in	Chapter	1.7).	Clinical	trials	are	underway	for	both	gene	therapy	via	direct	intercranial	infections	of	viral	vectors	expressing	CLN2	(http://www.clinicaltrials.gov/ct2/show/NCT01161576)	and	ERT	infusing	 rhTPP1	 into	 the	 CNS	(http://www.clinicaltrials.gov/ct2/show/NCT01907087)	 in	 human	 late	 infantile	CLN2	disease	patients.	Both	 trials	are	 currently	ongoing,	however	 there	are	 safety	concerns	 relating	 to	 the	use	of	viral	vectors	 in	gene	 therapy	and	with	ERT,	due	 to	their	 relatively	 short	 half-life	 lysosomal	 enzymes	 would	 need	 to	 be	 administered	frequently.	 I	shall	now	discuss	the	potential	of	using	NSCs	as	a	potential	treatment	for	the	NCLs	and	late	infantile	CLN2	disease	in	particular.		
5.1.1 Neural	Stem	Cell	Therapy	Stem	cells	are	undifferentiated	cells	with	the	capacity	for	self-renewal	and	the	ability	to	differentiate	into	several	types	of	mature	cells	(Macarthur	et	al.,	2009,	Jones	and	
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Wagers,	 2008).	 NSCs	 are	 multipotent	 and	 have	 the	 capacity	 to	 differentiate	 into	neurons,	 oligodendrocytes	 and	 astrocytes	 (Flax	 et	 al.,	 1998,	 McKay,	 1997).	 It	 has	been	proposed	 that	neuronal	 stem	cells	 could	also	be	used	 to	provide	 the	missing	enzyme	 in	 enzyme	 deficient	 NCLs	 (Hobert	 and	 Dawson,	 2006,	Wong	 et	 al.,	 2010,	Tamaki	et	al.,	2009),	and	may	also	provide	some	degree	of	cell	replacement.	In	this	scenario,	NSCs	may	 integrate	 into	 the	diseased	brain	 and	 replace	 lost	 or	damaged	cells	by	differentiating	into	the	appropriate	cell	types	of	the	brain	(Kruer	et	al.,	2013,	Kim	et	al.,	2013b).	In	addition,	the	grafted	NSCs	may	be	capable	of	providing	trophic	factors	 such	 as	 brain-derived	 neurotrophic	 factor	 (BDNF),	 which	 could	 promote	survival	 of	 the	 host	 cells,	 as	 is	 seen	 in	 a	 mouse	 model	 of	 Alzheimer’s	 disease	transplanted	 with	 human	 NSCs	 (Blurton-Jones	 et	 al.,	 2009),	 although	 there	 is	 no	direct	evidence	that	BDNF	has	a	positive	effect	on	the	degenerating	neurons	in	the	NCLs.	Numerous	 laboratories	 through	multi-lineage	differentiation	of	 cultured	 cells	have	demonstrated	 the	 existence	 of	 both	 mouse	 and	 human	 NSCs	 (Temple,	 1989)	(Cattaneo	and	McKay,	1990,	Reynolds	and	Weiss,	1992,	Kilpatrik	and	Barlett,	1993,	Ray	et	al.,	1993).	 It	 is	possible	to	isolate	clonogenic	human	central	nervous	system	stem	 cells	 (huCNS-SCs)	 from	 human	 foetal	 brain	 tissue	 (16-20	 weeks	 gestation)	(Uchida	et	al.,	2000).	Using	antibodies	against	cell	surface	markers	and	fluorescence-activated	cell	sorting	it	is	possible	to	produce	a	CD133+,	5E12-,	CD34-,	CD45-,	CD24-/low	cell	population,	from	which	single	cells	initiate	neurosphere	cultures	(Uchida	et	al.,	2000).	From	these	neurospheres	single	cells	can	be	replated	and	will	re-establish	a	new	neurosphere	culture,	indicating	their	self-renewal	properties.	The	progeny	of	such	 cultures	 are	 also	 capable	 of	 differentiating	 into	 neuronal	 and	 glial	 cells,	demonstrating	their	differentiation	potential	(Uchida	et	al.,	2000).	HuCNS-SCs	have	been	 transplanted	 into	 neonatal	 non-obese	 diabetic/severe	 combined	immunodeficient	 (NODSCID)	 mice,	 which	 lack	 adaptive	 T-	 and	 B-lymphocyte	mediated	 immunity	 reducing	 the	 probability	 of	 immune	 rejection	 (see	 Chapter	 4	section	1),	where	 they	were	shown	to	migrate,	proliferate	and	differentiate	 in	vivo	(Tamaki	 et	 al.,	 2002,	 Guzman	 et	 al.,	 2007).	 The	 ability	 of	 huNSC-Scs	 to	 proliferate	and	 self-renew,	 make	 them	 targets	 for	 malignant	 transformation	 (Vescovi	 et	 al.,	2006).	There	 is	 a	body	of	 research	 that	 advises	 caution	before	 transplanting	NSCs	into	 patients,	 including	 evidence	 that	 glioblastomas	 may	 arise	 from	 oncogenic	transformation	of	NSCs	(Vescovi	et	al.,	2006,	Singh	et	al.,	2004),	the	fact	that	similar	molecular	 pathways	 govern	 neurogenesis	 and	 tumorigenesis	 (Gil-Perotin	 et	 al.,	
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2006,	Groszer	et	al.,	2006,	McQuibban	et	al.,	2003)	and	because	glioma-like	growths	are	seen	after	growth	factor	stimulation	of	the	sub-ventricular	zone	(SVZ)	(Jackson	et	 al.,	 2006).	 However,	 importantly,	 huCNS-SCs	 did	 not	 form	 tumours	 when	transplanted	 into	 the	 brains	 of	 NODSCID	 mice,	 rats	 and	 non-human	 primates	(Tamaki	et	al.,	2002).				Encouragingly,	stem	cell	therapy	has	already	shown	benefit	in	clinical	trials	of	other	severe	neurological	diseases	with	onset	in	childhood,	such	as	Pelizaeus-Merzbacher	disease	 (PMD),	 a	 rare	 leukodystrophy	 in	which	 oligodendrocytes	 fail	 to	myelinate	axons	resulting	in	global	neurological	dysfunction	(Gencic	et	al.,	1989).		HuCNS-SCs	were	transplanted	into	the	white	matter	of	children	with	PMD	and	impressively,	one	year	 later	 three	 out	 of	 the	 four	 children	 showed	 apparent	 gains	 in	 neurological	function	 and	 improvements	 in	 MRI	 parameters	 suggestive	 of	 de	 novo	 myelin	production	(Gupta	et	al.,	2012).	Along	with	the	positive	pre-clinical	data	from	PPT1-deficient	mice	 treated	with	 huCNS-SCs,	 these	 findings	 suggest	 that	 huCNS-SCs	 are	potentially	suitable	for	use	as	a	therapeutic	tool	for	the	NCLs.			Neural	stem	cell	grafting	has	been	tested	in	LSD	mouse	models	and	a	mouse	model	of	 the	NCLs.	Mouse	NSCs	without	genetic	modification	have	been	 injected	 into	 the	brain	of	Sandhoff	 [beta-hexosaminidase(-/-)]	mice;	 the	 cells	migrated	 far	 from	 the	injection	 site,	 restored	 enzyme	 activity,	 improved	 pathology	 and	 behaviour,	 and	extended	 the	 lifespan	 of	 the	 animals	 (Jeyakumar	 et	 al.,	 2007,	 Lee	 et	 al.,	 2007);	 in	addition,	 NSCs	 transplantation	 also	 downregulated	 the	 expression	 of	proinflammatory	cytokines	and	corrected	lysosomal	storage	pathology	in	this	model	(Jeyakumar	 et	 al.,	 2007).	 Mouse	 and	 human	 NSCs	 have	 both	 been	 experimentally	injected	 into	 the	 brains	 of	 Niemann-Pick	 disease	 type	 A	 (NPA)	mice,	 and	 in	 both	cases	 there	was	 a	marked	 reduction	 in	 neuronal/glial	 vacuolation	 and	 cholesterol	accumulation	throughout	the	brain	(Sidman	et	al.,	2007).	Infantile	 CLN1	 disease	 mice	 were	 grafted	 with	 the	 huCNS-SCs	 cell	 line	 made	 by	Uchida	 et	 al.,	 (2000)	 .	 The	 cells	 were	 transplanted	 into	 PPT1-deficient	 mice	 on	 a	NODSCID	background	and	were	shown	to	be	capable	of	delivering	biologically	active	PPT1	enzyme	and	providing	some	degree	of	neuroprotection	and	slowing	of	disease	progression	 (Tamaki	 et	 al.,	 2009).	 In	 these	 mice,	 very	 little	 neuron	 replacement	occurred	with	the	majority	of	surviving	huCNS-SCs	remaining	in	an	undifferentiated	state,	however	from	a	translational	viewpoint,	as	long	as	the	huCNS-SCs	deliver	the	
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missing	 enzyme,	 this	 is	 not	 necessarily	 a	 problem	 if	 patients	 are	 treated	 early	enough	that	significant	neuron	loss	has	not	already	occurred		(Tamaki	et	al.,	2009).			On	 the	 basis	 of	 these	 promising	 pre-clinical	 data,	 a	 phase	 I	 trial	 of	 huCNS-SCs	 in	infantile	CLN1	disease	and	late	infantile	CLN2	disease	was	initiated	at	Oregon	Health	Sciences	 University,	 sponsored	 by	 StemCells	 Inc	(http://www.stemcellsinc.com/therapeutic-programs/clinical-trials.htm).	 In	 this	clinical	 trial,	 six	 children	 with	 infantile	 CLN1	 or	 late	 infantile	 CLN2	 disease	 were	given	stereotactically	guided	injections	of	huCNS-SCs	into	each	cerebral	hemisphere	and	 ventricles	 and	 immunosuppression	 for	 12	 months	 (Selden	 et	 al.,	 2013,	Tsukamoto	 et	 al.,	 2013).	 The	 therapy	 was	 well	 tolerated,	 however	 substantial	functional	 improvements	 were	 not	 observed,	 perhaps	 due	 to	 the	 fact	 that	 the	enrollment	 criteria	 required	 that	 patients	were	 in	 the	 advanced	 stages	 of	 disease	where	pronounced	neurodegeneration	has	already	taken	place	(Selden	et	al.,	2013).			This	 was	 the	 first-ever	 clinical	 use	 of	 huCNS-SCs	 in	 a	 human	 neurodegenerative	condition	(Kruer	et	al.,	2013).	Although	these	cells	have	already	been	administered	to	 late	 infantile	 CLN2	 disease	 patients,	 on	 the	 basis	 that	 they	 are	 capable	 of	delivering	TPP1,	they	remain	to	be	tested	in	TPP1-deficient	mice.		In	the	next	section,	I	will	describe	for	the	first	time	the	fate	of	transplanted	huCNS-SCs	 in	 Tpp1-/-/NODSCID	 mice	 and	 speculate	 as	 to	 whether	 this	 is	 a	 feasible	therapeutic	option	for	late	infantile	CLN2	disease	patients.		
5.2 RESULTS	
5.2.1 Transplanted	human	Neural	 Stem	Cells	 Survive	 and	Migrate	 in	Tpp1-/-
/NODSCID	mice		As	 described	 above,	 it	 has	 previously	 been	 shown	 that	 transplanted	 huCNS-SCs	survive	 in	 the	brains	of	NODSCID	mice	 (Uchida	et	al.,	2000),	and	when	huCNS-SCs	were	injected	into	Ppt1-/-/NODSCID	mice,	diffuse	engraftment	of	these	cells	was	seen	throughout	 the	 brain	 (Tamaki	 et	 al.,	 2009).	 Fixed	 brain	 tissue	was	 provided	 from	StemCells	Inc.,	including:	a)	non-grafted	Tpp1+/-/NODSCID	and	Tpp1-/-/NODSCID	for	establishing	pathological	 landmarks	as	discussed	in	Chapter	4;	and	b)	grafted	with	huCNS-SCs	as	neonates	(p0	or	p1)	as	early	post-natal	mice	(p21)	or	at	both	ages	(p0	and	 p21).	 The	mice	 were	 sacrificed	 between	 4-6	months	 of	 age,	 an	 age	 at	 which	
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TPP1-deficient	mice	would	be	severely	affected	(see	Chapter	4.1).	 	Neonatal	grafts	were	bilateral	grafts	into	the	lateral	ventricles	and	post-natal	injections	were	given	directly	 into	 the	 brain	 parenchyma,	 in	 the	 striatum,	 thalamus	 and	 cerebellum	(Figure	33).		In	 order	 to	 assess	 the	 fate	 of	 transplanted	huCNS-SCs	 in	Tpp1-/-/NODSCID	mice	 in	the	outlined	 treatment	groups,	a	1	 in	6	series	of	 sagittal	 sections	were	 taken	 from	each	 treatment	group	and	 immunostained	 for	 the	human	cell	 cytoplasmic	marker,	SC121	(Kelly	et	al.,	2004,	Kallur	et	al.,	2006).			 	
150	
Figure	 33	huCNS-SCs	 Transplantation	 Scheme.	Tpp1-/-/NODSCID	 and	Tpp1+/-/NODSCID	mice	were	grafted	with	huCNS-SCs	as	(A)	neonates	(p0	or	p1)	as	(B)	early	post-natal	mice	(p21)	or	(C)	at	both	ages	(p0	and	p21).	The	mice	were	sacrificed	between	4-6	months	of	age.		Neonatal	 grafts	were	bilateral	 intraventricular	 grafts	 and	post-natal	 injections	were	 given	directly	into	the	brain	parenchyma,	in	the	striatum,	thalamus	and	cerebellum.	Atlas	images	adapted	from	Paxinos	and	Franklin	(2001).		 	
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	In	addition	to	dense	masses	of	intensely	stained	cells	at	parenchymal	injection	sites,	SC121	immunostaining	revealed	varying	distributions	of	huCNS-SCs	within	the	CNS	of	Tpp1-/-/NODSCID	mice	according	to	which	huCNS-SCs	injection	regimen	they	had	received.	 This	 distribution	 was	 recorded	 semi-quantitatively,	 by	 mapping	 the	relative	density	of	SC121	positive	cell	 labeling	 in	mice	 from	each	 treatment	group.	Very	 densely	 populated	 areas	 of	 cells	 suggestive	 of	 injection	 tracts,	 with	 many	overlapping	cells	to	a	point	where	there	are	very	few	gaps,	were	assigned	to	be	red.	Orange	denoted	dense	regions	of	cells,	where	the	cells	are	touching	and	overlapping	but	 there	 are	 clear	 gaps	 between	 cells	 as	 well.	 Yellow	 denotes	 more	 sparsely	populated	areas,	where	huCNS-SCs	are	still	evident	but	not	touching	or	overlapping,	and	clear	space	between	each	cell.	When	 these	 brains	were	 analysed,	 it	was	 clear	 that	 there	was	 a	 varied	 amount	 of	migration	 of	 SC121	 positive	 cells	 from	 injection	 sites	 between	 treatment	 groups.		Comparing	the	extent	of	this	variation	in	cell	distribution	to	the	timing	and	delivery	of	cell	grafts	revealed	some	consistent	trends.	In	neonatal	animals	that	were	injected	bilaterally	into	the	lateral	ventricles,	the	huCNS-SCs	stayed	largely	near	the	injection	site	 or	 exhibited	 limited	 migration	 into	 neighbouring	 brain	 regions	 (Figure	 30).	These	SC121-positive	huCNS-SCs	did	not	spread	into	the	cortex	in	mice	that	received	only	 bilateral	 intraventricular	 injections	 at	 p0.	However,	 there	were	many	 SC121-positive	cells	populating	the	olfactory	bulb,	which	was	not	injected	in	these	animals.	This	suggests	that	these	huCNS-SCs	in	the	olfactory	bulb	had	migrated	to	this	site	via	the	 rostral	 migratory	 stream	 (RMS),	 the	 normal	 migration	 route	 of	 endogenous	neurogenesis	 in	 the	 olfactory	 system	 (Alvarez-Buylla	 et	 al.,	 2001,	 Rakic,	 2002),	although	 there	 was	 not	 direct	 evidence	 of	 this	 in	 neonatally	 injected	 mice.	Interestingly,	 there	 were	 also	 dense	 dorso-ventrally	 oriented	 patches	 of	 SC121-positive	cells	 in	 the	striatum	and	cerebellum	of	 these	mice	that	were	suggestive	of	injection	tracts,	which	according	to	the	information	supplied	by	StemCells	Inc	these	animals	had	not	received.	Nevertheless,	these	huCNS-SCs	stayed	close	to	these	dense	clusters	of	cells	within	these	brain	regions.	 	In	this	treatment	regime,	there	did	not	appear	 to	be	an	effect	of	genotype	upon	 the	extent	of	huCNS-SCs	migration	with	a	similar	distribution	of	SC121-positive	huCNS-SCs	in	both	Tpp1-/-/NODSCID	mice	and	
Tpp1+/-/NODSCID	 controls	 (Figure	 34).	 Due	 to	 the	 similar	 distribution	 of	 cells	 in	




Figure	34	Migration	of	 transplanted	huCNS-SCs	 in	neonatally	 injected	Tpp1-/-/NODSCID	mice.	The	huCNS-SCs	remain	mainly	next	to	 injection	tracts	 in	mice	injected	at	p0.	However	the	olfactory	bulb	is	highly	populated	with	huCNS-SCs	and	was	not	injected.	Red	indicates	very	densely	populated	areas	of	cells	suggestive	of	injection	tracts.	Orange	denotes	dense	regions	of	cells,	where	the	cells	are	touching.	Yellow	denotes	more	sparsely	populated	areas,	where	huCNS-SCs	are	still	evident	but	not	touching.	Atlas	images	adapted	from	Paxinos	and	Franklin	(2001).	
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Figure	35	Migration	of	 transplanted	huCNS-SCs	 in	 early	post-natally	 injected	Tpp1-/-
/NODSCID	mice.	Early	post-natal	mice	(p21)	were	injected	with	huCNS-SCs	directly	into	the	brain	 parenchyma	 (thalamus,	 striatum	 and	 cerebellum).	 SC121	 immunostaining	 suggests	that	that	the	huCNS-SCs	have	migrated	to	the	olfactory	bulb	and	in	addition	have	migrated	to	adjacent	neighbouring	structures,	such	as	the	deepest	laminae	of	the	cortex.	Red	indicates	very	densely	populated	 areas	of	 cells	 suggestive	of	 injection	 tracts.	Orange	denotes	dense	regions	of	cells,	where	the	cells	are	touching.	Yellow	denotes	more	sparsely	populated	areas,	where	huCNS-SCs	are	still	evident	but	not	touching.	Atlas	images	adapted	from	Paxinos	and	Franklin	(2001).	
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Figure	 36	 Migration	 of	 transplanted	 huCNS-SCs	 in	 neonatal	 and	 early	 post-natally	
injected	 Tpp1-/-/NODSCID	mice.	 The	mice	 received	 bilateral	 intraventricular	 injection	 of	huCNS-SCs	 at	 p0	 and	 subsequently	 at	 p21	 directly	 into	 the	 brain	 parenchyma	 (thalamus,	striatum	 and	 cerebellum).	 SC121	 immunostaining	 suggests	 that	 that	 the	 huCNS-SCs	 have	migrated	to	the	olfactory	bulb	and	 in	addition	have	migrated	 into	neighbouring	structures	and	 into	 the	more	 superficial	 laminae	of	 the	 cortex.	Red	 indicates	very	densely	populated	areas	of	cells	suggestive	of	injection	tracts.	Orange	denotes	dense	regions	of	cells,	where	the	cells	are	touching.	Yellow	denotes	more	sparsely	populated	areas,	where	huCNS-SCs	are	still	evident	but	not	touching.	Atlas	images	adapted	from	Paxinos	and	Franklin	(2001).	
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In	mice	treated	at	p21,	(the	‘early	post-natal’	age	treatment	group),	with	cell	grafts	made	into	the	striatum,	thalamus	and	cerebellum,	there	was	far	more	migration	of	huCNS-SCs	evident	than	those	animals	treated	at	p0	with	ventricular	grafts	(Figure	
35).	 In	 these	 early	 post-natally	 grafted	 animals,	 SC121	 staining	 was	 evident	 as	intensely	 stained	 compact	 masses	 of	 cells	 at	 the	 injection	 sites,	 but	 rather	 than	staying	 within	 these	 injection	 sites	 and	 neighbouring	 structures,	 SC121-positive	cells	 spread	 further	 into	 the	 deeper	 laminae	 of	 the	 cortex	 and	 into	 the	 corpus	callosum.	 As	 in	 the	 neonatally	 grafted	 animals,	 the	 olfactory	 bulb	 was	 highly	populated	with	SC121-positive	huCNS-SCs	suggesting	the	huCNS-SCs	have	migrated	specifically	 to	 this	 region	 in	 juvenile	 treated	animals	as	well	and	 there	were	many	SC121-positive	cells	in	the	SVZ,	suggesting	the	huCNS-SCs	migrated	to	the	olfactory	bulb	via	the	RMS.	Again,	there	did	not	appear	to	be	a	genotype	effect	on	the	extent	of	huCNS-SCs	 migration,	 with	 a	 similar	 distribution	 of	 SC121-positive	 huCNS-SCs	 in	both	Tpp1-/-/NODSCID	mice	and	Tpp1+/-/NODSCID	controls	(Figure	35).		The	treatment	regime	that	resulted	in	the	most	widespread	migration	of	huCNS-SCs	was	to	inject	the	huCNS-SCs	at	p0	bilaterally	into	the	ventricles,	and	then	again	with	grafts	 into	 the	brain	parenchyma	at	p21	 (Figure	 36)	These	double	grafted	brains,	treated	 at	 both	 time	points,	 showed	huCNS-SCs	 engraftment	 throughout	 the	 brain	into	not	only	bordering	structures	but	also	disconnected	structures,	such	as	laminae	I/II	of	the	cortex,	which	did	not	receive	any	injections.	In	 these	 double	 grafted	mice	 SC121-immunostained	 cells	were	 evident	 as	 densely	packed	cell	masses	 in	the	striatum,	thalamus,	and	cerebellum,	and	also	adjacent	 to	the	 ventricles.	 Compared	 to	 either	 neonatal	 or	 early	 post-natally	 grafted	 mice,	huCNS-SCs	migration	was	much	more	widespread	 in	 these	dual-treated	mice	with	SC121-positive	cells	evident	in	the	majority	of	the	brain.	Within	the	cortex	of	these	dual-grafted	mice,	huCNS-SCs	were	evident	throughout	all	subfields	examined,	even	reaching	 the	 more	 superficial	 laminae.	 These	 SC121	 positive	 cells	 were	predominantly	present	in	laminae	IV-VI,	but	many	cells	were	also	present,	although	to	a	 lesser	extent,	 in	more	 superficial	 laminae	 I/II.	Engraftment	of	huCNS-SCs	was	evident	through	the	whole	structure	of	the	thalamus	and	also	throughout	the	entire	striatum	in	Tpp1-/-/NODSCID	mice.	HuCNS-SCs	were	evident	 in	the	white	matter	of	the	cerebellum	and	in	the	sections	containing	the	 injection	tract	of	the	cerebellum,	huCNS-SCs	 could	 be	 found	within	 the	molecular	 and	 granular	 cell	 layer	 of	 all	 ten	lobes	 of	 the	 cerebellar	 vermis.	 There	 did	 not	 appear	 to	 be	 any	 preference	 for	 the	
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huCNS-SCs	 to	 migrate	 to	 a	 particular	 lobe,	 instead	 they	 were	 scattered	 evenly	throughout	the	lobes,	most	concentrated	around	the	injection	tract.	HuCNS-SCs	were	also	present	in	the	brain	stem	of	early	post-natally	dual	grafted	mice,	where	SC121-positive	cells	were	evident	 in	the	medulla	of	 the	brain	stem,	which	did	not	receive	any	injections.	As	seen	in	the	other	treatment	regimens,	SC121-positive	huCNS-SCs	filled	 the	olfactory	bulb	and	 in	 these	dual-injection	 treated	animals	 the	huCNS-SCs	could	clearly	be	visualised	migrating	in	the	RMS	(Figure	36).	Taken	 together,	 this	 study	 shows	 that	 huCNS-SCs	 successfully	 survive	transplantation	 into	 Tpp1-/-/NODSCID	 mice	 and	 that	 how	 far	 they	 migrate	 is	dependent	 on	 the	 timing	of	 treatment,	 and	 the	number	 and	 site	 of	 injections	 they	receive;	whereas,	genotype	does	not	noticeably	affect	migration	of	huCNS-SCs.	From	this	 initial	 survey,	 it	 appears	 that	 bilateral	 intraventricular	 injection	 at	 p0,	 in	combination	 with	 further	 huCNS-SCs	 transplantation	 at	 p21	 into	 the	 brain	parenchyma	and	cerebellum	results	in	the	most	widespread	engraftment	of	huCNS-SCs	in	both	Tpp1-/-/NODSCID	mice	and	controls.		
5.2.2 Transplanted	huCNS-SCs	differentiate	 into	various	 cell	 types	 in	Tpp1-/-
/NODSCID	mice	After	assessing	migration	of	 transplanted	huCNS-SCs	 in	Tpp1-/-/NODSCID	mice	and	controls,	we	sought	to	discover	what	the	fate	of	 these	migrated	cells	was:	whether	they	remained	 in	an	undifferentiated	state	(as	was	 the	case	when	these	cells	were	grafted	 into	 PPT1-deficient	 mice	 (Tamaki	 et	 al.,	 2009)),	 or	 whether	 they	differentiated	 into	neurons	or	glia,	 and	whether	 this	was	dependent	on	 treatment,	genotype	or	the	area	the	huCNS-SCs	migrated	to.		Using	high	power	magnification	 (x63	objective),	 a	 series	 of	 SC121-immunostained	sagittal	 sections	described	 above	were	 examined	 to	 identify	what	morphology	 the	SC121-positive	 cells	 had	 adopted,	 and	 images	 were	 taken	 to	 document	 this	appearance	in	different	brain	regions	(where	these	cells	resided).		In	 neonatal,	 intraventricularly	 injected	 mice,	 transplanted	 huCNS-SCs	 remained	largely	 undifferentiated,	 with	 a	 spindle	 shaped	 cell	 body	 and	 one	 or	 two	 short	processes,	 in	 both	 Tpp1-/-/NODSCID	 and	 Tpp1+/-/NODSCID	mice.	 However,	 in	 the	olfactory	 bulb	 of	 both	 genotypes	 of	 mice,	 SC121-positive	 cells	 had	 a	 neuronal	morphology	 with	 larger	 cell	 bodies	 than	 the	 huCNS-SCs	 assumed	 to	 be	undifferentiated,	each	with	much	 longer	processes.	The	huCNS-SCs	appeared	to	be	organised	 with	 their	 long	 processes	 aligned	 within	 the	 glomerular	 layer	 of	 the	
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olfactory	 bulb.	 Although	 there	 did	 not	 appear	 to	 be	 a	 greater	 proportion	 of	differentiated	 huCNS-SCs	 in	Tpp1-/-/NODSCID	mice	 compared	 to	Tpp1+/-/NODSCID	control	 mice,	 many	 of	 the	 undifferentiated	 huCNS-SCs	 had	 a	 ‘sick’	 or	 ‘unhealthy’	appearance	 in	 Tpp1-deficient	 mice,	 with	 swollen	 somas	 and	 twisted	 processes,	which	was	less	apparent	in	control	mice.		Transplanted	 huCNS-SCs	 in	 early	 post-natally	 treated	 mice,	 which	 were	 injected	directly	into	the	brain	parenchyma	only,	showed	a	similar	differentiation	fate	to	the	transplanted	huCNS-SCs	in	neonatally	injected	mice,	with	more	than	half	of	SC121-positive	cells	appearing	to	be	undifferentiated	on	the	basis	of	their	small	spindle-like	somas	 with	 short	 processes.	 However,	 since	 there	 were	 proportionally	 more	surviving	huCNS-SCs	in	these	early	post-natally	grafted	mice	more	examples	of	the	different	cell	 fates	adopted	by	huCNS-SCs	were	also	observed.	Approximately	75%	of	the	olfactory	bulb	area	was	covered	in	SC121-positive	cells	with	a	neuronal-like	morphology	 in	 early	 post-natally	 transplanted	 mice	 of	 both	 genotypes.	 Unlike	neonatally	grafted	mice	however,	there	were	also	some	isolated	examples	of	SC121-positive	cells	present	in	early	post-natally-injected	mice	which	took	on	an	astrocytic-like	morphology.	These	cells	were	mostly	observed	in	the	corpus	callosum,	and	had	multiple	short	bushy	processes	extending	radially	from	the	cell	soma.		As	well	as	having	the	widest	engraftment	of	transplanted	huCNS-SCs,	double-grafted	mice	 treated	 at	 both	 p0	 and	 p21	 with	 multiple	 injections	 of	 huCNS-SCs	 into	 the	ventricles	 and	 parenchyma	 showed	 subjectively	 a	 higher	 proportion	 of	differentiated	 cells,	 compared	 to	 single	 treated	 neonatally	 and	 early	 post-natally	treated	mice,	across	all	 regions	 that	 the	cells	migrated.	 In	both	TPP1-deficient	and	heterozygous	control	mice,	SC121-positive	cells	with	a	neuron-like	appearance	were	highly	abundant	 in	 the	olfactory	bulb	 (Figure	 37a,	 b	 and	 c),	but	unlike	 the	other	two	 treatment	 groups,	 huCNS-SCs	 were	 also	 evident	 in	 the	 hippocampus	 and	sporadically	throughout	the	rest	of	the	brain.	Despite	an	abundance	of	huCNS-SCs	in	the	olfactory	bulbs	of	all	mice	regardless	of	treatment	and	genotype,	SC121-positive	huCNS-SCs	were	only	present	in	the	RMS	of	the	mice	that	received	grafts	at	both	p0	and	 p21	 (Figure	 38).	 SC121-positive	 cells	 that	 looked	 like	 neurons	 were	 highly	organised	in	the	olfactory	bulb	of	early	post-natally	treated	mice	of	both	genotypes,	with	their	 long	processes	arranged	parallel	 to	one	another	 in	the	gromerular	 layer	and	 were	 seen	 in	 even	 greater	 abundance	 than	 in	 the	 other	 treatment	 groups,	covering	more	than	80%	of	the	olfactory	bulb	in	the	sections	corresponding	to	the	middle	 of	 the	 brain	 (Figure	 37c).	 However,	 there	 were	 also	 SC121-positive	
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processes	 in	the	olfactory	bulb	that	took	on	a	different	morphology	with	what	one	would	assume	are	many	twisted	dendrites,	within	 the	mitral	cell	axon	 layer	 in	 the	very	 centre	 of	 the	 olfactory	 bulb	 (Figure	 37b).	 One	 hypothesis	 is	 that	 these	processes	could	be	dendrites	from	huCNS-SCs	that	have	differentiated	into	mitral	or	tufted	 cells	 (indistinguishable	 from	 one	 another	 in	 lower	 vertebrates),	 which	together	 form	 the	 glomerulus	 in	 the	 olfactory	 bulb	 and	 have	 a	 very	 similar	appearance	 to	 the	 huCNS-SCs	 morphology	 seen	 in	 Figure	 37b	 (Ache	 and	 Young,	2005).	 The	morphology	 of	mitral	 and	 tufted	 cells	 in	 rodents	 is	 a	 small	 soma	 that	extends	radially	a	single	apical	dendrite	 that	arborizes	 in	a	complex	tuft	(Imamura	and	Greer,	2009).		
	
Figure	37	Differentiation	of	transplanted	huCNS-SCs	in	neonatal	and	early-postnatally	
injected	 Tpp1-/-/NODSCID	 mice.	 The	mice	 received	 bilateral	 intraventricular	 injection	 of	huCNS-SCs	 at	 p0	 and	 subsequently	 at	 p21	 directly	 into	 the	 brain	 parenchyma	 (thalamus,	striatum	and	 cerebellum).	 SC121	 immunostaining	 suggests	 that	 that	migrating	huCNS-SCs	have	differentiated	within	the	olfactory	bulb	into	cells	with	neuronal	like	morphology	(A,	B,	C).	SC121-positive	cells	with	astrocytic-like	morphology	were	also	identified	at	the	margins	of	 white	 matter	 tracts	 (D),	 the	 cerebellum	 (F),	 and	 within	 the	 corpus	 callosum	 and	 the	adjacent	 cortical	 laminae	 (G)	 however,	 most	 transplanted	 huCNS-SCs	 remained	undifferentiated	(E).			SC121	positive	cells	with	astrocyte-like	morphology	were	also	identified	in	this	dual-treated	group	and	were	most	frequently	found	in	the	corpus	callosum,	but	were	also	present	in	the	cortical	neuropil	in	lamina	VI	directly	adjacent	to	the	corpus	callosum		
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(Figure	37g),	in	the	white	matter	of	the	cerebellum	(Figure	37f)	and	at	the	margins	of	white	matter	tracts	throughout	the	ventral	portion	of	the	midbrain	(Figure	37d).	In	general	however,	as	in	the	other	treatment	groups,	the	majority	of	huCNS-SCs	in	these	 double	 grafted	 mice	 that	 were	 outside	 of	 the	 olfactory	 bulb	 in	 the	 brain	parenchyma	 and	 the	 cerebellum,	 remained	 undifferentiated	 irrespective	 of	 the	genotype	of	the	mouse	(Figure	37e).		Similarly	 to	 some	 of	 the	 transplanted	 huCNS-SCs	 in	Tpp1-/-/NODSCID	mice	 in	 the	other	 treatment	 groups,	 there	was	morphological	 evidence	 that	 some	 SC121-cells	were	sick	or	dying,	particularly	within	the	thalamus,	where	pathology	is	advanced	in	
Tpp1-/-/NODSCID	mice	(Chapter	4.2)	although	subjectively	these	were	less	frequent	in	this	dual-treatment	group.	These	morphologically	‘unhealthy’	cells	were	even	less	frequent,	 but	 were	 also	 apparent	 in	 Tpp1+/-/NODSCID	 mice	 that	 received	 two	huCNS-SC	grafts.	
	
Figure	 38	Migration	 of	 transplanted	 huCNS-SCs	 in	 the	 rostral	 migratory	 stream	 in	
dual-injected	 early	 post-natally	 Tpp1-/-/NODSCID	 mice.	 The	 mice	 received	 bilateral	intraventricular	injection	of	huCNS-SCs	at	p0	and	subsequently	at	p21	directly	into	the	brain	parenchyma	(thalamus,	striatum	and	cerebellum).	(A)	SC121	immunostaining	suggests	that	that	the	huCNS-SCs	have	migrated	to	the	olfactory	bulb	in	a	fashion	that	is	characteristic	of	the	 rostral	 migratory	 stream	 (RMS).	 (B)	 Many	 SC121-positive	 huCNS-SCs	 populated	 the	olfactory	 bulb	 in	 dual-injected	 Tpp1-/-/NODSCID	 mice.	 (C)	 HuCNS-SCs	 that	 migrate	 to	 the	olfactory	 bulb	 differentiate	 into	 a	 neuronal-like	 morphology	 in	 dual-injected	 Tpp1-/-
/NODSCID	mice.	Scale	bar	=	1000	μm.		The	data	presented	in	this	Chapter	suggests	that	although	the	majority	of	huCNS-SCs	transplanted	into	Tpp1-/-/NODSCID	mice	remain	in	an	undifferentiated	state,	a	very	large	proportion	of	those	huCNS-SCs	that	migrate	to	the	olfactory	bulb	differentiate	into	neurons	on	 the	basis	of	 their	morphology.	 In	 comparison,	 in	Ppt1-/-/NODSCID	
160	
mice,	which	received	the	same	stem	cell	grafting	as	the	mice	injected	at	p0	and	p21	in	 the	 present	 chapter	 (as	 it	 was	 also	 performed	 by	 the	 same	 researchers	 at	StemCells	Inc.),	only	about	3-5%	of	surviving	huCNS-SCs	differentiated	into	neurons	(Tamaki	et	al.,	2009).	These	preliminary	results	in	Tpp1-/-/NODSCID	mice	suggest	a	much	 higher	 percentage,	 which	 one	 might	 estimate	 at	 around	 10%,	 though	 this	needs	confirmation,	of	huCNS-SCs	differentiating	into	neurons,	at	least	in	this	cohort	of	Tpp1-/-/NODSCID	mice.	However,	 in	order	 to	more	 conclusively	determine	what	cell	types	these	SC121-positive	cells	have	differentiated	into,	it	is	necessary	to	do	co-localization	studies	with	cell-specific	markers.			
5.2.3 Co-localization	did	not	reveal	SC121	positive	neurons		In	 order	 to	 ascertain	 whether	 the	 SC121-positive	 cells	 that	 appeared	 to	 look	 like	neurons	had	indeed	differentiated	into	mature	neurons,	I	co-immunostained	a	1	in	6	coronal	series	of	Tpp1-/-/NODSCID	mice	and	control	sections	for	SC121	(the	human	stem	cell	cytoplasmic	marker)	and	Fox3	(a	neuronal	nuclear	marker).	These	sections	were	 then	 examined	 using	 multichannel	 confocal	 microscopy	 The	 representative	images	 presented	 here	 are	 from	 a	 dual	 grafted	 Tpp1-/-/NODSCID	 mouse,	 which	received	huCNS-SCs	grafts	at	both	p0	and	p21,	since	this	treatment	regimen	resulted	in	 the	 highest	 proportion	 of	 huCNS-SCs	with	 a	 neuronal	morphology.	 The	 control	




/NODSCID	 mice	 or	 control	mice.	 (A)	DAPI	 stain	 in	 olfactory	bulb	 visualized	by	 confocal	miscroscopy	at	 low	–power	 (B)	SC121-	positive	huCNS-SCs	 in	olfactory	bulb	visualized	by	confocal	miscroscopy	at	low	magnification.	(C)	Fox3	staining	not	evident	in	olfactory	bulb	at	low	magnification.	 (D)	 DAPI	 stain	 in	 olfactory	 bulb	 visualized	 by	 confocal	miscroscopy	 at	high	magnification.	 (E)	SC121-	positive	huCNS-SCs	 in	olfactory	bulb	visualized	by	confocal	miscroscopy	 at	 high	 power	 magnification.	 (F)	 High	 magnification	 confirms	 anti-Fox3	antibody	 binds	 only	 unspecifcially	 in	 the	 olfactory	 bulb	 of	Tpp1-/-/NODSCID	mice.	 Green-	SC121,	 cytoplasmic	 human	 cell	 marker.	 Red-	 Fox3,	 nucleic	 human/mouse	 neuronal	 cell	marker.	Blue-	DAPI-	marks	cell	nucleus.		The	 analysis	 was	 then	 extended	 to	 the	 parenchyma	 within	 the	 forebrain	 to	determine	 whether	 any	 huCNS-SCs	 were	 also	 labeled	 with	 Fox3.	 As	 would	 be	expected	for	a	neuronal	marker,	Fox3	staining	revealed	many	positively	stained	cell	nuclei	within	 the	 forebrain	of	mice	of	 all	 genotypes.	Although	SC121-positive	 cells	were	 evident	 as	 dense	masses	 of	 cells	 at	 injection	 sites	 (as	 described	 above,	 and	green	 cells	 in	 Figure	 4036a),	 there	 was	 no	 Fox3	 immunostaining	 within	 these	injection	sites,	 confirming	 that	 those	huCNS-SCs	 that	 remain	at	 the	 injection	 tracts	do	not	differentiate	into	neurons.	The	SC121-positive	cells	that	had	migrated	a	short	distance	 away	 from	 the	 injection	 site	 (Figure	 40b),	 for	 example	 those	 in	 the	thalamus,	 also	 did	 not	 co-express	 Fox3,	 and	 had	 not	 taken	 on	 a	 neuronal	morphology.	These	data	confirm	that	the	majority	of	the	huCNS-SCs	in	this	area	had	not	differentiated	into	neurons,	but	remained	relatively	undifferentiated,	as	we	had	previously	identified	by	their	morphology	alone.	
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Figure	 40	 Transplanted	 SC121-positive	 huCNS-SCs	 do	 not	 express	 the	 neuronal	
marker	Fox3	at	the	injection	site,	or	close-by	in	Tpp1-/-/NODSCID	mice	or	control	mice	






SC121,	 do	 not	 when	 examined	 using	 confocal	 microscopy.	 (A)	 A	 huCNS-SC	 in	 the	thalamus,	which	appeared	to	show	co-expression	of	SC121	and	Fox3.	(B)	Another	example	of	a	migrated	huCNS-SC	in	the	thalamus,	which	appeared	to	show	co-localization	of	SC121	and	Fox3	but	in	fact	remains	in	an	undifferentiated	state.	Green-	SC121,	cytoplasmic	human	cell	marker.	(C)	A	huCNS-SC	in	the	hippocampus,	which	may	express	both	SC121	and	Fox3	but	 is	 inconclusive.	 Red-	 Fox3,	 nucleic	 human/mouse	 neuronal	 cell	 marker.	 Blue-	 DAPI-	marks	cell	nucleus.		This	 co-localization	experiment	 reveals	 that	although	huCNS-SCs	 transplanted	 into	
Tpp1-/-/NODSCID	mice	 frequently	 display	 clear	 neuronal	morphology,	 they	 do	 not	necessarily	 express	 neuronal	markers	 such	 as	 Fox3.	 This	 suggests	 the	 huCNS-SCs	have	 differentiated	 into	 cells	 that	 appear	 to	 be	 neurons	 on	 the	 basis	 of	 their	morphology	 but	 that	 they	 have	 not	 yet	 fully	 matured.	 Furthermore,	 the	 most	obviously	differentiated	huCNS-SCs	appeared	to	have	become	mitral	cells	within	the	olfactory	bulb,	however	these	cells	could	not	be	 identified	with	the	Fox3	antibody,	which	will	be	discussed	below.			
5.3 Discussion	This	Chapter	has	shown	that	transplanted	huCNS-SCs	survive	transplantation,	they	persist	in	the	brain	for	at	least	16	weeks	and	they	are	capable	of	variable	degrees	of	migration	within	the	Tpp1-/-/NODSCID	mouse	brain,	depending	upon	the	route	and	timing	of	 administration.	The	data	 in	 this	Chapter	 reveals	 that	huCNS-SCs	migrate	
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furthest	if	they	are	double	grafted	once	the	mice	have	just	been	born	at	p0	and	then	again	at	p21,	migrating	much	further	than	if	just	grafted	at	either	one	of	these	time	points	 alone.	 It	 is	 also	 apparent	 that	 transplanted	 huCNS-SCs	 display	 a	 range	 of	different	 morphologies,	 depending	 on	 where	 they	 migrate	 to	 within	 the	 Tpp1-/-
/NODSCID	mouse	 brain.	 These	 results	 suggest	 that	 there	 are	 local	 environmental	cues	 in	 the	 Tpp1-/-/NODSCID	 CNS,	 which	 may	 influence	 both	 differentiation	 and	migration.	In	 this	 qualitative	 study	 of	 huCNS-SCs	 engraftment	 in	 Tpp1-/-/NODSCID	mice,	 it	appears	 that	 the	 huCNS-SCs	migrate	 further	when	 injected	 straight	 into	 the	 brain	parenchyma	at	p21	rather	than	if	transplanted	into	the	ventricles	at	p0.	This	better	outcome	 is	 at	 odds	with	 the	 concept	 that	 early	 therapeutic	 intervention	 has	 been	shown	to	be	more	effective	than	delayed	treatment,	in	a	number	of	mouse	models	of	lysosomal	storage	disorders	(Escolar	et	al.,	2005,	McGraw	et	al.,	2005,	Sondhi	et	al.,	2005).	Of	course,	p21	is	still	very	early	in	the	disease	progression	of	TPP1-deficient	mice	 on	 either	 a	 C57BL/6J	 or	 NODSCID	 background,	 and	 these	 mice	 have	 no	detectable	 neuropathology	 at	 this	 age	 as	 outlined	 in	 Chapter	 4.	 Nevertheless,	 we	cannot	rule	out	 that	more	subtle	deleterious	effects	may	have	already	occurred	by	P21	 and	 delaying	 the	 treatment	 in	 order	 to	 obtain	more	widespread	 cell	 grafting	may	 compromise	 any	 impact	 of	 such	 grafts	 upon	disease	progression.	However,	 if	we	 assume	 that	 treatment	 at	 p0	 and	 p21	 in	 the	 TPP1-deficient	 mouse	 are	 both	sufficiently	 early	 to	 confer	 benefit	 before	 extensive	 neuronal	 degeneration	 takes	place,	then	our	data	clearly	suggest	that	injecting	huCNS-SCs	straight	into	the	brain	parenchyma	is	more	effective	than	injecting	these	cells	into	the	ventricles	in	terms	of	promoting	 widespread	 huCNS-SCs	 engraftment	 in	 Tpp1-/-/NODSCID	 mice.	Furthermore,	 given	 that	 making	 grafts	 at	 both	 ages	 produces	 more	 favourable	engraftment	than	just	performing	these	grafts	singly	at	either	age,	it	is	possible	that	the	 initial	 injection	 at	 p0	 creates	 an	 environment	 in	 the	 Tpp1-/-/NODSCID	 mouse	brain	 that	 supports	 the	 subsequent	 injection	 of	 huCNS-SCs	 at	 p21,	 allowing	additional	huCNS-SCs	 to	 survive	and	migrate	 in	 these	mice.	One	might	expect	 that	the	presence	of	additional	huCNS-SCs,	which	are	widespread	throughout	the	brain,	would	also	result	 in	 increased	 levels	of	TPP1	enzyme	activity.	Therefore,	 it	will	be	important	to	examine	the	TPP1	enzyme	activity	 levels	 in	non-fixed	tissue	from	the	different	treatment	regimens	in	the	larger	scale	study	on	huCNS-SCs	transplantation	in	TPP1-deficient	mice.		
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Either	 way,	 the	 data	 presented	 in	 this	 Chapter	 suggests	 that	 huCNS-SCs	 migrate	furthest	 in	 Tpp1-/-/NODSCID	 mice	 when	 injected	 into	 the	 brain	 parenchyma	compared	to	the	ventricles	alone.	It	may	simply	be	that	these	stem	cells	survive	less	well	 in	 the	 fluid	 filled	 space	 of	 the	 lateral	 ventricle,	 but	 additional	 experiments	should	be	carried	out	to	conclusively	determine	whether	it	is	the	site	of	injection	or	the	age	of	injection	that	has	the	greater	influence	upon	huCNS-SCs	engraftment.	As	such,	 injecting	 these	 cells	 directly	 into	 the	 brain	 parenchyma	 at	 p0	 would	 be	important	 to	 determine	 if	 this	 improves	 huCNS-SCs	 engraftment	 and	migration	 in	
Tpp1-/-/NODSCID	mice.	Irrespective	of	age	and	the	genotype	of	mice,	the	transplanted	huCNS-SCs	appeared	to	 migrate	 in	 the	 RMS.	 The	 RMS	 is	 a	 specialized	 migratory	 route	 for	 neuronal	precursors,	 which	 starts	 in	 the	 subventricular	 zone	 (SVZ)	 and	 finishes	 in	 the	olfactory	bulb	(Sun	et	al.,	2010,	Kornack	and	Rakic,	2001).	Neuroblasts	are	formed	in	the	 neurogenic	 niche	 of	 the	 SVZ	 and	 migrate	 through	 a	 tunnel	 comprised	 of	astrocytes	called	the	glial	tube	(Curtis	et	al.,	2007b,	Lois	and	Alvarez-Buylla,	1994).	HuCNS-SCs	transplanted	into	Ppt1-/-/NODSCID	mice	were	also	shown	to	migrate	 in	the	 RMS	 and	 human	 astrocytes	 were	 also	 found	 in	 the	 RMS	 as	 well,	 where	 they	appeared	 to	contribute	 to	 the	glial	 tube,	 surrounding	migrating	human	and	mouse	neuroblasts	 (Tamaki	 et	 al.,	 2009).	 Taken	 together,	 these	 findings	 suggest	 that	transplanted	 huCNS-SCs	 respond	 to	 the	 mouse	 brain	 structure	 and	 local	environmental	cues,	even	in	a	diseased	brain	environment	and	this	seems	to	occur	in	both	PPT1-	and	TPP1-deficient	mice.		It	was	disappointing	not	 to	 conclusively	 identify	whether	 the	 transplanted	huCNS-SCs	 that	 reliably	 migrated	 to	 the	 olfactory	 bulb	 in	 all	 treatment	 regimens	 and	genotypes,	 were	 differentiating	 into	 neurons	 or	 even	 perhaps	 mitral	 cells	 (a	neuronal	subtype	of	the	olfactory	bulb)	as	their	morphology	suggested.	This	failing	may	have	been	caused	by	our	choice	of	neuronal	marker,	neuronal	nuclear	protein	(NeuN/fox3).	 NeuN	 is	 expressed	 exclusively	 in	 neurons	 and	 as	 such	 antibodies	against	 NeuN	 are	 routinely	 used	 to	 identify	 neurons	 immunohistochemically	(Mullen	et	al.,	1992).	NeuN	was	 recently	 identified	as	Fox3	(Kim	et	al.,	2009),	 and	can	be	used	to	identify	nearly	all	the	neuronal	subtypes	of	the	mouse	CNS.	However	it	has	recently	become	apparent	that	this	marker	will	not	reliably	identify	the	mitral	cells	 of	 the	 olfactory	 bulb.	 Mitral	 cells	 remain	 notoriously	 difficult	 to	 specifically	identify	 with	 immunohistochemistry	 (Mitsui	 et	 al.,	 2011).	 One	 commercially	available	antibody	to	use	however	is	anti-Tbr1,	which	is	raised	against	a	member	of	
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the	T-box	family	of	transcription	factors,	which	play	central	roles	in	specification	of	many	 cell	 types	 in	 the	 nervous	 system.	 Tbr-1	 is	 expressed	 in	 mitral	 cells	 in	 the	olfactory	bulb	and	required	for	their	proper	differentiation	(Mizuguchi	et	al.,	2012,	Kimura	 et	 al.,	 1999).	 In	 future	 studies	 evaluating	 transplanted	 huCNS-SCs	 fate,	 an	anti-Tbr-1	antibody	could	be	trialled.	Another	antibody	that	could	be	trialled	is	anti-cerebellin-1	(cbln1),	which	is	another	protein	expressed	in	mitral	and	tufted	cells	in	the	 olfactory	 bulb	 (Hirai	 et	 al.,	 2005,	Miura	 et	 al.,	 2006).	 The	 fate	 of	 transplanted	huCNS-SCs	in	the	olfactory	bulb	of	Ppt1-/-/NODSCID	mice	was	successfully	evaluated	using	doublecortin	(DCX)	to	identify	immature	neurons	and	microtubule-associated	protein	 2	 (MAP2)	 to	 identify	 mature	 neurons	 in	 the	 brain	 parenchyma.	 In	 PPT1	deficient	 mice,	 17%	 of	 huCNS-SCs	 in	 the	 olfactory	 bulb	 presented	 with	 DCX	expression	and	a	few	single	cells	were	identified	that	expressed	MAP2	(Tamaki	et	al.,	2009).	 	DCX	and	MAP2	could	certainly	be	used	in	sections	from	huCNS-SCs	treated	
Tpp1-/-/NODSCID	 mice	 to	 identify	 huCNS-SCs	 that	 have	 become	 immature	 and	mature	 neurons	 in	 the	 brain	 parenchyma,	 however	 these	markers	would	 still	 not	specifically	identify	any	cells	which	had	become	mitral	or	tufted	cells	in	the	olfactory	bulb.	Due	to	the	fact	that	this	was	a	preliminary	study,	our	treatment	group	sizes	were	not	sufficient	 in	 order	 to	 make	 a	 properly	 informative	 quantitative	 study	 on	 the	neuropathology	 of	 these	 huCNS-SCs–treated	mice.	 As	 such,	we	 are	 yet	 to	 evaluate	whether	 these	 promising	 data	 of	 widespread	 engraftment	 of	 huCNS-SCs	 seen	 in	








This	 Chapter	 focuses	 on	 different	methods	 that	 can	 be	 used	 to	 introduce	 specific	mutations	 into	 human	 cell	 lines	 in	 order	 to	 recapitulate	 disease.	 The	 rationale	behind	 this	 is	 that	 although	 it	 is	 possible	 to	model	 neurological	 diseases	 in	mice,	these	animal	models	do	not	always	faithfully	reproduce	the	human	disease	at	either	the	molecular	or	anatomical	levels,	largely	due	to	important	species	differences	(as	discussed	further	in	Chapter	8).	The	study	of	diseased	human	brain	tissue	is	crucial	for	 understanding	 how	 mutant	 proteins	 or	 toxins	 might	 lead	 to	 neuronal	dysfunction.	However,	this	tissue	is	both	scarce	and	difficult	to	manipulate.	Human	stem	 cells	 represent	 a	 renewable	 source	 of	 tissue	 that	 can	 generate	 both	 neurons	and	 glia.	 Studies	 in	 human	 stem	 cell	 lines	 may	 provide	 new	 insights	 into	 the	mechanisms	 that	 underlie	 neurological	 diseases. In	 this	 Chapter	 and	 Chapter	 7,	 I	describe	the	design	and	production	of	custom	gene	editing	tools	called	Transcription	activator-like	effector	nucleases	(TALENs)	that	will	target	and	mutate	the	CLN2	gene	in	 human	 neural	 progenitor	 cells	 (hNPCs)	 in	 order	 to	 create	 a	 human	 stem	 cell	model	of	CLN2	disease	in	the	exact	cell	types	that	are	most	affected	in	the	disease. 	
6.1 Why	Human	Cell	Models?	The	use	of	animal	models	has	greatly	improved	our	understanding	of	the	cause	and	progression	 of	 human	 genetic	 diseases	 and	mouse	models	 have	 successfully	 been	used	to	explore	basic	pathophysiological	mechanisms	(Justice	et	al.,	2011).	However,	mouse	models	have	a	number	of	limitations,	as	do	all	models	of	human	disease.	For	example,	 the	 evolutionary	 distance	 between	 mice	 and	 humans	 results	 in	 species	differences	 where	 mice	 do	 not	 fully	 recapitulate	 human	 disease	 (as	 discussed	 in	Chapter	 8);	 mice	 for	 experimental	 use	 are	 invariably	 inbred,	 which	 reduces	variability	but	diversity	in	the	population	is	no	longer	reflected;	in	addition,	the	cost	and	 ethical	 considerations	 involved	 in	 experiments	 using	 mice	 means	 that	 group	sizes	 are	 kept	 as	 small	 as	 possible	 and	 replications	 are	 limited	 (Hartung,	 2008)	(discussed	in	detail	in	Chapter	8,	section	8.2.1).		In	Chapters	3-5,	the	neuropathology	of	the	Tpp1neoinsArg446His	mouse	model	of	late	infantile	CLN2	disease	and	 its	similarities	and	dissimilarities	 to	 the	human	disease	were	 investigated.	The	TPP1-deficient	mouse	described	 in	 this	 thesis	 recapitulates	aspects	 of	 late	 infantile	 CLN2	 disease	 in	 patients	 such	 as	 neuroinflammation	 and	neurodegeneration	(Chapter	3,	section	3.2.3-5).	However	other	phenotypes	seen	in	patients	 were	 not	 seen,	 for	 instance	 there	 was	 no	 evidence	 of	 autofluorescent	storage	 material	 (Chapter	 3,	 section	 3.2.6)	 or	 seizures	 in	 these	 mice	 (Miscenyi,	
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personal	 communication).	 While	 this	 TPP1-deficient	 mouse	 model	 has	 yielded	important	insights	into	some	molecular	mechanisms	of	disease	development,	it	does	not	provide	 the	opportunity	 to	 study	mechanisms	of	neurodegeneration	 in	human	neurons	at	risk	and	thus,	developing	effective	therapies	may	require	human-specific	models,	which	more	closely	recapitulate	human	pathogenesis.	Stem	cell	technologies	allow	the	development	of	such	human-based	disease	models.	Stem	 cells	 are	 cells	with	 the	potential	 to	 differentiate	 into	different	 cell	 types	 and	self-renew	 to	 provide	 more	 stem	 cells	 (Mitalipov	 and	 Wolf,	 2009,	 Evans	 and	Kaufman,	 1981).	 Neural	 stem	 cells	 (NSCs)	 have	 the	 potential	 to	 differentiate	 into	neurons,	 astrocytes	 and	 oligodendrocytes	 (Temple,	 1989,	 Clarke,	 2000,	 Reynolds	and	Weiss,	1992).	Although	true	human	NSCs	would	have	limitless	capacity	for	self-renewal,	hNSCs	derived	from	post-mortem	tissue	frequently	terminally	differentiate	after	prolonged	passaging	and	as	a	result	are	often	referred	to	as	neural	progenitor	cells	 (NPCs)	 when	 cultured	 to	 reflect	 the	 more	 limited	 expansion	 potential	compared	to	true	NSCs	in	the	brain	(Sterneckert	et	al.,	2014).	In	order	to	allow	long-term	 expansion	 of	 NPCs,	 they	 can	 be	 conditionally	 immortalized	 using	 genetic	modification	as	described	in	Chapter	7.1.6.	Human	stem	cell-based	models	of	late	infantile	CLN2	disease	could	be	used	to	study	how	mutations	 in	CLN2	affect	 the	 functioning	of	 cells	because	 there	 is	 still	 a	basic	lack	of	understanding	of	the	cell	biology	underlying	TPP1	deficiency	and	developing	a	 human	 NPC	 based	 model	 of	 late	 infantile	 CLN2	 disease	 would	 provide	 an	invaluable	resource	for	investigating	these	issues.	Once	a	clonal	late	infantile	CLN2	disease	hNPC	line	is	established,	it	could	be	differentiated	into	neurons	and	glia	and	the	phenotypes	of	the	mutated	cells	can	be	compared	to	the	wild	types.	Dysfunctions	in	 glia	 have	 been	 seen	 in	 cultures	 of	 primary	 astrocytes	 from	 Cln3-/-	 mice	(Parviainen,	PhD	Thesis)	and	synaptic	defects	are	seen	in	primary	neuron	cultures	from	Ppt1-/-	mice	(Virmani	et	al.,	2005).	Whether	these	or	additional	phenotypes	are	seen	 in	 astrocytes	 and	neurons	derived	 from	a	human	NPC	model	of	 late	 infantile	disease	 would	 be	 of	 considerable	 interest.	 This	 is	 discussed	 in	 further	 detail	 in	Chapter	 8	 section	 8.5	 along	 with	 the	 caveats	 for	 relying	 on	 in	 vitro	models	 to	characterise	cellular	phenotypes.	But	 perhaps	 the	 best	 use	 for	 a	 human	 NPC	 model	 of	 late	 infantile	 CLN2	 disease	would	be	as	a	drug	discovery	tool.	It	is	important	to	use	human	cells	where	possible	for	 drug	 screens,	 due	 to	 the	 differences	 in	 receptor/ligand	 binding	 and	 many	signalling	pathway	differences	between	 rodent	 and	human	 cells	 (Schattauer	 et	 al.,	
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2012,	Colucci	et	al.,	2002).	Adherent	monolayer	culture	of	NPCs	is	possible	with	the	addition	of	the	mitogens	epidermal	growth	factor	(EGF)	and	fibroblast	growth	factor	(FGF)	 (Sun	 et	 al.,	 2008)	 and	 adherent	 monolayers	 of	 cells	 facilitate	 stable	transfection	 of	 NPCs	 to	 provide	 reporter	 lines	 and	 allow	 imaging	 in	 live	 cultures,	making	 them	 perfect	 for	 high	 content	 genetic	 and	 chemical	 screens	 (discussed	 in	Chapter	8,	section	8.6)	(Danovi	et	al.,	2012,	Welsh	et	al.,	2009).	Once	the	phenotypes	of	 the	 CLN2	 disease	 hNPC	 line	 are	 established,	 as	 outlined	 above,	 the	 effects	 of	different	small	molecules	on	their	gene	expression	and	cell	biology	can	be	evaluated.			
6.2 How	to	genetically	modify	human	stem	cells			There	are	different	approaches	one	can	take	to	genetically	modify	human	stem	cells	in	order	to	produce	a	hNPC	of	disease,	I	will	now	discuss	these	and	then	describe	the	approach	taken	in	this	thesis	to	make	a	human	neural	progenitor	cell	model	of	late	infantile	CLN2	disease.		
6.2.1 RNA	interference	(RNAi)	Inactivation	of	specific	genes	via	homologous	recombination	(HR)	has	been	used	for	evaluating	 gene	 function	 for	 at	 least	 the	 last	 decade	 (Capecchi,	 2005).	 However,	progress	with	this	technique	was	initially	impeded	by	the	low	efficiency	with	which	the	 engineered	 constructs	 correctly	 integrate	 into	 their	 chromosomal	 target.	 In	addition,	 identifying	 successful	 mutagenic	 events	 involves	 time-consuming	 and	labour-intensive	selection	and	screening	processes	(Gaj	et	al.,	2013).	RNA	 interference	 (RNAi)	 has	 been	 used	 as	 an	 alternative	 to	 HR	methods	 as	 it	 is	quick,	 inexpensive	 and	 can	 be	 used	 on	 high	 throughput	 platforms	 (Agrawal	 et	 al.,	2003).	 RNAi	 is	 a	 process	 where	 small	 RNA	 molecules	 are	 used	 to	 inhibit	 gene	expression	(McManus	and	Sharp,	2002,	Fire	et	al.,	1998).	There	are	several	types	of	regulatory	 RNAs:	 short	 interfering	 RNAs	 (SiRNAs)	 are	 derived	 from	 long	 double-stranded	 (ds)-RNAs,	 either	 produced	 in	 the	 cell	 itself	 or	 delivered	 experimentally	and	 are	 widely	 used	 to	 manipulate	 gene	 expression;	 micro	 RNAs	 (miRNAs)	 are	derived	 from	 RNA	 transcribed	 in	 the	 nucleus	 which	 are	 processed,	 folded	 and	exported	out	of	the	nucleus	as	ds-precursor	miRNAs	(Kurreck,	2009).	siRNAs	and	the	double-stranded	precursor	miRNAs	bind	to	dicer,	an	endonuclease		that	 cuts	 these	RNAs	 into	 short	 segments	mostly	 around	 21	 nucleotides	 in	 length	(Elbashir	et	al.,	2001).	The	short	dsRNA	then	binds	an	Argonaut	protein,	one	strand	
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of	the	RNA	remains	bound	to	Argonaut	(called	the	guide	strand),	this	argonaut:short	dsRNA	 complex	 along	 with	 other	 proteins	 is	 called	 the	 RNA-induced	 silencing	complex	(RISC)	(Nykanen	et	al.,	2001).		SiRNAs	guide	the	RISC	to	bind	specific	mRNAs,	this	process	is	very	precise	because	the	siRNA	and	 the	mRNA	base	pair	and	often	have	 the	completely	complementary	sequences	 to	 one	 another	 (Valencia-Sanchez	 et	 al.,	 2006).	 Once	 bound	 Argonaut	catalyses	 cleavage	 of	 the	mRNA,	which	will	 then	 be	 degraded.	miRNAs	 also	 guide	RISC	 to	mRNAs,	 however	usually	 only	part	 of	 a	miRNA	 (known	as	 the	 seed)	pairs	with	the	target	mRNA,	this	imprecise	matching	allows	miRNAs	to	target	hundreds	of	mRNAs	 (Valencia-Sanchez	 et	 al.,	 2006,	 McManus	 and	 Sharp,	 2002).	 Targeting	 via	miRNAs	 can	 lead	 to	 mRNAs	 being	 degraded	 and	 translation	 therefore	 being	inhibited.	However,	 RNAi	 does	 not	 always	 offer	 complete	 knockdown	 of	 a	 gene,	 with	 the	effects	only	being	temporary	and	the	effectiveness	of	this	technique	varying	not	only	among	the	genes	being	studies	but	also	between	laboratories	(Holmes	et	al.,	2010).	In	addition,	RNAi	may	result	 in	unpredictable	off-target	effects;	 this	ultimately	has	impeded	investigators’	ability	to	unequivocally	link	phenotype	to	genotype	in	RNAi	experiments	(Gaj	et	al.,	2013).		
6.2.2 Genomic	editing	Over	 the	past	decade,	 the	 field	of	 genome	editing	has	gradually	 emerged	whereby	researchers	 can	manipulate	 almost	 any	 gene	 in	 various	 cell	 types	 and	 organisms.	Genome	editing	is	based	on	using	sequence-specific	DNA-binding	domains	fused	to	an	endonuclease.		These	engineered	nucleases	work	by	introducing	targeted	double	stranded	breaks	 (DSBs)	 and	 stimulating	 inherent	 cellular	DNA	 repair	mechanisms	such	as	 the	error-prone	nonhomologous	end	 joining	 (NHEJ)	pathway	or	homology	directed	repair	(HDR)	(Gaj	et	al.,	2013,	Wyman	and	Kanaar,	2006).	This	approach	is	extremely	versatile	as	 the	DNA-binding	domains	can	be	programmed	to	 target	 the	user’s	sequence	of	interest.	Below	I	will	discuss	three	methods	of	genome	editing	which	make	use	of	sequence-specific	 DNA	 binding,	 zinc-finger	 nuclease	 (ZFNs)	 and	 transcription	 activator-like	effector	 nucleases	 (TALENs)	 and	 the	 relatively	 new	 method	 of	 genome	 editing,	clustered	regulatory	interspaced	short	palindromic	repeats	(CRISPRs).	I	will	discuss	why	TALENs	were	chosen	to	target	the	CLN2	gene	and	how	TALENs	are	constructed.			
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6.2.3 Zinc	Finger	Nucleases	The	 Cys2-His2	 zinc	 finger	 domain	 is	 one	 of	 the	most	 common	DNA-binding	motifs	found	 in	 eukaryotic	 organisms	 (Laity	 et	 al.,	 2001).	 An	 individual	 zinc-finger	 is	comprised	of	approximately	30	amino	acids	and	adopts	a	simple	ββα	fold.	 	Several	amino	 acids	 on	 the	 α-helix	 (sometimes	 called	 the	 recognition	 helix)	 can	 make	sequence-specific	contacts	with	3	base	pairs	(bp)	in	the	major	groove	of	DNA	(Beerli	and	Barbas,	2002).	 Zinc	 finger	 nucleases	 (ZFNs)	 usually	 consist	 of	 pairs	 of	 zinc-finger	 DNA-binding	proteins	 (ZFPs),	 containing	 three	 or	 four	 zinc	 fingers	 each,	 linked	 to	 a	 FokI	endonuclease	domain,	creating	a	sequence	specific	nucleases	following	dimerization	(Figure	42)	(Isalan,	2012).	The	ZFNs	can	then	be	used	to	mutate	genes	of	 interest	via	the	introduced	DSB	either	with	NHEJ	(Bibikova	et	al.,	2002)	or	HDR	(Urnov	et	al.,	2005)	with	a	donor	DNA	template.			ZFPs	are	an	attractive	prospect	for	custom-built	DNA-binding	proteins	due	to	their	modular	structure.	In	order	for	ZFNs	to	be	used	to	target	sequences	in	the	complex	human	 genome,	 unnatural	 arrays	 had	 to	 be	 developed	 that	 contained	 more	 than	three	 zinc-finger	 domains	 (Liu	 et	 al.,	 1997,	 Kim	 and	 Pabo,	 1998),	 which	 allows	recognition	 of	 contiguous	DNA	 sequences	 specific	 to	 complex	 genomes	 (Gaj	 et	 al.,	2013).	 This	 was	 made	 possible	 by	 the	 discovery	 of	 a	 highly	 conserved	 linker	sequence,	 enabling	 construction	 of	 zinc-finger	 proteins	 that	 can	 recognize	 DNA	sequences	9-18	bp	in	length	(Beerli	and	Barbas,	2002,	Beerli	et	al.,	1998).		ZFNs	 can	 be	 constructed	 using	 several	 different	 approaches.	 Zinc	 finger	 domains	have	been	developed	which	can	recognize	nearly	all	64	possible	nucleotide	triplets	and	most	methods	involve	linking	together	preselected	zinc	finger	modules	to	target	a	sequence	containing	these	DNA	triplets	(Gonzalez	et	al.,	2010,	Bhakta	et	al.,	2013).	Other	 approaches	 select	 new	 zinc-finger	 arrays	 taking	 into	 consideration	interactions	that	could	occur	between	neighbouring	fingers	(Maeder	et	al.,	2008).		
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Figure	42	Diagram	of	Zinc-finger	nucleases	on	target	sequence.	This	diagram	highlights	the	main	 engineering	 constraints	 that	 are	 imposed	 on	 researchers	 hoping	 to	 design	 zinc-finger	nucleases	to	target	specific	sequences.	Reproduced	from	Isalan,	2012.		However,	 construction	 of	 ZFNs	 for	 particular	 target	 DNAs	 is	 not	 simple	 for	 the	average	research	group	(Isalan,	2012).	Success	with	ZFNs	usually	relies	on	using	the	considerable	 resources	 of	 companies	 such	 as	 Sigma-Aldrich,	 which	 will	 produce	custom	ZFNs	for	a	large	fee,	or	collaboration	with	other	academic	groups	using	the	Zinc	 Finger	 consortium	 open	 source	 tool	 (http://www.zincfingers.org)(Maeder	 et	al.,	 2008).	 There	 are	 several	 reasons	 why	 ZFNs	 are	 difficult	 to	 build,	 which	 are	summarised	in	Figure	42	(and	reviewed	in	Isalan,	2012),	but	the	major	problem	is	that	it	is	not	possible	to	target	any	DNA	sequence.	ZFNs	prefer	a	G-rich	sequence	and	assembly	of	ZFNs	targeting	other	types	of	sequence	are	often	unsuccessful	(Ramirez	et	al.,	2008).	This	 preference	 for	 a	 G-rich	 sequence	 constricts	 which	 specific	 sequences	 can	 be	targeted	successfully	by	ZFNs	and	is	connected	to	another	problem	that	one	needs	to	identify	 a	 sequence	 where	 two	 DNA	 binding	 domains	 can	 bind	 in	 the	 correct	orientation	with	the	appropriate	spacing	to	yield	a	functional	nuclease	(Pabo	et	al.,	2001,	Isalan,	2012).		Due	to	the	difficulties	of	constructing	custom	ZFNs	in	a	research	laboratory	 setting	 and	 the	 fact	 that	 I	wanted	 to	 target	 a	 very	 specific	 locus	 of	 the	
CLN2	gene,	ZFNs	are	not	the	ideal	genome-editing	tool	for	this	project.	
	
6.2.4 CRISPRs	A	new	player	in	genome-editing	technology	is	clustered	regularly	interspaced	short	palindromic	 repeats	 (CRISPR),	 which	 were	 first	 discovered	 in	 bacteria	 and	 they	function	 as	 a	 defence	 mechanism	 to	 identify	 and	 destroy	 foreign	 DNA	 (viral	 or	
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plasmid)	(Sander	and	Joung,	2014,	Wiedenheft	et	al.,	2012).	There	are	three	distinct	bacterial	CRISPR	systems:	type	I,	 II	and	III.	Type	II	 is	 the	basis	 for	current	genome	engineering	 technology	 (Sander	 and	 Joung,	 2014).	 In	 bacteria,	 the	 endogenous	CRISPR/Cas	 system	 targets	 foreign	 DNA	 with	 a	 short,	 complementary	 single-stranded	 (ss)-RNA	 (CRISPR	 RNA,	 crRNA)	 that	 directs	 the	 CRISPR	 associated	endonuclease	 (Cas9)	 to	 the	 target	 DNA	 sequence	 (Horvath	 and	 Barrangou,	 2010,	Wiedenheft	et	al.,	2012).	The	DNA	target	sequence	can	be	on	a	plasmid	or	integrated	into	the	bacterial	genome.	crRNA	are	transcribed	from	DNA	sequences	called	protospacers	(Jiang	et	al.,	2013).	Protospacers	are	grouped	together	 in	 the	bacterial	genome	in	a	CRISPR	array.	The	protospacers	are	known	foreign	DNA	sequences	of	around	20bp	separated	by	short	palindromic	 repeats	 and	are	 stored	as	 a	 record	against	 future	 encounters	 (Sander	and	Joung,	2014,	Wiedenheft	et	al.,	2012).	There	are	some	restrictions	specific	to	the	CRISPR	system.	Potential	target	sequences	must	have	a	specific	sequence	on	the	3’	end	(the	protospacer	adjacent	motif,	PAM).	The	Type	II	CRISPR	system	is	currently	limited	 to	 target	 sequences	 that	 are	 G-N12-20-GG,	 where	 NGG	 represents	 the	 PAM	(Sander	and	Joung,	2014,	Wiedenheft	et	al.,	2012,	Jiang	et	al.,	2013).		
Users	 of	 this	 new	 technology	 can	 design	 gRNA	which	 target	 the	DNA	 sequence	 of	interest.	 The	 gRNA	 is	 expressed	 intracellularly	 with	 a	 Cas9	 nuclease	 (Cong	 et	 al.,	2013).	 The	 gRNA	 binds	 on	 either	 strand	 of	 DNA	 and	 directs	 Cas9	 to	 the	 target	sequence	where	it	unwinds	and	cleaves	double-stranded	DNA	(Cho	et	al.,	2013).	The	Cas9	will	 cleave	 both	 strands	 of	DNA	 resulting	 in	 a	 double-stranded	 break,	which	causes	silencing	of	that	DNA	sequence.	If	the	DNA	target	is	not	unique	and	appears	in	multiple	locations,	all	of	these	will	be	targeted	by	the	Cas9	nuclease	for	cleavage	(Cong	et	al.,	2013,	Cho	et	al.,	2013).	The	CRISPR	system	is	very	cost-effective	as	it	is	delivered	 to	 cells	 via	 plasmids	 expressing	 the	 gRNA	and	Cas9	nuclease,	which	 are	freely	 available	 (https://www.addgene.org/CRISPR/).	 Inserting	 a	 complimentary	oligo	into	the	gRNA	expression	vector	confers	specificity.	
When	I	was	designing	the	strategy	for	targeting	the	CLN2	gene,	there	were	reports	that	 using	 CRISPR	 to	 edit	 genes	 resulted	 in	 substantial	 off-target	 DNA	 cleavage,	which	is	now	an	established	phenotype	of	this	technology	(Fu	et	al.,	2013,	Hsu	et	al.,	2013,	Mali	et	al.,	2013,	Pattanayak	et	al.,	2013).	As	the	aim	was	to	introduce	specific	late	infantile	CLN2	disease-causing	mutations	into	cell	lines,	DNA	damage	elsewhere	
175	
in	 the	 genome	 is	 very	 undesirable	 and	 I	 decided	 that	 CRISPR	 was	 therefore	unsuitable	for	targeting	CLN2.	However,	there	have	been	many	new	developments	in	the	 CRISPR	 field	 and	 a	 recent	 study	 using	 a	 Cas9	 nickase	 rather	 than	 Cas9	endonuclease	reports	undetectable	levels	of	off-target	mutations	(Shen	et	al.,	2014)	so	perhaps	CRISPR	will	be	used	to	introduce	NCL-causing	mutations	into	cell	lines	in	the	future.	
6.2.5 TALENs	In	 2009,	 the	 simple	modular	DNA	 recognition	 code	 by	 transcription	 activator-like	effectors	 (TALEs)	was	 discovered	 and	 the	 recognition	 code	was	 published.	 TALEs	are	 naturally	 occurring	 proteins	 from	 the	 bacterial	 plant	 pathogen	 Xanthomonas	(Moscou	and	Bogdanove,	2009,	Boch	et	al.,	2009).	The	central	DNA	targeting	domain	of	the	TALE	is	composed	of	33-35	amino	acids	(33-35	aa).	These	repeats	only	differ	from	 each	 other	 by	 two	 amino	 acids.	 This	 is	 called	 the	 repeat	 variable	 di-residue	(RVD)	 and	 it	 determines	 which	 single	 nucleotide	 the	 TAL	 effector	 will	 recognize	(Mak	et	al.,	2012,	Deng	et	al.,	2012).	In	this	thesis,	I	will	refer	to	the	33-35	aa	repeats	as	 monomers.	 	 When	 the	 RVD	 is	 histidine	 and	 aspartic	 acid	 (HD)	 the	 monomer	recognizes	 cytosine	 (C)	 (Figure	 43a);	when	 the	RVD	 is	 asparagine	 and	 isoleucine	(NI)	 the	 monomer	 recognizes	 adenine	 (A)	 (Figure	 43b);	 when	 the	 RVD	 is	asparagine	and	glycine	(NG)	the	monomer	recognizes	thymine	(T)	(Figure	43c)	and	when	 the	 RVD	 is	 two	 asparagines	 (NN)	 the	 monomer	 recognizes	 guanine	 (G)	although	it	also	recognizes	A	with	less	specificity	(Figure	43d)	(Mak	et	al.,	2012).	Like	 ZFPs,	 TALEs	 are	 assembled	 by	 linking	 together	modular	 repeats	 in	 order	 to	recognize	 a	 contiguous	 sequence.	 For	 TALEs	 these	 are	 the	 monomers	 that	 each	recognise	 an	 individual	 base.	 Numerous	 effector	 domains	 have	 been	 successfully	fused	 to	 the	 TALE	 DNA	 recognition	 and	 binding	 domain,	 including	 transcription	factors	 to	 modulate	 gene	 expression	 (Zhang	 et	 al.,	 2011,	 Miller	 et	 al.,	 2011),	nucleases	to	induce	double	strand	breaks	into	the	DNA	at	a	specific	site	(Christian	et	al.,	2010,	Mussolino	et	al.,	2011,	Miller	et	al.,	2011)	and	site-specific	 recombinases	(Mercer	et	al.,	2012).		TALE	nucleases	(TALENs)	consist	of	the	TALE	DNA-binding	domain	fused	to	a	FokI	endonuclease	 and	 like	 ZFNs,	 they	 function	 in	 pairs	 (Joung	 and	 Sander,	 2013).	Because	the	DNA	binding	domain	of	TALENs	is	comprised	of	a	1:1	correspondence	of	 RVDs	 to	 single	 base	 pairs,	 the	 number	 of	 sequences	 that	 can	 be	 targeted	with	TALEN	 technology	 versus	 ZFNs,	 which	 target	 triplets	 of	 base	 pairs	 and	 have	 a	
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preference	for	a	G-rich	sequence,	is	greatly	increased	(Carlson	et	al.,	2012).	TALEN	binding	sites	are	predicted	to	occur	every	35	base	pairs,	compared	to	approximately	every	 500	 base	 pairs	 for	 ZFNs,	 providing	 much	 greater	 flexibility	 over	 target	selection	(Cermak	et	al.,	2011).	Due	to	the	fact	that	there	are	methods	suitable	for	constructing	custom	TALENs	in	a	typical	 academic	 research	 lab	 (discussed	 in	 the	 next	 section)	 and	 the	 increased	number	of	target	sequences	that	TALENs	can	target	compared	to	ZFNs	and	because	CRISPR	 has	 reportedly	 high	 off-target	 effects,	 I	 decided	 to	 use	 TALENs	 as	 the	genome	editing	tool	to	introduce	late	infantile	CLN2	disease-causing	mutations	into	a	human	NPC	line.		
	




6.3.1 Constructing	TALENs	The	 repetitive	 nature	 of	 the	 TALE	 binding	 domain	 means	 that	 cloning	 of	 TALEs	represents	a	significant	challenge.	To	overcome	these	difficulties,	several	strategies	have	 been	 proposed	 for	 the	 assembly	 of	 custom	 TALEs.	 These	 methods	 include	GoldenGate	molecular	 cloning	 (Cermak	et	 al.,	 2011,	 Sanjana	 et	 al.,	 2012),	which	 is	the	method	I	used	to	construct	custom	TALENs	and	will	be	further	explained	below.	High-throughput	 methods	 have	 also	 been	 developed	 such	 as	 fast	 ligation-based	automatable	solid-phase	high-throughput	(FLASH)	assembly,	which	utilises	a	solid-phase	 strategy	 to	 ligate	 several	 TALE	 repeats	 on	 an	 immobilized	 DNA	 construct	(Reyon	 et	 al.,	 2012).	 Ligation-independent	 cloning	 (LIC)	 has	 also	 been	 used	 to	quickly	construct	large	numbers	of	custom	TALENs	(Schmid-Burgk	et	al.,	2013).	LIC	relies	 on	 longer	 single-stranded	 overhangs	 of	 double-stranded	 DNA,	 which	 are	designed	to	specifically	anneal	with	the	overhangs	of	another	fragment	(Geu-Flores	et	 al.,	 2007,	 Schmid-Burgk	et	 al.,	 2012).	By	 incorporating	a	bacterial	 replication	of	origin	during	transformation	in	E.coli,	the	overlapping	DNA	fragments	will	be	ligated	together	by	bacterial	ligases	(Schmid-Burgk	et	al.,	2013).		When	 targeting	 the	 CLN2	 gene	 locus	 I	 chose	 to	 assemble	 custom	 TALENs	 using	GoldenGate	cloning,	and	the	method	published	by	(Sanjana	et	al.,	2012)	along	with	the	 TALE	 toolbox	 Kit	 from	 this	 publication.	 The	 TALE	 Toolbox	 kit	 was	 requested	from	 and	 supplied	 by	 AddGene.	 It	 contains	 8	 plasmids	 of	 interest	 to	 us:	 four	monomer	plasmids	 to	be	used	as	 templates	 for	PCR	amplification	and	 four	TALEN	cloning	 backbone	 plasmids	 corresponding	 to	 each	 of	 the	 four	 different	 bases	targeted	by	the	0.5	monomer	repeat	and	containing	the	genetic	material	required	to	complete	and	translate	the	assembled	custom	TALEN	protein.		The	production	of	 custom	TALENs	using	 the	GoldenGate	 cloning	method	 relies	on	the	use	of	type	IIs	restriction	enzymes	(Engler	et	al.,	2009,	Engler	et	al.,	2008).	Type	IIs	 restriction	 enzymes	 are	 capable	 of	 cleaving	 DNA	 outside	 their	 restriction	 site,	resulting	in	5’	or	3’	DNA	overhangs	that	can	consist	of	any	base	(Engler	et	al.,	2009).		Therefore,	 a	 type	 IIs	 restriction	 enzyme	 that	 produces	 a	 four-nucleotide	 overhang	can	create	256	(4x4x4x4)	different	overhangs.	Using	this	property,	 it	 is	possible	to	
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ligate	 two	 digested	 DNA	 fragments	 together	 to	 generate	 a	 product	 without	 the	original	 restriction	site.	Over	 time,	 this	 technology	has	developed	 from	being	used	merely	to	assemble	premade	modules	together	(Rebatchouk	et	al.,	1996),	to	merging	digestion	and	ligation	of	several	DNA	fragments	in	one	tube	in	a	single	step	(Fromme	and	Klingenspor,	2007,	Engler	et	al.,	2009)	When	constructing	custom	TALENs,	type	IIs	restriction	enzymes	are	used	to	create	unique	overhangs	 that	 should	 specify	 the	order	of	 ligation	of	 the	TALE	monomers	during	their	assembly.	First,	each	nucleotide	specific	monomer	plasmid	is	amplified	with	 primers	 that	 will	 form	 ‘ligation	 adaptors’	 when	 the	 amplified	 monomer	 is	digested.	 These	 ‘ligation	 adaptors’	 will	 specify	 the	monomer’s	 position	within	 the	TALEN’s	tandem	repeat	DNA	binding	domain.	In	theory,	the	monomer	library	can	be	used	for	the	assembly	of	many	TALENs	in	the	future	(Sanjana	et	al.,	2012).	Then,	the	appropriate	monomers	are	ligated	together	to	form	hexamers,	which	are	amplified	by	 PCR.	 Following	 this	 the	 assembled	 hexamers	 are	 ligated	 together	 to	 form	 the	TALEN	 DNA	 binding	 domain	 and	 simultaneously	 ligated/digested	 into	 the	appropriate	TALEN	cloning	backbone	to	yield	the	final	assembled	TALENs.		
6.3.2 TALEN	Target	site	selection	In	 creating	 a	 human	 stem	 cell	 model	 of	 late	 infantile	 CLN2	 disease,	 I	 wanted	 to	recapitulate	the	human	disease	as	closely	as	possible.	As	such,	I	chose	the	gene	locus	in	CLN2	where	the	most	common	disease-causing	mutation	in	CLN2	is	as	the	target	for	 mutation,	 which	 is	 a	 C	 to	 T	 substitution	 in	 exon	 6	 at	 position	 3670,	 which	produces	 a	 nonsense	mutation	 (Liu	 et	 al.,	 1998,	 Sleat	 et	 al.,	 1997).	 This	 causes	 an	arginine	to	be	replaced	by	a	premature	stop	codon	(Arg208X),	and	hence	results	in	a	much	shorter	transcript,	which	may	or	may	not	be	degraded	(Sleat	et	al.,	1997).	This	mutation	occurs	at	an	allele	frequency	of	32%	in	CLN2	disease	patients	(Kousi	et	al.,	2012).	The	genomic	DNA	sequence	of	CLN2	was	downloaded	in	FASTA	format	from	the	 NCBI	 nucleotide	 resource	 and	 the	 location	 of	 the	 Arg208X	 mutation	 was	identified	 (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs119455955).	 From	this,	 the	 nucleotide	 sequence	 100	 bp	 upstream	 and	 100bp	 downstream	 of	 the	desired	 target	 site	 was	 obtained	 and	 this	 was	 entered	 into	 the	 TAL	 Effector	Nucleotide	Targeter	2.0	tool	(TALE-NT)	from	Cornell	University	(Doyle	et	al.,	2012,	Cermak	et	al.,	2011).	This	is	an	online	tool,	which	is	used	to	design	pairs	of	TALENs,	to	 target	 a	 specific	 gene	 sequence:	 in	 our	 case	 the	 200	bp	 sequence	 of	CLN2	with	Arg208X	in	the	centre.		
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Most	 naturally	 occurring	 TAL	 effector	 targets	 are	 preceded	 by	 a	 T	 at	 the	 5’	 end	(Moscou	 and	 Bogdanove,	 2009).	 However,	 TAL	 effector	 targets	 are	 also	 rarely	preceded	by	a	C	(Yu	et	al.,	2011)	and	have	been	shown	to	be	active	on	sites	preceded	by	 a	 C	 as	 well	 (Miller	 et	 al.,	 2011).	 The	 structure	 of	 the	 TAL	 effector	 protein	 N-terminal	 to	 the	 central	 repeat	 domain	 is	 what	 purportedly	 determines	 the	preference	for	T	at	this	site	(Deng	et	al.,	2012,	Mak	et	al.,	2012).	Taking	these	issues	into	 consideration,	 it	 was	 specified	 that	 the	 upstream	 base	 of	 our	 TALEN	 target	would	be	a	T	but	all	other	presets	remained	off.	The	newest	version	of	TALE-NT	has	an	option	to	select	a	NH	monomer	instead	of	the	NN	monomer,	which	is	used	in	this	thesis.	The	NH	plasmid	monomer	has	greater	binding	capacity	for	G	than	NN	(Cong	et	al.,	2012,	Streubel,	2012).	However,	the	NH	monomer	plasmid	was	not	included	in	the	 TALE	 toolbox	 kit	 when	 designing	 our	 TALENs	 so	 was	 not	 used	 to	 generate	TALENs	 in	 this	 thesis.	 The	 TALE-NT	 software	 detected	 only	 one	 TALEN	 pair	 that	could	cut	directly	at	the	Arg208X	mutation	site.	Thinking	that	the	site	of	the	DSB	was	the	most	 important	 factor,	 this	 TALEN	design	was	 taken	 forward,	 despite	 the	 fact	that	 the	 spacer	 length	 was	 at	 the	 maximum	 recommended	 length	 of	 30	 bp.	 The	TALEN	 target	 sequence	 and	 design	 is	 described	 in	 Table	 9	 and	 a	 schematic	representation	of	the	TALENs	binding	to	the	CLN2	gene	is	in	Figure	44..			
6.3.3 Targeting	the	CLN2	gene	to	achieve	the	Arg208X	mutation	As	 described	 above,	 gene	 inactivation	 can	 be	 achieved	 by	 homologous	recombination	(HR).	However,	homology-directed	repair	(HDR)	occurs	at	low	rates	in	mammalian	 cells	 and	 decreases	with	 lineage	 commitment,	 correlating	with	 the	lower	 fraction	of	cells	 in	 the	S	phase	of	 the	cell	 cycle	where	DNA	replication	 takes	place	and	a	lack	of	recombination	proteins	(Saleh-Gohari	and	Helleday,	2004,	Kass	et	al.,	2013).	The	introduction	of	a	DSB	increases	the	efficiency	of	HDR	4-fold	due	to	the	fact	 that	 HR	 is	 the	 repair	 mechanism	 that	 is	 favoured	 for	 repair	 of	 DSBs	 in	mammalian	cells	(Liang	et	al.,	1998,	Richardson	et	al.,	1998)	and	since	this	discovery	nucleases	have	been	used	to	improve	gene	inactivation	using	HDR	(Ran	et	al.,	2013,	Ramirez	et	al.,	2012,	Joung	and	Sander,	2013).		I	initially	considered	delivering	the	TALENs	alone	into	hNSCs	and	taking	advantage	of	 NHEJ-mediated	 repair,	 where	 the	 nuclease	 induced	 DSB	 results	 in	 the	introduction	of	small	insertions	or	deletions	(Santiago	et	al.,	2008).	These	mutations	may	 result	 in	 loss	 of	 gene	 function	 via	 frame	 shift	 mutations.	 However,	 as	 the	objective	 is	 to	 specifically	 recreate	 the	Arg208X	mutation	 in	 the	CLN2	 gene,	NHEJ-
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TALEN	plasmid	cloning	backbone	 NN	 backbone	 due	 to	 the	 final	 G	(pTALEN_v2(NN)).	 NG	backbone	due	to	the	final	T	in	the	target	sequence	(pTALEN_v2(NG))			
Table	9	Design	of	custom	TALENs	to	target	the	CLN2	gene	at	the	Arg208X	locus.										
Figure	44	Schematic	representation	of	custom	TALENs	binding	in	situ	to	the	CLN2	gene
GGACTGTAGGCCTGCAT C T G G G G G T A A C C C C C T C  TGTGATCCGTAAGC GATACAACTTGACCTCACAAGACGTGGGCTCTGGCACCAGCAATAACAGCCAAGCCTGTGCCCAG
CCTGACATCCGGACGTAGACCCCCATTGGGGGAGACACTAGGCATTCGCTATGTT GAACTGGAGT G T T C T G C A C C C G A G A C C G  TGGTCGTTATTGTCGGTTCGGACACGGGTC




6.4 Overview	of	TALEN	construction	procedure		 																					The	 construction	 of	 the	 custom	TALENs	 using	 the	 Sanjana	 et	 al.,	 (2012),	 can	 be	broken	down	into	several	tasks	as	described	in	Table	10.	 I	shall	now	explain	the	steps	 taken	 to	 achieve	 each	 of	 the	 tasks	 in	Table	 10	 in	 the	 construction	 of	 the	custom	TALENs.				
6.4.1 Task	1:	Generate	monomer	library	plate	using	PCR		First	 a	monomer	 library	must	 be	 produced	 in	 order	 to	 produce	 all	 the	 different	monomer	 building	 blocks	 for	 TALEN	 construction;	 this	 is	 task	 1	 in	Table	 9.	 As	described	 in	 Sanjana	 et	 al.	 2012,	 primer	 pairs	 were	 mixed	 to	 achieve	 a	 final	concentration	of	10	μM	for	each	primer.	These	primer	pairs	ensure	that	each	PCR	
Stage	 	1	 Generate	monomer	library	plate	using	PCR		2	 Purify	and	normalize	concentration	of	each	monomer			3	 Assemble	 monomers	 using	 golden-gate	 ligation	 to	 generate	 circularized	hexamer	4	 Exonuclease	treatment	to	remove	non-hexamers		5	 Amplify	hexamers	using	PCR		6	 Gel	purify	amplified	hexamers	and	normalise	concentration			7	 Golden-gate	ligation	to	ligate	assembled	hexamers	into	TALE	backbone	and	generate	final	TALEN	construct	8	 Transform	Golden-gate	ligation	product		 	9	 Coloby	PCR	to	identify	successful	TALEN	clones		10	 Mini-prep	to	increase	TALEN	DNA	quantity	and	sequencing	verification	
Table	10	Overview	of	TALEN	construction	procedure	
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product	has	unique	sticky	ends	so	that	they	can	only	ligate	together	in	the	correct	order	 following	digestion.	Two	96-well	monomer	 library	plates	were	set	up	with	each	 containing	 a	 total	 of	 72	 PCRs	 (Sanjana	 et	 al	 2012).	 Following	 PCR,	 gel	electrophoresis	 was	 used	 to	 confirm	 that	 the	 monomer	 amplification	 had	 been	successful.		A	2%	agarose,	1%	EtBr	gel	was	cast	in	1X	TAE	electrophoresis	buffer.	5	μl	of	PCR	product	was	run	on	the	gel	with	1	μl	6X	loading	dye.	I	had	trouble	making	the	 monomer	 library	 in	 the	 first	 instance	 using	 the	 Herculase	 II	 Fusion	 DNA	polymerase	(Herculase	II,	Agilent	Technologies,	UK)	specified	by	Sanjana	et	al.	(see	appendix	 1.2).	 So,	 I	 switched	 to	 using	 Phusion®	 high	 fidelity	 DNA	 polymerase	(Phusion®)(New	England	Biolabs,	UK)	as	described	in	Table	11	and	12.			Reagent	 Amount	(μl)	 Final	concentration	Monomer	template	plasmid	(5	ng	μl-1)	 2	 50	pg	μl-1	dNTP,	10	mM	 2	 200	μM	each	Phusion	HF	buffer,	5X	 20	 1X	Primer	mix,	 20	 μM	 (10	 μM	forward	primer	 and	10	μM	reverse	primer)	 2.5	 500	nM	Phusion	Polymerase	 1	 0.02	U	μl-1	Distilled	water	 72.5	 	Total	 100	μl	
	
Table	11.	Reagents	 for	modified	monomer	 library	PCR	with	Phusion®	high	 fidelity	




Cycle	Step	 Temperature	 Time		 Cycles	Initial	denaturation	 98	°C	 1	min	 1	Denaturation	 98	°C	 20	s	 35	Annealing	 62	°C	 20	s	Extension	 72	°C	 30	s		Final	extension	 72	°C	 3	min	 1	
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6.4.2 Task	2:	Purify	and	normalize	concentration	of	each	monomer	Following	 switching	 to	Phusion®,	 PCR	amplification	of	 the	monomer	 library	was	successful	 and	 both	 PCR	plates	were	 pooled	 and	 purified	 using	 a	Wizard	 SV	Gel	and	 PCR	 Clean-Up	 System	 (Promega,	 UK),	 as	 described	 in	 manufacturers	instructions,	and	eluted	 in	100	μl	DNAse-free	water.	 It	 is	 important	 that	 the	PCR	products	 are	 very	 clean	 and	 there	 are	 no	 primers	 and	 free	 dNTPs	 left	 in	 the	monomer	stock	library	because	the	monomers	will	undergo	subsequent	rounds	of	ligation	and	the	primers	must	not	be	incorporated	instead.		The	 purified	 PCR	 products	 were	 then	 normalized	 to	 the	 same	 concentration	 by	adding	 DNAse-free	 water,	 the	 DNA	 was	 checked	 for	 purity	 (260/280	 ratio	 of	absorbance	 approximately	 1.8)	 and	 quantified	 using	 a	 nanodrop	 2000	(Thermoscientific,	Wilmington,	USA).	The	monomers	that	are	located	at	the	end	of	hexamers	 are	 longer	 in	 sequence	 than	 the	 other	 monomers;	 as	 such	 it	 was	necessary	to	adjust	them	to	a	higher	concentration	of	18	ng	μl-1,	compared	to	15	ng	μl-1	for	the	other	monomers.	The	amplified	monomers	were	then	stored	at	-20	°C	until	needed.	
	
6.4.3 Task	 3:	 Assemble	 monomers	 using	 golden-gate	 ligation	 to	 generate	
circularized	hexamer	The	target	sequence	that	each	TALEN	will	bind	to	in	CLN2,	was	then	divided	into	hexamers	(Table	12)	and	1	ul	of	each	normalised	monomer	was	pipetted	into	the	corresponding	 hexamer	 reaction	 tube	 (task	 2,	 Table	 9).	 The	 GoldenGate	digestion/ligation	was	 then	performed	using	 the	 reaction	 conditions	 specified	 in	(Table	13	and	14,	primer	sequences	are	in	appendix	1.1).		
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Table	13.	 	Choice	of	monomers	from	the	monomer	library	arranged	into	hexamers.	The	 target	 sequence	 is	 divided	 into	 hexamers	 with	 the	 monomers,	 which	 have	 been	amplified	with	the	appropriate	primers	 in	order	to	have	the	correct	 ligation	adaptor	and	determine	their	position	in	the	TALEN	DNA	binding	domain.			
Component	 Amount	(μl)	 Final	concentration	Esp3I	(BsmBI),	10	Uμl-1	 0.75	 0.375	Uμl-1	Tango	buffer,	10	X	 1	 1	X	DTT,	10	mM	 1	 1	mM	T7	ligase,	3000	Uμl-1	 0.25	 75	Uμl-1	ATP,	10	mM	 1	 1mM	Total	 4	 	Six	monomers	 6	x	1	 		 	 	Total	 10	 	
		
Table	 14.	 Reagents	 for	 hexamer	 assembly.	 The	 relevant	 monomers	 were	simultaneously	digested	and	 ligated	 together	 to	 form	hexamers	using	 the	reagents	 listed	here.			 Cycle	number	 Digest	 Ligate	1-15	 37	°C,	5	min	 20	°C,	5	min	Hold	at	4	°C	 	 	
		
Table	 15.	Thermal	 profile	 for	 hexamer	 ligation.	 Monomers	were	 ligated	 together	 to	form	 hexamers	 using	 the	 reagents	 described	 in	 Table	 13	 and	 the	 cycling	 conditions	described	here.		
6.4.4 Task	4:	Exonuclease	treatment	to	remove	non-hexamers	During	 the	golden	gate	reaction,	 in	 theory,	only	 fully	 ligated	hexamers	should	be	able	 to	 circularize.	As	 such,	 it	 is	necessary	 to	degrade	any	 reactions	 that	 are	not	circularised	hexamer	products	so	that	they	are	not	incorporated	into	the	next	step.	
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The	 hexamers	 were	 treated	 with	 plasmidsafe	 exonuclease,	 which	 should	selectively	 degrade	 noncircular	 (incomplete)	 ligation	 products.	 Following	 the	protocol	 from	 Sanjana	 et	 al.,	 (2012)	 there	 was	 incomplete	 digestion	 of	noncircularized	products	(for	original	reaction	see	appendix	section	1.2).	As	such,	in	order	to	increase	the	degradation	of	non-circularized	products	concentration	of	PlasmidSafe	 exonuclease	 was	 increased	 and	 carried	 out	 using	 the	 reagents	described	 in	 Table	 15	 and	 incubated	 at	 37°C	 for	 30	 minutes	 followed	 by	inactivation	at	70°C	for	30	minutes.			Component	 Amount	(μl)	 Final	concentration	PlasmidSafe	DNAse,	10	Uμl-1	 2	 0.66	Uμl-1	PlasmidSafe	 reaction	 buffer,	10X	 1	 1X	ATP,	10	mM	 1	 1	mM		 3	 	Golden	Gate	reaction	 6	 	Total	 10	 	
	
Table	16.	Reagents	 for	modified	plasmidsafe	 exonuclease	digestion.	The	assembled	hexamers	were	digested	 to	 remove	 incomplete	monomer	 ligations	 (5	 or	 less	monomers	ligated	together	using	PlasmidSafe	exonuclease	along	with	the	other	reagents	 listed	here	with	the	thermal	profile	described	below.		
6.4.5 Task	5:	Amplify	hexamers	using	PCR	In	 order	 to	 increase	 the	 DNA	 concentration	 of	 each	 hexamer,	 each	 PlasmidSafe-treated	hexamer	was	 then	amplified	 in	 two	100	μl	PCR	reactions	using	 the	high-fidelity	 polymerase	 Herculase	 II	 Fusion	 DNA	 polymerase	 (Agiilent	 Technologies,	UK).	 I	 used	 this	 large	 PCR	 volume	 in	 order	 to	 further	 increase	 yields	 of	 the	amplified	 hexamers.	 The	 hexamer	 PCR	 amplification	 was	 carried	 out	 using	 the	reagents	described	in	Table	16	and	the	thermal	profile	described	in	Table	17.	A	schematic	representation	is	in	Figure	46.	The	initial	PCR	with	reaction	conditions	as	in	Sanjana	et	al.,	(2012)	was	unsuccessful	but	with	repetition	and	optimisation	of	 the	 concentration	 of	 DMSO	 (original	 reaction	 conditions	 in	 appendix	 1.2)	 the	ligated	monomers	were	successfully	amplified.	Following	 amplification	 the	 PCR	 products	 were	 pooled	 and	 purified	 using	 the	wizard	PCR	purification	kit	(Promega,	UK)	and	eluted	in	a	smaller	volume	of	40	μl.	This	purification	step	is	necessary	as	cloning	techniques	using	restriction	enzymes	are	 very	 sensitive	 to	 pH	 and	 the	 downstream	 reactions	may	 be	 inhibited	 by	 the	presence	of	 the	salts	 in	 the	PCR	reaction	buffer.	Purification	 in	this	way	removes	the	 salts	 but	 also	 removes	 any	 unincorporated	 dNTPs	 and	 primers.	 In	 order	 to	
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concentration	dNTP,	100	mM	(25	mM	each)	 0.5	 1	mM	Herculase	II	reaction	buffer,	5X	 10	 1X	Hex-F	and	Hex-R	primers,		10	μM	each	 1	 200	nM	Herculase	II	fusion	DNA	polymerase	 0.5	 1X	Distilled	water	 36	 	DMSO	 1	 	PlasmidSafe-treated	hexamer	 1	 	Total	 50	 	
	
Table	 17.	 Reagents	 for	 modified	 hexamer	 amplification	 PCR	 with	 DMSO.	 PCR	was	performed	 using	 Herculase	 II	 fusion	 DNA	 polymerase	 using	 the	 plasmidsafe	 treated	hexamers	in	order	to	increase	the	DNA	concentration	of	the	hexamers.			
	
Table	18	Thermal	profile	for	hexamer	amplification	PCR	The	assembled	hexamers	were	amplified	by	PCR	using	Herculase	II	fusion	DNA	polymerase	with	the	thermal	profile	described	here.	





6.4.6 Task	6:	Gel	purify	amplified	hexamers	and	normalise	concentration		To	avoid	any	incomplete	hexamer	ligations	being	incorporated	into	the	final	TALEN	protein,	 it	was	 necessary	 to	 purify	 the	 amplified	 hexamer	 product	 from	 the	 other	amplicons.	A	2	%	(wt/vol)	agarose	gel	was	cast	and	loaded	with	as	much	hexamer	product	 as	 possible	 and	 electrophoresed	 as	described	 in	 section	6.4.5	 above.	 	 The	band	 that	was	most	clearly	aligned	with	 the	600-bp	band	 from	the	 ladder	was	cut	out	 using	 a	 clean	 razor	 blade.	 Cross	 contamination	 was	 minimized	 by	 ethanol	sterilization	 of	 work	 surfaces	 and	 by	 using	 fresh	 razor	 blades	 for	 each	 individual	band	excision.	The	hexamer	gel	bands	were	purified	using	the	MinElute	gel	extraction	kit	(Qiagen,	UK)	according	to	the	Manufacturer’s	instructions.	The	DNA	from	each	reaction	was	eluted	 in	 20	 μl	 of	 DNAse	 free	water	 pre-warmed	 to	 55°C.	 The	 yield	 from	 the	 gel	extraction	process	was	very	low	in	initial	attempts	(below	5	ng	μl-1)	and	so	the	final	elution	volume	was	kept	to	a	minimum	in	order	to	maximise	the	final	concentration.	Inevitably	this	meant	some	of	the	DNA	was	lost	but	a	final	concentration	of	20	ng	μl-1	was	required	and	larger	elution	volumes	that	exceeded	20	μl	did	not	reach	this	level	of	DNA	concentration.	Following	successful	gel	extraction	at	a	sufficient	yield,	the	DNA	concentration	of	the	gel-purified	hexamers	was	estimated	by	 running	a	 small	 amount	on	a	2%	agarose	gel	 with	 1%	 EtBr	 as	 described	 above.	 	 The	 nanodrop	 could	 not	 be	 used	 in	 this	instance	 as	 the	 salts	 in	 the	 buffer	 from	 the	 gel	 extraction	 kit	 interfered	 with	 the	nanodrop	reading.	The	DNA	concentration	of	the	purified	hexamers	was	adjusted	to	20	ng	μl-1	by	the	addition	of	DNAse	free	water.	
	
6.4.7 Task	 7:	 Golden-gate	 ligation	 to	 ligate	 assembled	 hexamers	 into	 TALE	
















1	 1	 1	 1	 10	ng	μl-1	
BsaI-HF	 (20	U	μl-1)	 0.75	 0.75	 0.75	 0.75	 1.5	U	μl-1	NEBuffer	 4,	10X	 1	 1	 1	 1	 1X	BSA,	10X	 1	 1	 1	 1	 1X	ATP,	10	mM	 1	 1	 1	 1	 1X	T7	 ligase	(3000	U	μl-1)	 0.25	 0.25	 0.25	 0.25	 75	U	μl-1		 5	 5	 5	 5	 	Three	purified	hexamers	(20	ng	μl-1)	
3	(1	each	of	L1,	 L2	 and	L3)	 3	 (1	 each	of	 R1,	 R2	and	R3)	 0	 0	 2	ng	μl-1	Distilled	water	 2	 2	 5	 5	 	Total	 10	 10	 10	 10	 	
	
Table	 19	Ligation	 and	 digestion	 of	 amplified	 hexamers	 into	 the	 appropriate	 TALEN	
background.	The	amplified	hexamers	were	simultaneously	digested	to	reveal	unique	sticky	ends	and	ligated	into	the	appropriate	TALEN	background	with	the	reagents	as	listed	in	this	table.		Cycle	number	 Digest	 Ligate	 Inactivate	1-20	 37	°C,	5	min	 20	°C,	5	min	 	21	 	 	 80	°C,	20	min	Hold	at	4	°C	 	 	 	
	










6.4.8 Task	8:	Transform	Golden-gate	ligation	product	To	 verify	 that	 the	 hexamers	 were	 successfully	 ligated	 into	 the	 TALEN	 protein	backbone,	the	ligation	product	was	then	transformed	into	bacteria,	screened	by	PCR	and	analysed	by	gel	electrophoresis	(Figure	48).	10	μl	of	ligation	product	was	added	to	 50	 μl	 of	 ice-cold	 chemically	 competent	 Stblr3	 cells	 (Life	 Technologies,	 UK)	 and	incubated	on	ice	for	5	minutes.	The	cells	were	then	incubated	at	42°C	for	45	seconds	and	then	returned	immediately	into	ice	for	5	min.	Then	250	μl	of	SOC	medium	(Life	Technologies,	UK)	was	added	and	the	cells	were	incubated	at	37°C	for	1	hour	on	a	shaking	incubator	(250	rpm).	150	μl	of	transformation	product	was	plated	out	on	LB	plates	 containing	 100	 μg	 ml-1	 ampicillin	 (Sigma-Aldrich,	 UK)	 and	 incubated	overnight	at	37°C,	5%	CO2.		
6.4.9 Task	9:	Colony	PCR	to	identify	successful	TALEN	clones	For	each	TALEN	plate	(left	and	right),	8	colonies	were	picked	to	check	the	assembly	fidelity.	A	sterile	20	μl	pipette	tip	was	used	to	touch	a	single	colony	and	swirled	into	50	μl	of	distilled	water	to	use	for	colony	PCR.	On	each	plate	the	colony	that	had	been	sampled	was	noted.			Component	 Amount	(μl)	 Final	concentration	Colony	suspension	 1	 	dNTP,	100	mM	(25	mM)	 0.25	 1	mM	Phusion-HF	buffer,	10	X	 2.5	 1X	TALE-Seq-F1	 and	 TALE-Seq-R1	 primers,	 10	 μM	each	 0.25	 100	nM	Phusion	Taq	(5	U	μl-1)	 0.1	 0.02	U	μl-1	Distilled	water	 20.9	 	Total	 25	 	
Table	21.	Reagents	for	Colony	screening	PCR.	PCR	amplification	was	performed	using	the	reagents	 listed	 in	 this	 table,	 here	 and	 diluted	 colonies	 from	 LEFT	 and	 RIGHT	 TALEN	transformed	cells	 in	Stbl3	E.coli	as	 template	 in	order	 to	determine	which	colonies	had	 the	correctly	assembled	TALEN	proteins.				Using	the	colonies	as	templates,	PCR	was	used	to	verify	that	the	assembled	tandem	18-mer	repeat	was	ligated	into	the	TALEN	backbone	(Table	20	and	21).		
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Table	22	Thermal	profile	for	Colony	screening	PCR.	This	table	shows	the	thermal	profile	used	to	determine	which	colonies	had	correctly	assembled	TALEN	proteins.		The	 TALEN	 cloning	 backbone	 plasmid	 contains	 a	 ccdB	negative	 selection	 cassette	between	 the	N	and	C	 terminals	of	 the	TALEN,	which	 is	 replaced	by	 the	assembled	18-mer	DNA	binding	domain	when	the	GoldenGate	reaction	has	been	successful	and	the	 TALEN	 has	 been	 successfully	 constructed.	 ccdB	 is	 the	 toxic	 component	 of	 a	toxin/anti-toxin	module	and	is	responsible	for	post-segregational	killing	of	plasmid-free	 bacteria.	 Therefore,	 the	 ccdB	 negative	 selection	 cassette	 will	 kill	 all	 cells	transformed	with	an	empty	backbone	(Bahassi	et	al.,	1995).	To	check	the	colony	PCR	result,	a	1%	(wt/vol)	agarose	gel	in	1X	TAE	electrophoresis	buffer	with	1	%	Ethidium	Bromide	was	used.	The	gel	was	run	at	15	V	cm-1	until	there	was	clear	separation	of	the	1500-	and	2000-bp	ladder	bands.	The	gel	was	imaged	to	identify	 which	 colonies	 have	 the	 correct	 insert	 size.	 As	 both	 the	 left	 and	 right	TALENs	had	an	insert	of	18	monomers	the	desired	product	length	was	around	2175	bp.			
6.4.10 Task	 10:	 Mini-prep	 to	 increase	 TALEN	 DNA	 quantity	 and	 sequencing	
verification	In	 order	 to	 determine	 whether	 the	 hexamers	 had	 been	 ligated	 into	 the	 TALEN	backbone	 in	 the	 correct	 order	 and	 whether	 any	 undesired	 mutations	 had	 taken	place,	 the	 sequence	 of	 each	 clone	 identified	 to	 have	 the	 correct	 sized	 insert	 was	sequenced.	Each	clone	with	a	correct	sized	 insert	was	 inoculated	 in	10	ml	of	LB	medium	with	100	 μg	 ml-1	 ampicillin	 and	 incubated	 at	 37°C,	 5%	 CO2	 in	 a	 shaking	 incubator	overnight.	 The	 plasmid	 DNA	 was	 isolated	 from	 overnight	 cultures	 using	 the	Wizard®	 Plus	 DNA	 Purification	 System	 (Promega,	 UK)	 according	 to	 the	manufacturer’s	 guidelines.	The	 sequence	of	 each	clone	was	verified	by	 sequencing	the	tandem	repeat	DNA	binding	domain	of	the	TALEN	using	the	sequencing	primers	TALE-Seq-F1	 (a	 forward	 primer	 which	 anneals	 before	 the	 first	 monomer),	 TALE-Seq-F2	(a	forward	primer	which	anneals	at	the	beginning	of	the	seventh	monomer	
Cycle	Step	 Temperature	 Time		 Cycles	Initial	denaturation	 94	°C	 3	min	 1	Denaturation	 94	°C	 30	s	 35	Annealing	 60	°C	 30	s	Extension	 68	°C	 2	min	Final	extension	 68	°C	 5	min	 1	
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i.e.	the	second	hexamer)	and	TALE-seq-R1	(a	reverse	primer	which	anneals	after	the	final	 monomer)	 (see	 appendix	 1.1	 for	 primer	 sequences	 and	 Figure	 50	 for	 gel	result).	 	 The	 samples	were	 prepared	 for	 sequencing	 using	 the	 BigDye	 Terminator	v1.1	Cycle	Sequencing	kit	(Life	Technologies,	UK)	as	per	manufacturing	instructions.	The	 sequence	 was	 analysed	 on	 a	 Beckman	 Coulter	 CEQ	 800	 genetic	 analysis	(Beckmann	Coulter	Ltd.,	High	Wycombe,	UK).	A	 reference	 sequence	 was	 generated	 for	 the	 custom	 made	 TALEN	 on	 the	 online	software	TALE	sequence	generator,	on	TAL	effector	tools,	created	by	(Sanjana	et	al	2011,	http://taleffectors.com/tools).		
6.5 RESULTS			
Constructing	Custom	TALENs	using	GoldenGate	cloning			In	this	Chapter,	I	attempted	to	produce	customized	TALENs	to	target	the	CLN2	gene,	which	 would	 be	 used	 to	 introduce	 the	 Arg208X	mutation	 into	 hNPCs	 in	 order	 to	produce	a	hNPC	model	of	late	infantile	CLN2	disease.	To	this	end,	I	chose	to	follow	the	 protocol	 outlined	 in	 Sanjana	 et	 al.,	 (2012)	 along	 with	 their	 TALE	 Toolbox	 kit	from	 Addgene.	 I	 found	 that	 the	 protocol	 needed	 modifications	 in	 order	 to	successfully	construct	customized	TALENs.			
6.5.1 Monomer	Library	 construction	 required	 a	Different	High	Fidelity	DNA	
polymerase	for	Successful	Amplification	A	monomer	library	was	constructed	by	amplifying	the	monomer	plasmids	provided	in	the	TALE	Toolbox	kit	with	specific	primers	which	will	generate	ligation	adapters	to	specify	the	monomers	position	in	the	tandem	repeat	TALEN	DNA	binding	domain	(Chapter	6,	section	6.3.1).	Initially,	 I	 had	 trouble	 making	 the	 monomer	 library,	 as	 some	 of	 the	 monomer	products	 were	 not	 successfully	 amplified.	 Sanjana	 et	 al.,	 (2012)	 use	 Herculase	 II	Fusion	DNA	polymerase	(Herculase	II),	a	high	fidelity	DNA	polymerase	that	is	often	chosen	 when	 the	 PCR	 template	 is	 very	 long	 or	 GC	 rich	 (Hogrefe	 et	 al.,	 2002).	However	 the	 yield	 using	 Herculase	 II	 was	 very	 low	 and	 some	 of	 the	 monomer	plasmid	templates	were	not	amplified	at	all,	despite	the	fact	it	is	reported	to	produce	high	 yields	 on	 difficult	 templates	 (Hogrefe	 et	 al.,	 2002).	 As	 a	 result,	 I	 switched	 to	using	Phusion®	high	fidelity	DNA	polymerase	(Phusion®).	Phusion®	is	a	high	fidelity	
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DNA	 polymerase	 enzyme	 with	 3’-5’	 exonuclease	 activity.	 Like	 Herculase	 II,	 it	 is	employed	 when	 a	 target	 is	 long	 and	 particularly	 GC-rich,	 when	 mutagenesis	 is	undesirable	 and	 for	 plasmid	 templates	 (Bohlke	 et	 al.,	 2000).	 For	 this	 project,	mutagenesis	 is	 very	 undesirable,	 as	 the	 exact	 sequence	 of	 the	monomers	must	 be	kept	 the	 same	 as	 they	 are	 designed	 in	 the	 plasmids	 in	 order	 that	 each	monomer	recognises	 the	 DNA	 base	 it	 is	 designed	 to.	 Following	 switching	 to	 Phusion®,	 PCR	amplification	of	the	monomer	library	was	successful	and	this	monomer	library	could	in	theory	be	used	to	construct	any	additional	custom	TALENs.		
6.5.2 Hexamer	 Assembly	 Required	 inclusion	 of	 Dimethyl	 Sulfoxide	 and	 an	




Figure	 49	 Gel	 showing	 successful	 assembly	 of	 hexamers.	 A.	 Plasmid-safe	 treated	amplified	 hexamers	 were	 run	 on	 a	 2	%	 (wt/vol)	 agarose	 gel	 in	 1	 X	 TAE	 electrophoresis	buffer	with	1	%	(vol/vol)	ethidium	bromide	(EtBr),	1	μg	of	 the	1-kb	Plus	DNA	 ladder	was	included	in	one	lane	to	determine	the	size	of	the	DNA	bands.	The	gel	was	run	at	15	V	cm-1	until	 there	 was	 clear	 separation	 of	 the	 600-bp	 ladder	 from	 neighbouring	 bands.	 The	 gel	image	 was	 visualised	 using	 UV	 and	 there	 were	 no	 amplicons	 evident.	 B.	 The	 PCR	 was	repeated	 using	 an	 increased	 concentration	 of	 dimethyl	 sulfoxide	 (DMSO)	 and	 analysed	 as	described	 in	 A.	 Now	 a	 product	 of	 approximately	 300	 bp	 was	 evident	 (arrow,	 300bp),	suggesting	 3	 monomers	 ligated	 together	 and	 amplified-	 so	 the	 PlasmidSafe	 exonuclease	digestion	 was	 unsuccessful.	 C.	 The	 PCR	 was	 repeated,	 with	 a	 higher	 concentration	 of	PlasmidSafe	 exonuclease	 in	 the	 pre-treatment	 step,	 to	 increase	 degradation	 of	 non-circularized	products	(incomplete	ligations	of	monomers)	and	analysed	as	described	in	A.	A	product	 of	 approximately	 600	 bp	 (arrow,	 600	 bp)	 was	 evident	 from	 each	 reaction.	 In	addition	 to	 the	main	amplicon	at	600	bp,	 there	was	a	minor	product	of	under	100bp	and	additional	minor	products	at	approximately	200,	300,	400	and	500	bp.			So	either	the	monomers	ligated	incorrectly,	missing	out	monomers	and	circularizing	anyway,	 or	 the	 PlasmidSafe	 exonuclease	 step	 was	 unsuccessful	 and	 a	 non-circularized	 ligation	was	amplified.	Different	 taq	enzymes	were	trialled	 in	order	to	troubleshoot	 amplification	 and	 different	 concentrations	 of	 plasmidsafe	were	 used.	Ultimately,	 the	 same	 PCR	 amplification	with	Herculase	 II	 Fusion	 DNA	 polymerase	and	 DMSO	 was	 included	 but	 the	 concentration	 of	 PlasmidSafe	 exonuclease	 was	increased	 in	 order	 to	 increase	 the	 degradation	 of	 non-circularized	 products.	 This	resulted	in	successfully	amplified	hexamers,	as	indicated	by	the	intense	DNA	band	at	
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approximately	 600	 bp	 for	 both	 the	 left	 and	 right	 hexamers	 (Figure	 49c,	 600	 bp	arrow).	However,	additional	products	were	also	visible	at	200,	300,	400	and	500	bp,	which	correspond	with	the	size	of	incomplete	dimer,	trimer,	tetramer	and	pentamer	products	 that	 were	 amplified	 by	 the	 PCR.	 The	 presence	 of	 these	 smaller	 bands	suggests	 that	 even	 the	 increased	 PlasmidSafe	 exonuclease	 concentration	 did	 not	digest	all	the	incompletely	ligated	products.	Alternatively,	it	is	possible	that	5	or	less	monomers	 have	 ligated	 successfully	 together	 and	 circularized,	which	 should	 have	been	 prevented	 by	 the	 unique	 ‘ligation	 adaptors’	 formed	 by	 the	 initial	 PCR	 and	subsequent	 digestion	 reactions,	 suggesting	 that	 the	 ligation	 adaptors	 are	 not	 as	specific	as	Sanjana	et	al.,	(2012)	claim.			In	this	section,	I	have	shown	that	the	monomers	were	successfully	ligated	together	to	 form	 the	 hexamers	 that	 will	 comprise	 the	 DNA	 binding	 domain	 of	 the	 finally	assembled	TALENs.	The	next	stage	was	to	 ligate	 these	hexamers	together	and	 into	the	appropriate	TALEN	cloning	plasmid	backbone.		
6.5.3 Successful	ligation	of	hexamers	into	the	TALEN	backbone		The	 hexamers	 were	 gel	 extracted	 and	 purified	 and	 then	 ligated	 into	 the	corresponding	 TALEN	 cloning	 backbone	 via	 another	 GoldenGate	 simultaneous	digestion	 and	 ligation	 reaction	 (Figure	 47).	 The	 assembled	 TALENs	 were	 then	transformed	 into	 E.coli	 bacteria	 and	 spread	 on	 LB	 agar	 plates	 with	 ampicillin.	 8	colonies	from	each	of	the	Left	and	Right	TALEN	plates	were	isolated	and	screened	by	PCR	 for	 the	 correct	 sized	 insert	 corresponding	 to	 3	 hexamers	 inserted	 into	 the	TALEN	cloning	backbone	plasmid.		7	out	of	8	clones	for	both	the	left	(Figure	50a)	and	right	(Figure	50b)	TALEN	had	the	 correct	 sized	 product	 of	 approximately	 2200	 bp	 (predicted	 size	 is	 2175	 bp,	arrow).	 However,	 the	 remaining	 1	 out	 of	 the	 8	 clones	 for	 both	 the	 left	 and	 right	TALENs	have	a	band	at	approximately	1600	bp	(arrow	at	1600	bp),	corresponding	to	the	TALEN	backbone	with	only	2	incorporated	monomers,	further	suggesting	the	ligation	adaptors	were	not	as	specific	as	described	by	Sanjana	et	al.,	(2012).						
200	
In	 this	 section,	 I	have	 shown	 that	 the	hexamers	were	 successfully	 ligated	 together	into	 their	 correspoding	 TALEN	 cloning	 plasmid	 backbone.	 The	 next	 stage	 was	 to	confirm	 that	 the	 hexamers	 have	 ligated	 together	 in	 the	 correct	 order	 and	 that	 no	mutations	had	been	 introduced,	which	could	potentially	alter	 the	specificity	of	 the	DNA	binding	domain.					
	
	




6.5.4 Sequencing	 of	 the	 TALENs	 reveals	many	mutations	 that	 are	 primarily	
silent	The	 fact	 that	 7	 out	 of	 the	 8	 clones	 for	 each	 TALEN	 contained	 TALEN	 cloning	backbones	 that	 had	 incorporated	 3	 hexamers	 was	 encouraging,	 however	 it	 was	important	 to	 check	 that	 the	 hexamers	 had	 assembled	 in	 the	 correct	 order,	particularly	 in	 light	 of	 the	 fact	 that	 the	 ligation	 adaptors	 did	 not	 appear	 to	 be	rigorously	 specific.	 In	 addition,	 it	 was	 important	 to	 see	 whether	 any	 undesirable	mutations	had	occurred	during	the	cloning	steps,	which	could	alter	the	DNA	binding	specificity	of	the	TALENs.	The	 sequence	 of	 each	 clone	 was	 verified	 by	 sequencing	 the	 tandem	 repeat	 DNA	binding	 domain	 of	 the	 TALEN	 using	 the	 sequencing	 primers,	 TALE-seq-F1,	 which	annealed	 before	 the	 first	 monomer	 to	 analyse	 the	 sequence	 of	 the	 first	 hexamer;	TALE-Seq-F2,	which	anneals	at	the	beginning	of	the	seventh	monomer	to	analyse	the	sequence	of	the	second	hexamer	and	TALE-seq-R1,	a	reverse	primer	which	anneals	after	 the	 final	 monomer	 to	 analyse	 the	 third	 hexamer	 (Figure	 51).	 A	 reference	sequence	was	generated	for	the	custom	made	TALEN	on	the	online	software	TALE	sequence	 generator,	 on	 TAL	 effector	 tools,	 created	 by	 (Sanjana	 et	 al	 2011,	http://taleffectors.com/tools).	Sequencing	 of	 the	 assembled	 TALENs	 was	 analysed	 using	 4peaks	 software	(Nucleobytes,	 Amsterdam,	 The	 Netherlands)	 and	 confirmed	 that	 the	 correct	monomers	were	assembled	in	the	correct	order	for	both	the	left	and	right	TALENs,	when	 aligned	 using	 BLAST	 software	 (Altschul	 et	 al.,	 1990)	 with	 the	 reference	sequence	generated	by	the	TALE	sequence	generator	(Figure	52	for	an	example	and	appendix	 1.6	 and	 1.7	 for	 all	 colony	 DNA	 sequences).	 The	 chromatograms	 were	checked	manually	 in	 order	 to	 identify	 any	mutations	 unambiguously.	 In	 all	 of	 the	samples	 there	were	small	point	mutations	and	deletions	 in	 the	assembled	TALENs	compared	 to	 the	 reference	 sequence.	 These	 point	 mutations	 occurred	 most	frequently	 close	 to	 the	 ligation	 site	 (Figure	 53a).	 In	 the	 case	 of	 some	 of	 the	mutations	close	 to	 the	 ligation	site	at	 the	beginning	and	end	of	each	hexamer,	 this	may	have	been	an	artifact	of	the	sequencing	readout	as	at	the	beginning	or	end	of	a	sequencing	reaction	where	 the	sequence	 is	often	unreliable	 (Figure	 53b)	and	 this	was	 confirmed	 by	 looking	 at	 the	 quality	 of	 the	 sequence	 readout	 manually	 and	determining	 whether	 it	 was	 reliable.	 When	 I	 examined	 the	 trace	 file	 from	 these	sequencing	 readouts	many	of	 the	base	 calls	made	by	 the	 software	was	unreliable.	For	 example	 Figure	 54b	 shows	 a	 portion	 of	 sequence	 from	 the	 beginning	 of	
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hexamer	2	 from	 left	TALEN	colony	1.	The	 software	 interpreted	 the	many	broad	G	peaks	as	several	Gs,	which	matched	the	reference	sequence.	However,	 then	a	 large	wide	A	peak	was	interpreted	as	TA	rather	than	AA,	the	nucleotides	in	the	reference	sequence.		Manually,	one	might	have	interpreted	the	wide	A	peak	as	2	As	especially	as	 there	 is	no	peak	 in	 the	T	range	at	all.	As	such,	 I	would	predict	 that	 this	and	the	similar	errors	seen	in	the	beginning	and	ends	of	the	readouts	were	artifacts	from	the	sequencing	software	trying	to	read	a	low	signal.	Indeed,	these	base	‘mis-calls’	varied	between	colonies,	 suggesting	 that	 they	are	not	mutations	which	have	been	carried	forward	from	mutations	introduced	in	earlier	cloning	steps.				
		
Figure	51	Vector	Map	of	fully	constructed	customised	TALEN	showing	Primer	binding	














Figure	 54	Example	 of	 the	 mutations	 present	 within	 hexamer	 3	 of	 the	 Right	
TALEN.	 The	 right	 TALEN	 sequence	 shows	 varied	mismatches	 at	 the	 ligation	 sites	when	 aligned	with	 the	 reference	 sequence	 (red	 circles).	 There	 are	 also	mutations	within	the	internal	monomers	of	the	hexamer,	which	are	not	seen	in	the	left	TALEN	and	 the	 exact	 same	mutations	 are	 seen	 in	 the	 sequences	 from	 each	 right	 TALEN	colony	in	the	last	hexamer.		 	
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Figure	55	Example	of	 translated	alignment	of	 left	TALEN	sequence	compared	 to	 the	




reference	 sequence.	 The	 right	 TALEN	 sequence	 from	 colony	 6	 was	 aligned	 to	 the	translated	sequence	of	 the	reference	sequence.	This	shows	that	there	are	mutations	 in	the	right	 TALEN	DNA	 binding	 domain	 in	 the	 third	 hexamer	 that	 could	 alter	 the	DNA	 binding	specificity	of	the	assembled	right	TALEN.				
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In	the	left	TALEN	there	were	generally	only	sequencing	differences	at	the	beginning	and	end	of	the	hexamer	sequencing	readout	compared	to	the	reference	sequence.	In	the	right	TALEN	however,	in	addition	to	the	many	varied	mismatches	at	the	ligation	sites	seen,	which	could	be	due	to	the	sequencing	errors,	there	were	also	mutations	within	the	internal	monomers	of	the	hexamer	(Figure	54).	Furthermore,	the	exact	same	mutations	were	 seen	 in	 the	 sequences	 from	each	 right	TALEN	 colony	 in	 the	last	hexamer.	This	suggests	 that	mutations	were	picked	up	during	 the	assembly	of	the	TALENs,	possibly	during	the	production	of	the	monomer	library.		In	 order	 to	 proceed,	 it	 was	 necessary	 to	 determine	 whether	 these	 nucleotide	changes	 had	 an	 effect	 on	 the	 amino	 acid	 sequence	 as	 this	 might	 change	 the	specificity	 of	 the	 DNA	 binding	 domain.	 Translation	 of	 the	 DNA	 sequence	 for	 the	colony	 sequnces	 for	 both	 left	 and	 right	 TALENs	 was	 carried	 out	 using	 BLAST	software	(Altschul	et	al.,	1990)	and	revealed	at	least	one	colony	(colony	1)	in	which	the	amino	acid	sequence	exactly	matched	the	reference	sequence	for	the	left	TALEN	(Figure	 55,	 for	 all	 translated	 alignments	 for	 the	 Left	 TALEN	 see	 appendix	 1.8).	However,	all	the	translated	alignments	for	the	right	TALEN	showed	that	there	were	differences	 in	 the	 amino	acid	 sequence	between	 the	 assembled	TALENs’	 sequence	and	the	reference	sequence.	Many	of	the	nucleotide	substitutions	resulted	in	silent	mutations,	which	did	not	change	the	identity	of	the	translated	amino	acid	sequence.	Colony	 6	 had	 the	 translated	 alignment	 that	 was	 closest	 in	 comparison	 to	 the	reference	 sequence	 (Figure	 56,	 for	 all	 translated	 alignments	 for	 the	Right	 TALEN	see	appendix	1.9).	Hexamers	1	and	2	were	free	of	amino	acid	alterations,	except	for	at	the	very	beginning	of	the	sequence.	Hexamer	3	contained	amino	acid	alterations	within	the	internal	monomers	of	the	hexamer.			In	hexamer	3,	the	amino	acid	changes	coincide	with	the	RVD	of	the	monomers.	This	will	 have	 resulted	 in	 changing	 the	 specificity	 of	 binding	 for	 the	 final	 hexamer	(Figure	56,	Table	22).	3	out	of	20	of	the	monomers	defining	where	the	right	TALEN	would	 bind	 were	 altered.	 Colonies	 2	 and	 3	 for	 the	 right	 TALEN	 also	 showed	additional	 mutations	 outside	 the	 RVD	 but	 we	 would	 not	 expect	 these	 to	 have	 an	effect	on	the	specificity	of	the	TALEN	for	the	CLN2	gene	region	of	interest.					
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Table	23.	Table	 to	 show	 the	altered	DNA	binding	 specificity	of	 the	 right	TALEN.	The	alterations	 in	 amino	 acid	 sequence	 determined	 by	 sequencing	 would	 alter	 DNA	 binding	specificity	so	that	the	right	TALEN	would	recognize	a	different	sequence.		In	this	section,	I	have	shown	that	the	left	TALEN	was	successfully	assembled	with	no	mutations	 that	 would	 have	 an	 effect	 on	 binding	 specificity.	 However,	 the	 right	TALEN	has	alterations	in	amino	acid	sequence	within	the	final	hexamer	compared	to	the	designed	TALEN,	which	one	would	expect	to	alter	DNA	binding.	
	




NG	 NG	 NN	 (NG)	
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210	
6.6.1 Possible	sources	of	mutations	in	the	constructed	custom	TALENs		
Step	in	Protocol	 Possible	Event	Plasmids	supplied	with	TALE	toolkit	 The	monomer	and	TALEN	cloning	backbone	plasmids	provided	in	the	kit	may	have	already	contained	mutations	Monomer	Library	Construction	 Use	of	Phusion	DNA	polymerase	instead	of	herculase-	less	proof-reading	activity	Hexamer	Assembly	 Human	error-	used	wrong	monomers	during	assembly?	Hexamer	Amplification	 Used	Herculase	II	DNA	polymerase-	should	have	better	proofreading.	But	did	many	cycles	of	PCR	=	more	chance	to	introduce	mutation.	Gel	extraction	 Used	a	standard	EtBr	agarose	gel-	EtBr	may	introduce	mutations	and	UV	used	to	visualise	the	DNA	bands	on	the	gel	may	also	introduce	mutations.	Cloning	in	bacteria	 Repetitive	nature	of	DNA	binding	domain	sequence	and	GC	content	contributed	to	structural	plasmid	instability	during	cloning	in	E.	coli.	
	
Table	24.	Summary	of	the	possible	source	of	mutations	in	the	Right	TALEN	and	when	
they	 could	have	 occurred.	Left	column	states	the	step	 in	the	protocol	 in	which	mutation	could	have	taken	place.	Right	column	states	what	could	have	happened	in	that	step	in	order	to	introduce	a	mutation.		Once	the	TALENs	were	constructed,	sequencing	showed	that	the	left	TALEN	had	the	correct	amino	acid	sequence,	so	it	should	successfully	bind	to	the	appropriate	region	of	 DNA	 in	 the	 CLN2	 gene	 to	 facilitate	 cutting.	 However,	 the	 right	 TALEN	 protein	contained	 amino	 acid	 changes	 in	 the	 RVD,	 which	 would	 alter	 the	 specificity	 of	binding	 of	 the	 constructed	 TALEN	 protein	 and	 as	 such	 the	 right	 TALEN	 protein	would	 probably	 not	 bind	 to	 the	 appropriate	 region	 of	 DNA	 in	 the	 CLN2	 gene	 to	
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facilitate	cutting.	These	mutations	may	have	plausibly	happened	at	several	points	in	the	construction	of	the	TALENs	(Table	23).		
a.	In	the	plasmids	themselves	There	 may	 have	 been	 errors	 in	 the	 monomer	 and	 plasmid	 cloning	 backbone	plasmids	in	the	original	TALE	toolbox	kit.	This	seems	unlikely	as	there	were	so	few	translated	 errors	 in	 the	 left	 TALEN,	 one	would	 expect	 that	mutagenesis	 occurred	during	construction	of	the	TALENs.	
	
b.	In	the	monomer	library	construction	During	 monomer	 construction,	 we	 used	 Phusion®	 DNA	 polymerase	 with	 many	cycles	 of	 PCR	 (35)	 in	 order	 to	 achieve	 sufficient	 yields	 of	 DNA	 from	 the	 difficult	template.	 Increasing	 the	number	of	PCR	 cycles	 increases	 the	 likelihood	of	 random	mutations	arising	during	amplification.	In	the	case	of	the	third	hexamer	in	the	right	TALEN,	 there	 is	 a	mutation	 in	 the	 fourth	monomer	 of	 this	 last	 hexamer,	 the	 RVD	should	be	NG	but	instead	is	HD.		However,	the	RVD	of	the	fourth	monomer	of	the	last	hexamer	should	also	be	NG	and	thus	uses	the	same	monomer.	In	the	left	TALEN	this	monomer	is	not	mutated,	therefore	at	least	for	this	monomer	the	mutation	was	not	introduced	during	the	construction	of	the	monomer	library.		
	
c.	Hexamer	amplification	Mutations	 could	 also	 have	 been	 introduced	 during	 hexamer	 amplification.	 Our	choice	of	DNA	polymerase	in	combination	with	the	high	number	of	PCR	cycles	may	have	introduced	mutations	 into	the	TALEN	sequence.	Both	Phusion®	and	Herculase	II	 are	 Fusion	 DNA	 polymerases	 (Bohlke	 et	 al.,	 2000).	 Fusion	 DNA	 polymerases	generally	employ	a	DNA	binding	domain	to	enhance	processivity,	which	is	fused	to	a	5’	to	3’	DNA	polymerase	(Hogrefe	et	al.,	2002).	The	DNA	binding	domain	anchors	the	DNA	 polymerase	 on	 the	 DNA	 preventing	 early	 dissociation	 from	 the	 DNA	polymerase.	The	choice	of	polymerase	enzyme	is	dependent	on	the	application	but	both	Phusion®	and	Herculase	II	have	polymerases	with	3’	to	5’	exonuclease	activity	to	 increase	 proofreading	 capabilities.	 However,	 this	 3’	 to	 5’	 exonuclease	 activity,	which	decreases	 the	 chance	of	 random	mutagenesis	 in	 low	number	of	PCR	 cycles,	may	actually	be	 a	 source	of	mutations	 as	 the	number	of	 cycles	 increases,	 as	 I	will	now	explain.	
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During	amplification	of	the	hexamers,	we	used	a	very	high	number	of	cycles	in	order	to	increase	the	poor	DNA	yield	seen	following	gel	extraction.	A	high	number	of	PCR	cycles	 is	 reported	 to	 dramatically	 decrease	 the	 cloning	 efficiency	 of	 PCR	 products	generated	 by	 high	 fidelity	 enzymes,	 such	 as	 Herculase	 II	 used	 in	 the	 hexamer	amplification	 (Li	 et	 al.,	 2011).	 These	 authors	 propose	 that	 proofreading	 DNA	polymerases	 may	 damage	 the	 ends	 of	 PCR	 products	 as	 the	 number	 of	 cycles	increases.	This	could	be	due	to	high	fidelity	enzymes	having	3’	exonuclease	activity.	In	 the	 early	 cycles	 of	 PCR,	 the	 ends	 of	 the	 PCR	 product	 are	 protected	 from	 3’	exonuclease	 activity	 by	 free	 dNTPs.	 The	 number	 of	 free	 dNTPs	 decreases	 as	 the	number	 of	 PCR	 cycles	 increases,	 leaving	 the	 ends	 of	 the	 PCR	 products	 open	 to	damage.	 The	herculase	 II	DNA	polymerase	used	 for	 amplification	 of	 the	hexamers	has	 3’	 exonuclease	 activity	 and	was	 used	 for	 35	 cycles.	 This	means	 the	mutations	seen	 in	 the	 ends	 of	 the	 hexamers	 in	 both	 left	 and	 right	 TALENs	 may	 not	 all	 be	artefacts	of	sequencing	but	may	be	caused	by	damaging	3’	exonuclease	activity.	If	I	were	to	repeat	the	construction	of	TALENs	I	would	use	a	lower	number	of	cycles	to	reduce	the	probability	of	random	mutagenesis	and	damage	to	the	ends	of	the	PCR	products	 induced	 by	 the	 3’	 to	 5’	 exonuclease	 activity	 in	 the	 later	 cycles.	 The	decreased	yield	could	be	dealt	with	by	optimising	the	gel	extraction	process	further	(see	below).		
d.	Gel	extraction	The	next	stage	in	which	mutations	could	have	been	introduced	into	the	constructed	TALENs	 is	 during	 purification	 of	 the	 amplified	 hexamers	 by	 gel	 extraction.	When	purifying	 these	 fragments,	 I	 initially	 tried	 an	 approach	 using	 visible	 light	 and	running	the	DNA	fragments	on	a	crystal	violet	gel.	The	advantage	of	this	strategy	is	that	it	does	not	use	UV	light	and	is	therefore	unlikely	to	introduce	mutations	into	the	amplified	hexamers.	However,	this	approach	did	not	yield	sufficient	DNA	following	gel	extraction	and	I	was	forced	to	use	a	traditional	ethidium	bromide	(EtBr)	agarose	gel	 visualised	 by	 UV	 light.	 As	 such,	 it	 is	 possible	 that	 mutations	 were	 introduced	when	 the	DNA	 fragments	were	exposed	 to	UV	during	gel	 extraction	 (Gründemann	and	Schömig,	1996).	Care	was	 taken	 to	 turn	off	 the	UV	source	as	often	as	possible	during	the	extraction	process	in	order	to	reduce	the	UV	exposure	time;	nevertheless,	UV	exposure	is	a	possible	source	of	mutation	in	our	assembled	TALENs.		If	 the	construction	of	TALENs	were	repeated	I	would	attempt	to	visualise	the	DNA	fragments	 by	 using	 SYBR	 SAFE	 dye	 and	 using	 visible	 light	 rather	 than	 with	
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traditional	EtBr	and	UV	light.	SYBR	SAFE	is	an	asymmetric	cyanine	dye,	which	binds	to	nucleic	acids	and	has	been	shown	to	be	significantly	less	mutagenic	than	EtBr	in	agarose	 gel	 electrophoresis	 (Singer	 et	 al.,	 1999).	 If	 the	 SYBR	 SAFE	 approach	 was	unsuccessful	as	with	our	other	attempt	to	extract	the	DNA	using	a	system	employing	visible	light,	I	would	modify	the	EtBr	protocol	to	reduce	the	chance	of	mutation	and	increase	yield.	This	could	be	achieved	by	not	casting	the	gel	with	EtBr	as	 I	did	but	only	staining	afterwards	with	EtBr	and	including	1	mM	cytosine	or	guanosine	to	the	gel	 and	 electrophoresis	 buffer,	 which	 should	 protect	 the	 DNA	 against	 UV-induced	damage	(Gründemann	and	Schömig,	1996,	Smith,	1980).			
d.	Cloning	in	bacteria		Another	 possibility	 is	 that	 mutations	 were	 introduced	 during	 the	 cloning	 of	 the	TALENs	in	E.coli	cells.	Structural	plasmid	stability	refers	to	when	all	 the	generated	plasmids	have	the	correct	base	sequence	(Friehs,	2004).	Plasmid	instability	is	more	likely	when	the	recombination	potential	of	sequences	present	in	the	plasmid	is	high,	such	 as	 in	 the	 DNA	 binding	 domain	 of	 the	 constructed	 TALENs	 (Corchero	 and	Villaverde,	1998).	Indeed,	plasmid	instability	has	been	shown	to	be	associated	with	multiple	 repeats	 (Bichara	 et	 al.,	 1999).	 It	 is	 possible	 that	 the	 repeated	monomers	high	 level	 of	 homology	 with	 each	 other	 have	 resulted	 in	 them	 rearranging	 and	changing	 the	 monomer	 order.	 Unfortunately,	 I	 do	 not	 have	 the	 full	 translation	readout	 as	 the	 sequencing	 did	 not	 return	 reliable	 sequence	 data	 that	 was	 long	enough	 to	 deduce	 the	 sequence	 of	 the	 whole	 hexamers.	 As	 such,	 it	 is	 not	 clear	whether	 the	 correct	 monomers	 were	 ligated	 together	 but	 were	 rearranged	 via	recombination	 events	 resulting	 in	 the	 incorrect	 order	 of	monomers.	Nevertheless,	the	 repeated	 sequences	 within	 the	 constructed	 TALEN	 plasmids	 may	 make	 them	unstable	during	replication	within	E.coli.		In	 addition,	 GC-rich	 regions	 of	 DNA	 called	 CpG	 islands	 may	 also	 be	 a	 source	 of	plasmid	instability	during	cloning	in	E.coli	cells.	Analysis	of	the	constructed	TALEN	sequence	 with	 the	 Sequence	 Manipulation	 Suite	(http://www.bioinformatics.org/sms2/reference.html),	 (Stothard,	 2000,	 Gardiner-Garden	and	Frommer,	 1987)	 revealed	 that	 there	 are	many	CpG	 islands	within	 the	DNA	 binding	 domain	 and	 TALEN	 cloning	 plasmid	 backbone.	 In	 GC-rich	 regions,	three	hydrogen	bonds	between	C	and	G	nucleotides	results	in	stronger	bonding	than	the	two	hydrogen	bonds	between	A	and	T	nucleotides.	Plasmid	replication	requires	
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unwinding	of	 the	DNA	 strands	 and	will	 be	 slowed	down	by	 the	GC-rich	 segments.	This	 slowing	 down	 may	 result	 in	 counter-selection	 against	 the	 GC-rich	 DNA	segments	 resulting	 in	 plasmid	 instability	 (Al-Allaf	 et	 al.,	 2013).	 Consequently,	 the	GC-rich	 nature	 of	 the	 TALEN	 sequence	 is	 another	 property	 that	 may	 make	 the	constructed	 TALEN	 plasmids	 more	 prone	 to	 instability.	 However,	 Al-Allaf	 et	 al.,	(2013)	found	that	an	instability-prone	plasmid	was	most	successfully	propagated	in	Stbl3	cells,	which	is	the	E.coli	strain	I	used	to	clone	the	constructed	TALEN	plasmids.	This	may	be	because	Stbl3	cells	contain	a	mutation	in	the	recA	gene,	which	codes	an	homology	dependent	DNA	strand	transferase.	RecA	is	reported	to	be	responsible	for	recombination	 errors	 within	 other	 E.coli	 strains,	 leading	 to	 plasmid	 DNA	rearrangements	 (Kowalczykowski,	 1991).	 Propagation	 of	 our	 TALEN	 plasmids	 in	
Stbl3	 cells	 should	have	minimised	 the	probability	of	 recombination	events	despite	the	repetitive	sequences	present	in	the	DNA	binding	domain.		If	 I	were	 to	construct	 the	TALENs	again,	different	E.coli	strains	could	be	 trialled	 in	order	 to	 assess	 which	 strains	 confer	 increased	 stability	 to	 the	 assembled	 TALEN	constructs.	 In	 addition,	 a	 lower	 cultivation	 temperature	 could	 be	 tested	 as	 lower	growth	 temperatures	 reportedly	 increase	plasmid	 stability	presumably	because	of	the	reduced	rate	of	bacterial	growth	(Liao,	1991).	
	
e.	Human	error	A	final	source	of	the	mutations	seen	in	the	third	hexamer	of	the	right	TALEN	could	have	been	due	to	the	wrong	monomers	being	pipetted	in	during	hexamer	assembly.	For	this	to	be	the	case,	monomers	with	the	correct	 ligation	adaptors	(i.e.	amplified	with	the	same	primers	in	the	monomer	library)	but	incorrect	RVD	would	have	had	to	be	chosen.	In	addition,	this	explanation	would	also	suggest	that	the	hexamers	for	the	right	TALEN	were	ligated	into	the	wrong	backbone	during	assembly.	While	this	is	 undoubtedly	 possible	 as	 the	 monomer	 library	 is	 labelled	 with	 names	 that	understandably	 look	 very	 similar,	 the	 utmost	 care	 was	 taken	 to	 use	 the	 correct	monomers	 while	 double-checking	 with	 the	 TALEN	 design	 and	 ticking	 off	 each	individual	monomer	 as	 it	was	 added	 to	 the	 reaction.	 It	 seems	 unlikely	with	 these	quality	 checks	 that	 the	 same	 mistake	 would	 be	 made	 three	 times.	 Nevertheless,	human	error	provides	a	convenient	explanation	as	to	the	source	of	the	mutations	as	the	 RVD	 would	 be	 the	 only	 thing	 different	 between	 these	 monomers,	 if	 another	monomer	with	the	correct	ligation	adaptors	was	incorporated	instead.		
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However,	 anecdotal	 evidence	 suggests	 that	 the	 RVD	 is	 most	 susceptible	 to	 point	mutations	 during	 assembly	 of	 custom	TALENs	using	 the	 Sanjana	protocol	 and	 the	TALE	 Toolbox	 Kit	 (TAL	 Effectors	 Discussion	 Forum,	https://groups.google.com/forum/#!topic/taleffectors/VALJZnEphR8).	 The	 RVD	may	be	more	vulnerable	to	any	of	the	mutation	inducing	scenarios	explored	above	(too	many	 PCR	 cycles,	 choice	 of	 DNA	 polymerase,	 UV	 exposure,	 propagation	 in	E.	
coli).	Several	research	groups	in	the	TAL	Effectors	Discussion	Forum	have	suggested	that	 rather	 than	 the	RVD	being	specifically	mutated	 the	monomers	have	 ligated	 in	the	incorrect	order	in	their	TALENs,	which	would	certainly	fit	the	sequencing	results	of	the	right	TALEN.	As	was	seen	in	the	hexamer	ligation,	it	seems	that	it	is	certainly	possible	 that	 the	 specific	 ligation	 adapters	 are	 capable	 of	 incorrectly	 ligating	 and	thus	 producing	 monomers	 assembled	 in	 the	 wrong	 order.	 Either	 of	 these	explanations	 could	 explain	 the	 altered	 RVD	 region	 of	 the	 monomers	 in	 the	 right	TALEN.	Although	 human	 error	 is	 certainly	 a	 possible	 source	 of	 the	mutations	 seen	 in	 the	internal	monomers	of	the	right	TALEN,	mis-assembly	of	the	monomers	 is	arguably	as	 likely	 given	 that	 I	 observed	 this	 property	 of	 the	monomers	 in	 earlier	 stages	 of	TALEN	construction.	
	
6.6.2 Recent	Advancements	in	Constructing	TALENs	Since	 I	 attempted	 to	 construct	 custom	 TALENs,	 a	 number	 of	 advancements	 have	been	made.	A	novel	RVD	has	been	described	with	increased	specificity	for	guanine.	When	 the	RVD	of	 the	monomer	 is	 asparagine	and	histidine,	NH,	 the	 specificity	 for	guanine	is	higher	than	that	of	the	NN	monomer	that	was	previously	available	(Cong	et	 al.,	 2012).	 With	 our	 GC-rich	 target	 sequence,	 I	 would	 expect	 that	 TALENs	constructed	 with	 the	 NH	 monomer	 would	 have	 a	 better	 binding	 affinity	 and	specificity	 than	 the	 TALEN	 design	 I	 constructed.	 In	 addition,	 when	 designing	 the	TALENs	 I	 used	 the	 default	 spacer	 length	 that	 the	 TALE-NT	 software	 suggested,	which	was	19-30	bp	at	 the	 time	of	conducting	 these	studies	 (Cermak	et	al.,	2011).	The	 only	 TALEN	 pair	 the	 TALE-NT	 software	 suggested	 would	 cut	 directly	 at	 the	desired	site	of	mutation	in	the	CLN2	gene	had	a	spacer	length	of	30	bp	and	therefore	I	chose	this	TALEN	design.	In	fact,	it	is	now	apparent	that	the	spacer	length	is	very	important	 when	 designing	 TALENs.	 TALEN	 pairs	 have	 optimal	 spacer	 lengths	depending	on	the	sequence	that	they	are	targeting	(Lin	et	al.,	2014).	Christian	et	al.,	(2010)	showed	that	most	TALEN	pairs	have	an	optimal	spacer	length	between	15-24	
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bp,	however	one	TALEN	pair	examined	would	still	cut	with	a	spacer	length	of	30	bp	(Christian	et	al.,	2010).	More	recently,	Lin	et	al.,	 (2014)	evaluated	37	TALEN	pairs,	separated	by	spacers	of	15-30	bp	and	found	no	detectable	gene	modification	activity	in	TALENs	with	spacers	 less	than	14	bp	or	greater	than	19	bp	 in	 length	(Lin	et	al.,	2014).	 Taken	 together	 this	 more	 recent	 evidence	 suggests	 that	 even	 if	 the	constructed	TALENs	had	the	correct	sequence,	they	still	may	not	have	cut.		







In	 this	 Chapter	 I	 will	 describe	 how	 an	 alternative	 strategy	 to	 produce	 TALENs	 to	target	the	CLN2	gene	was	initiated	with	a	commercial	company	in	order	to	introduce	a	 late	 infantile	CLN2	disease-causing	mutation,	 into	human	neural	progenitor	cells		(hNPCs).	 I	will	 then	 describe	 the	 attempt	 to	 produce	 a	 clonal	 cell	 line	 of	mutated	cells	and	the	barriers	that	need	to	be	overcome	to	achieve	this.	
	
7.1 Methodology	
7.1.1 CLN2	 mutation	 profile	 and	 Production	 of	 TALENs	 from	 Cellectis	
Bioresearch	






and	 proposed	 TALEN	 binding	 sites.	 Exons	 are	 in	upper	 case;	 introns	 are	 in	 lower	 case.	Bold	 italic	denotes	splice	 junction.	Pink	shows	the	nucleotide	which	when	mutated	causes	splice	mutation,	 intron	 5	 (c.509-1G>C).	 Green	 shows	 the	 nucleotide	which	when	mutated	causes	 premature	 stop	 codon,	 C3670T,	 (Arg208X).	 Both	 are	 late	 infantile	 CLN2	 disease	causing	mutations.	Left	TALEN	is	in	red,	right	TALEN	is	in	blue.	The	TALEN	which	binds	in	the	intron	is	most	suited	to	introducing	c.509-1G>C;	the	TALEN	which	binds	in	the	exon	is	most	suited	to	introducing	C3670T	(Arg208X).		
7.1.2 Checking	for	single	nucleotide	polymorphisms	In	order	to	check	that	there	were	no	single	nucleotide	polymorphisms	(SNPs)	in	the	region	of	interest	within	CLN2,	which	could	alter	binding	of	the	TALENs,	I	needed	to	obtain	 genomic	 sequencing	 data	 from	 200	 nucleotides	 (nt)	 upstream	 and	downstream	 from	 the	 intended	 site	 of	 each	 mutation	 in	 the	 cell	 type	 that	 the	targeting	 would	 occur.	 As	 such,	 CTXOE16/02	 cells	 were	 grown	 to	 confluency	 as	described	 in	 section	 7.1.6	 of	 this	 Chapter	 and	 then	 the	 genomic	DNA	 (gDNA)	was	extracted	 using	 the	 phenol/chloroform	extraction	method	 (Sambrook	 and	Russell,	2006).	The	gDNA	was	then	sequenced	in	the	region	of	interest	within	the	CLN2	gene	using	 the	 BigDye	 Terminator	 v3.1	 Cycle	 Sequencing	 Kit	 (Applied	 Biosciences:	
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4337455),	 the	 sequencing	 primers	 (CLN2	 FWD,	 CLN2	REV,	 see	 appendix	 1.1)	 and	the	 reactions	 were	 run	 on	 a	 Beckman	 Coulter	 CEQ8000	 genetic	 analysis	 system	(Beckman	Coulter,	High	Wycombe,	UK).	 The	DNA	 sequencing	 results	were	 sent	 to	
Cellectis	 Bioresearch	 along	 with	 the	 mutation	 profile	 of	 the	 CLN2	 disease-causing	mutations	(Figure	57).	The	company	used	this	information	to	generate	TALENs	that	should	cut	as	close	as	possible	to	the	intended	mutations	(Figure	57).		
7.1.3 Amplification	of	TALEN	plasmid	DNA	The	TALENs	were	provided	as	plasmids,	 (5	μg	of	 each	 at	1	μg/μl).	To	 amplify	 the	TALENS,	 Max	 efficiency	 DH5α	 cells	 (Invitrogen:	 18258-012)	 (Wang	 et	 al.,	 2001,	Wang	 and	Wilkinson,	 2000)	were	 transformed	with	 5	 ng	 of	 TALEN	 plasmid	DNA,	according	 to	 manufacturer’s	 instructions	 and	 spread	 onto	 LB	 agar	 plates	 with	ampicillin	 to	 select	 for	 transformants	 (100	 μg/ml)	 and	 grown	 overnight	 in	 an	incubator	at	37°C,	5%	CO2.	 Individual	 colonies	were	picked	and	grown	 in	4	ml	LB	broth	with	ampicillin	 (100	μg/ml,)	 for	8	hours	 in	a	shaking	 incubator	at	37°C,	5%	CO2.	 100	 μl	 of	 this	 starter	 culture	 was	 then	 diluted	 in	 100	 ml	 of	 LB	 broth	 with	ampicillin	 (100	 μg/ml)	 and	 grown	 in	 a	 shaking	 incubator	 at	 37°C,	 5%	CO2	 for	 16	hours.	 The	 TALEN	 plasmid	 DNA	 was	 then	 extracted	 using	 PureYield™	 Plasmid	
Maxiprep	System	(Promega:	A2392)	according	to	manufacturers	instructions.	
	
7.1.4 Design	and	production	of	Donor	Matrix	As	 outlined	 in	 Chapter	 6,	 section	 6.2,	 homologous	 recombination	 can	 be	 used	 to	integrate	 or	 replace	 genomic	 sequences	 in	 many	 cell	 types	 (Capecchi,	 2005,	Capecchi,	2001,	Thomas	and	Capecchi,	1987,	Smithies,	2001).	Introducing	a	double-stranded	break	(DSB)	at	the	targeted	locus	can	enhance	the	efficiency	of	homologous	recombination	(Liang	et	al.,	1998,	Richardson	et	al.,	1998).	DSBs	can	be	introduced	by	sequence-specific	endonucleases	as	described	in	Chapter	6.2.	Cellectis	Bioresearch	recommended	 that	 the	 DSB	 occurs	 as	 close	 as	 possible	 to	 the	 point	 where	 the	nucleotide	 substitution	 will	 take	 place,	 as	 it	 has	 been	 shown	 that	 nucleotide	substitution	 efficiency	drops	by	20%	when	 the	DSB	occurs	260	bp	away	 from	 the	substitution	site	(Thomas	and	Capecchi,	1987).		As	such,	a	TALEN	which	binds	in	the	intron	 is	most	suited	 to	 introducing	 the	mis-splicing-causing	mutation,	c.509-1G>C	and	the	TALEN	which	binds	in	the	exon	is	most	suited	to	introducing	the	premature	stop	 codon	 causing	 mutation,	 C3670T	 (Arg208X)	 (Figure	 57).	 However,	 either	
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TALEN	 pair	 could	 in	 theory	 be	 used	 to	 introduce	 either	mutation	 or	 in	 fact	 both	mutations	by	the	design	of	the	donor	matrix	(Figure	58).				
	
Figure	58	The	function	of	a	donor	matrix.	The	custom	TALENs	bind	and	cleave	the	CLN2	gene	 around	 the	 locus	 of	 the	 desired	 mutation	 and	 introduce	 a	 double-stranded	 break	(DSB).	 The	DSB	 increases	 the	 frequency	 of	 homologous	 recombination	 between	 the	CLN2	gene	 and	 the	 donor	matrix,	 a	 plasmid	 containing	 the	 desired	 late	 infantile	 CLN2	 disease-causing	mutation	 flanked	 by	 regions	 homologous	 to	 the	 targeted	 genomic	 sequence.	 The	donor	matrix	also	includes	silent	mutations,	which	prevent	it	from	also	being	cleaved	by	the	TALENs.	As	a	result,	the	DNA	sequence	bearing	the	nucleotide	substitution	is	incorporated	into	the	CLN2	gene.	
	






Figure	 59	 shows	 the	 design	 for	 the	 donor	 matrix	 to	 introduce	 the	 mis-splicing-causing	mutation,	c.509-1G>C	into	the	human	CLN2	gene.	The	G	at	position	c.509-1	is	 substituted	 for	 a	C,	 introducing	 the	CLN2	disease-causing	mutation.	 In	 addition,	the	T	at	the	beginning	of	the	left	TALEN-binding	site	has	been	substituted	for	a	G	so	that	 the	 left	 TALEN	 will	 no	 longer	 bind,	 and	 the	 T	 at	 the	 beginning	 of	 the	 right	TALEN	binding	site	has	been	substituted	for	a	C	so	the	right	TALEN	will	no	 longer	bind.	 Two	 more	 silent	 mutations	 have	 been	 included	 in	 order	 to	 introduce	 a	restriction	site	for	the	enzyme	StuI,	which	will	be	used	for	screening	purposes.			
	
Figure	59	Design	of	“Splice	donor	matrix”	to	introduce	the	mis-splicing	Late	Infantile	
CLN2	disease-causing	mutation,	c.509-1G>C	into	CLN2.	Exons	are	in	upper	case;	introns	are	 in	 lower	 case	 and	 bold.	 Bold	 italic	 denotes	 splice	 junction.	 Pink	 shows	 the	 nucleotide	which	 when	mutated	 causes	 splice	mutation,	 intron	 5	 c.509-1G>C.	 Orange	 denotes	 silent	mutations	that	prevent	the	TALENs	binding	and	cleaving,	the	T	at	the	beginning	of	the	left	TALEN-binding	 site	 has	 been	 substituted	 for	 a	 G,	 and	 the	 T	 at	 the	 beginning	 of	 the	 right	TALEN	binding	site	has	been	substituted	for	a	C.	The	restriction	site	for	screening	purposes	is	underlined	in	purple;	AggC	is	a	restriction	site	for	StuI.		
b.	Donor	matrix	design	to	introduce	C3670T	mutation	





Figure	 60	 Design	 of	 “Stop	 Codon	 donor	 matrix”	 to	 introduce	 the	 premature	 stop	
codon	 late	 infantile	 CLN2	 disease-causing	 mutation,	 C3670T,	 (Arg208X)	 into	 CLN2.	Exons	 are	 in	 upper	 case;	 introns	 are	 in	 lower	 case	 and	 bold.	 Bold	 italic	 denotes	 splice	junction.	 Green	 shows	 the	 nucleotide	which	when	mutated	 causes	 premature	 stop	 codon,	C3670T,	(Arg208X).	Orange	denotes	silent	mutations	that	prevent	the	TALENs	binding	and	cleaving,	the	T	at	the	beginning	of	the	left	TALEN-binding	site	has	been	substituted	for	a	G,	and	a	G	within	the	right	TALEN	binding	site	has	been	substituted	for	an	A.	The	restriction	site	for	screening	purposes	is	underlined	in	purple;	ggacC	is	a	restriction	site	for	AvaII.	
	
c.	Construction	of	donor	matrices	The	 efficiency	 of	 cutting	 varies	 for	 different	 TALENs	 and	 cell	 types	 (Hendel	 et	 al.,	2014).	As	such,	 I	 chose	 to	 introduce	both	 the	different	 late	 infantile	CLN2	disease-causing	 mutations	 separately	 using	 each	 TALEN	 pair	 with	 the	 respective	 donor	matrix.	As	explained	above,	 the	TALEN	that	will	bind	 in	 the	exon	 is	most	suited	to	introducing	the	mis-splicing	mutation,	c.509-1	G<C,	and	hence	would	be	used	with	the	donor	matrix	in	Figure	59.	So	this	TALEN	pair	will	be	referred	to	as	the	“Splice	
TALENs”	 and	 the	 corresponding	 donor	 matrix	 as	 “Splice	 donor	 matrix”.	 The	TALEN	 that	 binds	 in	 the	 intron	 is	most	 suited	 to	 introducing	 the	 premature	 stop	codon	mutation,	C3670T,	and	hence	would	be	used	with	the	donor	matrix	in	Figure	
60.	 So	 this	 TALEN	 pair	will	 be	 referred	 to	 as	 the	 “Stop	 Codon	 TALENs”	 and	 the	“Stop	 Codon	 donor	 matrix”.	 The	 nucleotide	 (nt)	 sequence	 for	 the	 “splice	 donor	matrix”	and	the	“stop	codon	donor	matrix”	 flanked	by	homology	arms	of	sequence	from	 200	 nt	 upstream	 and	 200	 nt	 downstream	 of	 the	 mutation	 site	 (taken	 from	CTXOE16/02	cells)	was	ordered	through	the	Gene	synthesis	service	from	GeneWiz,	cloned	 into	 the	 pUC57-Amp	 vector	 (GeneWiz,	 London,	 UK).	 The	 donor	 matrices	sequence	were	cloned	into	the	multiple	cloning	site	(MCS)	using	BamHI	downstream	
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of	 EcoRI,	 which	 can	 be	 used	 to	 linearise	 the	 vector,	 in	 the	 direction	 of	 EcoRI	 to	
HindIII	(Figure	61).		
	
Figure	 61	 Map	 of	 Donor	 Matrix	 Vector.	 The	 nucleotide	 sequence	 for	 the	 “splice	 donor	matrix”	and	the	“stop	codon	donor	matrix”	flanked	by	homology	arms	of	sequence	from	200	nt	 upstream	 and	 200	 nt	 downstream	 of	 the	 mutation	 site	 (in	 grey)	 was	 cloned	 into	 the	pUC57-Amp	vector,	which	has	ampicillin	 resistance	 (green).	The	donor	matrices	sequence	were	cloned	into	the	multiple	cloning	site	(MCS)	using	BamHI	downstream	of	EcoRI,	which	can	 be	 used	 to	 linearise	 the	 vector,	 in	 the	 direction	 of	 EcoRI	 to	 HindIII.	 Only	 relevant	restriction	 enzyme	 sites	 are	 shown.	Vector	map	produced	using	SnapGene	Software	(from	GSL	Biotech;	available	at	snapgene.com)		
7.1.5 Transfection	of	the	Donor	Matrix	vector	into	CTXOE16/02	cells	The	conditionally	immortalized	multipotent	human	fetal	cortical	progenitor	cell	line	CTXOE16/02	 (provided	 by	 ReNeuron	 Ltd,	 UK)	was	 used	 for	 these	 experiments,	 it	was	 chosen	 because	 there	 are	 robust	 protocols	 in	 place	 for	 its	 maintenance	 and	differentiation	within	the	laboratory,	which	will	facilitate	downstream	experiments.	CTXOE16/02	is	a	conditionally	immortalized	cell	line	using	c-mycERTAM	technology	(Littlewood	et	al.,	1995).	The	c-myc	proto-oncogene	has	been	used	to	promote	tissue	culture	 expansion	 of	 hNSCs	 whilst	 maintaining	 a	 normal	 karyotype	 (Ryder	 et	 al.,	
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1990);	the	c-mycERTAM	transgene	is	useful	as	immortalization	of	cells	is	conditional	on	 the	presence	of	4-hydroxytamoxifen	 (4-OHT)	 (Stevanato	et	al.,	2009,	Pollock	et	al.,	 2006).	Clonal	 cell	 lines	 from	 the	developing	 foetal	human	cortex	were	 infected	with	an	amphotropic	replication-incompetent	retroviral	vector	(pLNCX-2,	Clontech,	Mountain	View,	CA,	USA)	encoding	the	c-mycERTAM	transgene	(Pollock	et	al.,	2006).	Thus,	 the	CTXOE16	cell	 line	will	 continuously	proliferate	 and	 remain	 stable	 in	 the	presence	of	4-OHT	due	to	the	ectopic	expression	of	the	c-mycERTAM	transgene.		
7.1.6 Neural	Progenitor	Cell	maintenance	CTXOE16/02	 cells	 were	 grown	 in	 Reduced	 Modified	 Medium	 (appendix	 1.5.1)	supplemented	with	human	FGF-basic	 (10	ng	ml-1),	human	EGF	(20	ng	ml-1)	and	4-OHT	(100	nM),	(RMM+++,	appendix	1.5.1).	Cells	were	seeded	from	frozen	aliquots	at	approximately	 6.5	 x	 104	 cells	 per	 cm2	 onto	 laminin	 (1.3	 μg/cm2,	 Sigma-Aldrich,	Gillingham,	UK)	coated	Nunc	Tissue	Culture	EasyFlasks™	(Nunc,	Rochester,	NY)	and	maintained	in	an	incubator	in	95%	air,	5%	CO2	at	37°C,	with	50%	of	medium	being	replaced	 with	 fresh	 medium	 every	 36	 hours.	 When	 the	 cells	 reached	 70-80%	confluence,	they	were	passaged	by	incubation	with	Accutase	(Sigma-Aldrich)	in	the	incubator	 in	95%	air,	5%	CO2	at	37°C	 for	3	 to	4	minutes.	The	detached	cells	were	then	 collected	 and	 diluted	 with	 non-supplemented	 GIBCO®	 Hank’s	 Basic	 Salt	Solution	 (HBSS)	 (Life	Technologies,	Paisley,	UK)	and	centrifuged	at	900	 rpm	 in	an	ALC	 PK130	 centrifuge	 equipped	 with	 a	 T535	 rotor	 (ALC,	 Cologno,	 Italy)	 for	 5	minutes	to	pellet	the	cells.	Cells	were	then	reseeded	at	approximately	3	x	104	cells	per	 cm2	 onto	 laminin	 (1.3	 μg/cm2,	 Sigma-Aldrich)	 coated	 Nunc	 Tissue	 Culture	EasyFlasks™	(Nunc).		
7.1.7 Nucleofection	of	TALENs	into	CTXOE16/02	cells		A	vial	of	frozen	passage	11	(p11)	CTXOE16/02	cells	were	thawed	and	plated	into	a	T75	flask	pre-coated	with	laminin	(1.3	μg/cm2,	Sigma)	as	described	in	section	7.1.6	above.	 The	 cells	 were	 passaged	 when	 the	 cells	 reached	 80%	 confluency.	 At	 80%	confluency,	 and	after	3	passages	 to	 allow	 the	 cells	 to	 re-adapt	 to	 culture,	 the	 cells	were	used	for	nucleofection.		I	chose	to	use	the	Human	Stem	Cell	Nucleofector®	Kit	(Lonza:	VVPH-5012)	and	the	Nucleofector™	 2b	 device	 (Lonza:	 AAB1-1001)	 to	 transfect	 the	 CTXOE16/02	 cells.	This	method	 for	 nucleofection	 is	 based	 on	 the	 protocol	 described	 by	 (Marchenko	and	 Flanagan,	 2007)	with	 a	 few	 crucial	 changes,	 described	 below.	 The	 day	 before	
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nucleofection,	T25	Nunc	Tissue	Culture	Easyflasks™	were	coated	with	 laminin	(1.3	μg/cm2,	Sigma)	and	left	in	the	incubator	in	95%	air,	5%	CO2	at	37°C.		On	 the	 day	 of	 nucleofection,	 the	 pre-prepared	 laminin-coated	 T25	 flasks	 were	washed	 once	 with	 HBSS.	 RMM+++	 medium	 further	 supplemented	 with	 the	 rho-asscoiated	protein	kinase	(ROCK)	inhibitor	Y-27632	dihydrochloride	(10	μm,	Sigma-Aldrich)	was	 then	added	and	 the	 flasks	put	back	 in	 the	 incubator	 ready	 to	 receive	the	 transfected	 cells.	 ROCK	 inhibitor	 was	 included	 in	 order	 to	 reduce	 apoptosis	following	transfection	(Watanabe	et	al.,	2007,	Kurosawa,	2012).		The	media	for	the	CTXOE16/02	cells	to	be	nucleofected	was	removed	and	replaced	with	warm	RMM+++/ROCK	media	and	the	cells	were	incubated	for	one	hour	in	95%	air,	5%	CO2	at	37	°C.	Cells	were	harvested	 from	flasks	using	accutase	as	described	above	and	nucleofected	one	at	a	time.	The	cells	were	then	collected	and	diluted	with	HBSS.	At	this	point,	a	sample	was	taken	and	the	number	of	cells	was	counted	using	a	haemocytometer.	The	volume	of	cell	suspension	was	calculated	so	as	to	collect	4	x	106	cells	in	total,	centrifuged	at	900	rpm	in	an	ALC	PK130	centrifuge	equipped	with	a	T535	rotor	(ALC,	Cologno,	 Italy)	 for	5	minutes	to	pellet	the	cells:	 this	quantity	of	cells	 is	 recommended	 by	 (Marchenko	 and	 Flanagan,	 2007).	 The	 pellet	 was	 then	carefully	resuspended	in	100	μl	room	temperature	nucleofection	solution	from	the	
Human	Stem	Cell	Nucleofector®	Kit	(Lonza),	transferred	to	a	sterile	1.5	ml	eppendorf	and	the	appropriate	amount	of	TALEN	or	control	DNA/mRNA	was	added.	This	was	mixed	by	gentle	pipetting	up	and	down	and	then	transferred	to	a	cuvette.	The	cells	were	 nucleofected	 using	 programme	 B-016	 on	 the	Nucleofector	 2b	 device	 (Lonza:	AAB1-1001)	 as	 this	 programme	was	 found	 to	 yield	 the	 highest	 transfection	 rates.	Following	 nucleofection,	 0.5	 ml	 warm	 RMM+++	 media	 was	 added	 to	 the	 cells	 in	order	to	return	the	cells	to	an	ambient	environment	as	quickly	as	possible	and	to	aid	in	removing	them	from	the	cuvette.	The	plastic	pipette	provided	in	the	nucleofection	kit	was	used	to	transfer	the	nucleofected	cells	into	the	pre-prepared	T25	flask.	The	nucleofected	 cells	 then	were	 immediately	 transferred	 to	 an	 incubator	 at	 95%	air,	5%	CO2	at	30	°C,	in	order	to	subject	them	to	cold	shock.	This	increases	the	level	of	stable	Zinc	finger	nuclease	induced	gene	disruption	(Doyon	et	al.,	2010).	The	next	day	the	media	was	replaced	to	remove	dead	cells,	with	fresh	RMM+++	supplemented	with	 ROCK	 (10	 μm,	 Sigma-Aldrich).	 Continuing	 with	 the	 cold	 shock	 method	proposed	 by	 Doyon	 et	 al.	 (2010),	 after	 a	 further	 3	 days	 at	 30	 °C	 the	 media	 was	replaced	with	fresh	RMM+++	and	the	cells	were	returned	to	the	37°C	incubator.	On	returning	the	cells	 to	37°C,	many	of	 the	cells	died,	 those	remaining	were	grown	to	
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confluency	before	being	passaged	 into	a	T75	 flask.	Once	confluent	half	of	 the	cells	were	 frozen	 while	 the	 other	 half	 was	 used	 for	 gDNA	 extraction.	 The	 gDNA	 was	extracted	 using	 phenol/chloroform	 with	 the	 aid	 of	 phase	 lock	 tubes	 (Fisher	Scientific:	FP2302810).		
	
7.1.8 Surveyor	 Nuclease	 Assay	 to	 assess	 Cutting	 Efficiency	 of	 Assembled	
TALENs	The	surveyor	nuclease	assay	 is	used	to	assess	whether	mutations	 in	the	DNA	have	taken	 place	 (Qiu	 et	 al.,	 2004).	 The	 surveyor	 nuclease	 is	 a	 member	 of	 the	 CEL-nuclease	 family,	 which	 are	 derived	 from	 celery	 (Yang	 et	 al.,	 2000).	 This	 group	 of	nucleases	 recognise	 and	 cleave	 many	 different	 types	 of	 mismatches	 that	 have	occurred	due	to	the	presence	of	single	nucleotide	polymorphisms	(SNPs)	and	from	small	insertions	or	deletions	(Pimkin	et	al.,	2007).	First,	the	sample	DNA	is	amplified	by	PCR	in	the	region	where	the	mutation	is	expected	to	be.		The	PCR	product	is	then	heated	at	high	temperature	to	denature	and	separate	the	DNA	strands.	The	strands	are	 then	 cooled	 gradually	 to	 allow	 the	 strands	 to	 reanneal.	 During	 this	 process,	 if	there	 are	 mutations	 present	 in	 the	 DNA,	 homoduplexes	 and	 heteroduplexes	 will	form	 and	 there	 will	 be	 mismatches	 at	 the	 point	 of	 the	 mutation	 when	 the	 DNA	strands	 reanneal	 with	 a	 non-mutated	 DNA	 strand	 (Shi	 et	 al.,	 2006,	 Pilato	 et	 al.,	2012).	 The	 surveyor	 nuclease	 is	 added	 and	 activated	 by	 heating	 to	 42°C.	 It	recognizes	 and	 cleaves	 the	 DNA	 at	 the	 sites	 of	 the	 mismatched	 base	 pairs.	 The	fragments	are	then	analysed	by	electrophoresis	on	an	agarose	gel	and	separated	by	size.	If	a	mutation	has	taken	place,	there	will	be	smaller	bands	corresponding	to	the	points	within	 the	PCR	product	where	 it	was	cleaved	by	 the	surveyor	nuclease	and	therefore	a	mutation	is	present	(see	Figure	62	for	a	schematic	representation).	To	 carry	 out	 the	 surveyor	 assay,	 I	 used	 the	 Surveyor®	 Mutation	 Detection	 Kit	(Transgenomic:	703060)	as	 to	manufacturers	guidelines.	PCR	was	used	 to	amplify	the	 region	of	 gDNA	250	bp	upstream	and	250	bp	downstream	of	 the	 c.509-1	G<C	mutation	 in	 the	CLN2	 gene	where	 the	TALENs	were	designed	 to	cut.	The	 template	was	gDNA	extracted	 from	 the	CTXOE16/02	cells	nucleofected	with	 the	TALENs	or	gDNA	from	non-nucleofected	CTXOE16/02	cells	as	a	control.	The	primers	used	were	
CLN2_FWD1	 and	 CLN2_REV1	 for	 amplification	 of	 gDNA	 from	 nucleofected	CTXOE16/02	cells	(or	untransfected	for	control).	The	same	PCR	was	used	to	amplify	control	 DNA	 supplied	 with	 the	 Surveyor	 Mutation	 Detection	 Kit	 and	 the	 primers	
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included	 as	well:	 Surveyor_FWD	and	 Surveyor_REV	 (See	 appendix	 1.1	 for	 primers	and	1.3	for	reagents	and	thermal	profile).			
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	The	 DNA	 mass	 of	 the	 PCR	 products	 was	 determined	 by	 gel	 electrophoresis	 as	described	in	Chapter	6,	section	6.4.5.	300	ng	of	PCR	product	per	sample	was	brought	to	a	total	volume	of	20	μl	with	Phusion®	HF	buffer	and	the	samples	were	heated	as	in	Table	 8,	 appendix	 1.3.	 The	 heat-treated	 PCR	 samples	 from	 CTXOE16/02	 cells	nucleofected	 with	 TALENs	 were	 then	 treated	 with	 Surveyor	 Nuclease	 S.	 It	 was	necessary	 to	 increase	 the	 concentration	 of	 Surveyor	 nuclease	 S	 and	 remove	 the	suggested	 MgCl2,	 in	 order	 to	 facilitate	 digestion	 in	 the	 Phusion®	 HF	 buffer.	 The	reagents	listed	in	Table	9,	appendix	1.3	were	mixed	on	ice	and	then	heated	at	42°C	for	one	hour,	 then	 the	 reaction	was	 stopped	by	 adding	1	μl	 of	 STOP	 solution.	The	cutting	 efficiency	 of	 the	 assembled	 TALENs,	 was	 then	 analysed	 by	 gel	electrophoresis	as	described	in	Chapter	6,	section	6.4.2.	
	
7.1.9 Establishing	a	clonal	line	Because	of	the	limited	growth	properties	of	the	CTXOE16/02	cells	(see	section	7.3.2	of	this	Chapter),	it	was	necessary	to	trial	different	techniques	in	order	to	encourage	single	cell	growth	to	produce	a	clonal	cell	line.			
a.	Limiting	dilution	In	 limiting	 dilution,	 a	 suspension	 of	 cells	 is	 distributed	 into	 96	 well	 plates	 in	 an	attempt	to	deposit	single	cells	into	individual	wells.	Cells	are	distributed	so	that	the	average	 number	 of	 cells	 is	 less	 than	 one	 per	 well	 (Coller	 and	 Coller,	 1986).	 This	results	in	some	wells	in	the	plate	that	have	a	single	cell,	many	empty	wells	and	some	wells	that	have	more	than	one	cell.	Depending	on	the	cleaving	efficacy	of	the	TALENs	the	formula	in	Figure	63	can	be	used	to	determine	the	number	of	clones	to	screen.	CTXOE16/02	cells	were	nucleofected	with	 left	and	right	TALENs	and	donor	matrix	as	described	in	section	7.1.7.	The	nucleofected	CTXOE16	cells	were	then	sequentially	diluted	 in	RMM+++	media	so	that	10	ml	contained	100	viable	cells.	The	60	central	well	 of	96	well	plates	were	 laminin-coated	 (1.3	μg/cm2	Sigma-Aldrich)	 and	 sterile	PBS	was	dispensed	into	the	outer	wells	to	maintain	humidity.	100	μl	of	nucleofected	cell	suspension	was	dispensed	 into	each	 laminin-coated	well	so	as	to	seed	one	cell	per	well,	with	10	plates	seeded	 in	total.	10	plates	with	60	wells	seeded	 is	equal	 to	600	wells.	If	37%	of	those	wells	have	at	least	one	cell	in	them	as	outlined	in	Figure	
64,	then	there	will	be	222	wells	with	cultures	(these	may	or	may	not	be	monoclonal-	see	 discussion	 in	 this	 Chapter).	 Not	 all	 of	 these	 cultures	 will	 be	 successfully	
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expanded,	 but	 one	would	 expect	 to	be	 able	 to	 screen	between	148	and	29	 clones,	which	 represents	 the	 number	 of	 clones	 needed	 to	 screen	 if	 our	 TALEN	 cutting	efficiency	 is	 between	 2	 and	 10%,	 respectively	 (Figure	 63).	 5	 seeded	 plates	were	placed	 at	 30°C	 for	 3	 days,	 and	 then	 37°C	 for	 7	 days	 (to	 recreate	 cold	 shock	conditions),	and	5	seeded	plates	were	placed	straight	at	37°C	and	these	plates	were	observed	 for	 the	 growth	 of	 clones.	 The	 two	 conditions	were	 to	 compare	whether	cold-shock	 treatment	 affect	 CTXOE16/02	 cell	 survival	 and	 whether	 it	 increases	TALEN	cutting	efficiency	in	these	cells.		
	
Figure	 63	 Formula	 explaining	 the	 number	 of	 clones	 to	 screen	 based	 on	 the	 TALEN	
cutting	 efficacy.	 The	 number	 of	 clones	 to	 screen	 increases	 as	 TALEN	 cutting	 efficiency	decreases.	
	
Figure	 64	 The	 poisson	 distribution	 for	 limiting	 dilution	 cloning.	 The	 poisson	distribution	 in	 this	context	can	be	used	to	determine	how	many	wells	will	contain	at	 least	one	cell.	For	derivation	(Staszewski,	1984,	Staszewski,	1990).	
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b.	Semi-solid	Cloning	Semi-solid	 cloning	 is	 an	 alternative	 method	 to	 limited	 dilution	 cloning,	 where	transfected	 cells	 are	 suspended	 in	 semi-solid	 cell	 culture	 medium	 (Caron	 et	 al.,	2009).	 Single	 cells	 are	 physically	 separated	 and	 immobolized	 within	 the	 viscous	medium,	allowing	discrete	monoclonal	colonies	to	grow	(Caron	et	al.,	2009,	Ito	et	al.,	1987).			A	 single	 cell	 suspension	 of	 CTXOE16/02	 cells	 nucleofected	 with	 left	 and	 right	TALENs	 and	 donor	 matrix	 as	 described	 in	 section	 7.1.7,	 were	 mixed	 with	 pre-warmed	 ClonaCell	 Flex	 Semi	 Solid	 Base	 medium	 (STEMCELL	 Technologies,	Vancouver,	Canada)	mixed	with	2X	concentrated	RMM+++	(see	appendix	1.5.1)	at	a	range	 between	 20	 and	 200	 cells/ml	 and	 shaken	 vigorously,	 as	 described	 in	 the	manufacturer’s	instructions.	The	semi-solid	medium	and	cell	suspension	was	left	to	settle	and	then	a	16	mm	guage	blunt	end	needle	(STEMCELL	Technologies)	was	used	to	dispense	2	ml	of	the	semi-solid	medium	and	cell	suspension	into	the	wells	of	non	tissue	culture	treated	6	well	plates	(Corning,	New	York,	USA),	leaving	one	well	free	for	 phosphate	 buffered	 saline	 (PBS)	 to	 keep	 the	 plate	 humidified	 and	 prevent	 the	semi-solid	suspension	from	drying	out.	The	plates	were	placed	at	37°C,	5%	CO2	for	8-12	days	without	being	disturbed	and	then	observed	for	colony	growth.			





a.	Restriction	digest	In	 order	 to	 determine	 which	 expanded	 clones	 contained	 the	 desired	 nucleotide	substitution,	 the	 gDNA	 was	 extracted	 from	 expanded	 cultures	 from	 individual	clones.	The	gDNA	was	amplified	 in	 the	region	of	 the	nucleotide	substitution	 in	 the	
CLN2	gene	using	Phusion	DNA	polymerase	(NEB:	MO5030L)	and	the	primers	(CLN2	FWD1,	CLN2	REV1,	appendix	1.1)	as	described	in	section	7.1.8.	A	restriction	digest	was	performed	using	StuI	(NEB:	R0187S)	to	screen	for	the	splice	donor	matrix,	on	1	μg	 amplified	 DNA	 at	 37	 °C	 for	 1	 hour	 according	 to	manufacturer’s	 guidelines.	 To	screen	 for	 the	 stop	 codon	 donor	 matrix,	 a	 restriction	 digest	 would	 have	 been	performed	using	AvaII	(NEB:	R0153),	on	1	μg	amplified	DNA	at	37°C	for	1	hour	as	to	manufacturer’s	guidelines.		A	 2%	 (wt/vol)	 agarose	 gel	 in	 1X	 TAE	 electrophoresis	 buffer	 with	 1%	 Ethidium	Bromide	was	cast	and	20	μl	of	the	restriction	digestion	product	was	run	along	with	E-gel	 low	range	quantitative	DNA	 ladder	 (Invitrogen,	UK)	The	gel	was	run	at	15	V	cm-1	and	imaged	using	VisionWorks	LS	software	(UVP,	Cambridge,	UK).	
	
b.	SNaPshot®	sequencing	As	 an	 additional	 screening	 method,	 SNaPshot®	 sequencing	 was	 used,	 which	 is	 a	method	to	interrogate	SNPs	at	known	locations	(Le	Hellard	et	al.,	2002).	In	this	case	the	 SNP	 is	 the	 nucleotide	 substitution	 in	 the	 CLN2	 gene	 introduced	 by	 the	 donor	matrix.	 This	 method	 is	 based	 on	 the	 dideoxy	 (dd)	 single-base	 extension	 of	 an	unlabelled	oligonucleotide	primer	(Le	Hellard	et	al.,	2002,	Norton	et	al.,	2002).	The	primer	binds	to	a	complementary	template	in	the	presence	of	fluorescently	labeled	ddNTPs	(which	will	not	extend)	and	DNA	polymerase.	The	polymerase	extends	the	primer	by	only	one	nucleotide,	adding	a	single	ddNTP	to	its	3´	end.	The	fluorescence	colour	readout	reports	the	base	that	was	added	to	the	end	of	the	primer	(Le	Hellard	et	al.,	2002,	Norton	et	al.,	2002).	
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The	gDNA	was	extracted	from	expanded	cultures	from	individual	clones.	The	gDNA	was	 amplified	 in	 the	 region	 of	 the	 nucleotide	 substitution	 in	 the	CLN2	 gene	 using	Phusion	 DNA	 polymerase	 (NEB:	 MO5030L),	 as	 described	 in	 section	 7.1.8	 for	 the	surveyor	 nuclease.	 In	 addition,	 two	 negative	 controls	 (no	 template	 or	 unmutated	CTXOE16/02	 gDNA	 as	 template)	 and	 a	 positive	 control	 (the	 splice	 donor	matrix)	were	included.	Only	the	CTXOE16	cells	which	received	the	splice	donor	matrix	and	splice	TALENs	were	interrogated	in	this	way.	The	 amplified	 gDNA	 was	 treated	 with	 exonuclease	 I	 (exoI)	 (NEB,	 Massachussets,	USA)	 to	 degrade	 single-stranded	 primers	 and	 shrimp	 alkaline	 phosphatase	 (SAP)	(NEB)	to	hydrolyse	dNTPs,	at	37	°C	for	1	hour,	followed	by	incubation	at	85	°C	for	15	minutes	 (see	 appendix	 1.4).	 The	 presence	 of	 extra	 dNTPs	 and	 primers	may	 cause	additional	extension,	which	would	lead	to	a	different	nucleotide	being	interrogated.	The	 treated	 PCR	 products	 were	 processed	 using	 the	 SNAPShot®	 Multiplex	 Kit	(Applied	 Biosystems®:	 4323151)	 as	 to	manufacturer’s	 guidelines	 as	 described	 in	appendix	1.4.	The	nucleotide	identity	was	analysed	on	a	Beckman	Coulter	CEQ	800	genetic	analysis	system	(Beckmann	Coulter	Ltd.,	High	Wycombe,	UK).		
	
7.2 RESULTS	In	 this	 Chapter,	 I	 describe	 the	 process	 of	 testing	 two	 TALEN	 pairs	 in	 the	 human	neural	 progenitor	 cell	 (hNPC)	 line,	 CTXOE16,	 and	 the	 progress	 made	 towards	making	a	clonal	late	infantile	CLN2	disease	hNPC	model.	This	is	important	as	this	cell	line	 could	 be	 used	 as	 a	 research	 tool	 to	 investigate	 the	 biological	 effects	 of	 TPP1-deficiency	 in	 human	 neural	 cells	 and	 as	 a	 drug	 discovery	 platform	 to	 identify	candidate	molecules	that	may	improve	disease	phenotypes	in	patients.			 	
7.2.1 Nucleofection	optimisation	In	 order	 to	 introduce	 the	 TALEN	 pairs	 into	 the	 CTXOE16/02	 cells,	 I	 chose	nucleofection	as	the	method	of	delivery.	Nucleofection	is	a	non-viral	method	of	gene	transfer,	 based	 on	 the	 temporary	 creation	 of	 small	 pores	 in	 cell	 membranes	 by	applying	an	electrical	pulse,	enabling	DNA	to	enter	the	cytoplasm	or	nucleus	(Piper	et	al.,	2000).	Nucleofection	has	been	shown	to	be	better	than	chemical	transfection	in	terms	of	cell	viability	and	transfection	efficiency	for	a	variety	of	human	and	other	mammalian	 adherent	 and	 non-adherent	 cell	 lines	 (Maurisse	 et	 al.,	 2010).	 Indeed,	despite	 many	 reports	 that	 cells	 of	 the	 central	 nervous	 system	 are	 difficult	 to	transfect	 (Bertram	 et	 al.,	 2012),	 nucleofection	 has	 been	 used	 to	 successfully	
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transfect	mouse	neural	stem	cells	 (Bertram	et	al.,	2012),	human	neural	progenitor	cells	 (Dieterlen	 et	 al.,	 2009),	 human	 neural	 stem	 cells	 (Arocena	 et	 al.,	 2005),	 and	adult	human	neurons	(Leclere	et	al.,	2005).		In	preliminary	nuceleofection	experiments	there	was	a	very	high	proportion	of	cell	death	and	no	cells	were	positive	for	pGFP	expression.	pGFP	is	a	plasmid	expressing	green	 fluorescent	 protein,	 used	 as	 a	 positive	 control	 to	 assess	 the	 transfection	efficiency	of	CTXOE16/02	cells.	Because	of	 the	 low	numbers	of	 surviving	cells	and	apparent	 lack	 of	 pGFP	 expression,	 representative	 images	 were	 not	 taken	 at	 this	stage.	However,	because	the	nucleofection	method	can	be	optimised	to	the	cell	type	used	 in	 the	 experiment	by	 altering	 the	nucleofector	program	and/or	 solution	 that	the	 cells	 are	 nucleofected	 in,	 I	 switched	 from	 using	 the	 mouse	 neural	 stem	 cell	nucleofection	 kit	 recommended	by	Marchenko	 et	 al.,	 (2007)	 to	 use	 a	 human	 stem	cell	 nucleofection	 kit,	 which	 contains	 a	 different	 nucleofection	 buffer.	 This	 also	meant	 changing	 the	nucleofection	program	 from	A-033	 to	B-016,	which	may	have	altered	the	amount	of	time	and	voltage	of	the	electrical	charge	applied	to	the	cells.			A	 number	 of	 other	 changes	 to	 the	 nucleofection	 protocol	 improved	 transfection	efficiency	and	 cell	 viability	of	 the	CTXOE16/02	 cells	 that	were	made	based	on	 the	suggestions	 of	 other	 molecular	 biologists	 in	 the	 department	 (Dr	 Graham	 Cocks,	personal	communication)	and	researching	online	for	other	researcher’s	experiences.	The	TALENs	and	donor	matrices	were	therefore	treated	to	remove	endotoxins,	since	eliminating	 endotoxins	 improves	 transfection	 into	 sensitive	 cells	 due	 to	 improved	cell	viability	(Dawson	et	al.,	1988).	In	addition,	the	CTXOE16/02	cells	were	treated	with	 a	 ROCK	 inhibitor	 (Kurosawa,	 2012,	 Watanabe	 et	 al.,	 2007),	 which	 prevents	apoptosis-induced	cell	death,	pre-	and	post-nucleofection.	Lastly,	as	transient	cold-shock	has	been	shown	to	increase	the	cutting	efficiency	of	ZFNs	(Doyon	et	al.,	2010),	I	 included	 a	 3	 day	 incubation	 at	 30°C,	 before	 returning	 cells	 to	 37°C.	 After	optimisation,	 the	procedure	described	 in	 section	7.1.7	gave	high	 cell	 viability	with	high	 transfection	 rates	as	 shown	by	pGFP	expression,	 (Figure	 65).	Comparing	 the	total	 number	 of	 cells	 (Figure	 65a)	with	 the	 number	 of	 cells	 expressing	 pGFP	 (all	green	cells	 in	Figure	 65b	 are	expressing	pGFP),	 I	would	estimate	 the	efficiency	of	transfection	under	these	conditions	to	be	at	least	60%.	Because	all	of	the	conditions	were	trialled	at	the	same	time,	 it	 is	difficult	to	determine	which	specific	conditions	improved	cell	viability	and	transfection	of	pGFP,	however	this	could	be	determined	
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by	 repeating	 the	 experiment	 and	 trialling	 each	 condition	 in	 turn.	However,	 as	 the	goal	 was	 to	 determine	 conditions	 that	 provide	 high	 levels	 of	 cell	 viability	 and	transfection	efficiency	 it	 is	not	particularly	 important	 for	 this	project	 to	determine	which	of	the	altered	conditions	produced	this	outcome.		
	
Figure	 65	Transfection	 efficiency	 following	 optimised	 protocol	 for	 Nucleofection	 of	
CTXOE16	cells.	(A)	CTXOE16	cells	nucleofected	with	2	ug	of	pGFP,	using	programme	B-016	on	 the	 nucleofector	 2b	 device,	 treated	 pre-	 and	 post	 nucleofection	 with	 RMM+++(see	appendix	1.5.1)	supplemented	with	1	μM	ROCK	inhibitor.	Cells	were	subjected	to	coldshock	at	 30°C	 for	 3	 days	 and	 then	moved	 to	 37	 °C	 until	 ready	 to	 passage.	 (B)	 The	 efficiency	 of	transfection	 under	 these	 conditions	 is	 estimated	 to	 be	 at	 least	 60%	 as	 shown	 by	 pGFP	expression	(green	cells).				In	 this	 section	 I	 have	 produced	 an	 optimised	 protocol	 for	 transfection	 of	CTXOE16/02	cells	with	TALENs,	which	can	be	used	for	future	experiments	involving	TALEN-mediated	 genomic	 alterations	 or	 as	 a	 starting	 point	 for	 transfection	 of	CTXOE16/02	cells	with	other	genome	editing	tools	such	as	CRISPRs	and	ZFNs.	This	optimised	 protocol	 is	 now	 being	 used	 by	 our	 lab	 to	 introduce	 a	 CLN3	 disease-causing	mutation	into	the	CTXOE16/02	cell	line.	
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7.2.2 Functional	Characterisation	of	TALENs		Once	 the	 TALENs	 were	 efficiently	 delivered	 into	 CTXOE16/02	 cells,	 the	 cutting	efficiency	 of	 the	 TALEN	 pairs	 was	 determined.	 To	 do	 this	 I	 used	 the	 surveyor	nuclease	 assay	 (see	 section	 7.1.8).	 The	 TALEN	 pairs,	 1-2	 μg	 each	 of	 left	 and	 right	splice	TALENs	and	1-2	μg	each	of	left	and	right	stop	codon	TALENs,	were	separately	nucleofected	 into	 CTXOE16/02	 cells,	 cold	 shocked	 for	 3	 days	 at	 30°C	 and	 then	returned	to	37°C	for	3	days	before	the	gDNA	was	extracted.	The	gDNA	was	amplified	at	the	locus	where	the	TALENs	should	bind	and	introduce	a	DSB	in	the	CLN2	gene.	This	was	analysed	by	gel	electrophoresis	to	ensure	a	single	product	of	the	expected	size	 (~500bp)	 was	 amplified	 and	 that	 primer	 dimers	 were	 absent	 (Figure	 66a),	each	 gDNA	 sample	 from	CTXOE16/02	 cells	 transfected	with	 Splice	 or	 Stop	 Codon	TALENs,	 was	 successfully	 amplified	 resulting	 in	 the	 expected	 500	 bp	 product	 A	surveyor	nuclease	assay	was	then	performed	on	the	successfully	amplified	products.			
a.	Cutting	Efficiency	of	the	Stop	Codon	TALENs		The	 stop	 codon	 TALENs	 showed	 no	 evidence	 of	 cutting	 in	 the	 surveyor	 assay	(Figure	 66b,	 lanes	 1-3,	 stop	 codon	 TALENs	 1-2	 μg	 each),	 showing	 the	 same	uncleaved	 band	 of	 approximately	 500	 bp	 seen	 in	 the	 gDNA	 extracted	 from	CTXOE16/02	 cells	 that	 went	 through	 the	 nucleofection	 procedure	 without	 the	addition	of	TALEN	DNA	(Figure	66b,	lane	4).	The	control	heteroplex	DNA	that	was	provided	 with	 the	 surveyor	 kit	 showed	 the	 results	 of	 positive	 surveyor	 assay	readout,	with	multiple	bands	present	(Figure	66b,	lanes	5	and	6).	In	 their	 validation	 experiments,	 Cellectis	 Bioresearch	 assessed	 the	 mutagenesis	activity	(cutting	efficiency)	by	deep	sequencing	on	a	GS	junior	system	(Roche).	The	TALENs	were	 transfected	 into	 the	human	colon	carcinoma	cell	 line	HCT116,	using	fugene,	 a	 chemical	 transfection	 reagent.	 Out	 of	 5475	 sequences	 analysed,	 only	 4	were	mutated,	 the	 rest	 were	wild	 type	 (the	 results	 of	 the	 validation	 experiments	were	 received	 after	 the	 surveyor	 assay	 was	 performed).	 Thus,	 the	 stop	 codon	TALENs	mutagenesis	 activity	was	 determined	 to	 be	 0.07%,	 revealing	 this	 to	 be	 a	weak	cutting	pair	of	TALENs.	The	stop	codon	TALENs	were	therefore	not	suitable	to	take	 any	 further	 in	 producing	 a	 clonal	 human	 late	 infantile	 CLN2	 disease	 hNPC	model.				
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b.	Cutting	Efficiency	of	the	Splice	TALENs		However,	 the	 splice	 TALENs	 did	 show	 evidence	 of	 cutting	 in	 the	 surveyor	 assay	(Figure	 66c,	 lanes	 1-3,	 splice	 TALENs	 1-2	 μg	 each),	 showing	 the	 same	 band	 of	approximately	500	bp	seen	in	the	gDNA	extracted	from	CTXOE16/02	cells	that	went	through	 the	 nucleofection	 procedure	without	 the	 addition	 of	 TALEN	DNA	 (Figure	




Figure	 66	 Results	 from	 surveyor	 nuclease.	 (A)	 Amplification	 of	 CLN2	 gene	 from	
CTXOE16/02	 cells	 nucleofected	 with:	 (1)	 1	 μg	 (2)	 1.5	 μg	 (3)	 2	 μg	 left	 and	 right	 Splice	TALENs,	 (4)	 1	 μg	 (5)	 1.5	 μg	 	 (6)	 2	 μg	 left	 and	 right	 Stop	Codon	TALENs.	Amplification	 of	region	 surrounding	 CLN2	 disease-causing	 mutation	 was	 successful	 in	 each	 condition	 as	shown	by	 500	 bp	 amplicon	 in	 each	 lane.	 (B)	 Surveyor	 nuclease	 result	 for	 Stop	 Codon	
TALENs:	(1)	1	μg	(2)	1.5	μg	(3)	2	μg	left	and	right	Stop	Codon	TALENs	(4)	No	TALENs,	just	went	through	nucleofection	procedure	(5)	and	(6)	Surveyor	nuclease	positive	control	1	and	2.	Absence	of	additional	bands	in	lanes	1-3	shows	that	Stop	Codon	TALENs	have	not	cut	the	
CLN2	 gene	 in	 CTXOE16/02	 cells	 under	 all	 Stop	 Codon	TALEN	DNA	 concentrations	 tested.	Additional	bands	 in	 the	positive	heteroduplex	control	DNA	demonstrate	 that	 the	surveyor	nuclease	assay	was	successful.	(C)	Surveyor	nuclease	result	 for	Splice	TALENs:	(1)	1	μg	(2)	 1.5	 μg	 (3)	 2	 μg	 left	 and	 right	 Splice	 TALENs.	 The	 presence	 of	 faint	 additional	 bands	suggests	 that	 Splice	 TALENs	 may	 have	 cut	 the	 CLN2	 gene	 in	 CTXOE16/02	 cells.	 (D)	
Surveyor	nuclease	result	for	Splice	TALENs:	the	agarose	gel	was	electrophoresed	for	
longer	to	allow	greater	separation	of	the	bands.	(1)	1	μg	(2)	1.5	μg	(3)	2	μg	left	and	right	Splice	TALENs.	With	additional	separation	it	is	clear	that	there	are	additional	bands	present,	which	correspond	to	the	presence	of	heteroduplex	DNA,	suggesting	the	Splice	TALENs	have	successfully	 cut	 the	 CLN2	 gene	 in	 CTXOE16/02	 cells	 under	 all	 Splice	 TALEN	 DNA	concentrations	tested.		
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7.2.3 Establishment	of	a	clonal	CLN2	Arg208X	 	human	neural	progenitor	cell	
line	Clonal	cell	lines	comprised	of	genetically	identical	cells	and	derived	from	one	cell	are	preferred	 for	 experimental	 biology	 as	 they	 are	more	 likely	 to	 give	 consistent	 and	reproducible	results	compared	to	a	heterogeneous	population	(Song	et	al.,	2011).		In	order	 to	 produce	 a	 clonal	 cell	 line,	 the	 nucleofected	 CTXOE16/02	 cells	 must	 be	grown	as	separated	single	cells.	I	tried	a	number	of	different	techniques	in	order	to	achieve	this.			
a.	Limiting	dilution	cloning	For	 this	 technique	 two	 conditions	 were	 tested:	 nucleofection	 with	 and	 without	 a	cold	shock	step	at	30°C	(see	section	7.1.9a).		In	both	cases	cells	were	seeded	into	96	well	 plates	 at	 a	 density	 of,	 on	 average,	 1	 cell	 per	 well.	 Unfortunately,	 the	nucleofected	CTXOE16/02	cells	did	not	 survive	 following	 limiting	dilution	 cloning.	This	 was	 repeated	 three	 times	 with	 the	 same	 outcome,	 where	 none	 of	 the	 cells	survived.	Other	collaborators	within	the	Unit	of	Cell	and	Behavioural	science	(King’s	College	 London,	 UK)	 have	 reported	 a	 similar	 phenomenon	 when	 trying	 to	 grow	cortical-	 and	 hippocampal-	 derived	 human	 neural	 progenitor	 cells	 as	 single	 cells	(Michael	Deans,	Dr	Matthew	Hill,	 personal	 communication).	 It	 appears	 that	hNPCs	will	not	readily	grow	as	single	cells	in	vitro	(see	discussion	7.3.2).			
b.	Semi-solid	medium	cloning	The	rationale	behind	using	semi-solid	media	was	that	this	would	support	the	growth	of	the	cells	whilst	keeping	the	arising	colonies	separate.	There	is	a	precedent	for	this	hypothesis,	as	neural	precursors	have	been	successfully	grown	in	semi-solid	methyl-cellulose	based	medium	before	(Suslov	et	al.,	2002,	Kukekov	et	al.,	1997,	Gritti	et	al.,	1999).		A	single	cell	suspension	of	nucleofected	CTXOE16/02	cells	was	mixed	with	methyl-cellulose	 based	 medium	 supplemented	 with	 the	 media	 components	 and	 factors	needed	for	growth	of	CTXOE16/02	cells	and	divided	into	6	well	plates	(see	section	7.1.9b).	Following	undisturbed	growth	in	the	incubator	for	10	days,	the	plates	were	observed	 for	 the	 growth	 of	 colonies.	 Unfortunately,	 no	 colonies	 had	 grown.	 This	experiment	was	repeated	twice,	both	with	and	without	cold	shock	and	no	colonies	grew	 with	 any	 of	 these	 conditions.	 Again	 this	 suggests	 that	 nucleofected	CTXOE16/02	 cells	 do	 not	 grow	well	when	 isolated	 from	other	 cells	 and	 they	may	
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require	contact	with	other	CTXOE16/02	cells.	In	addition,	the	insult	of	nucleofection	may	make	them	more	vulnerable	to	changes	in	environment	and	reductions	in	cell	viability.		
c.	Growth	as	Low	density	neurosphere	cultures	As	 CTXOE16/02	 cells	 do	 not	 grow	 well	 in	 isolation,	 I	 subsequently	 looked	 for	alternatives	and	chose	to	grow	the	nucleofected	CTXOE16/02	cells	as	neurospheres	at	a	low	density	(see	section	7.1.9c).	I	hypothesised	that	the	presence	of	other	cells	within	 the	 culture	 would	 provide	 the	 secreted	 factors	 necessary	 to	 support	CTXOE16/02	 cell-growth	 and	 that	 culturing	 these	 cells	 at	 low	 density	 would	increase	the	probability	that	the	resultant	neurospheres	were	derived	from	a	single	cell.	The	 nucleofected	 CTXOE16/02	 cells	 were	 diluted	 in	 RMM+++	 media	 (appendix	1.5.1)	to	give	a	final	concentration	of	1	x	102	cell/cm2	and	plated	in	T75	flasks	then	left	undisturbed	in	a	37°C	incubator	for	7	days	to	allow	time	for	the	neurospheres	to	develop	 and	 to	 prevent	 the	 cells	 from	 aggregating	 together.	 Over	 this	 time	many	neurospheres	 emerged.	 A	 dissecting	 microscope	 was	 used	 to	 transfer	 single	neurosphere	to	individual	wells	of	96	well	laminin-coated	plates	in	order	to	return	the	cells	to	adherent	culture.	These	cells	were	expanded	into	sequentially	larger	well	plates	up	 into	T25	 flasks	 to	produce	cultures	 from	individual	neurospheres,	which	were	 then	 used	 for	 screening	 to	 identify	 the	 cultures	 that	 have	 the	 desired	nucleotide	substitution.			In	 this	 section,	 the	 difficulties	 in	 cloning	 CTXOE16/02	 cells	 as	 single	 cells	 using	limiting	 dilution	 and	 a	 semi-solid	 medium	 cloning	 method	 have	 been	 described.	Because	a	clonally	derived	cell	line	is	preferable	in	terms	of	reproducibility,	I	looked	for	alternatives	and	grew	the	CTXOE16/02	cells	as	neurospheres	seeded	at	a	clonal	density	 following	 nucleofection.	 This	 resulted	 in	 discrete	 cell	 aggregations,	 which	could	 be	 isolated	 from	 one	 another,	 and	 expanded	 to	 produce	 cultures	 that	 arose	from	one	cell.			
7.2.4 Screening	for	nucleotide	substitution	In	 order	 to	 determine	 whether	 cultures	 expanded	 from	 individual	 neurospheres	contained	 the	 desired	 nucleotide	 substitution,	 the	 gDNA	 was	 extracted	 from	duplicated	 6	 well	 plates	 of	 each	 of	 the	 cultures	 while	 the	 other	 half	 was	 further	
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expanded	into	T25	flasks	and	then	frozen	down.	Only	26	cultures	were	successfully	expanded	 from	 neurospheres,	 the	 rest	 of	 the	 cultures	 did	 not	 survive	 expansion	from	96	well	plates	to	24	well	plates.	From	the	calculations	in	section	7.1.9a	Figure	
59,	 with	 a	 cutting	 efficiency	 of	 10%	 (Cellectis	 Bioresearch	 estimated	 cutting	efficiency	 at	 9.64	%	 in	 HCT116	 cells),	 29	 cultures	 would	 need	 to	 be	 screened	 in	order	 to	 have	 a	 95%	 chance	 of	 identifying	 a	 positive	 clone.	 With	 respect	 to	 the	results	obtained	 in	 the	surveyor	assay	(Figure	 66d),	10%	cutting	efficiency	 in	 the	CTXOE16/02	 cells	 is	 probably	 an	overestimate.	However,	 I	 chose	 to	 go	 ahead	 and	screen	the	26	clones	in	the	hopes	of	identifying	one	that	was	positive	for	the	desired	mutation.		The	splice	donor	matrix	was	designed	 to	have	a	unique	restriction	site,	StuI,	 to	be	used	for	detecting	which	cultures	have	the	c.509-1	G<C	mutation	(Figure	59).	The	gDNA	was	amplified	 in	 the	 region	 surrounding	 the	 locus	of	 the	desired	nucleotide	substitution	in	the	CLN2	gene.	A	restriction	enzyme	digest	was	performed	using	StuI,	as	described	in	section	7.1.10.	The	restriction	digest	did	not	show	a	positive	result	despite	 the	 fact	 that	 the	donor	matrix	was	 included	as	a	positive	control.	 I	believe	this	was	because	the	gDNA	was	amplified	using	Phusion®	DNA	polymerase	and	StuI	has	 <25%	 cutting	 activity	 in	 the	 Phusion®	 DNA	 polymerase	 buffer	(https://www.neb.com/tools-and-resources/usage-guidelines/activity-of-restriction-enzymes-in-a-q5-taq-or-phusion-pcr-mix#chart-S).	 In	 fact,	 StuI	 has	 low	activity	with	most	commercial	high-proofreading	DNA	polymerase	buffers.	However	high	 fidelity	 is	 needed	 to	 ensure	 no	 extra	mutations	 are	 introduced,	 which	 could	produce	a	falsely	positive	result.		Rather	than	spending	time	troubleshooting	the	restriction	digest	protocol	I	chose	to	carry	 out	 SNaPShot	 sequencing	 (Le	 Hellard	 et	 al.,	 2002,	 Norton	 et	 al.,	 2002,	 or	section	 7.1.10),	 which	 can	 identify	 a	 nucleotide	 at	 a	 certain	 locus.	 SNaPshot	sequencing	 identifies	nucleotides	at	known	 locations	by	designing	a	primer,	which	will	 anneal	next	 to	 the	nucleotide	of	 interest	and	 then	using	a	DNA	polymerase	 to	extend	by	one	complementary	base	using	ddNTPs	(see	section	7.1.10).		To	screen	for	 the	nucleotide	substitution	 in	the	CTXOE16/02	cells,	 the	primer	was	designed	to	anneal	to	the	anti-sense	strand	of	the	gDNA	to	identify	the	nucleotide	at	c.509-2	 (Figure	 59),	 the	 nucleotide	 before	 the	 disease-causing	mutations	 c,509-1	
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G<C.	The	nucleotide	at	c.509-2	is	the	A	to	C	mutation	introduced	to	prevent	cleaving	by	the	TALEN	(representation	 in	Figure	67).	When	the	primer	 is	extended	by	one	nucleotide	the	identity	of	the	base	that	is	present	on	the	sense	strand	is	revealed.	As	such	 the	 donor	 matrix,	 which	 harbours	 the	 AG	 to	 CC	 mutation,	 should	 read	 C.	Therefore,	any	cultures	that	have	incorporated	the	mutations	will	also	read	C.	In	the	wild	 type	 DNA,	 the	 SNaPShot	 sequencing	will	 read	 A.	 Cultures	 derived	 from	 cells	which	did	not	incorporate	the	splice	donor	matrix	will	also	read	A.	A	second	reverse	primer	was	designed	 to	detect	 the	c.509-1	G<C	mutation,	however	 this	primer	did	not	successfully	extend	in	the	SNaPshot	reaction,	perhaps	due	to	the	high	GC	content	of	this	region.		The	donor	matrix	was	confirmed	to	have	a	C	nucleotide	at	the	c.509-2	locus	(Figure	
68a),	confirming	that	the	A	to	C	nucleotide	substitution	(sense	strand)	in	the	donor	matrix	had	occurred,	and	therefore	cells	that	incorporated	the	donor	matrix	would	include	this	mutation	as	well.	The	gDNA	from	the	CTXOE16/02	cells	harboured	the	wild	 type	A	nucleotide	at	 the	c.509-2	 locus	 (not	 shown),	 confirming	 that	 cells	 that	did	not	incorporate	the	donor	matrix	would	read	as	A	as	well.			Of	the	26	samples	successfully	expanded,	25	harboured	the	wild	type,	A	at	the	c.509-2	 locus	 (Figure	 68b).	 However,	 one	 culture	 had	 a	 large	 peak	 corresponding	 to	 A	plus	 a	 smaller	 peak	 corresponding	 to	 C	 (Figure	 68c).	 This	 phenotype	 could	represent	a	culture	that	is	comprised	of	predominantly	wild	type	CTXOE16/02	cells,	with	a	small	population	of	mutated	cells,	which	have	been	outgrown	by	the	wild	type	cells.	 This	 would	 suggest	 that	 the	 neurosphere	 culture	 was	 not	 successful	 in	producing	a	clonal	population	of	cells	and	that	separate	colonies	may	have	merged	together.			Another	alternative	explanation	for	these	data	is	that	the	C	peak	is	an	artefact	of	the	sequencing	reaction.	The	average	fluorescence	is	expressed	in	relative	fluorescence	units	 (RFUs),	 which	 is	 an	 arbitrary	 scale.	 Ideally,	 the	 signal	 strength	 should	 be	around	 1000	 RFU;	 whereas,	 the	 signal	 strength	 for	 the	 culture	 with	 the	 possible	population	 of	 mutated	 cells	 is	 around	 4000	 RFU.	 When	 the	 RFU	 is	 over	 5000,	 a	phenomenon	 called	 peak-pull-up	 can	 occur	(http://www.dnaseq.co.uk/analysis_support_4.html),	 which	 is	 when	 additional	peaks	 are	 inserted	 into	 the	 sequence	 by	 the	 analysis	 software,	 as	 it	 cannot	
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discriminate	between	the	different	dye	colours.	It	is	possible	that	the	signal	strength	is	 too	high	 from	 the	 sample	 that	has	additional	peak	at	C	 (Figure	 68c)	 and	 this	C	peak	is	an	artefact	of	peak	pull	up.	Signal	strength	is	usually	too	high	when	too	much	template	 is	used	 i.e.	 too	much	DNA	has	been	used	 in	 the	 reaction.	With	additional	time	 and	 resources,	 I	would	have	 repeated	 the	SNaPshot	 sequencing	with	 a	 lower	DNA	concentration	and	seen	if	there	was	still	the	additional	C	peak	in	this	culture.		In	this	section,	I	have	shown	that	screening	for	mutations	introduced	by	homologous	recombination	into	the	CTXOE16/02	cells	also	presented	a	unique	set	of	challenges.	Although	 only	 26	 expanded	 cultures	 could	 be	 screened,	 the	 SNaPshot	 screening	method	 proved	 to	 be	 a	 robust	 method	 to	 screen	 for	 nucleotide	 substitutions	 in	CTXOE16/02	 cells	 that	 could	 be	 used	 in	 future	 experiments	 evaluating	 whether	nucleotide	 substitutions	 have	 taken	 place.	 One	 of	 the	 key	 advantages	 of	 SNaPshot	sequencing	is	that	it	indicates	what	proportion	of	the	cells	in	the	culture	harbour	the	nucleotide	 substitution.	 In	 25	 of	 the	 expanded	 cultures	 of	 CTXOE16/02	 cells	nucleofected	 with	 TALENs,	 there	 was	 no	 evidence	 of	 the	 donor	 matrix	 being	incorporated.	However,	one	culture	had	a	phenotype	that	could	be	interpreted	as	a	largely	 wild	 type	 population	 of	 CTXOE16/02	 cells,	 with	 a	 smaller	 subset	 of	CTXOE16/02	 cells,	which	 did	 incorporate	 the	 donor	matrix.	 This	 culture	 could	 be	taken	forward	for	further	investigation	and	rounds	of	cloning,	in	order	to	isolate	the	mutation-carrying	cells	and	form	a	clonal	population.			 	
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Figure	 68	Results	 of	 SNaPshot	 Sequencing.	CTXOE16/02	cells	nucleofected	with	Splice	TALENs	 and	 the	 Splice	 donor	 matrix	 were	 grown	 as	 individual	 neurospheres	 and	 then	expanded	 as	 separate	 cultures.	 The	 gDNA	 was	 extracted	 and	 SNaPshot	 sequencing	 was	performed	 in	order	 to	determine	whether	 the	splice	donor	matrix	had	been	 incorporated	into	the	CTXOE16/02	cells	genome.	(A)	The	splice	donor	matrix	was	confirmed	to	have	a	C	nucleotide	at	the	c.509-2	locus.	(B)	25	out	of	26	expanded	cultures	harboured	a	wild-type	A	nucleotide	 at	 the	 c.509-2	 locus.	 (C)	One	 culture	 however,	 had	 a	 smaller	 peak	 at	 C,	which	could	represent	a	culture	that	is	comprised	of	predominantly	wild	type	CTXOE16/02	cells,	with	a	small	population	of	mutated	cells,	which	have	been	outgrown	by	the	wild	type	cells.								
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7.3 DISCUSSION	In	 this	 Chapter,	 I	 have	 described	 some	 of	 the	 obstacles	 encountered	 when	attempting	to	produce	a	clonal	late	infantile	CLN2	disease	human	neural	progenitor	cell	 line.	 One	 of	 the	major	 complications	was	 the	 difficulty	 growing	 CTXOE16/02	cells	 as	 single	 cells.	 Different	 methods	 to	 encourage	 clonal	 cell	 growth	 from	 the	nucleofected	CTXOE16/02	cells	were	trialled,	however	none	were	successful.	In	this	discussion,	 I	 will	 speculate	 as	 to	 the	 reasons	 behind	 this	 and	 some	 possible	alternatives.	 It	 may	 be	 that	 to	 create	 a	 human	 CLN2	 disease	 cell	 line	 a	 different	starting	 point	 is	 necessary,	 such	 as	 human	 embryonic	 stem	 cells,	 which	 can	 be	grown	 as	 single	 cells	 (Bajpai	 et	 al.,	 2008).	However,	 this	 approach	would	 require	additional	 differentiation	 steps	 in	 order	 to	 determine	 the	 effects	 of	 late	 infantile	CLN2	disease-causing	mutations	in	human	neurons	and	glia	in	vitro.	
	
7.3.1 CTXOE16	 cells	 can	 be	 successfully	 transfected	 with	 high	 rates	 of	 cell	
viability	and	efficiency	Successful	 transfection	 of	 the	 CTXOE16/02	 cells	 required	 extensive	 trouble-shooting	 (section	 7.1	 and	 7.2).	 A	 very	 high	 proportion	 of	 cell	 death	 following	nucleofection	was	 initially	observed,	but	 this	was	partially	alleviated	by	switching	from	 using	 the	 mouse	 neural	 stem	 cell	 nucleofection	 kit	 to	 the	 human	 stem	 cell	nucleofection	kit,	which	contains	a	different	nucleofection	buffer.	Marchenko	et	al.,	(2007),	 have	 reported	 great	 success	 using	 the	 mouse	 neural	 stem	 cell	 kit	 to	nucleofect	 human	 neural	 stem/progenitor	 cells,	 isolated	 from	 adult	 human	 post-mortem	tissue	(as	 in	Schwartz	et	al.,	2003).	Perhaps	the	CTXOE16/02	cells,	which	are	fetally	derived,	are	more	sensitive	to	insult	than	the	human	adult-derived	neural	stem/progenitor	cells.	The	components	of	the	AMAXA	nucleofection	buffers	are	not	publically	available,	however	one	would	expect	 them	to	be	a	based	on	phosphate-buffered	saline	(PBS)	with	different	components	added	dependent	on	the	cell	type	(such	 as	 HEPES	 or	 MgCl2),	 to	 optimise	 nucleofection	 (Kang	 et	 al.,	 2009).	 In	 our	nucleofection	experiments,	the	CTXOE16/02	cells	were	found	to	be	very	sensitive	to	the	changes	of	the	nucleofection	buffer.	However,	primary	human	endothelial	cells,	which	 are	 relatively	 easily	 transfected,	 have	 been	 successfully	 nucleofected	 using	PBS	alone	as	the	nucleofection	buffer	(Kang	et	al.,	2009).		The	Amaxa	nucleofector	also	has	many	different	‘programs’	for	nucleofection,	which	are	altered	depending	on	the	cell	type.	Much	like	the	buffer	composition,	the	precise	parameters	 of	 these	 nucleofection	 programs	 are	 not	 publically	 known;	 however,	
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speculatively,	 the	 differences	 may	 include	 voltage,	 number	 of	 milliseconds	 the	voltage	 is	 applied	 for	 and	 the	 number	 of	 pulses	 of	 electrical	 stimulation	 the	 cells	receive.	A-033,	 the	program	used	 initially,	which	 is	recommended	with	the	mouse	neural	 stem	 cell	 kit,	 is	 optimised	 for	 mouse	 neural	 stem	 cells	 cultured	 as	neurospheres.	 Whereas,	 the	 program	 suggested	 with	 the	 human	 stem	 cell	 kit	suggests	program	B-016.	Some	of	 the	differences	 in	cell	viability	and	transduction	efficiency	 may	 therefore	 be	 attributed	 to	 using	 a	 different	 cell	 program	 that	 is	designed	 for	 adherent	 cells	 like	 the	 CTXOE16/02	 cell	 line,	 rather	 than	 a	 program	designed	for	suspension	adapted	cells.		Nevertheless,	 the	 protocol	 as	 described	 in	 methods	 section	 7.1.7,	 was	 eventually	determined	for	effective	transfection	of	 the	CTXOE16/02	cells	as	shown	in	Figure	
65,	which	can	be	used	for	other	researchers	hoping	to	transfer	genetic	material	into	the	CTXOE16/02	human	neural	progenitor	line.	Indeed,	this	optimised	protocol	for	successful	nuclefection	of	the	CTXOE16/02	cell	line	is	now	being	used	by	our	lab	to	introduce	a	CLN3	disease-causing	mutation	using	ZFNs.		
7.3.2 CTXOE16/02	cells	do	not	survive	and	grow	readily	as	single	cells	After	confirming	cutting	efficiency	with	the	Splice	TALENs	in	the	CTXOE16/02	cells,	I	attempted	to	produce	a	clonal	population	of	cells	with	the	c.509-1	G<C	mutation	induced	by	homologous	recombination.	As	explained	in	section	7.1.9,	in	order	to	do	this	the	cells	must	grow	as	single	cells	and	one	method	to	do	this	is	limiting	dilution	cloning.	Limiting	dilution	resulted	 in	universal	 cell	death	and	one	reason	 that	 this	may	 be	 is	 because	 the	 CTXOE16/02	 cells	 require	 cell-to-cell	 contact	 in	 order	 to	maintain	their	self-renewal	properties.		In	humans,	NSCs	and	NPCs	exist	in	two	highly	specialized	areas	where	neurogenesis	persists	in	adulthood:	the	subependymal	zone	(SEZ)	(Doetsch	et	al.,	1999,	Goldman,	1983),	 bordered	 by	 a	myelin-rich	 area	 (Curtis	 et	 al.,	 2007a),	 and	 the	 subgranular	zone	 (SGZ),	 the	 granule	 cell	 layer	 of	 the	 dentate	 gyrus	 (DG)	 of	 the	 hippocampus		(Seri	et	al.,	2004,	Seri	et	al.,	2001).	Both	the	SEZ	and	SGZ	are	often	characterised	as	stem	 cell	 niches	 (Riquelme,	 2008).	 A	 stem	 cell	 niche	 is	 a	microenvironment	 that	promotes	 the	 survival	 and	 self-renewal	 capacity	 of	 stem	 cells,	 the	 production	 of	actively	dividing	precursors	and	in	the	case	of	adult	CNS	stem	cell	niches	leading	to	committed	 post-mitotic	 progeny	 (Kazanis	 et	 al.,	 2013).	 Contact	 of	 stem	 cells	with	adjacent	 cells	within	 the	niche	 is	 thought	 to	be	very	 important	 for	 retaining	 stem	cell	 properties	 (Kazanis	 et	 al.,	 2013).	 The	 ependymal	 cells	 of	 the	 SEZ	 provide	 a	
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supporting	and	regulatory	function	in	the	niche	by	modulating	transport	of	ions	and	other	factors	from	the	CSF	(Bruni,	1998)	and	are	a	source	of	pro-neurogenic	factors	such	as	pigment	epithelium-derived	factor	(PEDF)	(Ramirez-Castillejo	et	al.,	2006)	and	noggin	(Lim	et	al.,	2000),	which	may	be	required	for	the	proliferation	of	NSCs	and	NPCs.		There	are	no	direct	instances	of	NPCs	failing	to	grow	as	single	cells	in	the	literature,	but	no	references	in	which	this	was	specifically	attempted	either,	so	whether	NPCs	require	cell-to-cell	contact	for	cell	growth	remains	to	be	seen.	However,	the	growth	of	 the	 CTXOE16/02	 cell	 line	 as	 a	 clonal	 population	 is	 a	 significant	 barrier	 to	overcome	 and	 some	 possible	 solutions	 to	 this	 problem	 are	 discussed	 below	 in	section	7.3.4	of	this	Chapter.		However,	even	if	the	cells	had	survived	and	proliferated	following	limited	dilution,	the	 probability	 of	 obtaining	 a	 clonal	 population	 carrying	 the	 relevant	 nucleotide	substitution	 would	 still	 have	 been	 relatively	 low,	 due	 to	 the	 probability	 of	monoclonality.	 The	 probability	 of	 monoclonality	 (PoM)	 is	 the	 likelihood	 that	 an	isolated	 culture	 is	 made	 up	 of	 genetically	 identical	 cells	 or	 the	 result	 of	 clonal	proliferation	 from	 a	 single	 cell	 (Staszewski,	 1984).	 In	 all	 limiting	 dilution	experiments	even	with	very	 low	seeding	densities,	 there	 is	a	possibility	 that	 there	are	wells	 that	 contain	more	 than	 one	 cell	 and	 thus	 the	 resulting	 cultures	 are	 not	monoclonal.	The	reason	that	methyl-cellulose	or	semi-solid	medium	based	cloning	is	 so	 attractive	 is	 that	 there	 is	 a	much	 higher	 PoM	 compared	 to	 limiting	 dilution	cloning	(Wognum	and	Lee,	2012,	Ito	et	al.,	1987).	Because	the	colonies	are	isolated	from	one	another	in	the	semi-solid	medium,	providing	the	cells	are	in	a	single	cell	suspension,	 they	 must	 have	 arisen	 from	 one	 cell.	 So	 although	 the	 chances	 of	isolating	a	colony	with	the	desired	nucleotide	substitution	using	semi-solid	cloning	has	a	similar	probability	to	limiting	dilution	cloning	(Wognum	and	Lee,	2012,	Ito	et	al.,	1987),	the	probability	that	the	culture	arose	from	one	cell	is	theoretically	much	higher.	Theoretically,	semi-solid	cloning	also	requires	less	time	and	resources,	due	to	the	fact	there	are	no	plates	with	empty	wells	and	additional	rounds	of	cloning	are	not	needed.	In	practice,	the	benefits	of	cloning	in	semi-solid	medium	were	not	seen	here,	because	the	nucleofected	CTXOE16/02	cells	did	not	grow	in	this	medium.	Primary	 mouse	 NPCs,	 isolated	 from	 the	 sub-ventricular	 zone	 (SVZ),	 have	 been	successfully	 propagated	 in	 methyl-cellulose	 based	 culture,	 where	 the	 methyl-cellulose	 was	 at	 a	 final	 concentration	 of	 1.5%	 (Kukekov	 et	 al.,	 1997,	 Gritti	 et	 al.,	
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1999).	 The	 methyl-cellulose	 concentration	 of	 the	 ClonaCell	 Flex	 from	 STEMCELL	Technologies	 is	 not	 publically	 known	 but	 this	may	 not	 be	 optimal	 for	 hNPCs	 and	different	 concentrations	 of	 methyl-cellulose	 supplemented	 with	 the	 components	and	growth	factors	necessary	for	CTXOE16/02	cell	growth	are	yet	to	be	evaluated,	in	order	to	ascertain	whether	methyl-cellulose	concentration	was	the	problem.	A	promising	method	based	on	similar	principles	to	growing	the	nucleofected	hNPCs	in	methyl-cellulose,	 is	to	use	an	agarose	encapsulation	method	(Dang	et	al.,	2004),	which	 has	 been	 used	 to	 successfully	 generate	 clonal	 cell	 aggregates	 from	 single	mouse	 NSCs	 (Coles-Takabe	 et	 al.,	 2008).	 This	 method	 allows	 the	 NSC	 to	 remain	clonal	 by	preventing	 other	 cells	 from	 fusing	with	 it	 but	 allows	 factors	 from	other	cells	 to	 diffuse	 through	 the	 agarose	 to	 the	 encapsulated	 cells,	 to	 support	 growth.	This	could	be	attempted	using	the	transfected	CTXOE16/02	cells	and	may	support	their	growth	better	than	methyl-cellulose	methods	due	to	the	greater	potential	for	diffusible	factors	to	reach	the	cells.		
	
7.3.3 Neurosphere	 culture	 does	 not	 result	 in	 clonal	 cell	 growth	 of	
CTX0E16/02	cells	In	a	final	attempt	to	encourage	the	nucleofected	CTXOE16/02	cells	to	grow	as	single	cells,	the	CTXOE16/02	cells	were	grown	as	neurospheres	plated	at	a	clonal	density	(section	 7.1.9c).	Many	 cultures	were	 lost	while	 trying	 to	 expand	 the	 neurosphere	cultures	during	this	process;	 further	highlighting	the	CTXOE16/02	cells	sensitivity	to	 changes	 in	 environment.	 The	 nucleofected	 CTXOE16/02	 cells	were	 plated	 at	 a	very	low	density	(1	x	102	cells	per	cm2	or	0.5	cells/μl),	which	should	ensure	that	the	neurospheres	 are	 clonal	 (Coles-Takabe	 et	 al.,	 2008).	 However,	 it	 has	 been	 shown	that	when	hNPCs	are	plated	at	densities	between	1	x	102	and	1	x	103	cells	per	cm2	after	 7d	 >40%	 of	 the	 neurospheres	 even	 at	 the	 lowest	 plating	 density,	 have	elements	of	chimerism	(Singec	et	al.,	2006).	Real	time	video	microscopy	has	shown	that	 neurospheres	 are	 constantly	merging	 and	 absorbing	 single	 cells,	 even	 at	 low	densities,	 which	 suggests	 that	 the	majority	 of	 neurospheres	 are	 not	 homogenous	cell	populations	(Singec	et	al.,	2006).	Floating	cells	tend	to	coalesce	to	the	centre	of	a	dish	(Suslov	et	al.,	2002),	providing	a	possible	explanation	as	to	how	at	such	low	cell	densities,	merging	 of	 cells	 and	 neurospheres	 still	 takes	 place.	 Neurospheres	 have	even	been	shown	 to	be	motile	on	coated	substrates	 (Singec	et	al.,	2006),	which	 is	worrying	 for	semi-solid	based	cloning	methods.	As	such,	neurospheres	should	not	
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be	thought	of	as	aggregates	of	clonal	cells,	even	when	plated	at	low	density,	which	should	theoretically	produce	clonal	populations.	Indeed,	neurospheres,	and	the	cells	that	form	them	are	heterogenous	(Reynolds	and	Rietze,	2005,	Bez	et	al.,	2003).		The	 results	 presented	 in	 the	 Chapter	 certainly	 suggest	 that	 the	 neurospheres	 I	cultured	were	not	clonal,	if	the	evidence	presented	in	Figure	68c	is	interpreted	as	evidence	 of	 a	 mixed	 population	 of	 CTXOE16/02	 cells	 and	 that	 the	 mutated	 cells	were	outgrown	by	wild-type	cells.	The	peak	from	nucleotide	present	in	the	mutated	cells	 is	expected	to	be	much	smaller	than	the	peak	from	the	wild	type	cells	 in	this	situation	as	they	will	be	very	much	in	the	minority,	as	appears	to	be	the	case	here.	However,	 the	C	peak	would	 ideally	be	present	around	138	rather	 than	140	where	the	 A	 peak	 is	 present,	 in	 the	 chromatogram	 as	 presented	 in	 Figure	 69.	 I	 have	already	 further	 described	 why	 the	 result	 may	 be	 an	 artefact	 of	 the	 sequencing	readout	 (section	 7.2.4).	 However,	 if	 wild-type	 cells	 outgrew	 the	 edited	 cells,	 this	would	 suggest	 that	 introducing	 the	 c.509-1	 G<C	mutation	 into	 CTXOE16/02	 cells	decreases	 cell	 proliferation	 rates	 or	 cell	 survival.	 As	 mutations	 in	 CLN2	 cause	neurodegeneration	 in	 patients	 (Chang	 et	 al.,	 2008)	 and	 the	 TPP1-deficient	mouse	model	 (Chapter	 3,	 (Sleat	 et	 al.,	 2004,	 Chang	 et	 al.,	 2008))	 it	 is	 possible	 that	introducing	CLN2	mutations	 in	 vitro	 has	 a	 similar	 effect.	 If	 this	 is	 the	 case	 it	 will	prove	 impossible	 to	 create	 a	 late	 infantile	 CLN2	 hNPC	 model.	 Nevertheless,	neurodegeneration	 appears	 to	 occur	 at	 a	 much	 later	 developmental	 stage	 than	hNPCs	represent,	 thus	one	would	expect	 that	 those	cells	carrying	 the	c.509-1	G<C	mutation	would	not	become	vulnerable	until	differentiated	into	mature	neurons.			
	




Despite	 not	 producing	 a	 clonal	 culture	 of	 cells,	 growing	 the	 CTXOE16/02	 cells	 as	neurospheres	was	the	only	method	I	tested	that	allowed	growth	of	the	CTXOE16/02	cells	when	seeded	at	low	density.	Taken	together,	these	results	show	that	it	is	very	difficult	 to	 isolate	 the	CTXOE16/02	 cells	 that	have	 incorporated	 the	donor	matrix	but	primarily	because	it	is	difficult	to	grow	these	cells	at	low	densities	and	as	such	there	were	not	many	cultures	to	screen.	Because	it	was	only	possible	to	screen	26	cultures,	 the	 likelihood	 of	 identifying	 a	 potential	 clone	 harbouring	 the	 desired	mutation	was	relatively	low,	and	future	efforts	should	be	concentrated	on	refining	methods	 to	 encourage	 single	 cell	 growth	 of	 the	 CTXOE16/02	 cells	 and	 for	identification	and	selection	of	the	mutated	cell	population.		
7.3.4 How	can	clonal	cell	growth	be	encouraged	in	the	CTXOE16/02	cell	line	
and	the	probability	of	identifying	mutated	cells	be	increased?	Single	 cell	 growth	 could	 theoretically	 be	 encouraged	 by	 swapping	 DMEM/F12	(which	 is	 the	 major	 component	 of	 RMM,	 appendix	 1.5.1)	 used	 to	 culture	 the	CTXOE16/02	cells,	for	neural	basal	medium	supplemented	with	Sato’s	components	(appendix	1.5.1)	as	well	as	B27,	a	commonly	used	serum-free	supplement	for	neural	cell	culture	(B27	preparations	often	contains	vitamin	A,	which	can	be	converted	to	retinoic	 acid	 and	 induce	 neural	 differentiation	 however	 formulations	 are	 now	available	that	do	not	contain	vitamin	A)	and/or	BIT	9500,	a	serum	substitute	which	supports	 neural	 growth	 and	 additionally	 supports	 growth	 in	 methyl-cellulose	(Wachs	et	al.,	2003).	This	medium	was	not	used	in	this	thesis	because	it	is	several-fold	more	expensive	than	the	DMEM/F12-based	RMM	used	instead,	however	it	may	prove	 cost-effective	 if	 it	 encourages	 single	 cell	 growth.	 Accutase-dissociated	 rat	SVZ-derived	 NSCs	 were	 successfully	 expanded	 from	 single	 cells	 plated	 at	 0.5	cells/μl,	 when	 the	 Neural	 basal	 growth	 medium	 was	 additionally	 supplemented	with	 B27	 or	 BIT	 9500	 (Wachs	 et	 al.,	 2003).	 	 In	 addition,	 neurotrophins,	 such	 as	BDNF	 and	 neurotrophic	 factor	 4	 (NT4),	 have	 also	 been	 shown	 to	 increase	 cell	viability	of	 transfected	human	stem	cells	and	single	cell	growth	(Pyle	et	al.,	2006)	and	 could	 be	 included	 in	 the	 medium	 pre-	 and	 post	 nucleofection	 of	 the	CTXOE16/02	cells.		Mimicking	 the	 interactions	with	other	cells	via	 the	use	of	a	 feeder	cell	 layer	could	also	plausibly	encourage	single	cell	growth	of	CTXOE16/02	cells.	Feeder	cell	layers	are	 traditionally	 used	 with	 embryonic	 stem	 cells	 to	 maintain	 their	 pluripotency	
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during	 cell	 culture	 (Evans	 and	 Kaufman,	 1981),	 and	 are	 generated	 using	 mouse	embryonic	 fibroblasts	(MEFs)	that	have	arrested	cell	cycles	due	to	treatment	with	irradiation	or	mitomycin	c	(Yue	et	al.,	2012).	It	is	proposed	that	MEF	feeder	layers	support	growth	and	maintain	pluripotency	by	secreting	unknown	factors	(Lee	et	al.,	2009),	 by	 providing	 cell-to-cell	 contact	 and	 an	 intact	 extracellular	 matrix	 for	 the	cells	 to	 interact	with	 (Kuang	et	 al.,	 2008,	Gilbert	 et	 al.,	 2010).	These	benefits	may	also	help	aid	the	clonal	growth	of	CTXOE16/02	cells	as	well.		The	use	of	a	selection	marker	within	the	donor	matrix,	such	as	antibiotic	resistance	or	 a	 fluorescent	 protein	 tag,	 would	 undoubtedly	 aid	 in	 identifying	mutated	 cells.	However,	 because	 I	 was	 trying	 to	 recreate	 a	 specific	 late	 infantile	 CLN2	 disease-causing	mutation	 seen	 in	 human	 patients	 to	 specifically	 evaluate	 its	 effect	 on	 the	CTXOE16/02	cell	biology,	incorporating	an	additional	marker	into	the	donor	matrix	would	also	knock	out	the	function	of	the	CLN2	gene	and	the	specificity	of	the	effect	of	the	particular	mutation	in	human	NPCs	will	be	lost.	Disrupting	the	CLN2	gene	and	evaluating	the	loss	of	CLN2	function	in	vitro	in	hNPCs	is	an	interesting	and	perhaps	more	achievable	concept	in	itself	though	and	is	discussed	in	Chapter	8.		A	selection	strategy	that	would	be	compatible	with	the	use	of	the	Splice	TALENs	and	splice	donor	matrix	is	to	use	a	surrogate	reporter	plasmid	(Kim	et	al.,	2011).	In	this	strategy	 a	 surrogate	 reporter	 encodes	 a	 fluorescent	 protein	 that	 is	 only	 in-frame	when	it	is	cleaved	by	TALENs,	is	co-transfected	with	the	TALENs	and	donor	matrix	(Kim	et	al.,	2011).	The	Splice	TALEN	DNA	binding	sequence	would	be	 included	 in	the	surrogate	reporter	plasmid	and	the	cells	in	which	the	TALENs	have	entered	and	are	active	and	 the	surrogate	reporter	plasmid	 is	 therefore	cleaved	 in,	are	selected	for	 using	 fluorescent	 activated	 cell	 sorting	 (FACS).	 More	 recently,	 surrogate	reporters	 have	 been	 designed	 which	 express	 H-2Kk,	 a	 cell	 surface	 antigen	 which	allows	 the	 cells	 to	 be	 separated	 magnetically	 and	 also	 HygroR,	 a	 hygromycin	resistance	 protein,	 allowing	 identification	 by	 antibiotic	 resistance	 (Kim	 et	 al.,	2013a).	 These	 methods	 avoid	 the	 laser	 and	 hydrostatic	 pressure	 of	 the	 FACS	machine,	which	I	predict	the	CTXOE16/02	cells	would	not	survive.	
	
7.3.5 Concluding	thoughts	This	 Chapter	 has	 presented	 evidence	 that	 a	 culture	 was	 isolated	 that	 contained	largely	wild-type	CTXOE16/02	cells	and	a	smaller	population	of	CTXOE16/02	cells	
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In	 this	 thesis,	 I	 have	 presented	 data	 from	 two	 different	 strategies	 to	 model	 late	infantile	 CLN2	 disease.	 The	 first	 employed	 a	 previously	 described	 TPP1-deficient	mouse	model	of	CLN2	disease	 (Sleat	et	al.,	2004),	but	extended	 its	analysis	 to	 the	thalamocortical	system	and	then	analysed	the	same	model	on	an	immunodeficient	background.	 This	 is	 the	 first	 time	 that	 the	 neuropathological	 features	 of	 disease	progression	 in	 this	mouse	model	have	been	documented	 in	 such	detail.	 Similar	 to	other	mouse	models	of	NCL	(apart	from	the	CLN5-deficient	mouse	(von	Schantz	et	al.,	2009)),	neuronal	cell	 loss	 in	these	Tpp1-/-	mice	 is	 initiated	 in	the	thalamus	and	subsequently	spreads	to	the	cortex	(Cooper	et	al.,	1999,	Blom	et	al.,	2013,	Oswald	et	al.,	2005,	Pontikis	et	al.,	2004,	Bible	et	al.,	2004,	Kuhl	et	al.,	2013,	Kielar	et	al.,	2007,	Thelen	et	al.,	2012,	Kuronen	et	al.,	2012).	However,	unlike	other	models	of	NCL,	 I	found	 a	 relatively	 delayed	 onset	 of	 glial	 activation	 that	 unexpectedly	 followed	neuron	 loss	 in	 the	 thalamus	 and	 accompanied	 the	 neuron	 loss	 seen	 in	 the	 cortex	(see	Chapter	3).	On	a	NODSCID	background	compared	with	a	C57BL/6J	background,	TPP1-deficient	 mice	 lived	 longer,	 but	 neuron	 loss	 in	 all	 regions	 was	 more	pronounced,	perhaps	as	a	consequence	of	this	longer	lifespan	(Chapter	4).		To	compliment	data	gleaned	from	the	TPP1-deficient	mouse	model,	I	also	attempted	to	 create	 a	 human	 neural	 progenitor	 cell	 (hNPC)	 model,	 which	 was	 genetically	modified	 with	 TALENs	 to	 recreate	 one	 of	 the	 most	 common	 late	 infantile	 CLN2	disease-causing	mutations	(Chapters	6	and	7).	Chapter	6	presented	the	difficulties	in	 targeting	 and	 growing	 hNPCs	 in	 this	 way	 and	 presented	 methods	 in	 order	 to	detect	whether	the	hNPCs	were	successfully	mutated.	In	the	future	a	population	of	CLN2-targeted	hNPCs	could	be	isolated	using	the	techniques	presented	and	further	expanded	to	produce	a	CLN2-disease	hNPC	line	to	evaluate	the	human	cell	biology,	or	as	a	basis	for	drug	screening	(discussed	in	section	8.6).	In	this	general	discussion,	I	will	examine	the	different	scenarios	in	which	in	vivo	and	
in	 vitro	 methods	 could	 be	 used	 to	 model	 CLN2	 disease	 and	 the	 merits	 and	drawbacks	of	them	both.			
8.1 The	CLN2	gene	is	difficult	to	target	for	modification	In	both	mice	and	human	neural	progenitor	cells,	the	CLN2	gene	has	proven	difficult	to	target.	When	targeting	the	CLN2	gene	with	TALENs,	the	stop	codon	TALEN	pair	showed	 low	 mutagenesis	 activity	 in	 human	 colon	 carcinoma	 cells	 and	 the	CTXOE16/02	 cell	 line	 used	 to	 produce	 a	 mutated	 hNPC	 line	 (Chapter	 7,	 section	7.2.2).	 The	 strategy	 of	 introducing	 a	 disease-causing	mutation	 in	 hNPCs	 relied	 on	
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homologous	 recombination	 but	 it	 is	worth	 being	 aware	 that	 this	 strategy	may	 be	particularly	difficult	for	CLN2	because	this	gene	is	in	a	particularly	gene-rich	region	of	the	genome	(Liu	et	al.,	1998).	Indeed,	Sleat	et	al.,	(2004)	found	that	there	was	a	low	 frequency	 of	 homologous	 recombination	 in	 the	 CLN2	 gene	 when	 generating	their	mouse	model,	with	the	only	successful	mutation	created	being	an	Arg446His	mutation,	 equivalent	 to	 the	 Arg447His	mutation	 in	 humans,	 resulting	 in	 an	 adult	onset	of	the	disease	(Sleat	et	al.,	1997,	Kousi	et	al.,	2012).		It	is	important	to	consider	that	the	neoinsArg446His	Tpp1-targeted	mouse	harbours	a	mutation	that	is	not	seen	in	patients	(see	Chapter	3,	section	3.1.2),	but	is	used	to	recapitulate	human	disease.	That	 the	model	 is	 based	on	 a	mutation	 that	does	not	naturally	occur	may	partly	explain	why	although	many	of	 the	hallmarks	of	human	late	 infantile	 CLN2	 disease	 such	 as	 cortical	 neuron	 loss,	microglial	 and	 astrocytic	activation	 are	 recreated	 in	 the	 Tpp1neoinsArg446His	 mouse,	 other	 manifestations	such	as	autofluorescent	storage	material	(Chapter	3,	section	3.2.6)	and	seizures	are	not	universally	seen	(Anderson	et	al.,	2013).	Nevertheless	 there	are	other	reasons	why	mouse	models	may	not	 fully	predict	 human	disease	outcomes,	which	will	 be	discussed	next.		
8.2 Why	 don’t	 we	 see	 the	 same	 results	 in	 human	 versus	 preclinical	
models?	
8.2.1 Experimental	design	is	flawed	Animal	experiments	contribute	to	our	understanding	of	mechanisms	of	disease,	but	are	not	always	effective	in	predicting	the	effectiveness	of	therapeutic	interventions	(Bart	van	der	Worp	et	al.,	2010,	Perel	et	al.,	2007,	Hackam	and	Redelmeier,	2006).	Indeed,	only	about	a	third	of	highly	cited	pre-clinical	animal	research	experiments	successfully	 translated	 in	 human	 randomized	 clinical	 trials	 (Hackam	 and	Redelmeier,	2006).		Sometimes	 these	 failures	 are	 due	 to	 insufficient	 statistical	 power,	 where	 in	experiments	involving	animals	sample	size	requires	a	balance	between	being	large	enough	to	have	a	high	probability	of	detecting	a	treatment	effect,	but	also	keeping	the	number	of	animals	used	to	a	minimum	to	keep	costs	low	and	adhere	to	ethical	requirements	(Bart	van	der	Worp	et	al.,	2010,	Campbell	et	al.,	1995,	Altman	et	al.,	2001).	Indeed,	traditionally,	n=	5	for	pathology	studies	and	n=10-12	for	behavioural	studies	 has	 been	 considered	 an	 adequate	 balance	 between	 statistical	 power	 and	
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ethical	requirements	(Jon	Cooper,	personal	communication).	However,	according	to	Perrin	 (2014),	 in	 order	 to	 get	 meaningful	 preclinical	 data	 that	 would	 translate	successfully	to	human	patients,	highly	variable	animal	models	would	require	up	to	a	hundred	animals	per	treatment	group,	and	even	homogenous	animal	models	would	need	around	ten	animals	per	group.	In	practice	this	would	be	very	hard	to	justify	in	terms	of	cost-benefit	for	initial	pathology	studies	that	are	merely	characterising	the	disease	 landmarks	of	 a	mouse	model,	 as	was	 the	 case	 in	Chapters	3	 and	4	of	 this	thesis.	Nevertheless,	 to	properly	analyse	 the	effects	of	stem	cell	 transplantation	 in	TPP1	deficient	mice	(Chapter	5),	a	larger	treatment	group	size	might	be	necessary.		As	 well	 as	 the	 number	 of	 animals	 in	 a	 treatment	 group,	 the	 environmental	conditions	in	which	these	animals	are	looked	after,	the	diet	they	are	given,	and	how	they	 are	 handled	 can	 also	 have	 profound	 effects	 on	 experimental	 outcomes,	 as	described	 in	 the	 introduction	 to	 Chapter	 6.	 For	 the	 main	 part,	 animals	 in	experimental	conditions	are	stressed,	with	insufficient	time	allowed	for	adaptation	to	handlers	(Bezard	et	al.,	2003).	Enriched	environments	involving	larger	cages	with	running	wheels	or	 toys	 can	have	powerful	effects	on	brain	 function	and	structure	(reviewed	 in	 Laviola	 et	 al.,	 2008).	 As	 such,	 enriched	 environments	 should	 be	included	in	experimental	designs	and	reported	in	publications.		
	
8.2.2 The	 Mouse	 model	 does	 not	 recapitulate	 the	 human	 disease-causing	
mutation		When	 creating	 disease-specific	 mouse	 models	 the	 typical	 goal	 is	 to	 reproduce	disease	phenotypes,	 regardless	of	how	 this	 is	 achieved.	This	 is	 seen	 in	 the	Tpp1-/-	mouse,	where	as	mentioned	above,	the	mouse	does	not	carry	a	naturally	occurring	human	late	infantile	CLN2	disease-causing	mutation	and	only	partially	recreates	the	human	disease.	Another	 example	of	 phenotypic	mouse	models	 failing	 to	 faithfully	recapitulate	 a	 human	 neurological	 disorder	 is	 mouse	 and	 rat	 models	 of	 motor	neuron	 disease	 (MND),	 which	 rely	 on	 overexpression	 of	 superoxide	 dismutase-I	(SOD1),	 the	gene	responsible	 for	a	 subset	of	 familial	human	cases	 (Betarbet	et	al.,	2002).	 Unlike	 in	 the	 human	 condition	 where	 only	 one	 mutant	 copy	 of	 the	 gene	causes	pathology,	homozygous	knockout	of	 the	equivalent	Sod1	gene	 in	mice	does	not	recreate	the	disease	(Reaume	et	al.,	1996),	and	the	mutant	copy	of	 the	human	gene	must	 be	 expressed	 in	 very	high	 copies	 in	 order	 to	 see	 symptoms	 in	 rodents	(Howland	et	al.,	2002).	
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Because	similar	phenotypes	can	be	produced	by	different	mechanisms,	observation	of	 a	 phenotype	 that	 resembles	 the	 human	 disease	 does	 not	 guarantee	 that	 the	primary	 mechanism	 involved	 is	 in	 both	 (Gusella	 and	 MacDonald,	 2002).	 	 For	example,	many	mouse	models	of	Alzheimer’s	disease	(AD)	have	been	produced	by	manipulating	the	various	genes	that	are	implicated	in	the	development	of	AD,	such	as	amyloid-β	precursor	protein	(APP),	the	product	of	which	is	laid	down	in	amyloid	plaques	characteristic	of	the	disease	(LaFerla	et	al.,	1995),	mutations	in	presenilin	1	and	2	 (Siman	et	al.,	2000)	and	apolipoprotein	E	 (Holtzman	et	al.,	2000).	Although	cognitive	 defects	 and	 amyloid	 plaques	 are	 seen	 in	 these	 models,	 none	 of	 these	phenotypic	models	exhibit	neurofibrillary	tangles,	a	hallmark	of	human	AD	(Elder	et	al.,	2010).		A	 genotypic	 approach	may	 have	 several	 advantages	 over	 a	 phenotypic	 approach.	This	 approach	 to	 producing	 mouse	 models	 aims	 to	 reproduce	 human	 genetic	mutations	as	precisely	as	possible	in	the	mouse,	with	the	assumption	that	unlike	a	phenotypic	mouse	model,	 the	same	pathological	mechanisms	 lead	to	 the	observed	phenotype	 in	 the	 human	 and	 the	 genetically	 modified	 mouse	 (Gusella	 and	MacDonald,	2002).	However,	precise	genetic	mouse	models	of	Parkinson’s	disease	(PD)	fail	to	show	the	selective	substantia	nigral	pathology	(Braak	et	al.,	2003,	Tieu,	2011,	 Dawson	 et	 al.,	 2010b),	 which	 is	 characteristic	 of	 this	 disease;	 so	 the	fundamental	 question	 central	 to	 PD	 research	 of	 why	 dopamine	 neurons	 are	vulnerable	in	this	disease,	remains	to	be	addressed	(Lee	et	al.,	2002,	Giasson	et	al.,	2002).	When	a	mouse	model	of	a	precise	human	genetic	mutation	fails	to	induce	the	phenotypic	outcomes	one	might	 expect	 to	 see	 from	clinical	 outcomes	 in	 this	way,	this	is	often	viewed	as	a	failure	of	the	model	and	the	validity	of	these	models	may	be	questioned.	 However,	 Gusella	 et	 al.,	 (2002)	 argue	 that	 this	 represents	 an	opportunity	to	define	what	prevents	the	pathogenic	process	from	being	completed	in	 these	 models.	 These	 factors	 could	 be	 biological	 differences	 between	mice	 and	humans,	the	genetic	background	or	the	shortened	lifespan	of	the	mouse.	Biological	differences	 between	 the	 species	 can	 sometimes	 be	 modified	 by	 further	 genetic	manipulation	 (see	 Giovanni	 et	 al.,	 2000).	 To	 determine	 whether	 the	 genetic	background	is	 the	 issue,	different	 inbred	strains	can	be	used.	 Indeed,	 the	different	lifespans	of	Tpp1neoinsArg446His	mice	on	a	129SV	strain	(Sleat	et	al.,	2004)	versus	a	mixed	 genetic	 background,	 C57BL/6J:129SV	 (this	 thesis),	 point	 to	modifier	 genes	being	present	(see	Chapter	.8.4).	If	the	human	disorder	develops	over	time,	the	full	pathogenic	pathway	may	not	be	completed	in	the	short	lifespan	of	a	mouse	(Gusella	
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and	MacDonald,	2002).	However,	data	obtained	from	these	models	can	allow	us	to	discover	early	events	in	the	disease	process,	which	are	not	possible	to	investigate	in	humans.	I	will	now	discuss	how	differences	between	animal	models	of	disease	and	humans	affect	how	we	can	interpret	models	of	NCL	disease	with	specific	examples.			
8.2.3 How	closely	do	NCL	animal	models	recapitulate	human	disease?		In	 evaluating	 the	 TPP1-deficient	 mouse	 in	 this	 thesis	 it	 would	 be	 beneficial	 to	compare	it	with	other	models	of	CLN2	disease.	However,	it	is	apparent	that	not	all	of	these	models	have	been	characterised	to	the	same	extent,	and	certain	crucial	pieces	of	 data,	 like	 for	 example	 the	 extent	 of	 retinal	 pathology	 in	mice,	 or	 the	 staging	of	events	in	either	the	dog	or	zebrafish	are	still	missing.	Perhaps	more	than	any	other	form	of	NCL,	most	studies	involving	Tpp1	deficient	mice	(Passini	et	al.,	2006;	Sondhi	et	 al.,	 2007,	2008;	Chang	et	 al.,	 2008),	 and	dogs	 (Vuillemenot	 et	 al.,	 2011,	2014a)	have	focussed	on	the	impact	of	therapy	upon	disease	end	stage.	In	this	respect	it	is	surprising	that	no	detailed	description	of	the	brain	regions	that	are	affected,	or	the	sequence	 of	 neuropathological	 changes	 has	 been	 attempted	 in	 before.	 As	 such,	 it	will	be	important	to	collect	these	data	from	both	dogs	and	zebrafish,	but	at	present	any	detailed	comparison	of	 the	staging	of	neuropathology	 is	necessarily	 limited	to	contrasting	our	data	with	that	obtained	in	mouse	models	of	other	forms	of	NCL.	A	 comprehensive	analysis	of	 the	extent	 to	which	mouse	and	other	 animal	models	mimic	their	human	NCL	counterparts	has	not	been	made.	This	is	mainly	due	to	the	fact	that	very	little	quantitative	work	is	carried	out	on	human	tissue	due	to	limited	access	to	tissue,	variable	quality	and	condition	of	the	tissue,	and	the	fact	that	to	do	quantitative	analysis	on	human	tissue	is	very	difficult	because	of	the	increased	brain	size	 and	 complexity	 (Cooper,	 personal	 communication).	 Broad	 parallels	 between	hallmarks	 of	 human	 NCL	 disease,	 such	 as	 storage	 material,	 inflammation	 and	neuron	 loss	 are	 often	 made,	 and	 a	 great	 deal	 of	 research	 has	 focussed	 on	determining	 the	 timing	 and	 location	 of	 neuroinflammation	 and	 neuron	 loss	 in	animal	models,	 in	order	to	better	target	therapies	to	where	they	are	most	needed.	However,	it	cannot	be	assumed	that	the	same	regional	patterns	of	pathology	and	the	timing	 of	 these	 events	will	 also	 be	 seen	 in	 human	patients,	 particularly	when	 the	mouse	model	 does	 not	 faithfully	 recapitulate	 a	 human	 NCL-causing	mutation	 (as	outlined	above)	and	 therefore	 therapies	based	on	 the	areas	most	affected	 in	mice	may	not	 target	 the	most	 affected	areas	 in	human	 cases.	Post-mortem	brain	 tissue	from	affected	patients	is	invaluable	in	providing	exact	information	on	the	extent	of	
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neuropathological	changes	in	the	human	disease	but	cannot	tell	us	anything	about	temporal	changes	in	disease	progression.		Another	 important	consideration	 is	 that	mice	may	not	 live	 long	enough	to	see	 the	full	extent	of	pathology	seen	in	human	patients.	In	addition,	the	brains	of	mice	are	obviously	much	more	simple	than	the	human	CNS.	Moving	from	a	small	vertebrate	model	to	a	larger	animal	model	to	humans	adds	a	degree	of	complexity	at	each	level,	which	appears	to	be	reflected	in	the	extent	of	pathology	seen	in	each.	For	example	this	can	be	seen	when	comparing	the	Cln6nclf	mouse	versus	the	CLN6	sheep	and	late	infantile	CLN6	disease	human	cases.	 In	 the	Cln6nclf	mouse,	 lifespan	 is	shortened	 to	around	half	normal	lifespan	(death	at	about	11	months),	and	neuroinflammation	is	seen	at	around	5-6	months	of	age	(Gao	et	al.,	2002,	Bronson	et	al.,	1998,	Thelen	et	al.,	 2012).	 CLN6-disease	 sheep	 live	 for	 around	 19	months	 compared	 to	 a	 healthy	sheep	that	will	live	for	around	12	years;	a	glial	response	can	be	seen	prenatally	and	GABAergic	 interneurons	are	 lost	 from	5	months	onwards	 (Kay	et	al.,	2006).	CLN6	disease	in	humans	has	a	variable	age	of	onset	from	18	months	to	8	years,	depending	on	the	mutation	(Schulz	et	al.,	2013,	Alroy	et	al.,	2011).	Deterioration	is	rapid	and	death	 usually	 occurs	 within	 5	 years	 of	 diagnosis.	 The	 proportional	 reduction	 in	lifespan	increases	as	brain	size	increases,	as	does	the	extent	of	pathological	change.	For	example	cortical	thinning	is	much	less	pronounced	in	Cln6nclf	mice	(Thelen	et	al.,	2012),	 compared	 to	CLN6	sheep	(Oswald	et	al.,	2005),	or	human	CLN6	deficiency.	Somewhat	 differently,	 in	 TPP1-deficient	 mice,	 neurodegeneration	 occurs	 from	 9	weeks	 of	 age	 and	 glial	 activation	 has	 a	 relatively	 late	 onset	 within	 a	 severely	shortened	lifespan	of	13	weeks	(Chapter	3).	As	such,	our	data	suggest	a	distinctive	and	atypical	glial	phenotype	in	TPP1	deficient	mice,	and	it	will	be	important	to	gain	similar	data	regarding	the	relative	timing	of	glial	activation	and	neuron	loss	in	TPP1	deficient	 Dachshunds.	 At	 present,	 this	 information	 is	 not	 available,	 with	neuropathological	observations	largely	confined	to	disease	end	stage	(Awano	et	al.,	2006,	 Katz	 et	 al.,	 2008),	 particularly	 in	 relation	 to	 assessing	 therapeutic	 efficacy	(Vuillemenot	et	al.,	2014a).	Ideally	such	data	should	include	a	more	comprehensive	characterisation	of	which	brain	regions	are	affected,	so	that	this	could	be	compared	to	 MRI	 data	 from	 CLN2	 disease	 patients.	 Such	 cross	 species	 comparisons	 are	important	for	determining	the	translational	validity	of	disease	models,	but	given	the	significant	 cost	 of	maintaining	dog	 colonies	 it	may	not	be	 feasible	 to	 obtain	 these	data	 readily.	 There	 is,	 however,	 more	 scope	 for	 obtaining	 such	 data	 of	 disease	
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progression	in	the	Tpp1	deficient	zebrafish	(Mahmood	et	al.,	2013),	and	it	 is	to	be	hoped	that	such	studies	will	be	undertaken	in	the	near	future.		Even	this	small	number	of	examples	highlights	the	difficulty	of	making	assumptions	when	extrapolating	or	predicting	phenotypes	between	species.	It	 is	also	important	to	consider	how	appropriate	each	disease	model	 is,	 in	 terms	of	what	 it	can	 tell	us	about	the	human	condition.		
8.2.4 Are	the	models	that	we	have	the	right	models?		The	 Tpp1neoinsArg446His	 mouse	 is	 a	 null	 mutant	 (Sleat	 et	 al.,	 2004),	 however	 a	more	 clinically	 relevant	 model	 would	 be	 to	 take	 a	 genotypic	 approach	 (outlined	previously	in	section	8.2.2)	to	recreate	a	specific	human	late	infantile	CLN2	disease-causing	mutation	in	mice,	such	as	the	mutations	described	in	Chapter	7,	c.509-1G>C	or	 Arg208X.	 The	 creation	 of	 an	 Arg208X	 mouse	 was	 recently	 described	 at	 the	NCL2014	 meeting	 (Pearce,	 2014),	 and	 a	 similar	 project	 has	 already	 been	undertaken	 to	 recreate	 the	most	 common	human	CLN1	disease-causing	mutation,	R151X	 in	 mice	 (Miller	 et	 al.,	 2014).	 The	 Cln1R151X	 mouse	 shows	 an	 arguably	 less	pronounced	 disease	 phenotype	 compared	 to	 the	 standard	 Ppt1-/-	 mouse	 model	(Bible	et	al.,	2004,	Kielar	et	al.,	2007),	 in	 terms	of	glial	activation	and	behavioural	phenotypes,	however	neurodegeneration	is	yet	to	be	quantitatively	assessed	in	this	model.	This	may	be	due	to	the	fact	the	Cln1R151X	mouse	still	exhibits	1.7-3.1	%	PPT1	activity	compared	to	wild-type	mice	(Miller	et	al.,	2014),	which	may	partially	rescue	the	disease	phenotype.	Such	disease	amelioration	has	already	been	described	in	the	
Tpp1Arg447His	 mouse	 hypomorph,	 where	 6	 %	 residual	 levels	 of	 TPP1	 activity	dramatically	 increased	 the	 lifespan	 of	 the	mice	 and	 reduced	 the	 disease	 severity	(Sleat	et	al.,	2008).		Another	possible	way	to	evaluate	the	clinical	relevance	of	NCL	mouse	models	to	the	human	NCL	disease	they	model,	will	be	to	observe	whether	interventions	which	had	significant	benefit	 in	NCL	mouse	models	have	 similar	benefits	 in	patients,	 such	as	human	 NSC	 therapy	 for	 infantile	 CLN1	 disease	 (Tamaki	 et	 al.,	 2009),	 enzyme	replacement	 therapy	 (Katz	 et	 al.,	 2014,	 Seehafer	 et	 al.,	 2011)	 and	 gene	 therapy	(Cabrera-Salazar	 et	 al.,	 2007)	 for	 late	 infantile	 CLN2	 disease	 and	 immune	suppression	(CellCept)	for	juvenile	CLN3	disease,	all	of	which	had	promising	enough	data	 for	 clinical	 trials	 to	 be	undertaken.	Nevertheless,	 it	 should	be	borne	 in	mind	that	 there	could	be	many	reasons	why	a	 therapeutic	strategy	may	 fail	 to	 translate	
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successfully	 from	 mice	 to	 humans,	 and	 such	 comparisons	 should	 be	 made	 with	caution.	The	 TPP1-deficient	 mice	 evaluated	 in	 this	 thesis	 (Chapter	 3)	 display	 a	 severely	shortened	lifespan,	an	effect	that	appears	to	be	strain-specific	since	these	mice	on	a	129SV	strain	background	live	longer	than	on	a	C57BL/6J	strain	background	(Sleat	et	al.,	2004,	Sleat	et	al.,	2008).	Both	the	C57BL/6J	and	129SV	mouse	strains	are	highly	inbred	to	produce	strains	that	are	almost	genetically	identical.	Such	homogeneity	is	normally	 seen	 as	 a	 positive	 trait	 of	 mouse	 models	 because	 this	 should	 lead	 to	reproducibility	 of	 results,	 but	 seeing	 as	 the	 human	 genome	 is	 very	 heterogenous,	perhaps	our	mouse	models	should	reflect	this	as	well.	The	Diversity	Outbred	(DO)	mouse	colony,	attempts	to	model	heterogeneity	in	a	mouse	population	(Churchill	et	al.,	2012).	Modelling	a	biological	response	in	a	diverse	population	may	better	reflect	the	 differences	 in	 patients	 and	 reveal	 why	 some	 therapies	 work	 better	 in	 some	patients	better	than	others.			
8.3 The	inflammatory	response	in	the	NCLs	All	 NCL	 mouse	 models	 show	 a	 large	 inflammatory	 response	 that	 becomes	 more	pronounced	 with	 disease	 progression,	 where	 GFAP	 and	 CD68	 (markers	 of	astrocytosis	 and	 activated	 microglia)	 are	 massively	 upregulated	 (see	 Chapter	 1,	section	1.6.4).	 In	 the	TPP1-deficient	mouse	model	studied	 in	 this	 thesis	 there	was	also	a	pronounced	neuroinflammatory	response,	albeit	with	a	relatively	 late	onset	relative	 to	 neuron	 loss	 compared	 to	 other	 NCL	 animal	 models.	 An	 inflammatory	response	 is	 also	 seen	 in	 human	 NCL	 patients,	 where	 neuronal	 cell	 loss	 is	 often	accompanied	by	microglial	activation	and	the	presence	of	reactive	astrocytes,	which	form	a	glial	fibrillary	network	and	fibrillary	gliosis	(as	reviewed	in	Anderson	et	al.,	2013).		
	
8.3.1 Modelling	inflammation	in	the	NCLs	in	vivo	In	 order	 to	 further	 examine	 the	 mechanism	 of	 CNS	 inflammation	 in	 NCL	 mouse	models,	 removing	 the	 source	 of	 neuroinflammation	 is	 an	 attractive	 experimental	design.	 This	 has	 been	 attempted	 in	 both	 PPT1-	 and	 CLN3-	 deficient	 mice	 by	crossbreeding	 these	mice	with	mice	 that	are	either	 recombination	activating	gene	(RAG-1)	or	sialoadhesin	(Sn)	deficient	(Thomas	Kühl,	PhD	thesis,	2012).	RAG-1	is	a	protein	that	is	essential	for	the	maturation	process	of	T	and	B	cells	(Mombaerts	et	al.,	1992).	RAG-1	deficient	Ppt1-/-	mice	showed	a	delay	in	the	progression	of	disease	
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pathology	 in	 the	 thalamocortical	 system	 (Kühl,	 PhD	 thesis,	 2012),	 together	 with	improved	pathology	and	function	in	the	visual	system,	and	a	moderate	extension	in	life	span	(Groh	et	al.,	2013).	Sn	 is	a	cell	adhesion	molecule,	expressed	in	the	brain	during	inflammatory	conditions	on	infiltrating	macrophages	and	resident	microglia	(Perry	 et	 al.,	 1992).	 Sn	 deficiency	 had	 a	 partially	 ameliorating	 effect	 on	neurodegeneration	in	both	PPT1-	and	CLN3-deficient	mouse	models	of	NCL	and	this	is	 predicted	 to	 be	 mediated	 through	 reduced	 inflammatory	 environment	 and	reduced	CD4-positive	and	CD8-positive	T-lymphocyte	infiltration	and	proliferation	and	 is	 supported	 by	 other	 studies	 (Kobsar	 et	 al.,	 2006,	 Ip	 et	 al.,	 2007).	 Another	mouse	model	 without	 normally	 functioning	microglia	 used	 in	 neurodegeneration	studies	 lacks	 CX3CR1	 (fracktaline	 receptor)	 (Grizenkova	 et	 al.,	 2014),	 a	 receptor	expressed	 exclusively	 on	 microglia.	 The	 corresponding	 CX3CL1	 (fracktaline)	 is	expressed	 on	 neurons,	 so	 mice	 with	 this	 phenotype	 have	 reduced	 interactions	between	neurons	and	microglia	(Hughes	et	al.,	2002,	Jung	et	al.,	2000).	 	Therefore,	Sn	 or	 CX3CR1-deficient	 mice	 could	 be	 crossbred	 with	 the	 Tpp1-/-	 mouse	 model	studied	 in	 this	 thesis,	 to	 determine	 whether	 microglia-neuron	 interaction	 affects	CLN2	disease	pathogenesis	and	how	this	might	be	mediated.	
	
8.3.2 Modelling	inflammation	in	the	NCLs	in	vitro	Models	 of	 neuroinflammation	 in	 vitro	 often	 concentrate	 on	 modelling	 microglia,	which	 hNPCs	 do	 not	 have	 the	 capacity	 to	 differentiate	 into	 (Sun	 et	 al.,	 2008)	(astrocytes,	other	key	players	in	neuroinflammation,	are	discussed	in	section	8.5	of	this	 chaper).	Efforts	 to	 characterise	microglia	 in	vitro	 for	 the	NCLs	have	 therefore	instead	focused	upon	primary	microglial	cultures	isolated	from	NCL	mouse	models	and	 found	 striking	 differences	 between	 mutant	 and	 wildtype	 microglia.	 For	example,	microglia	isolated	from	Cln3∆ex7/8	mice	exist	 in	a	primed	state	and	release	pro-inflammatory	mediators	including	tumor	necrosis	factor	α	(TNF-α),	interleukin	(Il)-1	 α	 and	 Il-9,	 without	 stimulation;	 and	 promote	 glutamate	 release,	 which	 is	 a	known	cause	of	neuronal	excitotoxicity	(Xiong	and	Kielian,	2013).	Microglia	derived	from	 Cln3∆ex1-6	mice	 also	 show	 an	 abnormal	 response	 to	 stimulation,	 and	 may	contribute	directly	to	neuron	loss	(Parviainen,	PhD	thesis,	2013).		Although	studying	microglial	phenotypes	and	function	in	the	absence	of	other	CNS	cell	 types	 is	very	informative	and	is	the	purpose	of	these	models,	 this	means	their	predictive	power	for	in	vivo	biology	is	somewhat	limited.	Microglia	are	highly	plastic	and	their	phenotype	is	determined	by	external	cues;	they	also	express	receptors	for	
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a	 range	 of	 molecules	 expressed	 by	 neurons	 (Carson	 et	 al.,	 2008,	 Melchior	 et	 al.,	2006),	suggesting	that	culturing	microglia	in	the	absence	of	neurons	may	alter	their	phenotype	from	that	of	their	in	vivo	counterparts.	In	 spite	 of	 the	 differences	 between	microglial	 phenotypes	 in	vitro	 and	 in	vivo,	 co-cultures	of	microglia	and	neurons	represent	a	powerful	tool	to	study	how	microglia	respond	 to	 pharmaceutical	 anti-inflammatory	 agents	 and	 whether	 this	 reduces	inflammation-mediated	 neurotoxicity	 (Gresa-Arribas	 et	 al.,	 2012).	 Microglia	 are	believed	 to	 play	 a	 key	 role	 in	 neurotoxicity	 induced	 by	 reactive	 glia	 (Glass	 et	 al.,	2010,	Perry	et	al.,	2010),	however	relatively	little	is	known	about	their	specific	role	in	 disease	 progression	 of	 the	 NCLs.	 In	 their	 studies	 of	 microglia	 isolated	 from	
Cln3∆ex7/8	 mice,	 Xiong	 and	 Kielian,	 (2013),	 found	 that	 when	 primary	 Cln3∆ex7/8	cortical	or	cerebellar	neurons	were	cultured	with	conditioned	medium	from	either	activated	 Cln3∆ex7/8	 or	 wild-type	 microglia,	 significant	 cell	 death	 was	 induced;	whereas,	 wild-type	 neurons	 were	 resistant	 to	 cytotoxicity.	 This	 suggests	 that	
Cln3∆ex7/8	neurons	 are	 particularly	 vulnerable	 to	 inflammatory	 insults	 generated	from	activated	microglia	and	in	the	context	of	the	CLN3	disease	brain,	exposure	of	mutant	 neurons	 to	 pro-inflammatory	mediators	 from	 Cln3∆ex7/8	microglia,	 may	 be	responsible	 for	 the	 neuron	 loss	 seen	 in	 the	 disease.	 Data	 from	 mixed	 glial	 and	neuron	 co-cultures	 from	 Cln3∆ex7/8	mice	 suggest	 that	 CLN3-deficient	 glia	 directly	harm	 neurons	 and	 affect	 their	 dendritic	 branching	 and	 viability	 (Parviainen,	 PhD	thesis,	2013).	It	would	be	interesting	to	find	out	whether	similar	phenotypes	would	be	 seen	 in	 primary	 microglial	 cultures	 derived	 from	 the	 TPP1-deficient	 mice	described	in	this	thesis.	These	studies	are	now	underway	and	already	suggest	that	TPP1-deficient	 microglia	 respond	 differently	 to	 lipopolysaccharide	 (LPS)	stimulation	(Cooper,	personal	communication).		It	is	possible	to	create	human	microglial	systems	in	vitro,	however	these	cells	have	to	be	derived	from	human	embryos,	or	hESCs,	which	have	ethical	concerns,	can	be	difficult	to	work	with	and	have	complex	differentiation	programs	that	are	not	fully	standardized	or	optimised	(see	section	8.6.1	and	Stansley	et	al.,	2012).	The	human	microglia	 cell	 line	 (HMO6)	 however,	 was	 produced	 from	 human	 embryonic	microglial	 cultures,	 which	 were	 immortalized	 using	 a	 viral	 vector	 expressing	 the	oncogene	v-myc	(Nagai	 et	 al.,	 2005).	 The	CLN2	 gene	 of	 this	 immortalised	 cell	 line	could	conceivably	be	targeted	using	genome	editing	tools	like	the	ones	we	describe	in	this	thesis	(Chapter	6,	section	6.2)	and	in	particular	the	splice	TALENs	and	donor	
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matrix	 that	 are	 described	 in	 Chapter	 7,	 in	 order	 to	 produce	 a	 human	 CLN2-/-	microglial	cell	line.	An	alternative	route	to	modelling	mutant	CLN2	human	microglia	
in	vitro	would	be	to	transfect	hESCs	with	the	splice	TALENs	and	donor	matrix	and	then	differentiate	the	cells	into	microglia	afterwards,	as	well	as	neurons	and	other	glia	(see	section	8.6.1	for	more	information	on	hESCs	and	iPSCs	models).		
	
8.3.3 Are	human	and	animal	mechanisms	of	inflammation	comparable?	Studying	 human	 rather	 than	 animal	 cell	 models	 may	 have	 greater	 relevance	 to	human	 disease,	 particularly	 if	 studying	 complex	 signalling	 pathways	 or	 gene	expression	profiles.	Indeed,	a	recent	study	highlighted	a	striking	difference	between	mice	 and	 humans	 in	 their	 responses	 to	 inflammation	 (Seok	 et	 al.,	 2013).	 Gene	expression	 changes	were	 correlated	with	 various	 inflammatory	 stressors	 such	 as	trauma,	burns	and	endotoxemia	between	human	subjects	and	corresponding	mouse	models	(Seok	et	al.,	2013).	The	researchers	noted	highly	similar	genetic	responses	between	human	subjects;	however	the	genetic	responses	amongst	these	genes	that	were	significantly	changed	in	people	corresponded	poorly	with	changes	seen	in	the	corresponding	 mouse	 models	 (close	 to	 random)	 (Seok	 et	 al.,	 2013,	 Leist	 and	Hartung,	 2013).	 The	 conclusions	 from	 this	 study	 are	 extremely	 contentious	(Tompkins	 et	 al.,	 2013,	 Cauwels	 et	 al.,	 2013)	 and	 a	 group	 of	 researchers	 have	recently	analysed	the	same	dataset	as	Seok	et	al.	(2013)	and	came	to	the	opposite	conclusion,	that	genomic	mouse	models	in	fact	greatly	mimic	human	inflammatory	diseases	(Takao	and	Miyawaka,	2014).	The	crucial	difference	in	their	analyses	of	the	data	is	that	Takao	and	Miyawaka	(2014)	only	focussed	on	genes	whose	expression	levels	were	 significantly	 changed	 in	 both	 humans	 and	mice;	whereas,	 Seok	 et	 al.,	(2013)	 analysed	 sets	 of	 genes	 that	 were	 significantly	 changed	 in	 the	 human	inflammatory	 response	 and	 compared	 them	 to	 the	 mouse	 ortholog	 equivalent,	regardless	 of	 whether	 the	 mouse	 gene	 was	 significantly	 changed.	 Takao	 and	Miyawaka,	(2014)	argue	that	their	interpretation	of	the	data	takes	into	account	that	mouse	 models	 only	 mimic	 partial	 aspects	 of	 human	 disorders.	 Although	 this	example	 is	 not	 specific	 to	 neuroinflammation,	 instead	 considering	 systemic	inflammation	 in	 response	 to	 trauma	 or	 injury,	 the	 understanding	 that	 mouse	models	 of	 inflammation	 will	 only	 ever	 partially	 recapitulate	 human	 disease	confirms	 the	 incompleteness	 of	 mice	 as	 a	 model	 for	 human	 inflammation.	 This	example,	in	particular,	also	highlights	the	importance	of	experimental	design	when	attempting	 to	 draw	 meaningful	 correlations	 between	 animal	 models	 and	 human	
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disease,	 and	 that	 the	 way	 that	 data	 is	 analysed	 can	 produce	 very	 different	conclusions.	Factors	such	as	the	strain	of	the	mouse	used,	timing	of	intervention	and	how	long	to	treat	for	and	dosage,	have	to	be	carefully	considered	when	using	animal	models	of	human	disorders	and	it	is	sometimes	difficult	to	judge	the	correct	way	to	balance	these	factors	to	avoid	bias.		As	 the	 inflammatory	 response	 appears	 to	 be	 involved	 in	 the	 pathogenesis	 of	 the	NCLs	(Cooper	et	al.,	1999,	Blom	et	al.,	2013,	Oswald	et	al.,	2005,	Pontikis	et	al.,	2004,	Bible	et	al.,	2004,	Kuhl	et	al.,	2013,	Kielar	et	al.,	2007,	Thelen	et	al.,	2012,	Kuronen	et	al.,	 2012),	 animal	 models	 of	 the	 NCLs	 should	 ideally	 reflect	 the	 inflammatory	response	 in	 humans	 as	 closely	 as	 possible	 in	 order	 to	 maximise	 translational	benefit.	As	described	in	this	section,	in	modelling	inflammation,	animal	models	have	the	benefit	 that	 all	 the	 known	and	unknown	 interactions	 of	 cellular	 and	 chemical	inflammatory	 mediators	 can	 occur	 in	 situ,	 although	 they	 only	 partly	 represent	features	 of	 human	 conditions;	 whereas,	 cell	 models	 can	 tease	 apart	 specific	interactions	between	cell	types	such	as	microglia	and	neurons	and	can	be	generated	from	human	sources	to	better	reflect	human	disease,	despite	the	overall	picture	of	microglia	in	vivo	being	lost.		
8.4 Modelling	the	Adaptive	Immune	System	in	the	NCLs	
8.4.1 Modelling	the	adaptive	immune	system	in	the	NCLs	in	vivo	An	obvious	advantage	to	modelling	the	NCLs	in	mice	is	that	the	immune	system	is	in	the	 context	 of	 a	 living	 organism	 and	 can	 freely	 interact	 in	 its	 native	 environment	and	 reflect	 the	 impact	 of	 the	 immune	 system	 upon	 the	 disease.	 Knockout	mouse	models,	 which	 remove	 all	 or	 specific	 parts	 of	 the	 immune	 response,	 can	 provide	information	 on	 how	 the	 adaptive	 immune	 system	 helps	 or	 hinders	 disease	progression	 (see	 Chapter	 4,	 Groh	 et	 al.,	 2013	 and	 Seehafer	 et	 al.,	 2011)	 but	 how	similar	are	the	adaptive	immune	systems	of	mice	and	humans?	The	overall	structure	of	the	immune	system	in	mice	and	humans	is	generally	similar	(reviewed	in	Haley,	2003),	but	specific	differences	between	them	are	evident.	One	of	the	most	striking	differences	is	the	balance	between	neutrophils	and	lymphocytes	in	 the	 blood:	 mouse	 blood	 is	 lymphocyte-rich	 (75-95%	 lymphocytes,	 10-25%	neutrophils),	 whereas	 human	 blood	 is	 neutrophil-rich	 (50-70%	 neutrophils,	 20-40%	lymphocytes)	(Doeing	et	al.,	2003).	Neutrophils	are	cells	of	the	innate	immune	system	 and	 lymphocytes	 are	 cells	 of	 the	 adaptive	 immune	 system	 (see	 Chapter	1.6.5).	Because	neutrophil	function	relies	on	degrading	ingested	foreign	material	via	
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the	lysosome,	one	could	speculate	that	mutations	that	deregulate	lysosome	function	such	as	 those	 in	 the	NCLs	would	be	manifested	more	detrimentally	 in	 the	human	immune	 response.	 Dogs	 have	 much	 more	 similar	 ratios	 of	 neutrophils	 and	lymphocytes	 to	 humans	 compared	 to	 mice	 (47-65%	 neutrophils,	 16-41%	lymphocytes)	(Doeing	et	al.,	2003),	so	may	represent	a	better	model	of	the	immune	system	 for	 the	NCLs.	What	 limited	neuropathological	 information	 that	 is	available	suggests	 a	 pronounced	 innate	 immune	 response	 in	 the	 brains	 of	 TPP1	 deficient	Dacshunds	(Vuillemenot	et	al.,	2014a).	Our	data	from	mice	also	reveal	pronounced	astrocytosis	 and	 microglial	 activation	 at	 disease	 end	 stage,	 but	 add	 the	 novel	information	tha	this	is	of	relatively	late	onset.	As	such,	these	data	highlight	the	need	to	 undertake	 similar	 studies	 in	 the	 dog	 and	 zebrafish	models	 of	 CLN2	 disease	 to	determine	 whether	 this	 is	 a	 phenotype	 that	 is	 maintained	 across	 species	boundaries.	 Also	 of	 relevance,	 is	 whether	 the	 neuropathological	 phenotypes	 we	have	 reported	 in	 the	 Sleat	 et	 al.,	 (2007)	 mouse	 model	 is	 a	 consequence	 of	 the	complicated	 targetting	 strategy	 that	 was	 employed.	 This	 involved	 attempting	 to	create	a	point	mutation,	which	accidentally	produced	a	hypomorph	allele	resulting	in	 very	 low	 Tpp1	 expression	 (Sleat	 et	 al.,	 2007).	 Attempts	 are	 underway	 using	CRISPR	 technology	 to	make	 a	more	 genetically	 accurate	mouse	model,	 recreating	the	 most	 common	 mutation	 present	 in	 CLN2	 disease	 patients	 (Cooper,	 personal	communication),	and	it	will	be	important	to	undertake	a	detailed	characterisation	of	these	mice	when	they	become	available.		There	are	additional	differences	between	mouse	and	human	immune	systems,	such	as	differences	in	expression	of	Toll-like	receptors	(TLRs)	on	the	cells	of	the	immune	and	adaptive	systems	(Rehli,	2002,	Heinz	et	al.,	2003),	lack	of	expression	of	CD4	on	mouse	 macrophages	 (Crocker	 et	 al.,	 1987)	 and	 lack	 of	 major	 histocompatability	class	 (MHC)	 II	 expression	 on	 mouse	 T	 cells	 (Barnaba	 et	 al.,	 1994,	 Denton	 et	 al.,	1999),	and	many	others	(reviewed	in	Mestas	and	Hughes,	2004).	It	is	not	clear	how	significant	such	differences	 in	mouse	and	human	 immune	systems	are	 in	 terms	of	relatable	 phenotypes.	However,	 it	 is	worth	 contemplating	 that	 any	 given	 immune	response	 seen	 in	 a	 mouse	 may	 not	 necessarily	 be	 the	 same	 in	 humans.	 As	 the	immune	system	is	believed	to	play	a	significant	role	in	the	pathogenesis	of	the	NCLs	and	because	there	is	currently	a	clinical	trial	for	immune	suppression	as	a	treatment	for	 juvenile	 CLN3	 disease	 (Seehafer	 et	 al.,	 2011),	 the	 differences	 in	 mouse	 and	
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human	 immune	 systems	 must	 be	 taken	 into	 consideration	 when	 interpreting	immunological	data	from	mouse	models	and	relating	them	to	human	disease.		
8.4.2 Modelling	the	adaptive	immune	system	in	the	NCLs	in	vitro	
In	 vitro	 systems	 lack	 a	 functional	 systemic	 immune	 response	 that	 will	 likely	contribute	to	the	neurodegenerative	process.	Indeed,	as	was	discussed	in	Chapter	4	section	4.3,	both	the	innate	and	adaptive	immune	response	appear	to	be	involved	in	the	 pathogenesis	 of	 the	 NCLs.	 The	 data	 presented	 in	 Chapter	 4	 of	 this	 thesis	suggests	that	TPP1-deficient	mice	lacking	an	immune	system	live	longer,	but	display	more	 extensive	 neurodegeneration.	 hNPC	 models	 cannot	 reflect	 the	 systemic	immune	 response	 or	 interaction	 with	 cytokines	 from	 the	 blood	 and	 so	 vital	information	about	 the	 relationship	and	mechanisms	controlling	 cell	death	may	be	lost	in	in	vitro	experiments.		Although	 human	 stem	 cell	 models	 cannot	 recapitulate	 the	 complex	 interactions	between	neurons,	glia	and	the	systemic	immune	system	as	mouse	and	other	animal	models	can,	in	vitro	models	can	nevertheless	answer	interesting	questions	as	to	the	interactions	between	specific	cell	 types	such	as	neurons	and	glia	 in	the	absence	of	other	cell	types	and	external	factors,	which	will	be	discussed	in	the	next	section.		
8.5 Modelling	 interactions	 between	 neurons	 and	 glia	 and	 their	
individual	roles	in	the	NCLs	As	considered	in	section	8.4	of	this	discussion,	in	vivo	models	can	tell	us	about	cells	interacting	 within	 a	 native	 environment,	 whereas	 in	 vitro	 models	 can	 answer	specific	questions	in	a	defined	environment.		The	TPP1-deficient	mouse	model	used	in	this	thesis	displays	an	unexpected	relationship	between	the	timing	of	neuron	loss	and	glial	activation.	Contrary	to	what	is	seen	in	all	other	forms	of	NCL	in	these	mice	neurons	 are	 lost	 in	 thalamic	 relay	 nuclei	 such	 as	 the	 ventral	 posterior	 nucleus	(VPM/VPL)	 and	 the	 lateral	 geniculate	nucleus	 (LGNd)	before	overt	 astrocytosis	 is	seen	in	these	areas.		
	
8.5.1 Modelling	 interactions	between	neurons	and	glia	 and	 their	 individual	
roles	in	the	NCLs	in	vivo	As	described	in	Chapter	1	section	1.6.4,	glial	upregulation	precedes	neuron	loss	 in	all	 other	 mouse	 models	 and	 it	 has	 been	 suggested	 that	 neuroinflammation	 may	
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contribute	 to	neuronal	 cell	 loss	 in	 the	NCLs	 (Kay	 et	 al.,	 2006,	Cooper	 et	 al.,	 1999,	Weimer	 et	 al.,	 2009,	 Oswald	 et	 al.,	 2005,	 Groh	 et	 al.,	 2013,	 Pontikis	 et	 al.,	 2004,	Oswald	et	al.,	2008,	Bible	et	al.,	2004,	Kuhl	et	al.,	2013,	Katz	et	al.,	2008,	Kielar	et	al.,	2007,	 Partanen	 et	 al.,	 2008).	 A	 recent	 study	 used	 Ppt1-/-	 mice	 deficient	 in	 the	astrocyte	 intermediate	 filament	 proteins	 GFAP	 and	 vimentin	 (Vim)	 in	 order	 to	interrogate	 the	 consequences	 of	 attenuated	 astrocyte	 activation	 in	 infantile	 CLN1	disease	(Macauley	et	al.,	2011).	Removal	of	the	reactive	astrocyte	response	actually	exacerbated	disease	progression	 in	Ppt1-/-	mice,	with	earlier	and	greater	neuronal	cell	 loss	 occurring	 (Macauley	 et	 al.,	 2011).	 Interestingly,	 treatment	 of	Ppt1-/-	mice	with	 an	 anti-neuroinflammatory	 molecule	 that	 attenuates	 glial	 cytokine	 release	enhanced	 AAV-mediated	 gene	 therapy,	 increasing	 lifespan	 and	 improving	 motor	deficits	 (Macauley	et	 al.,	 2014).	Taken	 together	 these	data	 suggest	 that	 astrocytes	may	play	both	a	neuroprotective	and	a	neurotoxic	role	in	this	infantile	CLN1	disease	mouse	 model	 (reviewed	 in	 (Shyng	 and	 Sands,	 2014)).	 It	 would	 be	 particularly	interesting	 to	 cross	 Tpp1-/-	mice	 with	 mice	 deficient	 in	 both	 GFAP	 and	 Vim,	 and	determine	whether	even	a	delayed	astrocytic	response	is	beneficial	in	these	TPP1-deficient	mice.	Although	the	knockout	of	Vim	is	not	a	potential	therapy	in	humans,	it	would	 still	 be	 interesting	 to	 further	 examine	 the	 role	 of	 astrocytes	 in	 the	 disease	progression	of	TPP1-deficient	mice.		Because	we	see	this	relatively	delayed	astrocytic	response	that	follows	neuron	loss	in	TPP1-deficient	mice,	this	raises	the	question	of	whether	Tpp1-/-	mice	are	missing	out	 on	 the	 neuroprotection	 conferred	 by	 astrocyte	 activation.	 Are	 TPP1-deficient	astrocytes	 defective	 in	 some	 way	 that	 means	 that	 they	 do	 not	 react	 to	 neuronal	damage,	as	they	should?		To	 determine	 the	 consequences	 of	 lack	 of	 TPP1	 activity	 in	 specific	 cell	 types,	 a	conditional	knockout	of	Tpp1	in	mice	could	be	created	which	prevents	expression	of	
Tpp1	 solely	 in	 astrocytes,	 neurons	 or	 microglia.	 This	 approach	 has	 already	 been	carried	out	with	conditional	knockouts	of	Cln3	in	mice,	which	prevent	expression	of	
Cln3	only	in	specific	cell	types.	Mice	have	been	created	in	which	the	1	kb	region	that	is	deleted	in	85%	of	human	juvenile	CLN3	disease	alleles	is	floxed	by	loxP	sites	and	then	 subsequently	 crossed	 with	 mice	 that	 express	 cre	 only	 in	 the	 cell	 type	 of	interest	 (Cooper,	 personal	 communication).	 For	 example,	 if	 cre	 is	 expressed	 by	 a	neuronal	promoter	then	the	CLN3	1	Kb	deletion	will	only	occur	in	neurons.		It	will	 be	 harder	 to	 take	 this	 approach	with	 the	NCL	 subtypes	 that	 are	 caused	by	mutations	in	soluble	enzymes	such	as	CLN1	and	CLN2	disease,	because	the	enzyme	
270	
will	be	secreted	by	non-targeted	cells	and	taken	up	by	the	cell	types	of	interest	by	cross	correction	(see	Chapter	1,	section	1.2.1).	One	method	to	avoid	this	is	to	use	a	membrane-tethered	 form	 of	 the	 enzyme,	 which	 is	 still	 biologically	 active.	 This	mouse	model	has	already	been	created	for	infantile	CLN1	disease	(Shyng,	NCL2014	presentation)	 and	 it	would	be	 interesting	 to	 see	 the	 same	mouse	model	made	 for	late	infantile	CLN2	disease.			
8.5.2 Modelling	 interactions	between	neurons	and	glia	 and	 their	 individual	
roles	in	the	NCLs	in	vitro	Another	 way	 to	 investigate	 the	 effects	 of	 TPP1	 deficiency	 on	 specific	 cell	 types	would	be	to	examine	primary	astrocyte,	microglial	or	neuron	cultures	derived	from	
Tpp1-/-	 mice.	 Primary	 astrocyte	 cultures	 from	 Cln3ex1-6	 (Cln3-/-	 mice)	 have	 been	examined	in	this	way	and	amongst	many	other	phenotypes	display	a	reduced	ability	to	 uptake	 excess	 glutamate	 (Parviainen,	 PhD	 Thesis),	 which	 combined	 with	 the	excess	 glutamate	 secreted	 from	 CLN3-deficient	 microglia	 (see	 section	 8.3.2	 and	Xiong	and	Kielian,	2013),	suggests	a	further	role	for	Cln3-/-	glia	in	neurotoxicity.	In	addition,	 co-cultures	 of	 glia	 and	 neurons	 from	Cln3-/-	mice	 show	 that	mutant	 glia	reduce	 the	survival	of	both	wild-type	and	Cln3-/-	neurons,	with	a	more	neurotoxic	effect	 on	 Cln3-/-	 neurons,	 and	 that	 wild-type	 glia	 can	 support	 growth	 of	 Cln3-/-	neurons	and	improve	their	disease	phenotypes	(see	section	8.3.2).		In	a	similar	experiment,	Benedict	et	al.,	(2009)	co-cultured	mutant	neurons	and	glia	from	 the	 Cln6nclf	mouse,	 which	 harbours	 a	 CLN6	 disease-causing	 mutation.	 The	authors	found	that	Cln6nclf	glia	had	a	detrimental	effect	on	the	maturation	of	Cln6nclf	neurons,	and	that	a	greater	proportion	of	Cln6nclf	neurons	died	when	cultured	with	
Cln6nclf	glia	(Benedict	et	al.,	2009).	These	experiments	reveal	that	Cln3-/-	and	Cln6nclf	glia	 are	 detrimental	 to	 neurons	 in	 vitro	and	 that	 targeting	 glia	may	 be	 beneficial.	However,	the	effect	of	removing	or	blocking	the	astrocytic	response	in	vivo	has	not	been	 attempted	 in	 a	mouse	model	 of	 CLN3	or	 CLN6	disease.	 Although	Cln3-/-	 and	
Cln6nclf	astrocytes	 display	 a	 neurotoxic	 phenotype	 in	 vitro,	 it	 is	 not	 clear	whether	within	 the	 context	 of	 a	 complete	 biological	 system	 that	 the	 overall	 effect	 of	removing	 the	 glia	 would	 prove	 to	 be	 therapeutic.	 Nevertheless,	 it	 would	 be	 very	informative	 to	 test	 these	 ideas	 experimentally.	 Primary	 astrocyte	 cultures	 from	
Tpp1-/-	mice	 are	 now	 being	 evaluated	 in	 a	 similar	method	 (van	 Trigt	 and	 Cooper,	personal	communication),	and	it	will	be	interesting	to	discover	whether	they	have	
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an	altered	response	to	stimuli	in	vitro,	as	they	appear	to	have	in	vivo,	and	if	they	also	display	neurotoxic	properties	when	co-cultured	with	neurons.		Cells	 derived	 from	 NCL	 mouse	 models	 can	 tell	 us	 more	 about	 why	 we	 may	 see	certain	phenotypes	in	vivo,	however	human	and	mouse	cells	are	physiologically	very	different.	For	 instance,	human	astrocytes	are	much	 larger	and	more	complex	 than	mouse	astrocytes	(Oberheim	et	al.,	2012	,	Oberheim	et	al.,	2009)	and	it	may	be	that	human	cell	models	will	be	more	relevant	to	human	NCL	disease.	Since	hNPCs	have	the	capability	to	differentiate	into	both	neurons	and	astrocytes,	a	hNPC	line	with	a	CLN2-disease	causing	mutation	 introduced	by	 the	strategy	described	 in	Chapter	7		(CLN2-targeting	 TALENs	 and	 a	mutation-specific	 donor	matrix),	 could	 be	 used	 to	produce	these	cell	types	and	investigate	their	individual	properties	and	interactions	




a	drug	screening	tool	A	late	infantile	CLN2	disease	hNPC	line	represents	a	useful	cellular	source	to	carry	out	high	content	screening	(HCS)	(Danovi	et	al.,	2012),	where	cells	are	exposed	to	libraries	 of	 small	 molecules	 or	 genetically	 screened.	 	 These	 authors	 suggest	 that	hNPC	 lines	 could	even	be	used	 in	 image-based	HCS,	using	automated	microscopy,	computers	and	image	processing	tools	available	in	individual	academic	laboratories	and	provide	details	on	how	this	could	be	achieved	(Danovi	et	al.,	2012).	Adherent	cell	 culture	such	as	described	 for	 the	CTXOE16/02	 line	 in	Chapter	7	section	7.1.6,	has	important	advantages	over	suspension	cultures,	such	as	the	use	of	fully	defined	media,	 a	 reduction	 in	 the	 spontaneous	 cell	 death	 and	 differentiation	 seen	 in	neurospheres,	and	the	lack	of	heterogenous	cell	interactions,	which	should	provide	more	consistent	results	(reviewed	in	Pollard	and	Conti,	2007	and	Pollard,	2013)).	In	HCS,	 neurological	 disease	 phenotypes	 such	 as	 changes	 in	 cellular	 morphology,	neurite	length,	and	soma	size	or	spine	densities	of	neurons	can	be	relatively	simply	interrogated	(Chailangkarn	et	al.,	2012).		In	order	to	evaluate	the	effects	of	the	c.509-1G>C	mutation	in	CLN2	in	different	cell	types	it	will	be	important	to	ensure	that	differentiation	programs	yield	the	cell	types	
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of	 interest.	 This	 can	 be	 determined	 initially	 by	 immunocytochemistry	 using	different	biological	markers,	such	as	the	neuronal	cytoskeletal	protein,	microtubule	associated	protein	 (MAP2)	 to	 identify	all	post-mitotic	neurons,	neurofilament	200	(NF200)	 for	 mature	 neurons,	 choline	 acetyltransferase	 (ChAT)	 for	 cholinergic	neurons,	 LIM/homeobox	 3	 (LHX3)	 and	 homeobox	 9	 (Hb9)	 for	 motor	 neurons	(Thaler	 et	 al.,	 2002),	 gamma	 aminobutyric	 acid	 (GABA)	 for	 GABAergic	 neurons,	serotonin	 for	 serotonergic	 neurons,	 and	 tyrosine	 hydroxylase	 (TH)	 (for	dopaminergic	 neurons)	 (as	 described	 in	 Xiong	 et	 al.,	 2014)	 and	 then	 cross-referenced	with	western-blot	 analysis.	The	 electrophysiological	 properties	 of	 cells	expressing	neuronal	markers	should	also	be	evaluated	using	patch-clamp	analysis	(as	 described	 in	 Fraichard	 et	 al.,	 1995).	 This	 work	 would	 take	 some	 time	 to	complete	and	lies	beyond	the	scope	of	the	present	thesis,	but	the	work	I	have	done	in	this	thesis	is	a	significant	step	towards	achieving	this	goal.		
8.6.1 Alternatives	to	a	human	neural	progenitor	cell	based	drug	screen	Because	of	the	changes	 introduced	by	immortalization,	 it	 is	sometimes	questioned	whether	 hNPC	 lines	 like	 CTXOE16/02	 accurately	model	 primary	 human	 cells	 (Xu	and	 Zhong,	 2013).	 One	 promising	 alternative	 is	 to	 use	 induced	 pluripotent	 stem	cells	(iPSCs)	instead.	iPSCs	are	pluripotent	cells	derived	from	somatic	cells	such	as	fibroblasts,	which	have	been	reprogrammed	into	an	early	stage	of	development	by	ectopic	 expression	 of	 the	 stemness	 genes	 octamer	 binding	 transcription	 factor	 4	
(OCT4),	sex	 determining	 region	 Y	 box	 (SOX2),	kruppel-like	 factor	 4	 (KLF4)	 and	C-
MYC	 (Takahashi	 et	 al.,	 2007,	 Takahashi	 and	 Yamanaka,	 2006).	 	 iPSCs	 have	 the	potential	to	differentiate	into	all	cell	lineages	and	so	it	is	possible	to	obtain	neurons,	astrocytes	and	microglia	from	these	cells.	iPSC	technology	provides	an	inexhaustible	source	 of	 genetically-relevant	 cells	 for	 drug	 screens	 (Xu	 and	 Zhong,	 2013).	 Such	iPSCs	 from	 neurologically	 normal	 individuals	 could	 be	 nucleofected	 with	 the	TALENs	 and	 donor	 matrix	 described	 in	 Chapter	 7,	 to	 produce	 iPSCs	 carrying	 a	defined	 CLN2-disease-causing	 mutation.	 These	 cells	 could	 then	 be	 differentiated	into	 the	 cell	 types	 of	 interest	 and	 used	 in	 HCS	 as	 previously	 described	 above.	 In	addition,	this	cell	line	would	have	an	ideal	control	of	the	same	iPSC	line,	but	without	genetic	editing.	An	alternative	 to	genetically	modifying	specific	 control	 iPSC	 lines	with	TALENs	or	other	 gene	 editing	 technology	 is	 to	 reprogram	 somatic	 cells	 from	 NCL	 patients.	Work	towards	the	use	of	iPSCs	as	a	model	for	the	NCLs	and	as	a	drug	discovery	has	
273	
already	 started	 and	 neuronal	 cell	 models	 have	 been	 produced	 from	 CLN2-/-	 and	
CLN3-/-	 patient-derived	 fibroblasts	 (Lojewski	 et	 al.,	 2014).	 Encouragingly,	 the	disease	 status	 of	 these	 cells	 did	 not	 prevent	 their	 differentiation	 into	 the	 three	major	germ	layers	and	functional	neurons	were	produced.	Distinct	disease-related	phenotypes	were	observed	following	neuronal	differentiation	of	the	iPSCs,	such	as	the	 appearance	 of	 storage	 material	 specific	 to	 each	 disease	 subtype	 and	abnormalities	 in	mitochondrial	 function	 and	 the	 endoplasmic	 reticulum	 and	 golgi	apparatus	 in	both	CLN2-/-	and	CLN3-/-	neuronal	derivatives	 (Lojewski	 et	 al.,	 2014).	These	 phenotypes	 can	 be	 used	 as	 benchmarks	 for	 these	 cells	 in	 culture	 and	 the	effects	of	small	molecules	on	these	parameters	can	now	be	investigated.	Despite	their	potential,	iPSCs	inevitably	have	their	own	caveats	when	considered	as	a	drug-screening	 tool	or	model	of	NCL	disease.	There	are	differences	between	 the	differentiation	potential	of	 individual	 lines,	Boulting	et	al.,	(2011)	found	that	3	out	of	the	16	iPSC	lines	they	generated	would	not	differentiate	into	neurons	(Boulting	et	al.,	2011).	 iPSCs	often	contain	genetic	abberations	caused	by	transduction	by	viral	integration	 such	 as	mutations	 at	 integration	 sites	 and	 variations	 in	 copy	 number	and	 karyotype	 (Laurent	 et	 al.,	 2011).	 iPSCs	 also	 often	 show	 significant	reprogramming	 ability	 and	 may	 not	 retain	 epigenetic	 memory	 from	 their	 donor	cells	 (Lister	 et	 al.,	 2011),	 and	hence	may	not	 fully	 recapitulate	 the	genetics	of	 the	patient	 the	 cells	 are	 derived	 from.	 Lack	 of	 epigenetic	memory	will	 also	 affect	 the	differentiation	potential	of	the	iPSCs	(Xu	and	Zhong,	2013).	Because	clone	variations	greatly	affect	the	phenotypes	of	iPSCs,	Xu	et	al.,	(2013)	suggest	that	more	than	one	iPSC	 line	 is	 derived	 from	 a	 patient	 and	 a	 diverse	 group	 of	 patients	with	 different	genetic	backgrounds	should	be	selected,	in	order	to	detect	disease-specific	cellular	phenotypes	beyond	the	normal	variability	observed	in	iPSC-derived	cells.		Another	 approach,	 which	 would	 avoid	 the	 time-consuming	 process	 of	differentiating	iPSCs	into	neurons,	involves	the	direct	conversion	of	somatic	cells	(in	this	 case	 from	 NCL	 patients)	 into	 NPCs	 (Lee	 et	 al.,	 2011,	 Tian	 et	 al.,	 2012)	 or	neurons	(Abdullah	et	al.,	2012,	Vierbuchen	et	al.,	2010)	by	the	ectopic	expression	of	certain	 transcription	 factors.	However,	 this	 technique	 does	 not	 currently	 produce	enough	 cells	 for	 use	 as	 a	 drug-screening	 tool.	 Since	 this	 is	 a	 relatively	 new	technology,	 it	remains	to	be	seen	 if	 these	cells	will	provide	an	alternative	strategy	for	 disease	 modelling	 or	 drug	 screening,	 or	 if	 they	 will	 be	 rejected	 for	 being	artificially	produced	cells	that	do	not	recapitulate	human	physiology	well	enough.		
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8.7 Ethical	issues	surrounding	mouse	and	human	cell	models		In	 the	 UK,	 experiments	 involving	 animals	 are	 assessed	 in	 terms	 of	 harm	 to	 the	animal	and	this	is	weighed	up	against	the	potential	benefit	to	humans.	(Festing	and	Wilkinson,	 2007).	 If	 there	 is	 a	 reasonable	 alternative	 to	 the	 use	 of	 animals	 in	 an	experiment	then	the	alternative	should	be	used	instead.	However,	there	will	always	be	people	who	 feel	 the	use	of	 animals	 for	human	benefit	 is	 not	 acceptable	 in	 any	situation.	The	use	of	the	3Rs	(replacement,	reduction	and	refinement)	 is	crucial	 in	order	to	continuously	reduce	suffering	for	animals	in	research	and	encourage	their	use	only	when	strictly	necessary	(Festing	and	Wilkinson,	2007).		Experiments	on	stem	cells	derived	from	foetal	tissue	such	as	the	CTXOE16/02	cell	line	 used	 in	 this	 thesis	 are	 regulated	 by	 guidelines,	 however	 those	 that	 regard	elective	termination	of	pregnancy	as	morally	questionable	may	also	have	doubts	on	the	use	of	foetal	tissue	for	this	purpose,	as	the	foetus	cannot	give	informed	consent	(McLaren,	2001).	In	contrast,	iPSCs	have	no	ethical	issues	surrounding	them	as	they	are	 derived	 from	 somatic	 cells,	 which	 can	 be	 acquired	 with	 informed	 consent.	Despite	 there	 being	 clear	 regulations	 on	 the	 use	 of	 both	 animal	 and	 stem	 cell	models,	it	is	important	to	be	aware	and	sensitive	to	the	ethical	issues	that	surround	their	use.	
	
8.8 Conclusions	In	 this	discussion,	 I	have	examined	 the	different	 scenarios	 in	which	 in	vivo	and	 in	
vitro	methods	could	be	used	to	model	late	infantile	CLN2	disease	and	the	merits	and	drawbacks	of	them	both.		Animal	models	 can	 inform	us	 about	 cells	 interacting	within	 a	 native	 environment	and	 the	 progression	 of	 disease	 over	 time.	 This	 thesis	 presents	 the	 first	 detailed	description	 of	 the	 neuropathological	 features	 of	 disease	 progression	 within	 the	thalamocortical	 system	 of	 Tpp1neoinsArg446His	 mice.	 Extensively	 characterizing	mouse	models	of	NCL	disease	in	this	 fashion	is	essential	to	determine	how	closely	these	models	mimic	 human	 disease,	 and	 hence	what	 can	 be	 expected	 of	 a	 such	 a	mouse	model	 in	 terms	of	 translational	 therapeutic	benefit.	 In	order	 to	 reduce	 the	number	of	false	positives	in	preclinical	trials,	 it	 is	 important	to	rigorously	assess	a	mouse	 model’s	 physical	 and	 biochemical	 traits	 in	 terms	 of	 human	 disease	 and	characterise	 when	 disease	 symptoms	 and	 death	 occur	 (Perrin,	 2014).	 Precisely	what	 causes	 the	 severely	 shortened	 lifespan	 of	 the	Tpp1neoinsArg446His	mouse	 is	
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still	to	be	determined,	and	it	will	be	crucial	to	determine	if	this	has	a	neurological	or	somatic	 basis.	 The	 results	 presented	 in	 Chapter	 3	 suggest	 that	 although	neuropathology	 is	 certainly	 present	 in	 these	mice	 it	 is	 not	 especially	 pronounced	until	 very	 late	 in	 disease	 progression.	 Without	 identifying	 what	 causes	 these	
Tpp1neoinsArg446His	 mice	 to	 die	 early,	 preclinical	 studies	 that	 extend	 survival	 of	this	 mouse	 model	 may	 be	 irrelevant	 to	 human	 disease	 if	 the	 cause	 of	 death	 is	ultimately	found	to	be	different	in	these	mice.	Cell	 based	 models	 have	 the	 great	 advantage	 of	 providing	 answers	 to	 specific	questions	 in	a	defined	environment.	 	 In	 this	 thesis,	 I	attempted	to	create	a	human	neural	progenitor	cell	(hNPC)	model,	which	was	genetically	modified	with	TALENs	to	 recreate	one	of	 the	most	common	CLN2	disease-causing	mutations	 (Chapters	6	and	 7).	 Human	 cell	 models	 obviously	 have	 greater	 direct	 relevance	 to	 human	disease	and	can	plausibly	explain	differences	seen	between	animal	and	human	cell	models.	A	CLN2	disease	hNPC	line	could	be	used	in	the	future	as	a	drug-screening	tool,	but	we	are	a	long	way	off	realising	this	for	CLN2	disease	at	present.	It	will	be	necessary	 to	 optimise	 growing	 the	 CTXOE16/02	 cells	 as	 single	 cells	 in	 order	 to	generate	a	clonal	population.	It	will	also	be	necessary	to	characterise	the	resultant	CLN2	disease	hNPC	 line	extensively	 to	ascertain	clear	phenotypes	 that	differ	 from	wild-type	 CTXOE16/02	 cells.	 Importantly,	 these	 landmarks	 can	 be	 used	 as	benchmarks	 of	 pathology	 if	 these	 cells	 were	 to	 be	 used	 as	 a	 drug	 or	 therapeutic	screening	 tool.	 Promising	 small	 molecule	 leads	 identified	 by	 such	methods	 could	then	be	taken	forward	for	preclinical	studies	in	animal	models	because	despite	their	similarity	to	human	biology,	a	CLN2	disease	hNPC	line	cannot	be	a	substitute	for	the	many	cellular	and	systemic	interactions	in	an	animal	model.	In	this	thesis,	I	do	not	intend	to	suggest	that	either	animal	models	or	cell	models	are	not	 valid	 systems	 for	 learning	 more	 about	 the	 pathogenesis	 of	 the	 NCLs	 or	 for	carrying	 out	 preclinical	 experiments	 for	 future	 therapeutic	 interventions.	 Instead,	information	gleaned	 from	 these	models	 should	be	 interpreted	with	caution	whilst	taking	 the	 factors	 explored	 in	 this	 discussion,	 such	 as	 species	 differences	 and	experimental	design,	into	account.	I	also	do	not	intend	to	suggest	that	either	model	is	superior	to	the	other.	In	fact	I	believe	both	animal	and	cell	models	of	late	infantile	CLN2	disease,	together	with	key	information	from	patients,	will	be	needed	to	fully	address	 the	 pathogenesis	 of	 CLN2	 disease	 in	 order	 to	 move	 towards	 finding	successful	therapies	for	this	profoundly	disabling	fatal	disorder.			 	
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Ex-F1		 TGCGTCcgtctcCGAACCTTAAACCGGCCAACATACCggtctcCTGACCCCAGAGCAGGTCGTG			Ex-F2		 TGCGTCcgtctcCGAACCTTAAACCGGCCAACATACCggtctcGACTTACACCCGAACAAGTCGTGGCAATTGCGAGC		Ex-F3	 TGCGTCcgtctcCGAACCTTAAACCGGCCAACATACCggtctcGCGGCCTCACCCCAGAGCAGGTCG		Ex-F4	 TGCGTCcgtctcCGAACCTTAAACCGGCCAACATACCggtctcGTGGGCTCACCCCAGAGCAGGTCG		Ex-R1	 GCTGACcgtctcCGTTCAGTCTGTCTTTCCCCTTTCCggtctcTAAGTCCGTGCGCTTGGCAC		Ex-R2	 GCTGACcgtctcCGTTCAGTCTGTCTTTCCCCTTTCCggtctcAGCCGTGCGCTTGGCACAG		
Ex-R3		 GCTGACcgtctcCGTTCAGTCTGTCTTTCCCCTTTCCggtctcTCCCATGGGCCTGACATAACACAGGCAGCAACCTCTG		Ex-R4	 GCTGACcgtctcCGTTCAGTCTGTCTTTCCCCTTTCCggtctcTGAGTCCGTGCGCTTGGCAC		In-F2	 CTTGTTATGGACGAGTTGCCcgtctcGTACGCCAGAGCAGGTCGTGGC		In-F3	 CCAAAGATTCAACCGTCCTGcgtctcGAACCCCAGAGCAGGTCGTG		In-F4	 TATTCATGCTTGGACGGACTcgtctcGGTTGACCCCAGAGCAGGTCGTG		In-F5	 GTCCTAGTGAGGAATACCGGcgtctcGCCTGACCCCAGAGCAGGTCGTG		In-F6	 TTCCTTGATACCGTAGCTCGcgtctcGGACACCAGAGCAGGTCGTGGC		In-R1	 TCTTATCGGTGCTTCGTTCTcgtctcCCGTAAGTCCGTGCGCTTGGCAC		In-R2	 CGTTTCTTTCCGGTCGTTAGcgtctcTGGTTAGTCCGTGCGCTTGGCAC		In-R3	 TGAGCCTTATGATTTCCCGTcgtctcTCAACCCGTGCGCTTGGCACAG		In-R4	 AGTCTGTCTTTCCCCTTTCCcgtctcTCAGGCCGTGCGCTTGGCACAG		In-R5	 CCGAAGAATCGCAGATCCTAcgtctcTTGTCAGTCCGTGCGCTTGGCAC		Hex-F	 CTTAAACCGGCCAACATACC		Hex-R	 AGTCTGTCTTTCCCCTTTCC		TALE-Seq-F1	 CCAGTTGCTGAAGATCGCGAAGC		TALE-Seq-F2	 ACTTACACCCGAACAAGTCG		TALE-Seq-R1	 TGCCACTCGATGTGATGTCCTC		CLN2	FWD	1	 CCACATCCCTACCAGCTTCC	CLN2	REV	1	 GAGCCAGGTCTGAGTCATGG	SNAPSHOT	CLN2	FWD	 TCAAGCCTGACTTCTCCCTAC	SNAPSHOT	CLN2	REV	 ACGGTGCAGGCCTCCCA	
Table	25	Primer	pairs	used	within	this	thesis	
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1.2	Conditions	trialled	for	construction	of	custom	TALENs	Reagent	 Amount	(μl)	 Final	concentration	Monomer	template	plasmid	(5	ng	μl-1)	 2	 50	pg	μl-1	dNTP,	100	mM	 2	 1	mM	Herculase	II	PCR	buffer,	5X	 20	 1X	Primer	mix,	 20	 μM	 (10	 μM	forward	primer	 and	10	μM	reverse	primer)	 4	 200	nM	Herculase	 II	 Fusion	Polymerase	 2	 	Distilled	water	 150	 	Total	 200	μl	(for	2	reactions)		
Table	 26	 Reagents	 for	 monomer	 library	 PCR	 with	 Herculase	 II	 Fusion	 DNA	
polymerase.	 The	 table	 list	 the	 reagents	 used	 for	 PCR	 amplification	 in	 order	 to	 obtain	products	with	 unique	 ligation	 adaptors	 following	 digestion.	 As	 described	 in	 Sanjana	 et	 al	2012.			Cycle	Step	 Temperature	 Time		 Cycles	Initial	denaturation	 95	°C	 2	min	 1	Denaturation	 95	°C	 20	s	 30	Annealing	 60	°C	 20	s	Extension	 72	°C	 10	s		Final	extension	 72	°C	 3	min	 1		
Table	 27	 Thermal	 profile	 for	 PCR	 for	 monomer	 library	 construction	 with	
Herculase	 II	 Fusion	 DNA	 polymerase	 Monomer	 library	 PCR	 amplification	 was	performed	 using	 the	 reagents	 described	 in	 table	 25	 and	 the	 cycling	 conditions	described	here.	
		Component	 Amount	(μl)	 Final	concentration	PlasmidSafe	DNAse,	10	Uμl-1	 1	 0.66	Uμl-1	PlasmidSafe	reaction	buffer,	10X	 1	 1X	ATP,	10	mM	 1	 1	mM1		 3	 	Golden	Gate	reaction	 7	 	Total	 10	 	
Table	 28	 Reagents	 for	 plasmidsafe	 exonuclease	 digestion.	 The	 assembled	hexamers	 were	 digested	 to	 remove	 incomplete	 monomer	 ligations	 (5	 or	 less	monomers	 ligated	 together	 using	 plasmidsafe	 exonuclease	 along	 with	 the	 other	reagents	listed	here	with	the	thermal	profile	described	in	table	26.						
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Component	 Amount	(μl)	 Final	concentration	dNTP,	100	mM	(25	mM	each)	 0.5	 1	mM	Herculase	II	reaction	buffer,	5X	 10	 1X	Hex-F	and	Hex-R	primers,		10	μM	each	 1	 200	nM	Herculase	 II	 fusion	 DNA	polymerase	 0.5	 1X	Distilled	water	 37	 	PlasmidSafe-treated	hexamer	 1	 	Total	 50	 		
Table	 29	 Reagents	 for	 hexamer	 amplification	 PCR.	 PCR	 amplification	 was	performed	using	Herculase	II	fusion	DNA	polymerase	along	the	reagents	listed	here	using	the	plasmidsafe	treated	hexamers	in	order	to	increase	the	DNA	concentration	of	the	hexamers.		
1.3	Conditions	trialled	for	Surveyor	Nuclease	Assay	Reagent	 Amount	(μl)	 Final	concentration	gDNA	from	nucleofected	CTXOE16/02	cells	(or	untransfected	for	control)	or	control	DNA	from	Surveyor	Mutation	Detection	Kit	 1	 50	pg	μl-1	dNTP,	10	mM	 1	 200	μM	each	Phusion	HF	buffer,	5X	 10	 1X	Primer	mix,	20	μM	(10	μM	forward	primer	and	10	μM	reverse	primer)	CLN2_FWD1	and	CLN2_REV1	OR	Surveyor_FWD	and	Surveyor_REV	
1.25	 500	nM	
Phusion	Polymerase	 0.5	 0.02	U	μl-1	Distilled	water	 36.25	 	Total	 50	μl		
Table	 30	 Reagents	 for	 PCR	 for	 Surveyor	 nuclease.	 	 The	 CLN2	 region	 in	 gDNA	 from	CTXOE16	cells	nucleofected	with	TALENs	was	amplified	using	the	reagents	described	here	and	the	thermal	profile	described	in	table	30.		
			
Cycle	Step	 Temperature	 Time		 Cycles	Initial	denaturation	 98	°C	 1	min	 1	Denaturation	 98	°C	 20	s	 35	Annealing	 65	°C	 20	s	Extension	 72	°C	 30	s		Final	extension	 72	°C	 3	min	 1	
Table	 31	 Thermal	 profile	 for	 PCR	 for	 Surveyor	 nuclease.	 	The	CLN2	 region	 in	 gDNA	from	CTXOE16	cells	nucleofected	with	TALENs	was	amplified	using	the	reagents	described	in	table	29	and	the	thermal	profile	described	here.	
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Cycle	Number	 Temperature	(°C)	 Time	(min)	1	 95		 10	2	 95-85	(-2	°C	s-1)	 	3	 85	 1	4	 85-75	(-2	°C	s-1)	 	5	 75	 1	6	 75-65	(-2	°C	s-1)	 	7	 65	 1	8	 65-55	(-2	°C	s-1)	 	9	 55	 1	10	 55-45	(-2	°C	s-1)	 	11	 45	 1	12	 45-35	(-2	°C	s-1)	 	13	 35	 1	14	 35-25	(-2	°C	s-1)	 	15	 25		 1	
	
Table	32	Thermal	profile	 for	 formation	of	 heteroduplexes.	The	CLN2	region	in	gDNA	from	CTXOE16	cells	nucleofected	with	TALENs	was	amplified	by	PCR	and	heat-treated	as	described	here.		 Component	 Amount	(μl)	 Final	Concentration	Surveyor	Nuclease	S	 2	 1X	Surveyor	 Nuclease	Enhancer	 1	 1X	Rennealed	Duplexes	 17	 	Total	 20	 		
Table	33	Reagents	for	Surveyor	S	digestion.		The	heat-treated	PCR	samples	from	CTXOE16	 cells	 nucleofected	 with	 TALENs	 were	 mixed	 with	 the	 following	components	on	ice	then	incubated	at	42	°C	for	one	hour.		
1.4	Conditions	for	Snapshot	Sequencing		
Reagent	 Volume	added/	25	μl	PCR	reaction	Shrimp	alkaline	phosphatase	 1	μl	(1	unit)	Exonuclease	I	 0.2	μl	(4	units)	Water	 1.8	μl	
Table	 34	 Reagents	 for	 Shrimp	 alkaline	 phosphatase	 and	 exonuclease	 I	
treatment.		
Reagent	 Volume	added/	2.5	μl	‘SAP/exo-treated’	





1.5.1	Reduced	Modified	Medium	(RMM)		For	 use	 with	 CTXOE16/02	 cells.	 Remove	 12ml	 of	media	 from	 a	 500	ml	 bottle	 of	DMEM:F12	with	 15	mM	HEPES	 and	 sodium	bicarbonate	 but	without	 L-glutamine	(Sigma:	D6421)	and	add:			
0.75	ml	 Human	 serum	 albumin	 solution	 (0.03%	 final	 concentration)(20%	stock,	PAA:	C11-096)		
1.0	ml	 Human	apo-transferrin	(100	µgml-1	final	concentration)(50	mgml-1	stock,	SCIPAC:	T100-5)	
1.0	ml	 Putrescine	 dihydrochloride	 (16.2	 µgml-1	 final	 concentration)(8.1	mgml-1	stock,Sigma:	P5780)	
0.25	ml	 Human	 recombinant	 insulin	 (5	 µgml-1	 final	 concentration)(10	mgml-1	stock,	Sigma:	I9278)	
1.0	ml	 Progesterone	(60	ngml-1	final	concentration)(30	µgml-1	stock,	Sigma:	P6149)	
5.0	ml	 L-glutamine	 (2	 mM	 final	 concentration)(200	 mM	 stock,	 Sigma:	G7513)	
1.0	ml	 Sodium	 selenite	 (40	 ngml-1	 final	 concentration)(20	 µgml-1	 stock,	Sigma:	S9133)		
0.5	ml	 Human	 FGF-basic	 (10	 ngml-1	 final	 concentration)(10	 µgml-1	 stock,	PeproTech:	100-18B)	





1.0	ml	 NaCl	(Sigma,	S7653)		Make	 up	 to	 1	 litre	 with	 distilled	 water,	 autoclave	 for	 20	 minutes	 at	 120°C,	 add	appropriate	antibiotic	when	cooled.		For	LB	agar,	 add	an	 additional	15	g	of	 agar	 (Sigma,	A5306),	 stir	 and	autoclave	 as	above.		
Cycle	Step	 Temperature	 Time		 Cycles	Initial	denaturation	 95	°C	 10	s	 1	Denaturation	 95	°C	 10	s	 30	Annealing	 50	°C	 5	s	Extension	 60	°C	 10	s		
Table	36	Thermal	profile	for	SNAPShot®	sequencing.	
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1.6	DNA	Sequencing	Results	of	constructed	custom	LEFT	TALEN	
1.6.1	COLONY	1	
a.	Seq-	F1		
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b.	Seq-	F2	
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c.	Seq-	R1	
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1.6.2	COLONY	2	
	
a.	Seq-F1	
	
	
	
b.	Seq-	F2	
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c.	Seq-R1	
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1.6.3	COLONY	3	
	
a.	Seq-F1	
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b.	Seq-F2	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
c.	Seq-R1	
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1.6.4	COLONY	4	
	
a.	Seq-F1	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
b.	Seq-F2	
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c.	Seq-R1	
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1.6.5	COLONY	5	
	
a.	Seq-F1	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
b.	Seq-F2	
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c.	Seq-R1	
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1.6.6	COLONY	6	
	
a.	Seq-F1	
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b.	Seq-F2	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
c.	Seq-R1	
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1.6.7	*COLONY	7	
a.	Seq-F1	
	
	
	
	
	
	
	
	
	
	
	
	
	
b.	Seq-F2	
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c.	Seq-R1	
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1.7	DNA	Sequencing	Results	of	constructed	custom	RIGHT	TALEN	
1.7.1	COLONY	1	
a.	Seq-F1	
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b.	Seq-F2	
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c.	Seq-R1	
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1.7.2	COLONY	2	
	
a.	Seq-F1	
	
	
	
	
	
	
	
	
	
	
	
	
	
b.	Seq-F2	
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c.	Seq-R1	
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1.7.3	COLONY	3	
	
a.	Seq-F1	
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b.	Seq-F2	
	
	
	 	
351	
c.	Seq-R1	
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1.7.4	COLONY	4	
	
a.	Seq-F1	
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b.	Seq-F2	
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c.	Seq-R1	
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1.7.6	*COLONY	6	
	
a.	Seq-F1	
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b.	Seq-F2	
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c.	Seq-R1	
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1.7.7	COLONY	7	
	
a.	Seq-F1	
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b.	Seq-F2	
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c.	Seq-R1	
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1.8	Translated	alignments	for	Left	TALEN	
1.8.1	Colony	1	First	hexamer-	no	mismatch	
	Second	hexamer-no	mismatch	
	Third	hexamer-	no	mismatches	
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1.8.2	Colony	2		First	hexamer:	1	mismatch	
		Second	hexamer-	no	mismatch	
		Third	hexamer-	few	mismatches	
		
363	
1.8.3	Colony	3	
	First	hexamer	
	Second	hexamer	
	Third	hexamer	
		
1.8.4	Colony	4-		Not	read	successfully	by	software.		
364	
1.8.5	Colony	5-	Not	read	successfully	by	software.		
1.8.6	Colony	6-	First	hexamer	
	Second	hexamer	
	Third	hexamer	
	
365	
1.9	Translated	alignments	for	Right	TALEN	
1.9.1	Colony	1		First	hexamer	
	Second	hexamer	
	Third	hexamer	
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1.9.2	Colony	2	First	hexamer	
	Second	hexamer	
	Third	hexamer	
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1.9.3	Colony	3		First	hexamer	
	Second	hexamer	
	Third	hexamer		
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1.9.4	Colony	4		First	hexamer	
	Second	hexamer	
	Third	hexamer	
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1.9.6	Colony	6		First	hexamer		
	Second	hexamer	
	Third	hexamer	
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1.9.7	Colony	7			First	hexamer	
	Second	hexamer	
	Third	hexamer	
			
